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Abstract 
 
Modifiable lifestyles factors such as obesity and physical activity play a clear 
independent role in the aetiology of cancer, based on mounting epidemiological 
evidence. However, cancer research has lagged behind other major chronic 
conditions as disease risk modification between body fatness and physical activity 
has been noted in the context of mortality and cardiometabolic outcomes. In those 
studies, increased risk usually conferred by a high body fatness may be attenuated or 
even eliminated by high levels of physical activity or fitness. This phenomenon 
described as “fat but fit” hypothesis has barely been evaluated in the cancer field. 
Given the negative impact of obesity on the burden of cancer, the examination of a 
possible interaction between body fatness and physical activity is of public health 
significance to understand cancer risk. Therefore, this thesis examined the 
independent and interactive (“fat but fit”) effects of body mass and physical activity 
or fitness on the risk of different types of cancer in multiple epidemiological studies. 
The interrelation between body mass and physical activity or fitness was 
methodologically assessed by appraising the interaction term between these two 
lifestyle factors in epidemiological studies used in this thesis.   
 
There was variability in the results of the independent effects of obesity and physical 
activity across the studies of this thesis. Overall, obesity had a positive association 
with new cases of colorectal cancer, in particular colon cancer and any cancer 
combined among both sexes, prostate cancer in men and breast or uterine cancer in 
women. Conversely, physical activity or fitness had an inverse association with all-
cancer sites combined or colon cancer amongst men and women; breast, uterine or 
lung cancer in females and with the incidence and mortality of respiratory and 
thoracic cancers in males. When evaluating the “fat but fit” hypothesis, there was no 
evidence of interaction between body mass and different levels of physical activity or 
fitness on many cancer outcomes. Thus, “fat but fit” might not be relevant to cancer 
risk. Obesity-related cancer risks appear not to be offset or eliminated by high levels 
of physical activity or fitness. Therefore, both a healthy body weight in addition to 
recommended levels of physical activity need to be promoted to impact the risk of 
cancer. 
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INTRODUCTION 
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Introduction 
 
Cancer is a health threat which places considerable strain upon individuals and the 
society overall. In 2015, cancer accounted for 17.5 million incident cases and 8.7 
million deaths globally, being the second leading cause of mortality after 
cardiovascular diseases.(1) In Australia, cancer was responsible for more than 130,000 
new diagnoses and 47,000 deaths in 2017.(2) The worldwide incidence of cancer has 
increased by 33% during the last decade and projections of the cancer burden further 
forecast a rise by 70% in the next two decades.(2, 3) Although the robust statistics on 
cancer paint a gloomy picture, 1 in 3 cancers have been attributed to modifiable risk 
factors.(4) Therefore, cancer prevention is pivotal to reducing this increasing burden 
of cancer.(3) This thesis considers two important modifiable lifestyle factors for 
cancer, obesity and physical inactivity.         
 
Obesity is an escalating global public health issue, whose prevalence has been 
steadily increasing not only in most of the developed world but also in many African, 
Asian and Middle East nations.(5) Excess body fatness in population studies is usually 
determined by body mass index (BMI); a high BMI defines a person as being 
overweight (BMI range 25 - 29.9 Kg/m2) or obese (BMI ≥30 Kg/m2).(6) A recent 
systematic analysis estimated that the total number of individuals with high BMI 
globally increased from 857 million to 2.1 billion between 1980 to 2013, so that the 
prevalence of overweight and obesity in adults rose by 27.5% and 47.1% in children 
over this period.(7) As a result, the term “globesity” was coined by John Speakman to 
describe the magnitude of this problem.(8) Data from the Australia Bureau of 
Statistics show that the prevalence of overweight and obesity amongst Australians 
aged over 18 was 63.4% or the equivalent of 11.2 million people in 2014-15, 
although this prevalence might be under-estimated, because BMI was not calculated 
for 26.8% of people due to missing height or weight data.(9)  
 
Obesity is a complex condition which simplistically stems from a chronic, excessive 
and positive energy balance. Its causes are multiple, being determined by the 
interaction of different factors such as: technological advancements, the built 
environment, cultural and economic circumstances, as well as a person’s genetic 
susceptibility and psychosocial influences.(10-12) This condition has been causally 
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linked to many major non-communicable diseases, including cardiovascular diseases, 
type 2 diabetes mellitus, sleep apnoea and some cancers. The World Health 
Organization (WHO) stated in 1997 that obesity is the greatest health challenge faced 
by mankind.(8) While it is well known that a large number of people will suffer from 
obesity-related disorders, its role as a significant contributor to the development of 
many types of cancer is not often acknowledged.(13) The majority of Americans, for 
instance, are not aware of the increased cancer risk that obesity carries,(13) even 
though there are around 84,000 diagnoses of cancer every year in the USA which are 
attributed to obesity alone.(13) In Oceania, the proportion of excess cancers 
attributable to a high BMI for those cancers with sufficient epidemiological evidence 
has been estimated to be around 15% in women and 18% in men.(6) With the WHO 
calculating that there will be around 300 million obese individuals in industrialized 
countries by 2025;(14) these results highlight the need for greater public awareness of 
obesity as a leading preventable cancer cause. 
 
Physical inactivity is an independent behavioural risk factor for poor health which 
goes beyond its involvement in the onset of obesity high levels of physical activity 
have been inversely associated with the leading risk factors for morbidity and 
mortality, including: hypertension, hyperglycaemia and hypercholesterolemia.(15) 
Thus, physical activity is related to a decreased incidence of coronary, 
cerebrovascular, metabolic diseases and premature death.(16) The observed effects of 
physical activity are not only limited to primary prevention but also to secondary and 
tertiary prevention. For instance, in patients with established cardiovascular disease, 
regular physical activity diminishes the risk of myocardial infarction, sudden cardiac 
death, mortality from other causes, and improves global quality of life.(16) 
Additionally, physical activity has been reported to exert a protective effect on some 
major types of cancer that contribute substantially to the global and Australian 
burden of cancer in terms of incidence, mortality and disability.(2, 3, 17) Lower cancer 
risks have been observed for oesophageal adenocarcinoma, lung, kidney, myeloid 
leukemia, myeloma, colon, head and neck, rectum, bladder and breast cancer.(18) The 
antineoplastic influence of physical activity could be due to direct or indirect effects 
on regulating sex hormones, insulin, glucose, inflammation and enhancement of the 
immune system.(19) Unfortunately, inactive lifestyles are increasingly common 
globally where 1 in 4 adults are categorised a physically inactive.(20) A survey carried 
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out in Australia in 2014-15 showed that the overall level of physical activity among 
Australians older than 18 years of age was low; with 14.8% of Australians being 
defined as inactive and 29.7% having low levels of exercise which failed to meet 
physical activity guidelines.(9) Therefore, physical inactivity is now considered to be 
one of the most important public health issues that urgently needs to be addressed.(21)  
 
Humans as a species are well suited to undertake physical activity, and historically it 
was required for our survival. However, with technological advancement and cultural 
changes, levels of activity have gradually declined to the point that physical activity 
has become optional, deviating from the usual patterns of activity in human 
evolution.(11) Furthermore, its importance in the field of public health and clinical 
medicine has previously been undervalued,(21) especially its role in cancer 
prevention. The World Cancer Research Fund (WCRF) panel has calculated that 
high BMI, unhealthy diet and physical inactivity contribute to 30 to 40% of all 
cancers.(14) Given the increasing life expectancy and increasingly sedentary lifestyle 
in many countries around the world, even a small protective effect of physical 
activity on cancer risk could have a significant health impact.(22) As a result, the 
WCRF and the American Institute for Cancer Research (AICR) advocate for 30 to 60 
minutes a day of moderate to vigorous intensity physical activity for cancer 
prevention.(23)   
 
Purpose and significance 
 
International research into body fatness and levels of physical activity as independent 
modifiable determinants of cancer outcomes is well established. However, despite 
these extensive efforts, cancer research to date has been limited in assessing the 
interaction between these two factors, which is of public health interest, since it is 
necessary to discern if obesity-related cancer risk can be modified by increasing 
levels of physical activity independent of weight-loss.(24) This so-called “fat but fit” 
hypothesis has been observed in some epidemiological studies on mortality and 
incidence of cardiometabolic diseases.(25) Blair et al. reported that individuals with 
high levels of adiposity measured by BMI or body fat percentage who were also 
physically active or fit had lower rates of all-cause and cardiovascular mortality than 
inactive or unfit subjects with similar levels of adiposity.(26) Additionally, it was 
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observed that fit or physically active participants with a high body fatness had no 
significant different risks from fit or active subjects with low body habitus 
measurements; exclusion of individuals with chronic diseases at baseline did not 
modify these findings.(26) Similar conclusions have also been noted for fatal and non-
fatal coronary heart disease outcomes and hypertension.(26-29) This “fat but fit” 
evidence is reviewed in greater detail in chapter 4. “Fat but fit” is an attractive 
hypothesis which has not been fully explored in the cancer field, considering that 
global work to reduce the burden of obesity has not yet succeeded and cancer risk 
modification still remains unclear. Thus, further research to elucidate the effects of a 
high body mass across levels of physical activity on cancer risk is needed. This thesis 
will investigate the overall effect of body fatness, physical activity and their 
interaction (“fat but fit”) with different cancer outcomes. Melanoma and/or skin 
cancers were excluded from analyses as the association of physical activity with 
these malignancies might be confounded by ultraviolet sun exposure and increased 
risk of sunburn.(18) In addition, this thesis will have a particular focus on colorectal 
cancer as it is one of the most commonly diagnosed cancer worldwide and in 
Australia among both sexes, and there is existing evidence of independent 
associations with a high BMI and physical activity.(2, 3, 30) 
 
Objectives 
 
1. To investigate the independent association of physical activity with the risk 
of developing the most common cancers in men and women. 
2. To examine the independent association of body mass index with cancer 
risk incidence amongst males and females for the most common cancers. 
3. To evaluate cancer risk modification between physical activity and body 
mass (“fat but fit” hypothesis). 
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Methodology 
 
The framework that underpins the analyses undertaken in this thesis will further our 
understanding of the independent and interactive effects of physical activity and 
body fatness as important modifiable determinants of cancer risk. This research will 
rely on multiple datasets from observational studies to accomplish its objectives. 
Australian data will be extracted from the New South Wales (NSW) Cancer, 
Lifestyle and Evaluation of Risk Study (CLEAR) a case-control study and the Sax 
Institute’s 45 and Up cohort Study.(31, 32) The former study is an unmatched case-
spouse control design, while the latter is a population-based prospective cohort study. 
Additional data were obtained from the Copenhagen Male Study (CMS) and from 
the Danish Health Examination Survey (DANHES).(33, 34) The CMS is a cohort study 
which collected objective and self-reported measures of physical activity, allowing 
the assessment of physical activity, cardiorespiratory fitness and its interaction with 
BMI for particular cancer types through prospective follow-up.  
 
The concept of interaction and effect modification are often used interchangeably 
and are logically equivalent.(35, 36) However, some authors believe that there is a 
subtle distinction between those two concepts. Interaction is defined in view of the 
effects of two interventions while effect modification is described in terms of the 
effect of an intervention across strata of a second variable.(36) Interaction or effect 
modification can be assessed by the coefficient of the product term in regression 
models and are determined using different scales of risk; of which, the multiplicative 
and the additive are the most common. Interaction on a multiplicative scale is 
defined as “a different relative risk (RR) for factor A across strata defined by factor 
B”, while on the additive scale, interaction is defined as “a different risk difference 
(RD) for factor A across strata defined by factor B”.(37)  
 
The analytical implications of these two scales are not straightforward;(35) for 
instance, the additive but not the multiplicative interaction might be useful to detect 
synergy between factors as the former equates to tests for mechanistic interaction.(38) 
On the other hand, it has been suggested that it is not unusual for interactions to be 
closer to the multiplicative scale as summary models relate to population-average 
with risk ratios and odds ratios being less heterogeneous than the risk difference.(35) 
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Lastly, additive-risk models are not exactly the same as additive relative-risk models 
when the model includes product terms for confounding adjustment. In case-control 
studies unfortunately the additive relative-risk models can only fit, thereby rendering 
it difficult or impossible to make unconfounded assessments of risk additivity.(35) 
  
In all the epidemiological studies used in this thesis, “fat but fit” was 
methodologically evaluated by examining the interaction between body fatness and 
physical activity or cardiorespiratory fitness. Given the characteristic of the “fat but 
fit” hypothesis, it could be interpreted as a qualitative interaction, since exposure has 
a positive effect on a particular subgroup, whereas a negative impact on a different 
subgroup.(38) Additionally, qualitative interactions do not hinge on the scale used, as 
presence of the interaction on one scale is also present on the other scale.(38, 39)  
 
Throughout this thesis the multiplicative scale was used to examine the “fat but fit”; 
and it was considered statistically significant if it yielded a p-value below the 
proposed cut-off of 0.10.(35) This value was used to accept that the effect of physical 
activity or cardiorespiratory fitness differs on cancer outcomes among subjects with 
different levels of BMI or adiposity.(37) In addition, graphic display of stratum-
specific effect estimates and 95% confidence intervals was conducted in order to 
provide an overall understanding of the interaction since basing conclusions only on 
p-values can be deceptive since the statistical power to detect interactions is often 
low.(35)  
 
Outline of the thesis  
 
This thesis contains nine chapters, including an Evidence Check Review published 
on the Sax Institute website and three peer reviewed journal articles. Besides, a 
preliminary analysis of the “fat but fit” in the DANHES was incorporated in the 
appendix to further examine the intended objectives. Collectively, these chapters 
outline the scientific studies which underpin this thesis. 
 
Chapter 1 outlines the rationale for the thesis and establishes the need to examine 
cancer risk modifications given the increased prevalence of obesity and the potential 
role of physical activity in modifying the risk associated with a high body mass. 
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Besides, this chapter explains in more detail the statistical approach taken in 
assessing the “fat but fit” hypothesis. 
 
Chapter 2 describes how excess adipose tissue may have evolved in the current 
climate in which modern humans live and the potential factors implicated in its 
causation. It also presents global epidemiological trends of obesity, susceptible 
groups and its possible association with cancer risk. 
 
Chapter 3 provides a definition of physical activity and its multiple domains. It also 
highlights factors which can influence this behaviour and presents how physical 
activity is measured in epidemiological studies. In addition, benefits on different 
health outcomes are presented, in particular its links with cancer risk.  
 
Chapter 4 gives an account of the “fat but fit” from its inception as a concept and 
summarises the epidemiological evidence which have assessed this hypothesis on 
different disease processes.    
 
Chapter 5 is a published Evidence Check Review conducted in order to address the 
current state of the evidence for an association between cancer risk and obesity or 
physical activity. This report identified that further studies are needed to deal with 
gaps in the evidence, in particular with cancer risk modifications between those two 
behavioural factors. Suggested citation: Nunez C, Nair-Shalliker V, Sarich P, Sitas F, 
Bauman A. Modifiable lifestyle factors and cancer risk an Evidence Check rapid 
review brokered by the Sax Institute (www.saxinstitute.org.au) for the Cancer 
Institute NSW, 2018.   
 
In light of the paucity of information regarding the “fat but fit” in the cancer field, 
the following four chapters investigated this hypothesis using Australian and 
international epidemiological data. 
 
Chapter 6 assesses the main and interactive effects of body fatness and physical 
activity, using data from a case-control study (the NSW Cancer, Lifestyle and 
Evaluation of Risk Study). This epidemiological study collected data from more than 
10,000 participants, including 8,569 cases and 2,247 cancer-free controls. Cases and 
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controls are residents in NSW, Australia who were recruited during 2006-2014 
through (i) a targeted approach using health related databases and (ii) non-targeted 
approach at community events and oncology units. Cancer risk was estimated 
according to different sex-specific types of cancer.(31, 40)  
 
Chapter 7 focuses on colon and rectal cancers since the evidence associating these 
malignancies with excess body fat or physical inactivity is strong, especially with 
colon carcinogenesis. This chapter assessed the independent and interactive role of 
body fatness and physical activity in the Sax Institute’s 45 and Up cohort study. This 
population-based cohort study recruited more than 250,000 participants aged 45 
years and over in the state of NSW, Australia. Additionally, their data were linked to 
different administrative databases, including the NSW cancer registry. Recruitment 
of this cohort took place between January 2006 and December 2009.(41)  
 
Chapter 8 investigates the “fat but fit” on different cancer outcomes extracting data 
from the Copenhagen Male Study. This prospective study recruited more than 5,000 
middle aged men in 1970-71 who were followed up for almost 47 years. Participants 
were obtained from different companies including the Danish railroad, the Post and 
Telegraph, and the Danish Army. The interaction between body fatness and physical 
activity was assessed using objective measures for those behaviours as 
cardiorespiratory fitness and body mass index were determined in a physical 
examination.(42)  
 
Chapter 9 summarises the findings from the different studies conducted to achieve 
the objectives of this thesis, putting the results into perspective in the cancer field. 
Additionally, special consideration was given to limitations of the thesis and 
recommendations for future research.  
 
Appendix E is an additional pilot analysis which examines the independent and 
interactive effects of BMI and physical activity on the risk of several types of cancer. 
This preliminary analysis used data from the DANHES. This survey was established 
as a research database for cross-sectional or follow-up analysis. More than 75,000 
participants were recruited from 13 municipalities of Denmark over a period of a 
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year, allowing the assessment of the effect of physical activity across different levels 
of body mass “fat but fit”. 
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CHAPTER 2 
  
BACKGROUND ON OBESITY 
 
 
 
 
 
 
 
 
 
 
 
 
In the preceding section, an introduction to the thesis was outlined. This chapter will 
describe the main drivers which have influenced the obesity epidemic, populations 
with heightened risk and global trends of obesity. In addition, clinical and 
epidemiological measures of body fatness will be outlined and why excess adiposity 
poses a substantial biological risk for cancer incidence. 
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High body mass index (BMI), defined as being overweight or obese, is amongst the 
most pressing public health challenges in the 21st century not only for its rapid 
increase in prevalence, but also for its associated comorbidity and mortality.(1) The 
widespread presence of overweight and obesity has increased in most regions of the 
world, with more than 70 countries doubling their prevalence of obesity in the past 
few decades.(2) Global statistics on high BMI have consistently worsened, affecting 
more than 2 billion people, of which, more than 100 million children and 600 million 
adults are obese today.(2, 3) Thus, the public health implications of this trend for 
health, quality of life, productivity and health care costs are substantial. Overweight 
and obesity are major risk factors for an expanding set of non-communicable 
diseases, including cardiovascular conditions, diabetes mellitus, chronic kidney 
disease and cancer.(2) A high BMI contributed to 120 million disability-adjusted life-
years and 4 million deaths worldwide in 2015.(2) The total direct and indirect costs of 
obesity in Australia amounted to an estimated $8.3 billion in 2008.(4) Although 
obesity results from a chronic imbalance between energy intake and expenditure, the 
causes of its epidemic increase in prevalence are not fully understood. Potential 
drivers include changes in the global food system and a reduction of physical activity 
that interact with sociocultural, environmental, economic and individual factors.(3, 5) 
These complex interactions lead to a positive energy balance and subsequently 
weight gain. In addition, a systemic decrease in energy expenditure has also occurred 
in many countries. 
 
This chapter will provide a definition of obesity and present potential explanations 
for population increases in obesity. Additionally, populations at greater risk in 
Australia will be further discussed as well as the global magnitude of the obesity 
problem. Methods for measuring obesity will also be reviewed with a particular 
emphasis on BMI. Finally, the biological links between obesity and cancer will be 
appraised.    
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Obesity 
 
Obesity is defined as an accumulation of excessive adipose tissue that becomes 
dysfunctional with the capacity to impair health.(6-8) It is also a complicated and 
stigmatizing disease, which at its simplest level, develops from a chronic positive 
energy imbalance.(6, 9) The impact of obesity on health-related risks depends on the 
fat distribution, with excess abdominal adiposity associated with greater 
comorbidities and a stronger predisposing factor for several leading causes of 
mortality.(7, 10) 
  
Causes 
 
Obesity develops from the complex and dynamic interactions between proximal 
(nutrition and energy expenditure) and distal factors (culture and the built 
environment).(11) Amongst the proximal factors, the striking changes in global 
dietary patterns are considered the major drivers of the obesity epidemic.(12) The so 
called “nutrition transition” has virtually transformed the entire food system;(13) these 
changes appear to have stemmed from agricultural policies to secure food after the 
Second World War(14) and occurred from the 60s onwards in developed nations and 
more recently across developing regions.(12)  
 
Since then, these policies have promoted the overproduction of refined grains, sugars 
and fats which are the basic components of low-cost, highly-processed, nutrient-
poor, and high energy dense foods.(15, 16) The consumption of high fructose corn 
syrup (HFCS), a food additive, was reported to increase by 1,000% from 1970 to 
1990, and today comprises more than 40% of all the sugar substitutes added to food 
products and beverages.(17) Vegetable oil consumption has increased worldwide, in 
particular n-6 fatty acids.(12) This reliance upon nutrient-poor foods in the 
manufacturing processes is worrisome as a high intake of food additives have been 
associated with changes in body fat distribution and weight gain.(12, 18)  
 
Another important change that has taken place is the accessibility and affordability of 
high energy dense foods compared to quality whole-food diets, being a major 
contributor to the observed decrease in consumption of legumes, coarse grains and 
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other vegetables.(12) Besides, this increased availability of high-density foods can 
explain the excessive intake of energy-dense snacks and sugar-sweetened soft 
drinks.(19) The 2011-12 Australian Health Survey reported that Australians consumed 
an average of 60 grams of free sugars per day, of which, 86% was derived from 
“empty calories”, surpassing the 10% limit recommended by the World Health 
Organization (WHO).(19, 20)  
 
Larger portion size is an additional fundamental dietary change that has developed 
over the last four decades.(21) This trend is not only seen when dining out but also 
when eating at home.(21, 22) Obtaining the best value for money could underscore the 
increased display of larger portions, especially in fast food restaurants.(23, 24) 
Research has demonstrated that when presented with larger portions, humans have a 
predisposition to eat beyond requirements and consumption norms with a distortion 
towards high energy dense foods, impacting total energy intake.(21, 22)  
 
Lastly, a key component which adversely modified the food system has been market 
penetration and presence of supermarket companies.(12) As a result, the fresh food 
market is now disappearing as the major source of food supply, being replaced by 
large multinational chains in both developing and developed nations. Supermarkets 
account for more than 80% of retail food sales, allowing access to cheaper processed 
food with high fat and sugar content.(12)      
 
Distal factors that contribute to obesity comprise the social and the built 
environment. There is increasing evidence that the occupational and physical 
environment exert influences on the individual’s behavioural decision making, 
including choices which promote or discourage energy consumption and 
expenditure.(25, 26) Research into the US labour force has observed a decline in the 
prevalence of physically active occupations while a dramatic growth in service jobs 
has been noticed from the 60s onwards.(5) This change in occupations accounts for a 
decrease in daily energy expenditure, which has been estimated around 140 calories a 
day in men and 124 in women, being responsible for the increased weight gain 
observed in recent decades.(5) The built environment is a multidimensional concept 
that encompasses human activity in different man-made structures, ranging from 
urban sprawl and compactness (macro scale) to individual perceptions (micro 
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scale).(23, 27) The ways in which the built environment may influence obesity directly 
or indirectly result from the interactions between the individual and their 
surroundings. Some studies have reported that some characteristics such as higher 
residential density, street connectivity and mixed land use tend to influence a 
person’s chance of becoming obese possibly through increased daily physical 
activity. On the other hand, urban sprawl and socio-economically disadvantaged 
communities have been associated with an increased risk of obesity.(25) The 
expression “food desert” has been used to describe deprived neighbourhoods with 
limited access to nutritious and affordable foods since healthy food is expensive and 
relatively inaccessible.(28) Moreover, these disadvantaged neighbourhoods are 
characterised by a high presence of convenience stores and fast food outlets.(28) 
Studies of the built environment in Australia have observed that overweight and 
obese adults are more likely to live in suburbs which lack recreational facilities and 
footpaths, highlighting the need for interventions that reset environmental factors to 
promote healthy lifestyles.(25) 
  
Other factors which can influence obesity include iatrogenic or medically induced 
obesity and genetics; although the contribution of these two determinants to the 
overall population level is likely to be minor.(29, 33) Iatrogenic obesity as a side effect 
can be conducive to obesity in individuals with specific medical conditions and has 
been reported with the use of particular groups of medications, namely 
corticosteroids, antipsychotics, antidepressants and some antiepileptic and 
antidiabetic drugs;(29-32) the vulnerability to obesity and severity appear to be 
associated with long-term maintenance treatment programmes.(29) Recent systematic 
reviews noted that the prevalence of obesity is higher in psychotic patients managed 
with olanzapine and in epileptic patients.(29, 30) Additionally, antidiabetic treatment 
with insulin and sulfonylurea has been related to weight gain.(32) Genetic forms of 
obesity are mainly caused by a single gene mutation or chromosomal rearrangements 
which lead to early onset and are very rare in the general population.(6, 33) Genome-
wide association studies (GWAS) have identified almost 100 loci related to BMI and 
together they only explain less than 5% of the phenotypic variance in body mass. A 
crucial development of GWAS was the identification that most of these genes are 
expressed in the central nervous system, supporting the potential role of the brain in 
the aetiology of obesity.(33)  
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Vulnerable populations 
 
The increase in prevalence of obesity is not equally distributed across populations 
since there are some segments at greater risk than others. In the United States, 
susceptible communities include socially disadvantaged, immigrants and minority 
groups.(34) Obesity is an indicator of social inequality, at least in developed nations, 
where considerable evidence shows an inverse relationship between low 
socioeconomic status (SES) and increased body weight in women, while this 
socioeconomic gradient is less consistent in men.(34, 35) Socioeconomic inequalities 
may influence the individual’s risk of obesity, with people in less disadvantaged 
neighbourhoods usually reporting more healthy behaviours and healthier food 
choices.(23) On the other hand, high SES has been correlated with high levels of 
adiposity in developing countries and countries with transitional economies.(36, 37) 
Reasons for the increase in rates of obesity are the adoption of dietary patterns of 
affluent societies and decreases in energy expenditure associated with economic 
development and urbanization.(36) However, the notion of a direct SES gradient with 
obesity in emerging countries may be challenged in the near future as obesity is 
becoming a problem in low SES countries, particularly in women.(3) In Australia, 
similar results as those observed in countries with a high human development index 
are reported. In the National Health Survey 2014-15, women living in more 
socioeconomically disadvantaged areas were more likely to be overweight or obese 
than those living in least disadvantaged areas (61.1% vs 47.8% respectively), 
whereas there was no difference amongst men across different SES groups.(38) 
Additionally, overweight and obesity rates vary by measures of geographic 
remoteness using the Accessibility and Remoteness Index of Australia (ARIA+); 
adults dwelling in major cities are less likely to be overweight or obese compared to 
people living in the inner, outer regional or very remote areas.(38) Possible 
explanations for this pattern include a higher concentration of people of low SES, 
riskier health behaviours such as not meeting physical activity guidelines, inadequate 
diet; and disparities in access to healthy foods with higher prices for basic healthy 
foods due to transportation and overhead costs.(39, 40) Aboriginality has also been 
associated with higher rates of obesity in men and women compared to non-
indigenous people of the same age in Australia.(39) This is probably because their 
traditional diet, lifestyle and culture have been dramatically disrupted, exposing these 
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groups to an excessive consumption of high energy dense foods and low levels of 
physical activity.(41) Moreover, Aboriginal populations are more likely to be at the 
lower end of the socioeconomic spectrum, unemployed, and to have experienced 
food insecurity and inadequate housing resulting from cultural fragmentation, a 
consequence of colonization.(40, 41)  
 
Global trends 
 
Obesity was once thought to be confined to the Western world. However, its 
ubiquitous presence has now affected virtually all regions of the world. Figure 2.1 
shows the global changes in the prevalence of obesity among men and women in the 
last three decades; overall, the global proportion of obese men increased from 4.8% 
in 1980 to 9.8% in 2008, whereas this prevalence in women rose from 7.9% to 
13.8%.(42) The use of routine surveillance data in the United States has allowed to 
track historical trends in obesity rates. In 1960, the prevalence of obese adults aged 
20-74 years was 13.4%, this proportion modestly increased to 15% by the beginning 
of the 1980s, and then escalated significantly, doubling by the year 2000. From 2007 
to 2013, the reported prevalence of obesity plateaued and currently appears to be 
remaining stable at around 35%.(43) Increasing obesity rates have had an impact on 
all ethnic groups in the USA, but have been particularly great in African-American 
and Mexican American populations.(43) Another marked pattern from the 1980s 
onwards is the escalation in prevalence of extreme obesity, defined as a BMI ≥40 
kg/m2, from 1% to 5% in the USA.(43)  In Europe, the overall prevalence of obesity in 
2015 was estimated to be 14% in men and 11.5% in women, varying considerably 
between regions and countries. The lowest prevalence was observed in Western and 
Southern Europe and the highest in Northern Europe, 11.1% and 18.0% respectively. 
Among men, the highest obesity rate was reported in England (24.8%), followed by 
Croatia (23.3%) and Finland (21.9%); whereas in women, the countries with the 
highest prevalence were Croatia (19.9%), Latvia (18.3) and Romania (16.9%).(44) 
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Figure 2.1 - Global trends of obesity among men and women from 1980 to 2008. 
Adapted from Malik VS, Willett WC, Hu FB. Global obesity: trends, risk factors and 
policy implications. Nature Reviews Endocrinology. 2013;9(1):13-27. 
 
 
In less developed countries, obesity has emerged as a growing public health problem. 
The prevalence of obesity in Latin America has become a significant concern, with 
the 2014 rates of obesity being particularly high in Mexico (28.1%), Chile (27.8%), 
Panama (26.8%), Uruguay (26.7%) and Argentina (26.3%).(37) Projections of 
overweight and obesity in this world region are estimated to affect 50% of males and 
60% of females by the year 2030.(37) Obesity rates have also increased in most 
regions of Africa and Asia. The occurrence of obesity in Sub-Saharan African 
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countries in general shows a higher prevalence in women than in men;(45) only two 
countries in this area observed a prevalence of obesity greater than 10% in men, 
while 17 countries reported rates of obesity greater than 10% in women in 2010.(45) 
Plausible reasons for this marked difference in obesity between the sexes could be 
due to cultural perceptions towards obesity, as some women associate increased body 
size with beauty, healthiness, prosperity, strength and respect.(45) Furthermore, there 
is stigmatisation of thinness resulting from HIV infection, which could then play a 
role in the female perceptions of desirable body weight in this region.(45) The Middle 
East and North Africa regions (MENA) have also reported a dramatic rise of obesity 
rates, particularly in countries with upper middle and high income.(46) Research in the 
MENA region has estimated that the prevalence rate of obesity in its low to middle 
income countries is around 20.5%, 25.4% in upper middle; and 33.1% in high 
income.(46) Additionally, a higher proportion of obesity is more prevalent in urban 
areas and in women, perhaps due to factors related to cultural and religious 
practices.(46) Although the overall rates of obesity still remain relatively low in most 
regions of Asia, the reported prevalence of obesity has doubled in men and women 
from 3.3% to 6.8% in Eastern Asia in the last three decades.(47)  
 
In Australia, the prevalence of obesity almost doubled between 1980 and 2000.(48) 
According to the World Health Statistics published by WHO, the current prevalence 
of obesity in adults is 27.8%, being slightly higher in women than in men (27.9% and 
27.6% respectively).(49) Age-specific trends in BMI have also shown an increase in 
the prevalence of overweight and obesity amongst young Australians (5 to 15 years) 
with higher rates reported in boys of any age and younger girls.(50) Similar findings 
were presented in a study that examined survey data from 1985 to 2015, observing 
that obesity rates increased three-fold in boys and six-fold in girls during the last 3 
decades.(51) Furthermore, it was noticed in that study that the likelihood of being 
overweight or obese showed a strong socioeconomic gradient. Young Australians 
from low SES backgrounds had 77% increased odds of being overweight and 136% 
increased risk of developing obesity compared to those of higher SES. The limited 
available data on BMI in Aboriginal Australian children show that the combined 
prevalence of overweight and obesity is similar to that in non-Aboriginal children 
during the first years of life.(41) However, after the age of 10 years, this proportion is 
significantly higher among children of Aboriginal background compared to non-
24 
 
Aboriginal children (38.6% vs. 28.1% respectively).(41) This highlights that 
interventions are needed in the first 10 years of life to diminish or decelerate the 
elevated rates of high BMI in this group.(41) Examination of age-specific changes 
across the BMI spectrum indicates that the mean BMI in Australian adults has 
virtually increased in all age groups, particularly affecting men and women aged 20-
29 years with an absolute growth of 23% during 1980 to 2008.(52) Possible 
explanations for weight gain during this period involve moving away from the 
physical activity and diet structure offered by schools and parents to a less structured 
environment.(53) Patterns of BMI across the BMI continuum also underlines that BMI 
gain is different by sex and age groups. The increase in BMI in men is uniformly 
distributed across the spectrum whereas in women this pattern is stronger at the end 
of the BMI distribution, particularly for those younger than 39 years.(52) This study 
suggests that young adults who are either overweight or obese are gaining the most 
weight, leading to a greater exposure of excess adiposity during adulthood and a high 
cumulative risk of obesity-related diseases. This assertion is supported by a recent 
study that modelled obesity trends, predicting a sudden reduction in healthy BMI 
among young adults and a rapid increase in the prevalence of obesity within the same 
group.(54) Severe obesity, defined as a BMI ≥35 kg/m2 in this study, was projected to 
skyrocket from 5% to 13% within the next decade, impacting on a higher percentage 
of women than men (14.8% vs. 11.2%).(54)  
 
Rationale for using BMI to assess obesity 
 
Many different techniques have been developed to classify individual’s levels of 
body fatness although the assessment of body composition is challenging as it 
includes the quantification and comparison of different body constituents.(72) The 
five–level framework partitions the body into different structures, from atoms (Level 
I) to whole body (Level V).(55) However, the appraisal of body composition in the 
epidemiological setting is mostly ascertained at levels (IV and V). Level IV (Tissue 
Level) divides the cellular components into adipose tissue, skeletal muscle, organs 
and bone. Different techniques are utilised to determine these compartments, 
involving dual energy x-ray absorptiometry, bioelectrical impedance, 
hydrodensitometry, air displacement plethysmography, computed tomography and 
magnetic resonance imaging.(55) Limitations to these methods include costs, time and 
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operational requirements.(56) Level V (Whole body assessment) provides information 
regarding weight, height, waist circumferences and skinfold thickness which can be 
obtained through anthropometric methods.(55) Reported shortcomings of these 
measurements include lack of standardization and reference values for waist 
circumference and measurement errors for waist circumference and skinfold 
assessments.(56) 
 
Compartment models are another alternative approach to determine body 
composition. The one compartment model considers the body as a whole and 
assumes that the involvement of different tissues in body weight remains constant 
across different age groups, ethnicity and health status. BMI is an example of this 
model. The Multi-compartment model depends on different relationships between 
mass, volume and density, separating total body mass into fat mass and fat free 
mass.(55) While the accuracy of body composition assessment improves with the 
number of compartments considered; this requires increasingly complex methods, 
which can be expensive, introduce increased risks for participants and are generally 
of limited feasibility for large epidemiological studies.(55, 57) It is important to remark 
that there is no gold standard to evaluate body composition and BMI is the most 
commonly used anthropometric measure to identify individuals with excess adiposity 
for public health and epidemiological purposes as it is reproducible and feasible for 
large samples and population measurement.(58)  
 
The body mass index was developed by Adolphe Quetelet in the 19th century and 
was coined as BMI in 1972 by Ancel Keys.(59, 60) Quetelet’s studies on human growth 
led him to conclude that weight in kilograms divided by the square of height in 
meters was more stable than weight divided by height or the cube root of height.(60) 
Consequently, the WHO developed BMI cut-offs to classify levels that correspond to 
health risks for adults. These categories are as follows: underweight <18.5, healthy 
weight range 18.5 - <25, overweight ≥25 - <30 and obese ≥30 kg/m2. The obesity 
category can be further divided into class I ≥30 - <35, class II ≥35 - <40 and class III 
≥40 kg/m2.(7) The major shortcoming of BMI is that the actual composition of body 
weight and fat distribution are not accounted for, failing to discriminate well between 
major contributors to body composition.(55, 61) Besides, this index is less sensitive to 
classify people of short stature or the tallest individuals.(62) The use of the predefined 
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standard WHO BMI categories are not recommended in populations from South and 
East Asia since these populations tend to have a greater body fat percentage and 
increased morbidity and mortality than people of European ancestry with the same 
BMI value, limiting the generalisability of BMI as a measure.(43) As a result, the 
WHO expert consultation group recommends different BMI cut-offs in Asians. The 
suggested categories based on health risks are: <18.5 underweight, 18.5 - <23 
acceptable risk, ≥23 - <27.5 increased risk and ≥27.5 kg/m2 high risk. Another 
constrain of BMI is its limited ability to assess the causal contribution to disease due 
to lack of long-term follow-up since most epidemiological studies measure BMI near 
or at the time of diagnosis.(63) Although BMI is not a perfect measure, its correlation 
to body fat percentage is between 0.70-0.80(64) and it is generally useful for public 
health action as it broadly classifies populations at risk. Other advantages of BMI 
include the ease of deriving this index in the clinical and epidemiological research 
settings as well as enabling the comparison of overall adiposity levels between 
populations and the assessment of obesity-related health risks, despite its limitations 
as a marker of internal pathological processes.(7, 55, 65) 
 
Possible biology to explain the link between obesity and cancer risk 
 
Experimental, clinical and epidemiological evidence have linked high body mass 
with cancer. In fact, the International Agency for Research on Cancer (IARC), and 
the World Cancer Research Fund and the American Institute for Cancer Research 
(WCRF/AICR) have stated that there is sufficient evidence to connect increased 
body fatness as a risk factor for several types of cancer.(66, 67) A systematic update of 
the evidence for an association between obesity and the top 10 most common cancers 
in Australia found that there is convincing evidence for increased risk of developing 
cancers of the colorectal, liver and thyroid amongst both men and women. For sex 
specific cancers, obesity was convincingly associated with increased incidence of 
female postmenopausal breast and uterine cancer, and advanced prostate cancer in 
males. A detailed account of this evidence between BMI and the most common 
cancers in Australia is provided in chapter 5 (Evidence Check Review). The 
contribution of obesity to the cancer burden is estimated to be around 21% in the US, 
17% in the United Kingdom, 13% in Brazil, 11% in China and 19% in Australia.(67, 
68)  
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It is hypothesized that the secretory profile and the different cells within excess 
adipose tissue are involved in the diverse metabolic changes implicated in 
carcinogenesis (Figure 2.2).(69) Adipokines or substances produced and secreted by 
the adipose tissue have been identified as being involved in many protumorigenic 
pathways, entailing the suppression of apoptosis (programmed cell death), initiation 
of cell cycle progression and growth, angiogenesis and migration. For instance, the 
adipose-derived hormone leptin, through activation of its receptor OBRb, stimulates 
the activation of biochemical cascades, including mitogen activated protein kinase 
(MAPK), Phosphatidylinositol 3-Kinase (PI3K) and the Janus Kinase (JAK)/signal 
transducers and activators of transcription (STAT).(70)  These signalling pathways are 
thought to be key determinants of cancer cell growth, migration and survival as they 
are frequently altered in cancer.(70) Additionally, leptin promotes inflammation by 
triggering activation of monocytes and lymphocytes, creating an inflammatory 
environment which may foster formation of malignant cells.(67) In vitro studies have 
demonstrated that leptin is expressed and nurtures human survival of colon, breast, 
endometrial, pancreatic and prostate cancer cell lines, highlighting the involvement 
of this adipokine with the development of those cancers.(71, 72) Vascular endothelial 
growth factor (VEGF) is another adipokine connected with oncogenesis, in particular 
with tumour vascularization and metastasis, thereby ensuring nutrient and oxygen 
supply.(67) Other adipocyte-derived substances related to cancer processes are visfatin 
and resistin. While these bioactive products are less studied, they are assumed to 
imitate the effects of insulin signaling and to possess pro-inflammatory properties.(72, 
73) On the other hand, adiponectin, an adipokine whose production is usually reduced 
with excess adiposity,(72) has been shown to down-regulate cascade signalling 
implicated in cancer initiation.(67) Experimental studies have reported that 
adiponectin inhibits proliferation of cancer cells in the colon, prostate, endometrium 
and breast. Thus, this adipokine has been associated with a reduced risk for those 
specific cancer types.(67, 71) 
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Figure 2.2 - Adipose tissue secretome and its possible link with cancer. Adapted from 
Nimptsch K, Pischon T. Obesity biomarkers, metabolism and risk of cancer: an 
epidemiological perspective.  Obesity and Cancer: Springer; 2016. p. 199-217. 
 
      
Another factor in the association between excess body fatness and cancer is the low-
grade chronic inflammation that characterises the dysfunctional adipose tissue 
observed in obesity.(74) This chronic inflammatory state appears to originate from 
adipocyte expansion and results from the release of several proteins or pro-
inflammatory substances, including tumour necrosis factor alpha (TNF-α), 
interleukins (IL) and C-reactive protein (CRP);(67) these inflammatory factors have 
been connected with a protumorigenic environment, tumour progression and 
invasiveness through activation of different cellular signalling pathways.(71) In 
addition, people with excess adiposity have an impaired immune response, and are 
therefore more vulnerable to precancerous cells possibly due to a defective immune 
system of natural killer (NK) and cytotoxic CD8+ T cells.(67) Conditions of chronic 
inflammation have been linked to colorectal, prostate, hepatic cancer and 
oesophageal adenocarcinoma.(73, 75) Additionally, malignant cells may co-opt these 
inflammatory mechanisms to further assist tumour growth and invasiveness.(76)  
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The correlation between a high BMI and increased levels of insulin and insulin-like 
growth factors (IGFs) may also be implicated in the development of cancer. Insulin 
resistance is the result of multiple counterproductive responses which occur in 
obesity; these maladaptive modifications encourage the shifting from glucose use to 
storage and fat oxidation for energy in different metabolic processes.(69) 
Simultaneously, there is an overproduction of insulin to compensate for the increased 
level of glucose systemically and a deficient expression of insulin receptors substrate 
and intracellular signalling.(69) Thus, resistance to insulin is characterised by a 
persistent hyperinsulinemic state and increased levels of bioavailable IGFs.(69) These 
conditions, in turn, are known to be involved in several types of cancers, namely 
breast, pancreas, colorectal, liver, endometrium and prostate cancer.(67, 75, 77, 78) The 
mechanisms through which these substances can be associated with obesity-related 
cancers implicate activation of pathways that promote tumour inception, growth, 
multiplication, survival and aggressiveness.(67, 79) Besides, as neoplastic cells 
preserve their insulin sensitivity and dependence on glycolysis, these circumstances 
further enable cancer growth in conditions of hyperinsulinemia and allow the 
utilization of glucose for neoplastic metabolic processes.(67, 77) 
 
The effect of body mass on sex hormones is also likely to influence the relationship 
between excess adiposity and cancer risk. Obese adults display alterations in 
circulating concentrations of testosterone which differ by gender. In men, it 
contributes to low levels, while obese women possess high plasma testosterone.(80) 
This sexual dimorphism may be partially explained by changes in hormone secretion, 
metabolism, delivery and action at target organs.(81) Reduced sex hormone-binding 
globulin (SHBG) levels have been detected in both obese men and women. The 
putative mechanisms for this observation are attributed to increased circulating levels 
of insulin which inhibits synthesis of SHBG in the liver.(71) Another regulatory factor 
in SBHG synthesis is the secretion of luteinizing hormone, which is progressively 
reduced in obesity.(71) Excess adipose tissue is marked by overexpression of 
aromatase activity. As a result, obese men and women convert significant amounts of 
androgens into estrogens and possess elevated systemic and local levels of this 
hormone.(71) Estrogen and its receptor-α have been identified as a contributor to the 
onset of female breast and endometrial cancer since activation of this receptor 
stimulates cell proliferation, inhibits apoptosis and induces angiogenesis.(67, 69, 71) 
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Although systemic concentrations of androgen levels have not been regularly 
connected to prostate cancer, obesity has been linked to aggressive prostate 
neoplasia, with the suggested mechanism being the activation of androgen receptors 
independently of androgen levels by pro-inflammatory cytokines, IGF-1 and 
activation of different intracellular pathways.(67, 71)  
 
More recently, several different emerging mechanisms have been posited in the 
connection between obesity and cancer.(74, 82) These potential mechanisms involve 
adipose tissue in the promotion of hypoxic conditions and as a source of metabolic 
substrate for cancer cells.(74, 82) As the adipocyte expands, its interstitial oxygen 
tension decreases, inducing hypoxia and stimulating the hypoxia inducible factor-1α 
(HIF-1α). Under normal oxygen concentrations, this oxygen sensor deteriorates 
quickly. Conversely, hypoxic conditions stabilise HIF-1α and enable its 
accumulation.(74) Increased levels of HIF-1α have been associated with cancer cell 
metastasis, poor prognosis and stimulation of VEGF release.(67, 73) Excess adiposity 
may also provide more availability of free fatty acids (FFAs) which could potentially 
create a supportive metabolic environment for proliferation and survival of malignant 
cells.(67, 82) Cancer cells excel at the biosynthesis of FFAs, in part through activation 
of fatty acid synthase (FASN), a multi-enzyme that is not present in most normal 
tissues.(82) Finally, it has been postulated that adipose tissue has the ability to bio-
accumulate exogenous environmental carcinogenic products.(69) Thus, in an 
individual with excess adipose tissue dioxins, organochlorines and organic pollutant 
might be constantly released to the circulatory system, stimulating and promoting 
cancer in the specific target organ of those chemicals compounds.(69)  
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Summary 
 
Over the last few decades, there has been a rapid increase in the prevalence of 
obesity, which is the result of complex and dynamic interrelations between the host 
factors and the environment. Due to comorbidities associated with body fatness, 
including cancer, obesity is now a major public health concern. Understanding the 
different epidemiological risks of obesity allows for the identification and 
prioritisation of interventions to help reduce the associated burden of disease. While 
the specific mechanism driving the connection between obesity-related cancers is 
incompletely understood, it is likely that this relationship is the result of complex 
interactions among different organs and physiological or biochemical perturbations 
which interplay and act synergistically to create and sustain an environment that 
increases cancer risk.  
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CHAPTER 3  
 
BACKGROUND ON PHYSICAL ACTIVITY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The previous chapter highlighted the problem of obesity and its association with 
cancer risk. This chapter will focus on physical activity, the multidimensional aspects 
of this behaviour and its association with cancer. Additionally, prolonged sitting will 
be described as a possible risk factor independent from physical activity.    
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Physical activity is a health-related behaviour which presents a great deal of variation 
in human populations. It contributes to energy expenditure and to a wide range of 
health benefits.(1, 2) Physical activity research has associated physical inactivity, 
defined as not achieving 150 minutes of moderate activity or 75 minutes of vigorous 
activity a week, with increased risks of major non-communicable diseases and 
premature mortality.(2) To date, a wealth of knowledge has provided evidence that 
physical activity reduces the risk for cardiovascular disease, type 2 diabetes mellitus, 
and some types of cancer.(3) However, given the evidence of meeting guidelines of 
activity for health-enhancing benefits, the World Health Organization (WHO) has 
estimated that 23% of adults older than 18 years were physically inactive globally in 
2010, with women (27%) being more likely to report an inactive lifestyle than men 
(20%).(4) Physical inactivity accounts for more than 5 million deaths each year, 
leading the WHO to conclude that this behaviour is now nearly as important a 
modifiable risk factor for chronic diseases as tobacco and obesity.(5) The global 
economic burden associated with inactivity was estimated to be around $53.8 billion 
in 2013; of which, almost $10 billion was out of the pocket expense.(6) Emerging 
epidemiological evidence has associated sedentary behaviour or prolonged sitting 
with negative health outcomes, including all-cause, cardiovascular and cancer 
mortality in addition to incidence of some cardiometabolic diseases.(7) Thus, 
sedentary behaviour has come to light as a potential determinant of health,(7) but may 
not be independent of physical activity.(8, 9)   
 
This chapter will provide a conceptual definition of physical activity and its 
components. Next, factors which may influence or impact on this behaviour in adults 
are presented as well as the different methods used for measuring it in 
epidemiological studies. The benefits of physical activity will also be discussed with 
its probable cancer links. Finally, sedentary behaviour as an emerging risk factor will 
be appraised in conjunction with its possible association with cancer risk. 
 
 
 
 
 
 
41 
 
Physical activity 
 
Physical activity (PA) is defined as any bodily movement created by skeletal muscles 
which results in energy expenditure (EE).(10) Based on this broad definition, there is 
not a conventional way of categorising PA.(10) Some classifications consider where 
the activity takes place, and include specific domains such as: leisure, commuting, 
occupational and household chores. Leisure-time physical activity (LTPA) is 
hypothesised to play a major role in total PA as a person could potentially engage in 
up to a couple of hours daily. Nonetheless, this amount of time varies, competing 
with personal needs and interests.(11, 12) Exercise, as a concept, has been used 
interchangeably with PA and despite sharing common elements; it is a subcomponent 
of LTPA.(10) Exercise is characterised by repetition of a structured activity conducted 
over a prolonged period of time with the aim of enhancing and maintaining physical 
fitness, performance or health.(12) Commuting activity also contributes to total PA. A 
recent study using global positioning system and accelerometer data concluded that 
active transportation (walking, cycling and using public transport) can account for 
38% of the steps taken over a 7 day-period and 31% of EE during the same time.(13) 
The contribution of occupational and household activity markedly hinge on the 
cultural context as industrialisation and automatization have shifted the amount of 
hard physical labour required at work or home towards increasing time spent in 
inactivity and light activities.(14)  
 
Physical activity may furthermore be divided into levels of intensity from light to 
very vigorous. These categories are determined by the metabolic costs associated 
with a specific activity.(15) The usual measurement is the metabolic equivalent of task 
(MET) where one MET is equivalent to the consumption of 3.5 mL O2/kg/min. Thus, 
activities whose metabolic cost are between 1.6 to <3.0 are considered light, 
moderate between 3.0 to <6.0, vigorous between 6.0 to <9.0 and very vigorous 
intensity for those activities demanding at least 9.0 METs.(15) Very vigorous 
activities hardly ever take place in daily life and only apply in training and 
performance amongst elite athletes.(15)  
 
Other ways of categorising PA include structured and non-structured activities as 
incidental or purposive. Despite these acceptable methods for categorisation, the only 
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requirement to classify PA is that the grouping must be subdivided into mutually 
exclusive categories with the aim of providing epidemiological exposures that are 
practical to measure and may be of public health significance.(10)  
 
Physical activity has been an asset in human evolution as it conferred survival 
advantages in the hostile environment in which early hominids lived.(16) The spread 
of Homo sapiens demanded conditions of constant PA which are believed to be 
comparable to requirements of modern humans established by total daily physical 
activity levels (PAL). This ratio is explained as the total EE divided by the basal 
metabolic rate.(12, 17) The mean PAL of ancestral foragers has been estimated at 1.7, 
ranging from 1.5 to 2.1 whereas the minimal PAL value in inactive modern humans 
has been calculated around 1.1 to 1.2 and the maximal between 2.0 and 2.5. Despite 
these PAL similarities, most people, in the current world, do not need to undertake 
demanding physical activity as technology has substantially contributed to a 
reduction in energy expenditure.(12)  
 
Some of the technological advancements which have been influential in the decline 
in physical activity levels include motor vehicles and screen-based devices.(18, 19) 
Changes in patterns of car ownership and utilization have markedly shaped mobility. 
For instance, shopping habits in the 50s were performed on foot on a regular basis in 
the United Kingdom; by the beginning of the 80s, most of the shopping was done in 
a single stop in a large out of town mall designed to be easily accessible by 
automobiles.(18) Alongside, there has been an increased popularity of inactive forms 
of entertainment, such as TV viewing and home computer use. The amount of time 
spent on traditional TV viewing was on average 4.5 hours a day in the second quarter 
of 2017 in the USA.(20) While in Australia, time spent on live TV was almost 2.7 
hours a day according to the Australian Video Viewing Report in 2017.(21) These 
estimates do not include TV viewing via connected devices such as video on 
demand.(21) Thus, screen time has replaced time which can be devoted to PA, 
favouring a sedentary lifestyle.(10, 19) The reduction in PA has contributed to the rising 
burden of chronic conditions related to an inactive lifestyle which is considered the 
biggest public health threat of the current century.(2) 
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Factors related to physical activity 
 
Physical activity is a behaviour influenced by many conditions.(17) At the individual 
level, associated factors include: age, sex, ethnic background and genetics.(11, 12) 
National surveys performed across diverse income countries constantly outline a 
progressive decrease in PA levels from adolescence to senescence.(12) Several 
explanations have been proposed to explain this tendency, including deterioration of 
motor abilities, biological mechanisms and neurobiological changes.(12) Age-related 
deterioration in physical activity has also been documented in zoos and laboratory 
animals.(12) Gender differences have been observed in surveillance systems, with 
males appearing to be more physically active throughout life than females.(12) 
Reports of physical activity by ethnic groups are completely different when activity 
is captured with different assessment tools, showing how cultural beliefs and 
practices can affect this estimation.(12) For instance, in the United States, activity 
levels derived from questionnaires are usually higher in white females and males 
compared to Hispanics. Conversely, when accelerometry data were considered, there 
was not difference in activity levels between white and Hispanic women; and 
Hispanic males displayed a greater number of moderate to vigorous bouts than any 
other ethnic group.(12) Finally, genetics plays a role in the individual variability of 
PA. Genetic studies on familial aggregation suggest that the heritability of PA ranges 
widely between 0 and 60% in accordance with the method used to estimate activity 
and a greater percentage of PA variance is observed with the use of objective 
methods through accelerometry data.(22)  
  
A review of determinants (causal factors) and correlates of (factors associated with) 
PA in adults reported that educational attainment and social support are correlated to 
activity levels, whereas psychosocial circumstances such as self-efficacy, perceived 
fitness and intention to exercise are highly likely to influence this behaviour.(17) 
Working conditions including job demand, working hours and overtime negatively 
impact LTPA.(17) The built environment possesses a wide range of characteristics 
which are correlates of physical activity; associated factors include density, 
urbanisation, land use, street connectivity and walkability. On the other hand, 
determinants of overall PA encompass location of recreational facilities; and safety 
conditions from traffic and crime.(17) PA can also be influenced by policy 
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interventions from local to national levels since these interventions can have a 
lingering effect specially through transformation of the human environment.(17) In 
Australia, a study of different determining factors of PA concluded that a supportive 
physical environment is necessary to enhance PA participation, accompanied by 
complementary strategies that influence this behaviour.(23)  
 
Measurement of physical activity in epidemiologic studies  
 
Physical activity is not only quantified with the purpose of gauging its relationship 
with disease risk but also for population surveillance and intervention effectiveness 
assessment. These measurements can be conducted at the individual or population 
level; however, lack of a gold standard complicates the appraisal of PA.(24) 
Additional challenges involve the selection of an adequate assessment tool in free-
living conditions and the numerous health-related dimensions of activity which cover 
cardiorespiratory, body composition, muscle strength, endurance and flexibility.(10, 24) 
The selection of a PA instrument depends on its purpose, validity and reliability.(25, 
26) Validity denotes the degree to which the instrument measures what it is intended 
to appraise against an external criterion “gold standard” and reliability is the 
consistency of the instrument when it is administered repeatedly to the same 
individual.(24, 25)  
 
There are objective and self-report measures of activity; the former incorporates 
direct and indirect calorimetry, including doubly labelled water, isotope labelled 
bicarbonate, and movement monitors, whereas the latter comprises self-report 
questionnaires and diaries.(24) Direct calorimetry is considered the most accurate 
measure of EE and it is normally established under stable laboratory environment in 
a hermetic chamber.(24) Drawbacks of this method encompass the high cost, 
specialised personnel required to operate the equipment and the limited assessment 
of free-living activities outside the laboratory.(27) Indirect calorimetry estimates EE 
from substrate oxidation in the form of heat release; this method requires the 
measurement of oxygen consumption and carbon dioxide production.(24, 27) 
Participants are restricted to respiratory chambers where air is inhaled at controlled 
concentrations and differences in it allow the estimation of EE. The same as direct 
calorimetry, this technique does not accurately measure free living activities.(24) 
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Doubly labelled water (DLW), a form of indirect calorimetry, evaluates total EE. A 
single dose of deuterium (2H) and oxygen tracer (18O) isotopes is given and their 
elimination are monitored during 7 to 21 days to extrapolate EE.(24, 28) In spite of the 
fact that DWL provides a precise estimate of EE in unrestrained conditions, it does 
not provide information on PA patterns such as frequency, duration or intensity.(24)  
 
Other forms of objective PA measurements in free-living conditions include motion 
sensors (accelerometers, pedometers and wearable technology). Accelerometers 
ascertain frequency and accelerations of the body part to which the device is attached 
to by measuring uniaxial or triaxial planes;(24, 25) quantified data are presented in the 
form of counts and EE is calculated based on counts and regression equations.(29) 
These sensors record and supply information on multiple dimensions such as 
frequency, duration, intensity and patterns over long periods of time. However, 
information regarding the specific type of PA cannot be represented with those 
devices.(24) Furthermore, accelerometry data tend to underestimate EE.(24, 29) 
Compliance is another limitation owing to the fact that participants are required to 
wear the device for a minimum of 10 hours a day for 7 consecutive days to obtain 
reliable estimates.(30) Pedometers allow the quantification of steps and possess 
moderate ability to measure distance.(25) Therefore, their use is predominantly to 
assess walking. In addition, this device cannot provide precise estimates of EE since 
other lifestyle activities are not quantified and individuals with slow gait speed are 
problematic to evaluate as the vertical forces of the foot-strike are not sufficient to 
record a step.(24) The combination of different wearable devices has found 
applicability to overcome the limitations of utilising a single instrument and includes 
the use of physiological assessments, in particular heart rate, with motion sensors. A 
shortcoming of this approach includes the intricate analytical process associated with 
multi-sensor data and the lack of standards for monitor calibration, validation and 
applicability in public health.(30, 31) Other motion techniques can include radar 
tracking, cine photography and floor pressure-pad displacement although their 
applicability is limited as activities are confined to research settings.(1) 
 
Physical fitness such as cardiorespiratory fitness (CRF) is a physiological construct 
which relates to the ability to perform PA.(3) CRF is a major element of physical 
fitness and can be used as an objective proxy of current PA, in particular LTPA, with 
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more than 70% of CRF variation being accounted for regular activity patterns.(14) 
Maximal oxygen uptake or VO2 max can accurately ascertain levels of CRF by 
determining the maximum consumption of oxygen in the body during peak 
exercise.(24) VO2 max may not be feasible to measure in large epidemiological studies 
although it can be estimated by using the submaximal volume of oxygen which relies 
on heart rate and its linear correlation with exercise workload.(24) This method was 
used in one of the studies in this thesis (Chapter 8). Additionally, cardiac frequency 
can be utilised to assess EE through individual calibration curves between heart rate 
and maximal oxygen uptake. This algorithm is used in experimental facilities and 
free-living surroundings, providing precise estimates of PA.(24) 
 
Subjective measures of physical activity rely on self-report to capture patterns of this 
behaviour. PA is measured using questionnaires, diaries, logs or interviews.(25) 
Questionnaires differ significantly depending on the level of detail and intended use 
of the information from single-item questions to more complex questionnaires.(24, 32) 
Questionnaires have been developed to determine frequency, intensity and duration 
in different domains of activity although the appraisal of LTPA is often used as the 
most representative form of activity;(24) this representativeness is based on the 
decline of demanding occupational activities in modern societies.(3) Some surveys 
emphasise the time frame in which the activity pattern took place ranging from past 
week to lifetime history. Short frame questionnaires provide behavioural patterns 
which are less biased due to imprecise recall of the activity. However, they are not 
likely to capture usual pattern of behaviour due to recent illness or seasonality.(24) 
Diaries and activity logs require individuals to record their PA information. In the 
first method, participants are instructed to collect the description of the activity (time, 
intensity and type) during or immediately after it was performed while in the second 
type, activities are registered at the end of the day.(25) A limitation of diaries is the 
substantial participant burden on account of the data collection characteristics.(25) 
Subjective measures of PA reliably estimate levels of vigorous activity in young and 
healthy populations. However, the discrimination of this type of activity in women 
and the elderly may be poor as they obtain the majority of their PA from low 
intensity activities.(24) Moreover, subjective assessments are prone to subject’s biases 
such as imprecise recall and social desirability which can distort levels of PA and 
data recording.(1) As a result, PA behaviour is often overestimated particularly in 
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those individuals with low levels of activity than in those with regular patterns.(32, 33) 
Despite the limitations of subjective measures, PA researchers use these methods in 
large populations as self-report is usually validated against objective measures such 
as accelerometers and most are validated PA measures as well as the low operating 
costs and lack of technology required to capture the data.(32, 34)  
 
Benefits of physical activity   
 
The benefits of PA on health outcomes had long been recognised as far back as 3,000 
B.C identified in ancient Chinese writings although the quantification of its effects 
on health was only possible in the middle of the last century with the advent of 
modern statistics and epidemiological methods.(12, 35) The first scientific article, 
which supported the association of PA with coronary heart disease (CHD), was the 
London Bus Study.(12) In that 1953 study, higher deaths of CHD were observed in 
drivers of the London’s double-decker bus compared to bus conductors.(36) However, 
at that time, the findings were subject to great scepticism and Jeremy Morris had to 
replicate his research by comparing CHD risk in active postal service workers to 
more sedentary occupations, comprising clerks and telephone operators.(35) Professor 
Ralph Paffenbarger was another notable epidemiologist who helped advance PA 
research in the 1970s; his work mostly focused on the role of PA in mortality from 
cardiovascular disease (CVD).(37) Since then, a substantial accumulation of 
epidemiological and experimental data has associated low levels of PA with 
increased incidence of chronic conditions and premature mortality.       
 
Insufficient levels of PA have been associated with higher prevalence of classical 
CVD risk factors, including dyslipidaemia, type 2 diabetes mellitus (T2DM), 
hypertension, obesity and metabolic syndrome.(38) Data from observational studies 
and randomized controlled trials (RCTs) support that PA moderately modifies 
plasma levels of high-density lipoprotein (HDL) in normolipidemic and dyslipidemic 
individuals;(39, 40) situation which is favourable as an increase in levels of HDL 
appears to be related to a reduced risk of CHD and is a key component of predicting 
cardiovascular risk.(41) Conversely, evidence is less consistent and smaller in 
magnitude for an effect of PA on reducing other forms of cholesterol and 
triglycerides concentrations.(39) Most RCTs evaluating PA in the prevention or 
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treatment of T2DM have assessed this behaviour in addition to other lifestyle 
interventions. As a result, the independent effect of PA in RCTs has not been 
examined.(40) A fairly recent meta-analysis of more than 78 cohort studies found that 
engagement in any type of PA is essential for the prevention of diabetes with a 
reported risk reduction which ranged from 25% to 34%.(42) Additionally, PA or CRF 
have been associated with better prognosis of CHD in high-risk individuals with 
prediabetes or T2DM as these patients possess higher incidence of CVD risk 
factors.(38, 43) Thereby, PA is considered a central component in the treatment and 
management of diabetes.(43) Hypertension is one of the most important preventable 
contributors to disease and mortality. As a result, the relationship between PA and 
blood pressure (BP) has been evaluated in large observational and controlled 
intervention studies.(40) The general conclusion drawn from those studies is that PA, 
in particular aerobic exercise, lowers systolic and diastolic BP in individuals 
categorised as having hypertension stage 1 and 2.(39) Given that hypertension leads to 
increased risks of myocardial infarction, stroke, renal failure and premature 
mortality, regular PA is part of the first line in its management.(44, 45) 
 
Evidence for a contributory role of PA in weight loss and weight maintenance is 
strong. A Cochrane Review of 41 RCTs, with a sample size of almost 3,500 
participants categorised as either overweight or obese, concluded that PA alone 
resulted in significant weight loss although this effect was even stronger when a 
restricted diet was added to PA.(43) Additionally, regular PA was observed to be 
essential in maintaining weight after a substantial loss.(43) The National Cholesterol 
Education Program (NCEP) defines metabolic syndrome (MetS) as a clustering of 
three or more of the following conditions: abdominal obesity, elevated blood 
pressure, glucose and triglycerides; and reduced levels of HDL.(46) The relationship 
between Mets and PA has recently been examined in a meta-analysis of 17 cohorts 
with a sample of more than 60,000 subjects, noting that PA was related to lower risk 
of MetS in both men and women.(47) 
 
The effects of PA extend beyond the prevention of cardiometabolic disease since 
some research has documented that in high risk patients with heart failure (HF) or 
chronic kidney disease (CKD) regular PA improves CVD health and function.(38, 48) 
These findings translate into lower rates of hospitalization and mortality.(38) 
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Likewise, PA may be an optimal strategy to enhance outcomes in psychotic disorders 
such as schizophrenia as these patients are often obese and suffer from hypertension, 
dyslipidaemia and dysglycemia due to side effects of antipsychotics and lifestyle.(49) 
A recent meta-analysis of schizophrenic individuals concluded that moderate to 
vigorous PA reduced psychological distress, negative thoughts and improved 
functioning and cognition along with concurrent metabolic disorders.(43) Amongst 
older populations, PA has been linked to improvements in some domains of 
cognitive function, including attention and processing speed as well as prevention of 
muscle loss or sarcopenia and enhancement of mental health.(50) Systematic reviews 
on average have observed risk reductions between 20-32% for dementia, Parkinson’s 
disease and falls in older adults who were physically active compared to less active 
counterparts.(50)  
 
Along with morbidity risk, PA has consistently been shown to decrease the risk of 
mortality in the general and high-risk populations.(39) Recent reviews inferred that 
engagement in any level of activity was associated with a 20% reduction in 
mortality(51) and regular PA was linked to greater than 50% lower risks of death from 
any cause and CVD.(52) Risk reductions between 10% and 25% have been reported 
for premature mortality in healthy men and women or in high risk populations for 
every increase in 1 MET of CRF. (39, 51)  
 
Despite the overwhelming evidence linking PA with risk reductions for chronic 
conditions and mortality, an inactive lifestyle is highly prevalent in today’s society. 
According to the WHO, physical inactivity is a major leading cause of global 
morbidity and mortality with an estimated number of 1 in 4 adults not doing enough 
PA for health-enhancing benefits.(4) Epidemiological evidence supports that meeting 
physical activity guidelines have been associated with diminished risks for premature 
mortality, CVD, T2DM, MetS, depression and several other chronic conditions;(43, 53) 
with the greatest benefits being observed in inactive individuals who become more 
active.(35, 51) 
 
The protective effects of PA appear to be due to muscle influences upon different 
organs, plasticity and the secretory profile of muscular contractions.(54-56) As a result, 
the musculoskeletal system is being recognised as an endocrine organ. Substances 
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produced, expressed and released by muscles are termed myokines, which are small 
proteins and proteoglycan peptides with the ability to act in an endocrine, paracrine 
and autocrine manner.(54) The different changes which occur in the body in response 
to regular PA are believed to be multifactorial and comprise stimulation of anti-
inflammatory processes, neuro-hormonal, vascular and structural adaptations.(43, 54) 
Some of the reported modifications at the neuro-hormonal level involve changes in 
the adipose tissue and muscle which lead to increases in lipolysis, lipid oxidation, 
insulin sensitivity and glucose uptake.(43) While some vascular and structural 
adaptations include improvement of the endothelial function through enhancement of 
the endothelium-mediated vasodilation system, blood flow, increased fibrinolysis, 
capillarity and decreased platelet aggregation.(43) Decrease in DNA methylation and 
increase in gene expression in skeletal muscles have also been observed, particularly 
with regular aerobic exercise(57) as well as hippocampal volume increase which may 
help prevent age-related hippocampal deterioration and maintain neuronal health.(43)  
 
Physical activity and cancer 
 
Physical activity is an important modifiable predictor of cancer risk and cancer 
survival.(58) LTPA has recently been linked to a reduced risk of ten cancers in a 
pooled analysis of 1.44 million participants from 12 prospective studies. Cancers 
associated with PA included oesophageal adenocarcinoma, lung, kidney, myeloid 
leukaemia, myeloma, colon, head and neck, rectum, bladder and breast.(59) Based on 
leading cancer authorities including the World Cancer Research Fund (WCRF) and 
the International Agency for Research on Cancer (IARC), the benefits of PA are only 
convincing for colon cancer and probable for breast and endometrial cancer.(60-62) 
However, a recent Evidence Check of the association between PA and the most 
common cancers (chapter 5 of this thesis) reported that there is convincing evidence 
for an inverse association with cancers of the lung and colorectum in both men and 
women, and breast cancer among female-specific cancers. A detailed account of this 
systematic update of the evidence between PA and the most common cancers in 
Australia is provided in chapter 5. Besides, reviews of the available epidemiological 
literature challenge the categorisation of the evidence by cancer authorities. For 
instance, a recent review of the association between PA and breast cancer concluded 
that PA convincingly reduces risk of breast cancer.(61) A review by Emaus et al.,(63) 
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inferred that the majority of studies assessing the effect of PA on lung cancer risk 
support a role of PA in lowering the risk between 20-30% in women and 20-50% in 
men. The authors also observed an inverse graded dose-response relationship which 
did not differ by sex or location where the study was conducted.(63) 
The multifactorial aetiology of malignant neoplasms and their long latency may 
challenge the individual effects of physical activity on cancer risk.(64) The 
hypothesised molecular mechanisms connected with carcinogenesis involve sex 
steroid and metabolic hormones, inflammation, the immune system, optimization of 
DNA repair and oxidative stress.(58, 64-66) Figure 3.1 shows the level of evidence 
associated with the possible cancer pathways. RCTs investigating biomarkers 
connected to cancer risk have reported that aerobic exercise reduces oestradiol and 
free oestradiol; hormones which have been involved in breast cancer oncogenesis.(64) 
PA has also an established effect on increasing insulin sensitivity and diminishing 
insulin growth factor 1 (IGF-1).(66) These substances have been implicated in several 
cancers including colon, endometrium and ovaries.(64) The anti-inflammatory effect 
and the enhanced immune function of PA are proposed pathways which are gaining 
more strength in their association with cancer risk as these mechanisms could 
potentially have anti-tumorigenic implications. However, exercise interventions have 
provided inconclusive evidence on reductions of inflammatory biomarkers.(64) Given 
the numerous suggested mechanistic pathways of PA, it is possible that each 
molecular mechanism might hence downregulate cancer specifically or act 
synergistically to impact cancer risk.  
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Figure 3.1 - Supporting evidence of the different effects of physical activity on cancer 
risk. Adapted from: Cancer, physical activity, and exercise. Brown JC. et al., 2012. 
Sedentariness (sitting time) 
Sedentary behaviour is the engagement in low energy cost activities generally below 
1.5 METs during the waking day, mostly involving sitting or lying down.(15, 30) 
Sedentary pursuits could be classified at the lower extreme of the PA continuum. 
However, emerging evidence suggests that this behaviour might possess detrimental 
health consequences which are partly distinct from insufficient PA.(12) Therefore, for 
the remainder of this thesis it will be considered an independent behavioural risk 
factor. The modestly negative effects on health outcomes are ascribed to large 
amounts of time spent on sedentary pursuits. However, the underlying pathological 
mechanisms are not fully understood. Therefore, the term “inactivity physiology” has 
been coined to refer to a series of responses that may occur after muscle inaction 
observed in animal models and several epidemiological studies.(67) The observed 
reactions in postural muscles during periods of prolonged sitting involve a decrease 
in capillary lipoprotein lipase (LPL),(68, 69) which may consequently result in reduced 
local uptake of plasma triglyceride, cholesterol, and defective glucose or fatty acid 
metabolism.(12, 68) Additionally, a recent study found that sedentariness was 
associated with anomalous mitochondrial functioning and chemical reaction 
(dysregulation of cellular redox), and chronic inflammation independently of age.(70) 
This reduced mitochondrial capacity can create intracellular conditions which alter 
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the intracellular levels of reactive oxygen species (ROS) toxicity, precipitating 
susceptibility to accelerated cellular senescence and cell death.(71) 
Factors which heavily influence sedentary behaviour include: unemployment, 
technological advancements, the built environment, aging and high educational 
attainment.(72, 73) Four decades ago, 2 in 10 American employees were in desk-bound 
jobs, by 2000, this ratio increased to 4 in 10.(16) Clerical work accounts for 77% or 6 
hours a day in sedentariness, being the major contributor to total sedentary time in 
office workers.(72) Transport related sitting time is commonplace as it has been 
documented that 86% of people in the United States and 78% of people in Australia 
utilise their cars as the predominant means of commuting with an average of 56 
minutes a day in the American adult population and around 120 minutes for people 
dwelling in the greater Sydney area.(72) Larger TV screens and number of computers 
also display positive correlations with home-based screen time,(73) whereas higher 
educational attainment has positively been associated with total work-related sitting 
time and low level of education associated with more time spent on TV viewing.(72) 
Prolonged sitting and its link with cancer 
Although research into sedentary behaviour and cancer risk is a relatively new field, 
the body of evidence supporting an association with specific types of cancer is 
growing. For instance, a meta-analysis conducted in 2014,(74) including 43 
epidemiological studies, found that the highest category of sedentary behaviour 
compared to the lowest was associated with increased cancer risk of the colon, 
endometrium and lung. As physical activity represents a potential confounding factor 
of sedentary behavior in the relation with cancer, the authors used risk estimates that 
were adjusted for physical activity in their meta-analysis when available. 
Additionally, this study reported higher risk for colon and endometrial cancer when 
TV viewing was the only domain considered in stratified analyses. Several reasons 
have been proposed for the increased risk associated with TV viewing and include 
accompaniment of unhealthy diet and smoking initiation.(74) A recent update of the 
evidence examining the potential link between prolonged sitting and cancer risk 
concluded that there is some evidence for a relationship with endometrial and 
ovarian cancer. The reported increased risk for these malignancies was around 36% 
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and 32% respectively.(75) Besides risk of cancer incidence, the authors noted 
increased risk for all-cancer mortality (13%) and colorectal cancer-specific mortality 
(38%). Probable evidence was reported for breast, colorectal and lung cancer 
incidence.(75) Chapter 7 of this thesis examined the association between total sitting 
time and the risk of developing colon or rectal cancer in a large prospective cohort 
study as previous research has suggested an increased risk for colon cancer. 
However, findings from this study observe no effect of sitting time on colon or rectal 
cancer risk.(76)   
The hypothesised pathways of sedentary behaviour and cancer are believed to be 
independent of excess adipose tissue and their contributions to carcinogenesis 
may be cancer-specific (Figure 3.2).(75, 77) Prolonged sitting has been associated 
with higher levels of estrone and estradiol. Exposure to high circulating levels of 
these sex hormones may increase the risk of hormone dependent cancers.(75) 
Additionally, long periods of sedentary behaviour have been related to increase 
metabolic biomarkers of insulin resistance, hyperglycaemia and inflammation. 
These conditions are known for inducing cell proliferation and inhibition of 
programmed cell death, favouring carcinogenesis.(75) Vitamin D deficiency is 
another pathway through which sedentary behaviour might be linked to cancer 
as it has been proposed that sedentary individuals may have inadequate 
sunlight exposure.(77) Vitamin D plays important roles in different cellular 
processes including cell regulation, proliferation and apoptosis. Nevertheless, 
the connection with prolonged sitting is limited based on current epidemiological 
studies.(77)  
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Figure 3.2 - Hypothesised mechanisms of sedentary behaviour and cancer risk. 
Adapted from: Sedentary behaviour and cancer: A systematic review of the literature 
and proposed biological mechanism. Lynch B. 2010. 
 
Summary 
 
Physical inactivity is now considered a leading factor for global health in the 21st 
century and its harmful consequences are strongly evidence-based. Physical activity 
was once necessary for human existence, whereas now it has been reduced to a 
personal choice. As any behaviour, physical activity poses challenges to accurately 
capture it and its patterns. Additionally, sedentary behaviour has come to light as a 
potential risk factor for several diseases, including cancer. The detrimental effects of 
prolonged sitting on health outcomes might be independent from not meeting 
physical activity guidelines. Therefore, physical activity and (possibly reducing time 
spent on sedentary pursuits) should be emphasised in public health and clinical 
medicine to decrease the burden of non-communicable diseases, including cancer.  
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CHAPTER 4 
 
FAT BUT FIT 
 
 
 
 
 
 
 
 
 
 
 
 
 
The previous chapter underlined the importance of physical activity and its health-
enhancing benefits, including cancer prevention. This chapter is a narrative review 
that provides a summary of the current state of knowledge on the “fat but fit” 
hypothesis on different health outcomes. Additionally, it presents possible biological 
mechanisms through which there may be a reduced risk for several major non-
communicable diseases, potentially including cancer.  
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Fat but fit hypothesis 
 
The “fat but fit” hypothesis was first reported in two studies from the Aerobics 
Center Longitudinal Study (ACLS) almost two decades ago.(1) In those studies, high 
levels of cardiorespiratory fitness attenuated or perhaps even eliminated all-cause 
and cardiovascular mortality risk associated with a high body mass measured by 
body mass index (BMI) or body fat percentage (BF%) in men.(1, 2) A summary of the 
cardiovascular findings are shown in Figure 4.1. Additionally, these two pioneer 
studies observed that unfit males had increased risk of all-cause and cardiovascular 
mortality irrespective of their body composition; further adjustments for smoking, 
alcohol consumption and parental history of ischemic heart disease did not modify 
the effect estimates.(1, 2) Even though the landmark studies consisted of only men, 
replication of these analyses in women, using cardiorespiratory fitness (CRF) or 
physical activity (PA), found that fit or physically active women with excess adipose 
tissue ascertained by BMI, BF% or waist circumference had no increased risk of 
death compared to fit or physically active females with a healthy body weight.(3, 4) 
Thus, this seminal work initially proposed that low CRF or physical inactivity are a 
potentially greater public health threat than excess body fatness(4, 5) and secondly, 
that stratification of body composition by levels of CRF or physical activity allows 
for a more robust analysis than just adjustments for either variable alone.(3) 
 
To date, studies on the “fat but fit” hypothesis have mostly given prominence to all-
cause or cardiovascular disease mortality as end points.(2, 6-16) However, this 
hypothesis has also been observed for incidence of cardio-metabolic conditions. For 
instance, the subsequent risk of cerebrovascular accident (ischemic or hemorrhagic) 
amongst men aged 18 years, in a national Swedish cohort of more than a million and 
a half participants, was very similar between overweight/obese men with high 
aerobic capacity and normal weight men with low aerobic capacity. The respective 
risks were 1.65 95% CI: 1.46-1.85 and 1.66 95% CI: 1.56-1.76 in comparison to 
normal weight men with high aerobic capacity.(17) On the other hand, it was noticed 
that overweight/obese participants with low aerobic capacity had double the risk of 
developing stroke later in life than normal weight men with high aerobic capacity.(17) 
In addition to stroke, “fat but fit” has been reported for coronary heart disease 
(CHD); Lee et al.(18) in their study concluded that the associated increase in risk with 
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body fatness appeared to be attenuated when fitness was maintained or enhanced. 
Similar findings were observed in a Dutch cohort in which overweight and obese 
participants with high levels of PA had no different risks of cardiovascular disease 
than normal weight individuals with high activity.(19) Conversely, participants with 
low levels of activity were at increased risk, particularly if they were defined as 
overweight or obese.(19) A recent systematic review and a meta-analysis advocates 
for the engagement of PA or fitness to lower the risks of cardiovascular disease, all-
cause and cardiovascular mortality independent of weight loss.(16, 20)  
 
 
Figure 4.1 - Summary of cardiovascular mortality in men based on the pioneer studies 
on the “fat but fit” hypothesis; (A) from Wei et al and (B) from Lee et al. Adapted from 
Obesity and cardiovascular disease. Ortega et al. Circ Res. 2016;118(11):1752-70. 
 
This chapter is a systematic narrative review which presents a detailed inventory of 
the epidemiological studies that have assessed the “fat but fit” hypothesis shown in 
Table 4.1; and particularly summarises finding for those studies that assessed “fat but 
fit” and cancer incidence. The comprehensive search strategy was carried out on 
Medline electronic database and was complemented by scanning the reference list of 
identified studies. The following keywords were used: (body weight OR obesity OR 
body size OR body mass index OR fatness) AND (physical activity OR physical 
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fitness) AND (diabetes mellitus OR heart diseases OR neoplasms) AND adults. To be 
included in this literature review, studies had to be in English and conducted in humans. 
The inclusion criteria included: (i) unique research articles from inception of the “fat but 
fit” concept until 2018 and (ii) results scrutinised the interaction effect between physical 
activity or fitness and obesity on the incidence or mortality from cardio-metabolic 
outcomes or cancer. 447 articles were identified after excluding duplicates and 53 met 
the inclusion criteria. The search process is provided in a Prisma Flow Diagram (Figure 
4.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 - Prisma Flow Diagram of the different phases of the “fat but fit” systematic 
review. 
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Summary 
 
The “fat but fit” hypothesis was first reported almost two decades ago and postulates 
that physical activity or cardiorespiratory fitness is important for maintaining a 
favourable cardiometabolic profile, independently of obesity. To date, a total of 53 
studies were identified to have investigated this hypothesis; 49 cohort, 1 cross-
sectional and 3 case-control studies. From those epidemiological studies which 
provided enough data, including 95% confidence intervals (CIs) to draw a 
conclusion, “fat but fit” was observed in 13 out of 17 studies on all-cause mortality 
and in 6 out of 10 studies on CVD mortality. However, 53% of those studies used 
data from the ACLS or the Cooper Center Longitudinal Study as it was later 
renamed, followed by 13% from the Veterans Affair Medical Centers or the National 
Health and Nutrition Examination Survey (NHANES); and 21% from the Lipids 
Research Clinics Study, the European Prospective Investigation into Cancer and 
Nutrition (EPIC) and the The Nord-Trøndelag Health Study (HUNT study). 
Regarding cardio-metabolic diseases, 4 out of 15 studies supported the “fat but fit”; 
reduced risks of diabetes and CVD events were the most common outcomes with the 
majority of those studies (50%) utilising data from the ACLS, followed by 25% from 
the EPIC or Rotterdam study. Although not all the “fat but fit” studies observed that 
physical activity or cardiorespiratory completely negates the health consequences 
related to obesity, the general consensus appears to be that higher levels of physical 
activity or fitness offset some of the elevated all-cause, cardiovascular mortality risk 
and minimises some cardiometabolic disease risk attributed to excess adiposity. This 
inference is promising given the continuous rise in obesity prevalence and the 
increased cancer risk that excess adiposity carries. However, this hypothesis is not 
well examined in the cancer epidemiology field.  
      
Given the global burden of cancer, the “fat but fit” hypothesis has not been 
investigated as much in the cancer field as there are very few studies assessing it.(21-
25) Below are described the four studies that have examined the “fat but fit and cancer 
incidence.  
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A population-based case-control study in Shanghai, China examined the interaction 
between commuting physical activity and BMI on colon cancer risk.(21) The study 
population consisted of 931 incident cases and 1,552 controls aged between 30-74 
years, residing in 10 districts of metropolitan Shanghai. Cases were identified by the 
Shanghai Cancer Registry and included similar numbers of females and males (469 
women and 462 men) whereas controls were randomly selected from the Shanghai 
Resident Registry. BMI was calculated from self-reported height and weight and 
participants were grouped into quintiles based on the BMI distribution of male or 
female controls as analyses were sex-specific. PA was derived from the metabolic 
cost associated with self-reported lifetime history of commuting and leisure time 
(LTPA). Study participants were categorised as low, medium or high. Levels of PA 
for active commuting were much higher than for LTPA; the respective cutoffs for 
commuting PA were: <48.3, 48.3 - <94.3 and 94.3 METs-hours/week whereas for 
LTPA were: <9.2, 9.2 - <13.6 and 13.6 METs-hours/week. Hou et al. found that 
commuting PA was the only domain associated with a reduced risk of colon cancer 
irrespective of sex. Thus, the “fat but fit” was only assessed with commuting PA.(21) 
In their interaction analysis, men and women in the highest quintile of BMI with high 
commuting PA completely offset the risk of colon cancer in comparison to the 
referent group (lowest quintile of BMI with high commuting activity). The respective 
odds ratios (ORs) were: 1.22 95% CI: 0.57-2.13 and 1.17 95% CI: 0.70-1.89. On the 
other hand, men and women in the highest quintile of BMI with medium or low PA 
had a significant increase in risk of developing colon cancer which ranged between 
two and seven-fold in comparison to the leanest with high PA. As a result, the 
authors concluded that high levels of PA performed over a long period of time 
modifies the risk associated with a greater BMI.(21) It is worth mentioning that the 
lowest level of commuting PA in this study population is high, being equivalent to 1 
hour a day of vigorous activity and the highest quintile of BMI was not that high. 
 
The work by Larsson et al.(22) explored the “fat but fit” and the risk of colorectal 
(CRC) adenocarcinomas in the Cohort of Swedish Men (COSM). This study 
comprised more than 45,000 men aged 45-79 years who were recruited in 1997; 
during follow-up, 496 cases of CRC were identified in the Swedish cancer registry. 
Information regarding different domains of PA in the year prior to recruitment was 
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gathered with a questionnaire. Total LTPA was determined by adding daily time 
spent on walking, cycling or doing exercise and BMI was calculated from self-
reported weight and height. In this cohort, LTPA was the only activity associated 
with CRC risk(22) so the interaction simply assessed LTPA and BMI. Although this 
interaction did not reach statistical significance (p-interaction = 0.33), Figure 4.3 
shows that the gradient of CRC risk diminished with increasing levels of activity, 
across all levels of BMI.   
 
 
Figure 4.3 - Multivariate hazard ratios of CRC by LTPA and BMI. Adapted from: 
Physical activity, obesity, and risk of colon and rectal cancer in a cohort of Swedish 
men. Larsson et al. 2006. 
 
“Fat but fit” results for female specific cancers have been reported in two studies. 
McCullough and et al. (23) assessed this interaction on breast cancer risk. This study 
used data from the US Long Island Breast Cancer Study Project (LIBCSP) which is a 
population-based case-control study. The sample population consisted of 1,504 cases 
and 1,555 controls. Cases were incident primary in-situ or invasive breast cancer 
aged between 20-98 years while controls were women without a history of breast 
cancer. Different measures of body size were self-reported and included weight gain 
and BMI. Recreational physical activity (RPA) was captured through a questionnaire 
and participants were allocated to low or high RPA based on the median response of 
controls.(23) Interaction was only significant between RPA and weight change, 
70 
 
leading the authors to conclude that women who participate in high levels of activity 
modify risk associated with weight gain.  
 
Conroy et al.(25) investigated the interaction between PA and BMI on endometrial 
cancer risk, using data from the Women’s Health Study (WHS). This prospective 
cohort recruited more than 30,000 relatively healthy females aged 45 years and over. 
PA and BMI were captured by self-report. Women’s response to different groups of 
activity were classified based on the energy cost of those activities as: inactive (<15 
MET-h/week) or active (15 MET-h/week). The authors observed that women who 
were both inactive and had a high BMI were at slightly increased risk than those who 
were active and had a high BMI compared to active women with a healthy BMI; the 
respective relative risks were 1.85 95% CI: 1.26-2.72 and 1.60 95% CI: 1.01-2.54. 
On the other hand, normal weight and inactive women were not at increased risk of 
endometrial cancer RR 1.17 95% CI: 0.77-1.77.(25) 
 
Byun et al.(24) examined the “fat but fit” hypothesis and the risk of incident prostate 
cancer, using data from the Aerobics Center Longitudinal Study (ACLS). In this 
study, 19,042 men were followed up for an average of 9.3 years in which 634 cases 
of prostate cancer were accrued. BMI and CRF were determined at baseline through 
a medical examination. CRF assessment was based on a maximal treadmill exercise 
test using a protocol; participants were defined on the specific distribution of the 
treadmill duration as: low (below the 20th percentile), moderate (between the 20th and 
40th percentile) and high fitness (above the 40th percentile).(24) The authors stated that 
in their interaction analysis obese participants with moderate and high CRF offset 
prostate cancer risk.(24)   
 
Possible physiology related to the “fat but fit”  
 
This section describes some of the potential mechanisms for the “fat but fit” 
hypothesis. Adipocytes or fat cells have an exceptional ability to expand so as to 
stockpile large amounts of lipids; however, this innate characteristic has a saturation 
point and when it is reached, fat becomes toxic in non-adipose cells, resulting in 
lipotoxicity (cellular dysfunction and death).(26-28) Therefore, adipose tissue (AT) 
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stores lipids for the positive advantage associated with its energy value and for the 
negative metabolic consequences of excess cellular lipid.(26) In conditions of excess 
adiposity, particularly visceral, AT becomes hazardous since this organ produces and 
secretes substances known as adipokines which affect the metabolic health, leading 
to increased inflammation, insulin resistance, angiogenesis, endothelial dysfunction 
and lipid disorders.(29) Regular PA or high CRF has been proposed to activate 
mechanisms that counteract these metabolic disturbances and promote a favourable 
metabolic profile irrespective of weight loss.(30) As a result, “fat but fit” individuals 
do not exhibit high levels of inflammatory markers and metabolic abnormalities such 
as: insulin resistance, dyslipidemia, hyperglycemia, and large deposits of ectopic 
fat.(31, 32) Additionally, adiponectin concentration has been reported to be within the 
same range as lean subjects in those considered “fat but fit”.(33) This phenotype may 
be an important feature as elevated plasma adiponectin concentrations are associated 
with reductions in obesity-related metabolic derangements and complications.(34) 
Thus, CRF or PA may confer and explain the beneficent metabolic profile observed 
in those who are “fat but fit”.(35, 36) 
 
Given the role that PA activity plays in maintaining a healthy metabolic profile 
independently of adiposity and the strong relationship between obesity and cancer, in 
particular its metabolic disturbances, as described in chapter 2. An insight of cancer 
risk modification between body mass by levels of PA or CRF is of public health 
significance since these two factors have been independently associated with cancer 
risk and contribute substantially to the global burden of cancer.(37) 
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Table 4.1 - Studies which have assessed the “fat but fit” hypothesis. 
 
Outcome Study type and population Main findings (Fat but fit) Comments 
All-cause mortality    
Lee et al. (1999)(1)  Prospective observational 
data from the Aerobics 
Center Longitudinal Study 
(ACLS). Participants: 
21,925 adult men (age 30-
83 years). During a mean 
follow-up of 8 years, there 
were 428 deaths. 
Lean – fit  
Lean – unfit 
Normal – fit  
Normal – unfit  
Obese – fit  
Obese – unfit  
1.00 (reference) 
2.07 (1.16-3.69) 
0.80 (0.59-1.08) 
1.62 (1.15-2.30) 
0.92 (0.65-1.21) 
1.90 (1.39-2.60) 
Cardiorespiratory fitness (CRF) 
was determined by a maximal 
exercise test on a treadmill and 
subjects were classified 
according to their fitness levels 
as fit (above the 20th percentile) 
and unfit (below 20th 
percentile). Body fat percentage 
(BF%) was derived from 
objective anthropometric 
measures and participants were 
categorised as lean (<16.7), 
normal (16.7 - <25) or obese 
(25 BF%). 
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Wei et al. (1999)(2) Prospective observational 
data from the ACLS. 
Participants: 25,714 adult 
men (mean age 43.8 
years). There were 1,025 
deaths during a mean 
follow-up of 10 years.  
Healthy BMI – fit  
Healthy – unfit  
Overweight – fit  
Overweight – unfit  
Obese – fit  
Obese – unfit  
1.00 (reference) 
2.20 (1.80-2.80) 
1.10 (1.00-1.30) 
2.50 (2.10-3.00) 
1.10 (0.80-1.50) 
3.10 (2.50-3.80) 
 
CRF was determined by a 
maximal exercise test and 
subjects were classified 
according to their fitness levels 
as fit (2 to 5th quintile) and unfit 
(1st quintile). Body mass index 
(BMI) was measured, and 
participants were assigned 
according to WHO categories. 
Stevens et al. 
(2002)(38) 
Prospective observational 
data from the Lipids 
Research Clinics Study 
(LRCS). Participants: 
2,506 women and 2,860 
men from 8 states of the 
United States; mean age 
of 46.6 years in women 
and 45.1 in men at 
baseline. There were 
1,166 deaths. 
Women 
Not fat – fit  
Fat – fit  
Not fat – unfit  
Fat – unfit  
 
Men 
Not fat – fit 
 Fat – fit  
Not fat – unfit  
Fat – unfit 
 
 
 
1.00 (reference) 
1.32 
1.30 
1.57 
 
 
1.00 (reference) 
1.25 
1.44 
1.44 
 
Confidence intervals 
were not provided.  
 
CRF was assessed using a 
treadmill test and BMI was 
calculated from measured 
height and weight. The 1st 
quintile of fitness was defined 
as unfit and the 2-5th quintile 
was considered fit whereas the 
1-4th of BMI was grouped as no 
fat and the 5th quintile was 
defined as fat. 
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Stevens et al. 
(2004)(6) 
Prospective observational 
data from the LRCS. 
Participants: 1,359 
Russian men and 1,716 
US men aged 40-59 years 
at baseline. There were 
460 deaths in the US 
cohort and 211 deaths in 
the Russian cohort. 
Russian men 
Not fat – fit 
Fat – fit  
Not fat – unfit  
Fat – unfit  
 
US men 
Not fat – fit 
Fat – fit  
Not fat – unfit  
Fat – unfit  
 
1.00 (reference) 
0.87 (0.55-1.37) 
1.86 (1.31-2.62) 
1.68 (1.06-2.68) 
 
 
1.00 (reference) 
1.40 (1.07-1.83) 
1.41 (1.12-1.77) 
1.54 (1.24-2.06) 
CRF was determined by an 
exercise test using a Bruce 
protocol and participants were 
categorised based on quintiles 
of the actual CRF distribution; 
first quintile (unfit) and 2-5th 
quintile (fit). BMI was derived 
from objective height and 
weight and individuals were 
classified based on quintiles; 1-
4th (no fat) and 5th (fat).  
Hu et al. (2004)(39) Prospective observational 
data from the Nurses’ 
Health Study. 
Participants: 116,564 
women who were between 
30-50 years at baseline. A 
total of 10,282 deaths 
occurred during 24 years 
of follow-up. 
Healthy BMI – 3.5 (h/w) 
Healthy – 1.0 - 3.4 (h/w)  
Healthy – <1.0 (h/w)  
Overweight – 3.5 (h/w)  
Overweight – 1.0 - 3.4 (h/w)  
Overweight – <1.0 (h/w) 
Obese – 3.5 (h/w) 
Obese – 1.0 - 3.4 (h/w)  
Obese – <1.0 (h/w) 
  
1.00 (reference) 
1.18 (1.09-1.29) 
1.55 (1.42-1.70) 
1.28 (1.12-1.46) 
1.33 (1.20-1.47) 
1.64 (1.46-1.83) 
1.91 (1.60-2.30) 
2.05 (1.82-2.30) 
2.42 (2.14-2.73) 
Physical activity (PA) and BMI 
were obtained from self-report. 
PA was calculated based on the 
time spend weekly as: 3.5, 10 
- 3.4 or <1.0 hour/week (h/w) 
and subjects were classified 
according to the recommended 
cut-offs of BMI by WHO. 
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Church et al. 
(2004)(40) 
Prospective observational 
data from the ACLS. 
Participants: 2,196 men 
with diabetes (mean age 
49.3 years). A total of 275 
deaths occurred during a 
mean follow-up 14.6 
years.  
Healthy BMI – 11.7 METs 
Healthy – <8.8 METs 
Healthy – 8.8 - 10.08 METs 
Healthy – 10.08 - 11.7 METs  
Overweight – <8.8 METs 
Overweight – 8.8 - 10.08 METs  
Overweight – 10.08 - 11.7 METs  
Overweight – 11.7 METs  
Obese – <8.8 METs 
Obese – 8.8 - 10.08 METs  
*Obese – 10.08 METs 
 
*Obese participants with 
engagement in the 3rd-4th 
quartiles of activity were 
combined due to small numbers.  
 
1.00 (reference) 
4.9 (2.3-9.9) 
3.5 (1.7-7.1) 
2.2 (1.1-4.5) 
4.5 (2.1-8.8) 
3.5 (1.6-6.4) 
1.5 (0.7-3.0) 
1.3 (0.5-3.3) 
5.5 (2.3-13.8) 
2.2 (0.8-5.6) 
2.0 (0.5-6.4) 
BMI was derived from 
objective height and weight and 
participants were categorised 
according to WHO guidelines, 
whereas metabolic equivalent 
of activity (METs) was 
calculated from the estimated 
VO2max as: <8.8, 8.8 - 10.08, 
10.08 - 11.7 or 11.7 METs. 
 
Hu et al (2005)(4) Surveys designed as a 
cohort study allowing 
follow-up analysis in 
Finland. Participants 
22,528 men and 24,684 
women aged 25-64 at 
baseline. There were 
7,394 deaths during a 
mean follow-up of 17.7 
years. 
Men 
Non-obese – active  
Non-obese – inactive  
Obese – active  
Obese – inactive  
 
Women 
Non-obese – active  
Non-obese – inactive 
Obese – active 
Obese – inactive  
 
1.00 (reference) 
1.53 
1.21 
1.78 
 
 
1.00 (reference) 
1.59 
1.12 
2.10 
PA domains were captured by a 
questionnaire as inactive (low) 
or active (moderate or high). 
While BMI was derived from 
measured height and weight 
and categorised as non-obese 
(<30) or obese (30). 
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Confidence intervals 
were not provided. 
 
Sui et al (2007)(41) Prospective observational 
data from the ACLS. 
Participants: 2,087 men 
and 516 women aged 60 
years and older with a 
mean age of 64.4. There 
were 450 deaths during a 
mean follow-up of 12 
years. 
 
Healthy BMI – fit 
Healthy – unfit  
Overweight – fit  
Overweight – unfit  
Obese – fit  
Obese – unfit  
BMI 35 – fit  
BMI 35 – unfit 
 
1.00 (reference) 
3.63 (2.47-5.32) 
0.88 (0.70-1.11) 
1.74 (1.23-2.46) 
1.12 (0.76-1.66) 
1.68 (1.02-2.78) 
0.86 (0.21-3.50) 
3.35 (1.74-6.44) 
CRF was determined by a 
maximal exercise test on a 
treadmill and subjects were 
classified according to their 
fitness levels as fit and unfit. 
BMI was measured, and 
participants were assigned 
according to WHO categories. 
Orsini et al. 
(2008)(9) 
Population-based 
prospective cohort study 
from the Cohort of 
Swedish Men (COSM). 
Participants: 37,633 men 
age 45-79 years at 
baseline. A total of 4,086 
deaths were accrued 
during a mean of 9.7 years 
of follow-up. 
 
Healthy BMI – high  
Healthy – medium  
Healthy – low  
Overweight – high  
Overweight – medium  
Overweight – low  
Obese – high  
Obese – medium  
Obese – low 
1.00 (reference) 
1.22 (1.06-1.39) 
1.56 (1.36-1.79) 
1.15 (1.00-1.32) 
1.09 (0.95-1.26) 
1.31 (1.14-1.50) 
1.49 (1.15-1.94) 
1.73 (1.37-2.18) 
1.91 (1.55-2.34) 
PA and BMI were obtained 
from a self-administered 
questionnaire. PA was 
categorised based on tertiles of 
MET as: low <39, medium 39-
44 or high >44 Mets-h/day 
while BMI was grouped 
according to WHO 
recommendations. 
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Lyerly et al. 
(2009)(42) 
Prospective observational 
data from the ACLS. 
Participants: 3,044 
women mean age 47.4 
years with impaired 
fasting glucose (IFG) or 
undiagnosed type 2 
diabetes mellitus (T2DM). 
There were 171 deaths 
during a mean follow-up 
of 16 years. 
 
Healthy BMI – fit  
Healthy – unfit  
Overweight/obese – fit  
Overweight/obese – unfit  
1.00 (reference) 
1.41 (0.87-2.31) 
1.85 (0.99-3.45) 
2.26 (1.27-4.03) 
 
CRF was determined by a 
maximal exercise test on a 
treadmill and subjects were 
classified according to their 
fitness levels as fit and unfit. 
BMI was measured, and 
participants were assigned 
according to WHO categories. 
 
McAuley et al. 
(2009)(43) 
Prospective observational 
data from the ACLS. 
Participants: 13,115 US 
men (mean age 47.7 
years) with history of 
hypertension at baseline. 
During a mean follow-up 
of 12 years, a total of 883 
deaths occurred. 
BMI 
Healthy – high  
Healthy – moderate  
Healthy – low  
Overweight – high  
Overweight – moderate  
Overweight – low  
Obese – high  
Obese – moderate  
Obese – low  
 
BF% 
Not fat – high  
Not fat – moderate  
Not fat – low  
Fat – high  
 
1.00 (reference) 
1.66 (1.28-2.15) 
2.77 (1.87-4.10) 
1.16 (0.93-1.46) 
1.24 (0.99-1.55) 
2.21 (1.65-2.95) 
1.59 (0.95-2.67) 
1.78 (1.35-2.34) 
2.95 (2.27-3.81) 
 
 
1.00 (reference) 
1.38 (1.14-1.68) 
2.61 (1.99-3.44) 
1.19 (0.90-1.56) 
Participants were classified by 
their CRF as low (below the 
20th percentile), moderate (20th-
40th percentile), and high 
(above the 40th percentile). 
BMI and BF% were objectively 
obtained. A BF% of <25% was 
categorised as not fat, whereas 
a BF% 25% was categorised 
as fat.  
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Fat – moderate  
Fat – low 
1.34 (1.09-1.64) 
2.41 (1.93-3.02) 
 
Farrell et al 
(2010)(3) 
Prospective observational 
data from the Cooper 
Center Longitudinal Study 
CCLS (CCLS). 
Participants: 13,335 adult 
women. During a mean 
follow-up of 12.3 years, a 
total of 292 deaths 
occurred. 
BMI 
Healthy – fit  
Healthy – unfit  
Overweight – fit  
Overweight – unfit  
Obese – fit  
Obese – unfit  
 
BF% 
Normal – fit 
Normal – unfit  
Obese – fit  
Obese – unfit  
 
 
 
1.00 (reference) 
1.5 
1.1 
1.9 
0.5 
2.5 
 
 
1.00 (reference) 
1.5 
1.0 
2.0 
 
Confidence intervals 
were not provided. 
 
Participants were classified by 
their CRF as low (below the 
20th percentile), moderate (20th-
40th percentile), and high 
(above the 40th percentile). 
BMI and BF% were objectively 
obtained. A BF% of <30% was 
categorised as normal, whereas 
a BF% 30% was categorised 
as obese.  
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McAuley et al. 
(2010)(7) 
Prospective observational 
data from the Veterans 
Affair Medical Centers in 
Washington. Participants: 
12,417 men. During a 
mean follow-up of 7.7 
years, a total of 2,801 
deaths occurred. 
 
Healthy BMI – high  
Healthy – moderate  
Healthy – low  
Overweight – high  
Overweight – moderate  
Overweight – low  
Obese – high  
Obese – moderate  
Obese – low  
 
1.00 (reference) 
1.65 (1.34-2.04) 
2.03 (1.60-2.58) 
0.43 (0.32-0.59) 
1.15 (0.93-1.42) 
1.79 (1.43-2.25) 
0.52 (0.34-0.82) 
0.99 (0.80-1.23) 
1.61 (1.27-2.03) 
 
CRF was quantified by a 
maximal exercise test and 
participants were categorized 
based on the METs achieved 
during the test as low (<5), 
moderate (5-10), and high 
(10Mets) and BMI was 
classified according to standard 
clinical guidelines. 
Lee et al (2011)(12) Prospective observational 
data from the ACLS. 
Participants: 14,345 men. 
During a mean follow-up 
of 11.4 years, a total of 
914 deaths occurred. 
Loss BMI – gain CRF  
Loss BMI – stable CRF  
Loss BMI – loss CRF  
Stable BMI – gain CRF  
Stable BMI – stable CRF  
Stable BMI – loss CRF  
Gain BMI – gain CRF  
Gain BMI – stable CRF  
Gain BMI – loss CRF  
1.00 (reference) 
1.19 (0.94-1.55) 
2.06 (1.59-2.71) 
1.22 (0.92-1.63) 
1.26 (0.98-1.61) 
1.77 (1.36-2.31) 
1.14 (0.86-1.53) 
1.29 (0.99-1.68) 
1.65 (1.30-2.10) 
 
Change in fitness and change in 
BMI as continuous variables 
were calculated as the 
difference in maximal METs or 
BMI between the baseline and 
last examination. 
Faselis et al. 
(2012)(44) 
Prospective observational 
data from the Veterans 
Affairs Medical Center. 
Participants: 4,183 
hypertensive men. During 
a mean follow-up of 7.2 
years, a total of 1,000 
deaths occurred. 
Healthy – low  
Healthy – moderate  
Healthy BMI – high  
Overweight – low  
Overweight – moderate  
Overweight – high  
Obese – low  
Obese – moderate 
1.00 (reference) 
0.60 (0.47-0.78) 
0.34 (0.21-0.54) 
0.82 (0.66-1.01) 
0.53 (0.43-0.67) 
0.40 (0.29-0.56) 
0.84 (0.66-1.05) 
0.22 (0.14-0.36) 
CRF was assessed using a 
Bruce protocol and fitness was 
categorised based on the METs 
during the test as low, moderate 
and high. BMI was categorised 
as recommended by WHO. 
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 Obese – high  0.45 (0.35-0.59) 
 
Uretsky et al. 
(2013)(45) 
Patients referred to a 
stress-rest myocardial 
perfusion single-photon 
emission computed 
tomography (SPECT). 
Participants: 5,203 adults 
without a history of heart 
disease and a normal 
SPECT. There were 939 
deaths during a mean 
follow-up of 8.1 years. 
 
 
 
Healthy BMI – high  
Overweight – high  
Obese – high  
Healthy – low  
Overweight – low  
Obese – low  
Healthy – pharmacologic  
Overweight – pharmacologic  
Obese – pharmacologic  
Event rate %/year 
 
1.4 
0.9 
0.6 
3.6 
1.9 
1.7 
5.3 
3.9 
2.9 
BMI categories were defined 
according to the WHO 
classification. Patients were 
divided into 3 groups based on 
their SPECT ability to exercise: 
those who reached ≥6 METs 
(high fitness), those who 
attained a level of <6 METs 
(low), and those who did not 
perform the test but required a 
pharmacologic stress (non-
exercise). 
 
McAuley et al. 
(2014)(46) 
Prospective observational 
data from the ACLS. 
Participants: 9,563 men 
with documented or 
suspected coronary heart 
disease (CHD). During a 
mean follow-up of 13.4 
years, a total of 733 
deaths occurred. 
 
BMI 
Healthy – fit 
Overweight – fit  
Obese (I) – fit  
Obese (II-III) – fit  
Healthy – unfit 
Overweight – unfit  
Obese (I) – unfit 
Obese (II-III) – unfit  
 
BF% 
Low BF% – fit  
Middle BF% – fit  
 
1.00 (reference) 
0.84 (0.68-1.03) 
0.65 (0.38-1.10) 
2.46 (0.61-9.96) 
1.60 (1.24-2.05) 
1.09 (0.88-1.36) 
1.38 (1.04-1.82) 
2.43 (1.55-3.80) 
 
 
1.00 (reference) 
0.85 (0.68-1.08) 
CRF was determined by a 
maximal exercise test on a 
treadmill and subjects were 
classified according to their 
fitness levels as fit and unfit. 
BMI and BF% were measured. 
Obese class (I) was defined as a 
BMI between 30.0 to 34.9 and 
class (II-III) ≥35.  
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Upper BF% – fit  
Low BF% – unfit  
Middle BF% – unfit  
Upper BF% – unfit  
 
0.96 (0.74-1.25) 
1.79 (1.35-2.38) 
1.28 (0.99-1.67) 
1.26 (1.01-1.57) 
McAuley et al. 
(2014)(10) 
Prospective observational 
data from the ACLS. 
Participants: 17,044 adults 
with pre-diabetes or 
impaired fasting glucose. 
During a mean follow-up 
of 13.9 years, a total of 
832 deaths occurred. 
BMI 
Healthy – fit 
Overweight – fit 
Obese – fit  
Healthy – unfit  
Overweight – unfit  
Obese – unfit  
 
BF% 
Low BF% – fit 
Middle BF% – fit  
Upper BF% – fit  
Low BF% – unfit 
Middle BF% – unfit  
Upper BF% – unfit 
 
 
1.00 (reference) 
1.02 (0.84-1.23) 
1.35 (0.92-2.00) 
1.70 (1.32-2.18) 
1.27 (1.03-1.57) 
1.91 (1.50-2.44) 
 
 
1.00 (reference) 
0.95 (0.78-1.17) 
1.11 (0.88-1.41) 
2.16 (1.60-2.93) 
1.37 (1.07-1.75) 
1.43 (1.16-1.76) 
CRF was determined by a 
maximal exercise test on a 
treadmill and subjects were 
classified according to their 
fitness levels as unfit or fit. 
BMI and BF% were objectively 
measured. 
 
Ekelund et al. 
(2015)(13) 
Prospective observational 
data from the European 
Prospective Investigation 
into Cancer and Nutrition 
Study (EPIC). 
Participants: 334,161 
subjects. During a mean 
Healthy – inactive 
Healthy – moderately inactive   
Healthy – moderately active 
Healthy – active 
Overweight – inactive 
Overweight – moderately 
inactive  
1.00 (reference) 
0.76 (0.72-0.81) 
0.71 (0.67-0.76) 
0.65 (0.60-0.70) 
1.00 (reference) 
0.82 (0.77-0.86) 
 
BMI was calculated from 
measured weight and height in 
some centers while it was 
derived from self-report in 
other centers. PA was captured 
by self-report and summarized 
into 4 groups: active, 
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follow-up of 12.4 years, a 
total of 21,438 deaths 
occurred. 
 
Overweight – moderately active  
Overweight – active  
Obese – inactive 
Obese – moderately inactive 
Obese – moderately active 
Obese – active 
 
0.78 (0.73-0.83) 
0.75 (0.70-0.80) 
1.00 (reference) 
0.84 (0.78-0.91) 
0.76 (0.69-0.84) 
0.84 (0.74-0.90) 
moderately active, moderately 
inactive and inactive 
Loprinzi (2016)(47) Data from the 1999-2006 
National Health and 
Nutrition Examination 
Survey. Participants: 573 
subjects with a diagnosis 
of congestive heart failure 
(HF). A total of 299 
deaths were accrued 
during a median of 75 
months of follow-up. 
   
Healthy BMI – inactive 
Overweight – inactive  
Obese – inactive  
Healthy – active  
Overweight – active  
Obese – active  
 
1.00 (reference) 
0.62 (0.41-0.93) 
0.71 (0.44-1.13)  
0.39 (0.17-0.82) 
0.48 (0.24-0.93) 
0.47 (0.22-0.99) 
BMI was calculated from 
measured height and weight 
whereas PA was captured by 
self-report. Participants were 
classified as active or inactive 
based on the distribution of 
moderate to vigorous PA. 
Loprinzi (2016)(11) Data from the 1999-2006 
National Health and 
Nutrition Examination 
Survey. Participants: 766 
subjects with a diagnosis 
of coronary artery disease 
(mean age 65.4 years). A 
total of 301 deaths were 
accrued during a median 
of 86 months of follow-
Healthy BMI – inactive 
Overweight – inactive 
Obese – inactive 
Healthy – active 
Overweight – active 
Obese – active 
 
1.00 (reference) 
0.95 (0.57-1.60) 
0.91 (0.57-1.44)  
0.35 (0.14-0.86) 
0.51 (0.28-0.93) 
0.43 (0.21-0.85) 
BMI was calculated from 
measured height and weight 
whereas PA was captured by 
self-report. Participants were 
classified as active or inactive 
based on the distribution of 
moderate to vigorous PA. 
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up. 
Dankel et al. 
(2016)(14) 
Data from the 1999-2006 
National Health and 
Nutrition Examination 
Survey. Participants: 
11,057 subjects aged 36-
85. A total of 1,865 deaths 
were accrued during a 
mean of 8.3 years of 
follow-up. 
 
Healthy BMI now and 10 years 
ago – active 
Healthy BMI now and 10 years 
ago – inactive  
Healthy BMI now but 
overweight 10 years ago – active 
Healthy BMI now but 
overweight 10 years ago – 
inactive 
Overweight now but normal 10 
years ago – active 
Overweight now but normal 10 
years ago – inactive 
Overweight now and 10 years 
ago – active 
Overweight now and 10 years 
ago – inactive  
 
 
1.00 (reference) 
 
 
1.53 
 
1.53  
 
 
2.00 
 
0.79 
  
1.42 
 
1.07 
 
1.37 
 
Confidence intervals 
were not provided. 
 
Change in BMI was calculated 
as the difference between BMI 
at baseline and 10 years prior. 
Participants were classified as 
active or inactive based on the 
distribution of moderate to 
vigorous PA question.  
84 
 
McAuley et al. 
(2016)(48) 
Prospective observational 
data from the Henry Ford 
Exercise Testing (FIT). 
Participants: 29,257 adults 
without cardiovascular 
disease or diabetes at 
baseline. There were 
1,898 deaths during a 
mean follow-up of 10.8 
years. 
 
Higher survival rates were 
observed for non-obese and 
obese groups achieving ≥10 
METs (around 90% for each 
group).  
This conclusion was 
based on Kaplan-
Meier survival curves. 
CRF was determined by a 
treadmill stress test and 
participants were grouped 
according to their exercise 
capacity as <10 or ≥10 METs. 
BMI was calculated from 
weight and height and 
participants were classified 
based on WHO groups. 
Cardiovascular 
(CVD) mortality 
    
Lee et al. (1999)(1) Prospective observational 
data from the ACLS. 
Participants: 21,925 US 
adult men (age 30-83 
years). During a mean 
follow-up of 8 years, there 
were 144 deaths due to 
CVD. 
Lean – fit 
Lean – unfit  
Normal – fit  
Normal – unfit  
Obese – fit  
Obese – unfit  
1.00 (reference) 
3.16 (1.12-8.92) 
1.43 (0.77-2.67) 
2.94 (1.48- 5.83) 
1.35 (0.66-2.76) 
4.11 (2.20-7.68) 
CRF was determined by a 
maximal exercise test on a 
treadmill and subjects were 
classified according to their 
fitness levels as fit (above the 
20th percentile) and unfit 
(below 20th percentile). BF% 
was derived from objective 
anthropometric measures and 
participants were categorised as 
lean (<16.7), normal (16.7 - 
<25) or obese (25 BF%). 
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Wei et al. (1999)(2) Prospective observational 
data from the ACLS. 
Participants: 25,714 adult 
men (mean age 43.8 
years). During a mean 
follow-up of 10 years, 
there were 439 
cardiovascular deaths. 
Healthy BMI – fit  
Healthy BMI – unfit  
Overweight – fit 
Overweight – unfit 
Obese – fit 
Obese – unfit 
 
1.00 (reference) 
3.10 (2.20-4.50) 
1.50 (1.10-2.00) 
4.50 (3.40-6.00) 
1.60 (1.00-2.80) 
5.00 (3.60-7.00) 
CRF was determined by a 
maximal exercise test on a 
treadmill and subjects were 
classified according to their 
fitness levels as fit and unfit. 
BMI was measured, and 
participants were assigned 
according to WHO categories. 
 
Stevens et al. 
(2002)(38) 
Prospective observational 
data from LRCS. 
Participants: 2,506 
women and 2,860 men 
from 8 states of the US. 
There were 449 CVD 
deaths during follow-up 
period. 
Women 
Not fat – fit  
Fat – fit  
Not fat – unfit  
Fat – unfit 
 
Men 
Not fat – fit  
Fat – fit  
Not fat – unfit  
Fat – unfit 
 
 
 
1.00 (reference) 
1.39 
1.53 
1.95 
 
 
1.00 (reference) 
1.39 
1.55 
1.67 
 
Confidence intervals 
were not provided. 
CRF was assessed using a 
treadmill test and BMI was 
calculated from measured 
height and weight. The 1st 
quintile of fitness was defined 
as unfit and the 2-5th quintile 
was considered as fit whereas 
the 1-4th quintile of BMI was 
grouped as no fat and the 5th 
quintile was defined as fat. 
 
Stevens et al 
(2004)(6) 
Prospective observational 
data from the LRCS. 
Participants 1,359 Russian 
men and 1,716 US men 
aged 40-59 years at 
Russian men 
Not fat – fit 
Fat – fit  
Not fat – unfit  
Fat – unfit  
 
1.00 (reference) 
0.94 (0.49-1.81) 
1.85 (1.09-3.15) 
3.05 (1.74-5.34) 
CRF was determined by an 
exercise test using a Bruce 
protocol and participants were 
categorised based on quintiles 
of the actual CRF distribution; 
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baseline. There were 178 
deaths due to CVD in the 
US cohort and 98 in the 
Russian cohort. 
 
US men 
Not fat – fit  
Fat – fit  
Not fat – unfit  
Fat – unfit 
 
 
1.00 (reference) 
1.32 (0.85-2.06) 
1.62 (1.01-2.58) 
1.56 (1.08-2.24) 
 
first quintile (unfit) and 2-5th 
quintile (fit). BMI was derived 
from objective height and 
weight and individuals were 
classified based on quintiles; 1-
4th (no fat) and 5th (fat).  
Hu et al. (2004)(39) Prospective observational 
data from the Nurses’ 
Health Study. 
Participants: 116,564 
women who were between 
30-50 years at baseline. A 
total of 2,370 CVD deaths 
occurred during 24 years 
of follow-up. 
Healthy BMI – 3.5 (h/w)  
Healthy – 1.0-3.4 (h/w) 
Healthy – <1.0 (h/w) 
Overweight – 3.5 (h/w) 
Overweight – 1.0-3.4 (h/w) 
Overweight – <1.0 (h/w) 
Obese – 3.5 (h/w) 
Obese – 1.0-3.4(h/w)  
Obese – <1.0 (h/w) 
 
1.00 (reference) 
1.51 (1.22-1.87) 
1.89 (1.51-2.37) 
1.58 (1.15-2.16) 
2.06 (1.62-2.60) 
2.52 (1.96-3.25) 
2.87 (1.94-4.25) 
4.26 (3.33-5.44) 
4.73 (3.68-6.09) 
PA and BMI were obtained 
from self-report. PA was 
calculated based on the time 
spend weekly as 3.5, 10-3.4 or 
<1.0 hr/week (h/w) and 
subjects were classified 
according to the recommended 
cut-offs of BMI. 
Hu et al (2005)(4) Surveys designed as a 
cohort study allowing 
follow-up analysis in 
Finland. Participants 
22,528 men and 24,684 
women aged 25-64 at 
baseline. There were 
3,378 deaths due to CVD 
during a mean follow-up 
of 17.7 years. 
Men 
Non-obese – active  
Non-obese – inactive  
Obese – active  
Obese – inactive  
 
Women 
Non-obese – active 
Non-obese – inactive  
Obese – active 
Obese – inactive 
 
1.00 (reference) 
1.35 
1.44 
2.09 
 
 
1.00 (reference) 
1.73 
1.15 
2.18 
PA domains were captured by a 
questionnaire as inactive (low) 
or active (moderate or high). 
While BMI was derived from 
measured height and weight 
and categorised as non-obese 
(<30) or obese (30). 
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Confidence intervals 
were not provided. 
 
Church et al. 
(2005)(49) 
Prospective observational 
data from the ACLS. 
Participants: 2,316 adult 
men with a diagnosis of 
diabetes (mean age 50.0 
years). During a mean 
follow-up of 15.9 years, 
there were 179 deaths due 
to CVD. 
Healthy BMI – high  
Healthy – moderate  
Healthy – low  
Overweight – high  
Overweight – moderate  
Overweight – low  
Obese - moderate/high 
Obese – low 
 
1.00 (reference) 
2.70 (1.40-5.30) 
4.20 (2.00-8.60) 
1.70 (0.80-3.80) 
1.90 (0.90-3.60) 
4.30 (2.30-7.90) 
1.70 (0.70-4.10) 
4.50 (2.30-8.70) 
CRF was determined by a 
maximal exercise test and 
subjects were classified 
according to their fitness levels 
as low, moderate or high. BMI 
was measured, and participants 
were assigned according to 
WHO categories. Subjects with 
a BMI <18.5 or >35 were 
excluded from the analysis. 
 
Vatten et al. 
(2006)(50) 
Prospective observational 
data from the HUNT 
Study. Participants: 
34,868 women and 32,872 
men. A total of 6,552 
CVD deaths were accrued 
during 16 years of follow-
up. 
Men 
Lean – high  
Extremely/very lean – high  
Extremely/very lean – medium  
Extremely/very lean – low  
Extremely/very lean – never  
Lean – medium  
Lean – low  
Lean – never  
Overweight – high  
Overweight – medium  
Overweight – low  
Overweight – never  
 
1.00 (reference) 
0.93 (0.55-1.56) 
1.26 (0.84-1.89) 
1.01 (0.58-1.75) 
1.28 (0.78-2.10) 
1.11 (0.88-1.38) 
0.98 (0.76-1.26) 
1.06 (0.79-1.41) 
1.27 (1.01-1.61) 
1.31 (1.07-1.62) 
1.23 (0.98-1.53) 
1.45 (1.12-1.86) 
PA and BMI were collected 
from self-report. A PA index 
was calculated based on 
frequency, duration and 
intensity as: high, medium or 
low or never. BMI was 
categorised as: extremely lean 
(18.5), very lean (18.5-20.9), 
lean (21-24.9), overweight (25-
29.9) or obese (30). 
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Obese – high  
Obese – medium  
Obese – low 
Obese – never 
 
Women 
Lean – high  
Extremely/very lean – high  
Extremely/very lean – medium  
Extremely/very lean – low 
Extremely/very lean – never  
Lean – medium  
Lean – low 
Lean – never 
Overweight – high 
Overweight – medium 
Overweight – low  
Overweight – never  
Obese – high  
Obese – medium  
Obese – low 
Obese – never 
 
1.62 (1.09-2.40) 
1.74 (1.28-2.37) 
1.97 (1.47-2.64) 
2.26 (1.61-3.15) 
 
 
1.00 (reference) 
0.93 (0.50-1.72) 
1.56 (0.97-2.50) 
1.59 (0.90-2.81) 
2.22 (1.29-3.81) 
1.16 (0.83-1.61) 
1.21 (0.83-1.76) 
1.38 (0.91-2.07) 
1.13 (0.80-1.60) 
1.26 (0.92-1.74) 
1.72 (1.23-2.39) 
1.55 (1.08-2.23) 
1.27 (0.80-2.00) 
1.79 (1.25-2.56) 
2.78 (1.97-3.93) 
2.76 (1.94-3.92) 
Lee et al. (2011)(12) Prospective observational 
data from the ACLS. 
Participants: 14,345 adult 
men. During a mean 
follow-up of 11.4 years, a 
Loss BMI – gain CRF 
Loss BMI – stable CRF  
Loss BMI – loss CRF 
Stable BMI – gain CRF 
Stable BMI – stable CRF 
1.00 (reference) 
1.49 (0.98-2.27) 
2.01 (1.24-3.27) 
1.03 (0.60-1.80) 
1.27 (0.81-2.00) 
Change in fitness and change in 
BMI as continuous variables 
were calculated as the 
difference in maximal METs or 
BMI between the baseline and 
89 
 
total of 300 CVD deaths 
occurred. 
 
Stable BMI – loss CRF  
Gain BMI – gain CRF 
Gain BMI – stable CRF  
Gain BMI – loss CRF 
1.71 (1.06-2.78) 
1.60 (0.99-2.57) 
1.48 (0.94-2.33) 
2.09 (1.39-3.14) 
 
last examination. 
Goel et al. (2011)(51) Prospective observational 
data from the Mayo Clinic 
Cardiac Rehabilitation 
Program. Participants: 
855 patients with 
coronary artery disease. 
There were 159 deaths 
during a mean follow-up 
of 9.7 years. 
Healthy BMI – fit  
Healthy BMI – unfit  
Overweight – fit  
Overweight – unfit  
Obese – fit  
Obese – unfit 
 
1.00 (reference) 
9.6 (2.9-31.8) 
2.2 (0.6-7.4) 
6.8 (2.1-22.2) 
3.2 (0.8-11.4) 
3.3 (0.9-11.4) 
Weight and height were 
measured to calculate BMI and 
participants were grouped 
according to recommended 
WHO categories. CRF was 
measured on a treadmill using 
an accelerated Naughton 
protocol; fitness was graded 
into high and low using sex-
specific median values for the 
study population. 
 
McAuley et al. 
(2014)(46) 
Prospective observational 
data from the ACLS. 
Participants: 9,563 men 
with documented or 
suspected CHD. During a 
mean follow-up of 13.4 
years, a total of 348 
deaths due to CVD 
occurred. 
 
BMI 
Healthy – fit  
Overweight – fit  
Obese – fit  
Healthy – unfit  
Overweight – unfit  
Obese – unfit 
 
BF% 
Low BF% – fit  
Middle BF% – fit  
 
1.00 (reference) 
0.94 (0.69-1.30) 
0.53 (0.21-1.31) 
1.87 (1.28-2.70) 
1.46 (1.07-2.00) 
1.93 (1.34-2.79) 
 
 
1.00 (reference) 
0.87 (0.61-1.26) 
CRF was determined by a 
maximal exercise test on a 
treadmill and subjects were 
classified according to their 
fitness levels as fit and unfit. 
BF% and BMI were objectively 
measured.  
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Upper BF% – fit  
Low BF% – unfit  
Middle BF% – unfit  
Obese BF% – unfit 
0.97 (0.65-1.46) 
1.83 (1.20-2.81) 
1.83 (1.28-2.61) 
1.52 (1.10-2.11) 
 
McAuley et al. 
(2014)(10) 
Prospective observational 
data from the ACLS. 
Participants: 17,044 adults 
with pre-diabetes or 
impaired fasting glucose. 
During a mean follow-up 
of 13.9 years, a total of 
246 CVD deaths occurred. 
BMI 
Healthy – fit  
Overweight – fit  
Obese – fit  
Healthy – unfit  
Overweight – unfit  
Obese – unfit 
 
BF% 
Low BF% – fit  
Middle BF% – fit  
Upper BF% – fit  
Low BF% – unfit  
Middle BF% – unfit  
Upper BF% – unfit 
 
 
1.00 (reference) 
1.28 (0.89-1.85) 
1.72 (0.84-3.51) 
1.88 (1.13-3.10) 
1.56 (1.04-2.32) 
3.20 (2.09-4.88) 
 
 
1.00 (reference) 
1.05 (0.70-1.58) 
1.50 (0.97-2.33) 
2.56 (1.43-4.58) 
1.70 (1.07-2.72) 
1.96 (1.32-2.90) 
 
CRF was determined by a 
maximal exercise test on a 
treadmill and subjects were 
classified according to their 
fitness levels as unfit or fit. 
BMI and BF% were objectively 
measured. 
 
Cancer mortality     
Evenson et al. 
(2002)(52) 
Prospective observational 
data from the LRCS. 
Participants: 5,475 men 
and women. 401 deaths 
due to cancer occurred 
during 24.9 years. 
Women 
Not fat – unfit  
Fat – unfit  
No Fat – fit  
Fat – fit 
 
 
1.00 (reference) 
1.33 (0.75-2.37) 
0.97 (0.64-1.49) 
1.54 (0.93-2.56) 
 
CRF was determined by an 
exercise test using a Bruce 
protocol and participants were 
categorised based on quintiles 
of the actual CRF distribution; 
first quintile (unfit) and 2-5th 
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Men 
Not fat – unfit  
Fat – unfit  
No Fat – fit  
Fat – fit 
 
1.00 (reference) 
1.01 (0.59-1.71) 
0.89 (0.63-1.26) 
0.94 (0.60-1.49) 
 
quintile (fit). BMI was derived 
from objective height and 
weight and individuals were 
classified based on quintiles; 1-
4th (no fat) and 5th (fat). 
 
Hu et al. (2004)(39) Prospective observational 
data from the Nurses’ 
Health Study. 
Participants: 116,564 
women who were between 
30-50 years at baseline. A 
total of 5,223 cancer 
related deaths occurred 
during 24 years of follow-
up. 
 
Healthy BMI – 3.5 (h/w)  
Healthy – 1.0 - 3.4 (h/w)  
Healthy – <1.0 (h/w)  
Overweight – 3.5(h/w)  
Overweight – 1.0 - 3.4 (h/w)  
Overweight – <1.0 (h/w)  
Obese – 3.5 (h/w)  
Obese – 1.0 - 3.4 (h/w)  
Obese – <1.0 (h/w) 
1.00 (reference) 
1.09 (0.98-1.22) 
1.32 (1.17-1.50) 
1.22 (1.02-1.45) 
1.20 (1.05-1.38) 
1.39 (1.19-1.62) 
1.57 (1.21-2.03) 
1.44 (1.21-1.71) 
1.68 (1.40-2.01) 
 
PA and BMI were obtained 
from self-report. PA was 
calculated based on the time 
spend weekly as 3.5, 1.0 - 3.4 
or <1.0 hr/week (h/w) and 
subjects were classified 
according to the recommended 
cut-offs of BMI. 
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Hu et al. (2005)(4) Surveys designed as a 
cohort study allowing 
follow-up analysis in 
Finland. Participants: 
22,528 men and 24,684 
women aged 25-64 at 
baseline. There were 
2,039 cancer deaths 
during a mean follow-up 
of 17.7 years. 
Men 
Non-obese – active 
Non-obese – inactive  
Obese – active  
Obese – inactive 
 
Women 
Non-obese – active 
Non-obese – inactive  
Obese – active  
Obese – inactive 
 
 
1.00 (reference) 
1.23 
0.96 
1.30 
 
 
1.00 (reference) 
1.24 
1.19 
1.52 
 
Confidence intervals 
were not provided. 
PA domains were captured by a 
questionnaire as inactive (low) 
or active (moderate or high). 
While BMI was derived from 
measured height and weight 
and categorised as non-obese 
(<30) or obese (30). 
Farrell et al. 
(2007)(53) 
Prospective observational 
data from the ACLS. 
Participants: 38,410 adult 
men. During a mean 
follow-up of 17.4 years, a 
total of 1,037 cancer 
deaths occurred. 
 
 
 
BMI 
Healthy – unfit  
Healthy – fit  
Overweight – unfit  
Overweight – fit  
Obese – unfit  
Obese – fit 
 
BF% 
Not fat – unfit  
Not fat – fit  
Cancer mortality 
/10,000 man-years. 
 
20.3 
13.0 
21.7 
15.2 
21.0 
15.9 
 
 
19.6 
12.2 
CRF was determined by a 
maximal exercise test and 
subjects were classified 
according to their fitness levels 
as fit and unfit. BMI and BF% 
were measured and participants 
were assigned according to 
WHO categories for BMI. 
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Fat – unfit  
Fat – fit 
25.0 
16.3 
 
Cardiometabolic 
diseases incidence 
    
Church et al. 
(2002)(54) 
Cross-sectional data from 
the ACLS. Participants 
4,057 men who underwent 
blood chemistry analyses 
to assess probability of 
metabolic syndrome 
onset. 
Healthy BMI – moderate  
Healthy – high  
Healthy – low  
Overweight – high  
Overweight – moderate 
Overweight – low  
Obese – high  
Obese – moderate  
Obese – low 
 
1.00 (reference) 
0.40 (0.27-0.59) 
2.37 (1.13-4.98) 
1.05 (0.74-1.48) 
2.18 (1.54-3.07) 
3.29 (2.13-5.09) 
1.91 (1.14-3.21) 
3.94 (2.72-5.72) 
6.47 (4.42-9.46) 
CRF was determined by a 
maximal exercise test on a 
treadmill and subjects were 
classified according to their 
fitness levels as low, moderate 
or high. BMI was measured, 
and participants were assigned 
according to WHO categories.  
Wessel et al. 
(2004)(55) 
Prospective observational 
data from the Women’s 
Ischemia Syndrome 
Evaluation. Participants: 
906 women with 
suspected myocardial 
ischemia, mean age 58 
years. 
 
 
 
 
Not obese – fit  
Obese – fit  
Not obese - not fit  
Obese - not fit 
 
Proportion of major 
adverse events 
 
5.6% 
9.5% 
16.8% 
14.3% 
PA was derived for self-report 
using the DUKE Activity 
Status Index and BMI was 
calculated from self-reported 
weight and height as not obese 
or obese. 
Hu et al. (2004)(56) Surveys designed as a 
cohort study allowing 
follow-up analysis in 
Finland. Participants: 
Men 
BMI < 30 – active  
BMI < 30 – inactive  
BMI  30 – active  
 
1.00 (reference) 
1.42 
1.35 
PA domains were captured by a 
questionnaire as inactive (low) 
or active (moderate or high). 
While BMI was derived from 
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18,892 men and women 
aged 25-74 without 
history of CVD at 
baseline. There were 818 
events of CVD during a 
median follow-up of 9.8 
years. 
BMI  30 – inactive 
 
Women 
BMI < 30 – active  
BMI < 30 – inactive  
BMI  30 – active  
BMI  30 – inactive 
 
 
2.02 
 
 
1.00 (reference) 
1.70 
1.56 
2.00 
 
Confidence intervals 
were not provided. 
 
measured height and weight 
and categorised as non-obese 
(<30) or obese (30). 
Weinstein et al. 
(2004)(57) 
Prospective observational 
data from the Women’s 
Health Study. 
Participants: 37,878 
women aged 45 years and 
over at baseline. A total of 
1,361cases of incidence 
T2DM occurred during 
6.9 years of mean follow-
up. 
Healthy BMI – active  
Healthy – inactive  
Overweight – active  
Overweight – inactive  
Obese – active  
Obese – inactive 
1.00 (reference) 
1.15 (0.83-1.59) 
3.68 (2.63-5.15) 
4.16 (3.05-5.66) 
11.5 (8.34-15.9) 
11.8 (8.75-16.0)  
 
PA and BMI were obtained 
from self-report. PA was 
defined as active based on the 
energy expenditure of activity 
(1,000 kcal/week) or inactive 
(<1,000 kcal/week). BMI was 
classified according to the 
recommended cut-offs. 
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Hu et al. (2004)(58) Surveys designed as a 
cohort study allowing 
follow-up analysis in 
Finland. Participants 
4,369 men and women 
aged 45-64 without 
history of T2DM at 
baseline. There were 120 
events of diabetes during 
a median follow-up of 9.4 
years. 
 
BMI < 30 – high  
BMI  30 – high  
BMI < 30 – moderate  
BMI  30 – moderate  
BMI < 30 – low  
BMI  30 – low 
 
 
1.00 (reference) 
4.10 
2.23 
7.56 
2.18 
9.86 
 
Confidence intervals 
were not provided. 
 
PA domains were captured by a 
questionnaire as low, moderate 
or high. BMI was derived from 
measured height and weight 
and categorised as non-obese 
(<30) or obese (30). 
Fransson et al. 
(2006)(59) 
Data from the Stockholm 
Heart Epidemiology 
Program (SHEEP) a 
population-based case-
control study of 1,754 
cases of CHD and 2,315 
controls. 
 
 
 
BMI 20 - <25 – very little  
BMI<20 – very little  
Overweight – very little  
Obese – very little 
BMI<20 – once/week  
BMI 20 - <25 – once/week  
Overweight – once/week  
Obese – once/week  
BMI<20 – twice or more/week 
BMI 20 - <25 – twice or 
more/week 
Overweight – twice or 
more/week 
Odds ratios for fatal 
and non-fatal CHD 
 
1.00 (reference) 
1.50 (0.97-2.34) 
1.19 (0.96-1.46) 
1.55 (1.20-2.01) 
1.09 (0.57-2.08) 
0.56 (0.44-0.73) 
0.88 (0.69-1.11) 
1.20 (0.82-1.76) 
0.62 (0.23-1.68) 
 
0.44 (0.32-0.59) 
 
0.79 (0.59-1.06) 
PA and BMI were obtained 
from self-report. PA was 
defined as: very 
little/occasional walks, now 
and then/once per week or 
twice per week or more. BMI 
was derived from self-reported 
height and weight.    
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Obese – twice or more/week 1.85 (1.07-3.18) 
 
Li et al. (2006)(60) Prospective observational 
data from the Nurses’ 
Health Study. 
Participants: 88,393 
women who were between 
34-59 years at baseline 
without a history of CHD. 
A total of 2,358 fatal and 
non-fatal CHD occurred 
during 20 years of follow-
up. 
 
Healthy BMI – 3.5 (h/w)  
Healthy – 1.0 - 3.4 (h/w)  
Healthy – <1.0 (h/w)  
Overweight – 3.5 (h/w)  
Overweight – 1.0 - 3.4 (h/w)  
Overweight – <1.0 (h/w)  
Obese – 3.5 (h/w)  
Obese – 1.0 - 3.4 (h/w)  
Obese – <1.0 (h/w) 
1.00 (reference) 
1.32 (1.12-1.56) 
1.48 (1.24-1.77) 
1.43 (1.13-1.82) 
1.92 (1.61-2.30) 
3.44 (2.81-4.21) 
2.48 (1.84-3.34) 
3.32 (2.74-4.01) 
3.44 (2.81-4.21) 
 
PA and BMI were obtained 
from self-report. PA was 
calculated based on the time 
spend weekly as 3.5, 1.0 - 3.4 
or <1.0 hr/week (h/w) and 
subjects were classified 
according to the recommended 
cut-offs of BMI. 
Weinstein et al. 
(2008)(61) 
Prospective observational 
data from the Women’s 
Health Study. 
Participants: 38,987 
women aged 45 years and 
over at baseline. A total of 
948 cases of incident 
CHD occurred during 
10.9 years of follow-up. 
 
Healthy BMI – active  
Healthy – inactive  
Overweight – active  
Overweight – inactive  
Obese – active  
Obese – inactive 
 
 
1.00 (reference) 
1.08 
1.54 
1.88 
1.87 
2.53 
 
Confidence intervals 
were not provided. 
 
PA and BMI were obtained 
from self-report. PA was 
defined as active based on the 
energy expenditure of activity 
(1,000 kcal/week) or inactive 
(<1,000 kcal/week). BMI was 
classified according to the 
recommended cut-offs. 
Kenchaiah et al. 
(2008)(62) 
Prospective observational 
data from the Physicians’ 
Health Study. 
Participants: 21,094 men 
Healthy BMI – active  
Healthy – inactive  
Overweight – active  
Overweight – inactive  
1.00 (reference) 
1.19 (0.94-1.51) 
1.49 (1.30-1.71) 
1.78 (1.43-2.23) 
PA and BMI were obtained 
from self-report. PA was 
defined based on the response 
to a single question on the 
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aged 40 to 84 years at 
baseline. A total of 1,109 
cases of incident HF 
occurred during a mean 
follow-up of 20.5 years. 
Obese – active  
Obese – inactive 
2.68 (2.08-3.45) 
3.93 (2.60-5.96)  
 
frequency of vigorous exercise. 
Active was defined as any form 
of vigorous activity while 
inactive was rare or never. BMI 
was classified according to 
suggested cut-offs. 
 
Sui et al. (2008)(63) Prospective observational 
data from the CCLS. 
Participants: 6,249 
women aged 20 to 79 
years at baseline. A total 
of 143 cases of T2DM 
occurred during 17 years 
of follow-up. 
Healthy BMI – fit 
Healthy – unfit  
Fat – fit  
Fat – unfit 
1.00 (reference) 
1.05 (0.67-1.65) 
1.79 (0.95-3.38) 
2.55 (1.49-4.37) 
CRF was determined by a 
maximal exercise test and 
subjects were classified based 
on tertiles according to their 
fitness levels as fit (2-3rd 
tertiles) and unfit (1st tertile). 
BMI was derived from 
measured height and weight 
and participants were 
categorised according to 
clinical definitions. 
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Lee et al. (2009)(64) Prospective observational 
data from the CCLS. 
Participants: 14,006 men 
aged 20 to 79 years at 
baseline. A total of 4,089 
cases of impaired fasting 
glucose (IFG) or T2DM 
occurred during 7.2 years 
of follow-up. 
IFG 
Healthy BMI – fit  
Healthy – unfit  
Overweight – fit  
Overweight – unfit  
Obese – fit  
Obese – unfit 
 
T2DM 
Healthy BMI – fit  
Healthy – unfit  
Overweight – fit  
Overweight – unfit  
Obese – fit  
Obese – unfit 
 
 
1.00 (reference) 
1.03 (0.84-1.27) 
1.23 (1.14-1.32) 
1.26 (1.08-1.46) 
1.37 (1.18-1.60) 
1.48 (1.22-1.80) 
 
 
1.00 (reference) 
1.55 (0.86-2.81) 
1.58 (1.26-1.97) 
2.10 (1.41-3.12) 
3.00 (2.13-4.23) 
5.69 (4.04-8.00) 
CRF was determined by a 
maximal exercise test and 
subjects were classified 
according to their fitness levels 
as fit and unfit. BMI was 
measured, and participants 
were assigned according to 
WHO categories. 
 
Lee et al. (2012)(18) Prospective observational 
data from the ACLS. 
Participants: 3,148 adults. 
During a mean follow-up 
of 6.6 years, a total of 
1,178 incident cases of 
metabolic syndrome 
occurred. 
 
Hypertension 
Loss BF% – gain CRF 
Loss BF% – stable CRF  
Loss BF% – loss CRF  
Stable BF% – gain CRF  
Stable BF% – stable CRF  
Stable BF% – loss CRF  
Gain BF% – gain CRF  
Gain BF% – stable CRF 
Gain BF% – loss CRF 
 
 
1.00 (reference) 
0.98 (0.75-1.29) 
1.25 (0.83-1.86) 
1.18 (0.86-1.62) 
1.19 (0.92-1.54) 
1.36 (1.01-1.84) 
1.19 (0.87-1.62) 
1.11 (0.84-1.46) 
1.70 (1.27-2.26) 
 
Change in fitness and BF% 
were calculated as the 
difference in maximal METs or 
BF% between the baseline and 
last examination. 
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Metabolic syndrome 
Loss BF% – gain CRF  
Loss BF% – stable CRF  
Loss BF% – loss CRF  
Stable BF% – gain CRF  
Stable BF% – stable CRF  
Stable BF% – loss CRF  
Gain BF% – gain CRF  
Gain BF% – stable CRF  
Gain BF% – loss CRF 
 
1.00 (reference) 
1.23 (0.86-1.77) 
2.03 (1.19-3.45) 
1.32 (0.87-2.00) 
1.29 (0.91-1.84) 
2.11 (1.40-3.18) 
1.58 (1.05-2.38) 
1.71 (1.20-2.45) 
2.82 (1.96-4.07) 
 
The InterAct 
Consortium 
(2012)(65) 
Observational data from 
the EPIC study. 
Participants: 12,403 
incident cases of T2DM 
and 16,154 controls. 
Healthy BMI – active  
Healthy – moderately active  
Healthy – moderately inactive  
Healthy – inactive  
Overweight – active  
Overweight – moderately active  
Overweight – moderately 
inactive  
Overweight – inactive  
Overweight – non-active  
Obese – active  
Obese – moderately active  
Obese – moderately inactive  
Obese – inactive 
1.00 (reference) 
0.83 (0.62-1.10) 
1.32 (1.01-1.72) 
1.81 (1.34-2.43) 
1.00 (reference) 
1.09 (0.93-1.28) 
 
1.15 (0.99-1.34) 
1.36 (1.14-1.62) 
1.63 (1.27-2.10) 
1.00 (reference) 
1.11 (0.87-1.40) 
1.36 (1.08-1.71) 
1.38 (1.08-1.78) 
 
PA and BMI were assessed by 
self-report. PA was assessed 
from three questions and 
subjects were allocated to four 
categories of activity as: 
inactive, moderately inactive, 
moderately active or active. 
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Kim et al. (2014)(66) Observational data from a 
sub study of the Korean 
Physical Activity and 
Obesity (K-POP). 
Participants: 232 
overweight and obese 
individuals to determine 
the metabolic syndrome.  
 
Low VA – high  
High VA – high  
Low VA – low  
High VA – low 
 
 
1.00 (referent) 
2.70 
3.42 
5.02 
 
Confidence intervals 
were not provided. 
 
Ratio of visceral adipose 
(VA)/subcutaneous adipose 
tissue was quantified by 
computerised tomography, 
whereas CRF was measured by 
a Tecumseh step test as high or 
low. 
   
Carlsson et al. 
(2014)(67)  
Observational data from a 
sub study of the Uppsala 
Health Survey (ULSAM-
study). Participants: 
2,196. During a median of 
30 years of follow-up, a 
total of 850 subjects 
suffered a cardiovascular 
event (myocardial 
infarction, stroke or heart 
failure). 
  
Healthy BMI – active  
Healthy – non-active  
Overweight – active  
Overweight – non-active  
Obese – active  
Obese – non-active 
1.00 (reference) 
1.21 (0.94-1.58) 
1.52 (1.16-1.98) 
1.63 (1.27-2.10) 
2.12 (1.42-3.14) 
2.36 (1.64-3.38) 
BMI and PA were captured by 
self-report. 
Loprinzi (2016)(68) Data from the 1999-2006 
National Health and 
Nutrition Examination 
Survey. Participants: 
2,289 subjects aged 40-79 
were assessed to predict 
10-year risk for a first 
Healthy BMI – inactive  
Overweight – inactive  
Obese – inactive  
Healthy – active  
Overweight – active  
Obese – active 
 
1.00 (reference) 
0.99 (0.53-1.87) 
1.75 (0.83-3.60)  
0.53 (0.20-1.04) 
0.53 (0.27-1.04) 
0.91 (0.16-5.20) 
BMI and PA activity were 
objectively measured. 
Accelerometry data were used 
to classify participants as 
meeting guidelines of PA; 
active was defined as meeting 
guidelines whereas inactive did 
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atherosclerotic CVD 
based on equations 
developed by the 
American College of 
Cardiology and the 
American Heart 
Association. 
 
not meet guidelines of activity.  
Crump et al. 
(2016)(17) 
Prospective observational 
data from the National 
Cohort Study of all 
Military Conscripts in 
Sweden. Participants: 
1,547,294 men. There 
were 16,979 incident 
cases of stroke during a 
mean follow-up of 25.7 
years. 
 
Healthy BMI – high  
Overweight/obese – high  
Healthy – medium  
Overweight/obese – medium  
Healthy – low 
Overweight/obese – low 
1.00 (reference) 
1.65 (1.46-1.85) 
1.20 (1.14-1.28) 
2.07 (1.89-2.27) 
1.66 (1.56-1.76) 
2.36 (2.14-2.60) 
CRF was measured by a 
bicycle ergometer test and 
categorised as high, medium or 
low. BMI was determined by 
measured height and weight. 
Crump et al. 
(2016)(69) 
Prospective observational 
data from the National 
Cohort Study of all 
Military Conscripts in 
Sweden. Participants: 
1,547,189 men. There 
were 93,035 incident 
cases of hypertension 
during a mean follow-up 
Healthy BMI – high  
Overweight/obese – high  
Healthy – medium  
Overweight/obese – medium  
Healthy – low  
Overweight/obese – low 
1.00 (reference) 
3.24 (3.12-3.37) 
1.36 (1.32-1.39) 
2.49 (2.43-2.56) 
1.66 (1.56-1.76) 
2.36 (2.14-2.60) 
CRF was measured by a 
bicycle ergometer test and 
categorised as high, medium or 
low. BMI was determined by 
measured height and weight. 
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of 25.7 years. 
 
Nguyen et al. 
(2017)(70) 
Prospective observational 
data from the 45 and Up 
study. Participants: 29,572 
adults without history of 
T2DM. During a mean of 
2.7 years of follow-up, 
611 incidence cases of 
diabetes occurred. 
Healthy BMI – low  
Healthy – medium  
Healthy – high  
Overweight – low  
Overweight – medium  
Overweight – high  
Obese – low  
Obese – medium  
Obese – high 
 
1.00 (reference) 
1.23 (0.78-1.94) 
0.80 (0.49-1.28) 
1.00 (reference) 
0.87 (0.64-1.19) 
0.95 (0.70-1.30) 
1.00 (reference) 
0.92 (0.67-1.25) 
0.82 (0.59-1.25) 
BMI and PA were captured by 
self-report. BMI was 
categorised based on 
recommended guidelines 
whereas PA was classified as 
low (<300), medium (300 to 
<660) or high (600 
min/week). 
Koolhass et al. 
(2017)(19) 
Observational data from 
the population-based 
Rotterdam Study. 
Participants: 5,344 aged 
55 years and over. There 
were 866 CVD events 
during a mean follow-up 
of 10.3 years. 
 
Healthy BMI – high  
Overweight – low  
Overweight – high  
Obese – low  
Obese – high 
 
 
 
1.00 (reference)  
1.33 (1.07-1.66) 
1.03 (0.82-1.29) 
1.35 (1.04-1.75) 
1.12 (0.83-1.52) 
BMI was derived from 
measured height and weight 
and PA was assessed by a 
questionnaire; participants were 
classified as having high or low 
PA based on the median of the 
study population. 
 
Cancer incidence     
Hou et al. (2004)(21) Observational data from a 
population-based case-
control study. 
Participants: 931 colon 
cases and 1,552 controls.  
Men 
BMI Q1 – high  
BMI Q1 – medium  
BMI Q1 – low  
BMI Q2 – high  
BMI Q2 – medium  
 
1.00 (reference) 
1.09 (0.56-2.02) 
1.07 (0.44-1.85) 
1.12 (0.32-1.89) 
1.35 (0.65-1.98) 
BMI was derived and 
determined based on quintiles 
(Q) of gender specific cut 
points of controls. PA was 
gathered by trained 
interviewers who collected 
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BMI Q2 – low  
BMI Q3 – high  
BMI Q3 – medium  
BMI Q3 – low  
BMI Q4 – high  
BMI Q4 – medium  
BMI Q4 – low  
BMI Q5 – high  
BMI Q5 – medium  
BMI Q5 – low 
 
Women 
BMI Q1 – high  
BMI Q1 – medium 
BMI Q1 – low  
BMI Q2 – high  
BMI Q2 – medium  
BMI Q2 – low  
BMI Q3 – high  
BMI Q3 – medium  
BMI Q3 – low  
BMI Q4 – high  
BMI Q4 – medium  
BMI Q4 – low  
BMI Q5 – high  
BMI Q5 – medium  
BMI Q5 – low 
 
1.46 (0.78-2.93) 
1.12 (0.46-1.92) 
1.24 (0.41-2.09) 
1.62 (0.82-3.29) 
1.12 (0.56-1.92) 
1.78 (0.91-2.15) 
3.41 (1.12-4.92) 
1.22 (0.57-2.13) 
2.61 (1.19-3.75) 
6.43 (1.82-8.54) 
 
 
1.00 (reference) 
1.14 (0.51-2.64) 
1.42 (0.47-2.35) 
1.07 (0.53-1.85) 
1.18 (0.42-2.05) 
1.71 (0.98-2.64) 
0.98 (0.42-1.72) 
1.06 (0.49-1.84) 
1.98 (1.04-3.10) 
1.12 (0.31-1.69) 
1.31 (0.72-2.16) 
3.56 (1.16-6.46) 
1.17 (0.70-1.89) 
2.47 (1.44-4.13) 
7.42 (2.84-10.01) 
information on different 
periods of life as high, medium 
or low.  
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Larsson et al. 
(2006)(22) 
Observational data from 
the Cohort of Swedish 
men (COSM). 
Participants: 45,906 men 
who were free of cancer at 
baseline. During a mean 
follow-up of 7.1 years, 
496 cases of colorectal 
cancer were accrued. 
 
Obese – <10 (m/d) 
Obese – 10-59 (m/d) 
Obese – ≥60 (m/d)  
Overweight – <10 (m/d) 
Overweight – 10-59 (m/d)  
Overweight – ≥60 (m/d)  
Healthy – <10 (m/d)  
Healthy – 10-59 (m/d)  
Healthy – ≥60 (m/d) 
1.00 (reference) 
0.70 (0.36–1.38) 
0.56 (0.26–1.23) 
0.84 (0.42–1.66) 
0.62 (0.34–1.13)  
0.45 (0.24–0.84) 
0.75 (0.36–1.55)  
0.49 (0.26–0.90)  
0.42 (0.22–0.78) 
 
BMI and PA were collected 
through a self-administered 
questionnaire. BMI was 
categorised according to WHO 
guidelines and PA as <10, 10 -
59 or ≥60 min/day (m/d).  
Byun et al. 
(2011)(24) 
Prospective observational 
data from the ACLS. 
Participants: 19,042 
males. During a mean 
follow-up of 9.3 years, a 
total of 634 incident cases 
of prostate cancer were 
accrued. 
 
BMI < 30 – low  
BMI < 30 – moderate  
BMI < 30 – high  
BMI  30 – low  
BMI  30 – moderate 
BMI  30 – high 
1.00 (reference) 
1.91 (1.18-3.14) 
2.00 (1.21-3.30) 
1.00 (reference) 
0.92 (0.45-1.89) 
0.53 (0.17-1.62) 
 
CRF was determined by a 
maximal exercise test and 
subjects were classified 
according to their fitness levels 
as low, moderate and high. 
BMI was measured, and 
participants were assigned as: 
non-obese (<30) or obese 
(30). 
 
McCullough et al. 
(2012)(23) 
Population-based sample 
of 1,504 female cases with 
breast cancer and 1,555 
female controls without a 
personal history of cancer 
from the Long Island 
Breast Cancer Study 
Project. 
Maintain weight – no RPA  
Lose – no RPA  
Low gain – no RPA  
High gain – no RPA  
Maintain weight – low RPA  
Lose – low RPA  
Low gain – low RPA  
High gain – low RPA  
1.00 (reference) 
1.05 (0.40-2.76) 
1.19 (0.62-2.27) 
1.28 (0.68-2.39) 
0.70 (0.33-1.46) 
0.48 (0.20-1.18) 
1.03 (0.56-1.90) 
1.48 (0.79-2.75) 
Recreational PA (RPA) was 
captured by self-report and was 
classified based on known 
periods of breast cancer 
susceptibility; low and high 
activity was defined based on 
the median of the control 
group. Likewise, BMI and 
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Maintain weight – high RPA 
Lose – high RPA  
Low gain – high RPA 
High gain – high RPA 
0.31 (0.11-0.88) 
0.97 (0.47-1.99) 
0.99 (0.54-1.84) 
1.02 (0.55-1.87) 
 
changes in weight were derived 
from self-report. 
  
Conroy et al. 
(2009)(25) 
Observational data from 
the Women’s Health 
Study. Participants: 
32,642 women aged 45 
and over. During a men 
follow-up of 8.8 years, 
264 women were 
diagnosed with 
endometrial cancer. 
 
Healthy BMI – active  
Healthy – inactive  
Overweight – active  
Overweight – inactive 
1.00 (referent) 
1.17 (0.77-1.77) 
1.60 (1.01-2.54) 
1.85 (1.26-2.72) 
PA and BMI were obtained 
from self-report. PA was 
defined as active based on the 
energy expenditure of activity 
(15) or inactive (<15 MET-
h/week). BMI was classified as 
healthy (<25) or overweight 
(25).  
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CHAPTER 5  
 
EVIDENCE CHECK EXAMINING CANCER RISKS 
ASSOCIATED WITH OBESITY OR PHYSICAL 
ACTIVITY   
 
 
 
In the preceding chapter, a detailed account of the “fat but fit” hypothesis was 
presented. The present chapter was part of an Evidence Check Review that was 
prepared for the Cancer Institute New South Wales. The lead author on this review 
was the author of this thesis, who did all the work on the updated review of all risk 
factors and cancer (except the alcohol section). The components of that report 
presented in this thesis only focus on the effects of physical activity or 
overweight/obesity on cancer risk.  
 
This chapter provides a systematic evidence review of the association between 
physical activity and cancer risk, and separately, between obesity and cancer risk. 
This review comprised an appraisal of systematic reviews and or meta-analyses 
conducted during the last 5 years. Tables 5.1 and 5.2 summarised the evidence for 
obesity and physical activity and cancer risks respectively, grading the evidence as 
convincing, probable, possible or weak. The “fat but bit” hypothesis was not part of 
the Cancer Institute NSW review due to the limited epidemiological evidence 
pertaining to cancer but is shown in the systematic review conducted in the previous 
chapter of this thesis. The final report can be found on the website of the Sax 
Institute. Suggested Citation: Nunez C, Nair-Shalliker V, Sarich P, Sitas F, 
Bauman A. Modifiable lifestyle factors and cancer risk an Evidence Check 
rapid review brokered by the Sax Institute (www.saxinstitute.org.au) for the 
Cancer Institute NSW, 2018.   
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Modifiable lifestyle factors and cancer risk 
 
Introduction 
 
Modification of cancer-related lifestyle risk factors is an important part of cancer 
prevention, as a recent report suggests one in three cancers is associated with 
lifestyle factors and thus may be preventable.(1) With the exclusion of tobacco 
exposure, the three most important modifiable determinants of cancer incidence are 
physical activity, maintaining a healthy weight and a healthy diet.  
 
Data from the Australian Bureau of Statistics (ABS) Australian National Health 
Survey (NHS) 2014-15(2) estimated unhealthy behaviours in the Australian 
population and reported that among adults older than 65, 44.7% did not achieve the 
recommended 30 minutes of moderate physical activity on most days of the week. 
Additionally, 45.5% of adults aged 18-64 years did not engage in the minimum 
recommended level of physical activity. The NHS also assessed rates of overweight 
and obesity, estimating the prevalence of being overweight or obese at 35.5% and 
27.9% respectively. Given the high prevalence of these unhealthy behaviours in the 
Australian population; the objective of this Evidence Check is to identify the most 
up-to-date available evidence linking physical activity, overweight and obesity to 
cancer risk. 
 
Notwithstanding the fact that the burden of cancer affects the society as a whole, 
there are priority populations with heightened susceptibility to these risk factors. 
Priority populations in Australia include, although are not limited to, Aboriginal and 
Torres Strait Islander people, culturally and linguistically diverse populations, 
socioeconomically disadvantaged people and rural and remote communities.(3) These 
population groups may be more likely to report unhealthy behaviours and lifestyles 
and consequently may be at increased risk of developing cancer.(3)  
 
The purpose of this Evidence Check was to examine the evidence currently available 
for the association between overweight and obesity, physical activity, diet, alcohol 
and cancer risk (the complete report is found in Appendix A). However, this chapter 
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presents only the obesity and physical activity sections of the report in order to 
answer the following questions:  
 
1. What is the evidence for the association between cancer risk and the following 
risk factors? 
 
(a) Overweight and obesity,  
(b) Physical activity 
 
2. What is the evidence for the above-mentioned risk factors on cancer risk in 
priority populations? 
 
3. What is the evidence for life course exposure of these risk factors on cancer 
risk? 
 
Methods 
 
Peer review literature 
 
I reviewed the academic literature to identify the association of these primary 
prevention risk factors and cancer incidence or mortality across the life course 
(pregnancy, childhood, adolescence, adulthood and lifetime) with a sub-focus on 
priority groups. The associations were reported overall and, where possible, stratified 
by sex. 
 
The methodology for the literature search is outlined below. Initially, I confined 
searches to systematic reviews or meta-analyses, but used large-scale single 
epidemiological studies if there were insufficient studies in any search within 
subgroups. 
 
Searches of the relevant academic literature published were conducted in English 
between 2012 and 2017 in key research databases including Cochrane, Medline, 
Scopus and PsycINFO. I used the search terms shown below for each risk factor. 
Note that for cancer types, I included the most commonly occurring cancer types in 
NSW, namely cancers of the prostate, oesophagus, colorectal cancer, melanoma, 
lung, head and neck, breast and uterine cancers, lymphoma, leukaemia, thyroid, 
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bladder, ovarian, kidney, pancreas and liver cancers. In addition, inclusion of 
cervical cancer and non-Hodgkin lymphoma were added, based on the greater burden 
of those cancers on Aboriginal populations. 
 
For overweight or obesity  
 
Primary search (of the overall global literature) 
- Cancer.mp OR exp neoplasms/ OR neoplasms/ep, et [Epidemiology, 
Etiology/ aetiology] OR neoplasms/ OR tumor.mp OR carcino*.mp OR 
Onco* OR neoplasms/ep [epidemiology] OR Neoplasms/pc [Prevention & 
Control] 
- AND 
- Overweight.mp OR obesity.mp OR high BMI OR body mass index OR WC 
OR waist circumference OR body fatness 
- Systematic reviews OR meta-analysis (OR review) 
 
Secondary search (which produced literature relevant to specific demographic sub-
groups but NOT unique to a group). The same above-mentioned strategy was used in 
addition to: 
- AND 
- Migrant* OR culturally diverse OR ethnic* OR Aboriginal OR Indigenous 
OR Oceanic ancestry group 
 
And then to further determine life stages, I included the following: 
- AND 
- Pregnancy OR gestation OR childhood OR adolescence OR adult* OR life 
 
A paucity of identified information redirected the focus of the research to any 
specific large population cohort studies that could be identified in the area; failing 
this, I sought case-control studies in the specific sub-areas. This also applied to other 
risk factors in relation to population sub groups. 
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For physical activity  
 
The same approach as above was used but for  
- Physical activity.mp OR physical activities.mp OR exercise/ OR motor 
activity 
A paucity of information redirected the focus of the research to large population 
cohort studies.  
 
Evidence grading 
 
The quality of the different systematic reviews and/or meta-analyses was assessed 
using the Assessment of Multiple Systematic Reviews (AMSTAR). This tool 
consists of 11 item criteria; each criterion is given a score of 1 if it is met, or a score 
of 0 if the criterion is not met, is unclear, or is not applicable.(4) An overall score was 
then calculated adding the individual item scores. An AMSTAR of 8 to 11 is 
considered high quality, 4 to 7 is medium, and 0 to 3 is low quality. 
 
One of the main objectives of this Evidence Check was to classify the evidence 
regarding the association of obesity and physical activity with cancer risk; a grading 
system was created to guide and inform policy strategies, classifying the evidence as 
“convincing”, “probable, “possible” and “weak”. This classification was slightly 
adapted from the World Cancer Research Fund’s criteria for judging the evidence 
(see below under criteria for grading the evidence). For practical public health 
interventions, efforts to reduce the burden of cancer should be implemented where 
the evidence is at convincing or probable levels since current evidence indicates a 
strong enough supportive association to guide practice. Possible evidence indicates 
some associations with the risk factor, but caution should be applied in using this 
evidence in practice, and weak evidence indicates limited capacity for use in practice.    
 
Criteria for grading the evidence  
 
The following criteria were used for grading the evidence in this Evidence Check. 
They were adapted from the World Cancer Research Fund/ American Institute for 
Cancer Research (WCRF/AICR).(5) 
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Convincing  
All the following criteria are essential: 
- Evidence from more than two systematic reviews and/or meta-analyses 
- More than half of the studies included in the review and/or meta-analysis are 
cohort studies 
- Reviews and/or meta-analyses are of medium-high to high quality (AMSTAR 
score of 6 or greater) 
- Where there is a paucity of information, data will be used from leading 
authorities (WCRF) in cancer prevention or at least two independent cohort 
studies. 
  
Probable  
This classification is also important to justify efforts and strategies designed to 
diminish cancer risks; all of the following are mostly required: 
- Evidence from more than one systematic review and/or meta-analysis 
- More than half of the studies included in the review and/or meta-analysis are 
cohort studies 
- Reviews and/or meta-analyses are of medium-high to high quality (AMSTAR 
score of 6 or greater) 
- Where there is a paucity of information, data will be used from leading 
authorities (WCRF) in cancer prevention or at least two independent cohort 
studies. 
 
Possible  
This classification is for evidence that is too limited to infer a convincing or probable 
judgement. However, there is a suggestive effect. 
 
Weak 
No conclusions can be drawn based on current evidence. 
 
Included studies 
 
The initial search strategy retrieved 2,316 records; after duplicates were removed, 
2,309 unique articles remained and were screened by the reviewing team, who 
119 
 
excluded 2,138 as irrelevant for this Evidence Check. A total of 171 full text articles 
were assessed for eligibility and this rapid review includes 120 systematic reviews 
and/or meta-analyses. Flowcharts of the literature selection process are included in 
Figures 5.1 and 5.2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 - Diagram flow of the included studies for overweight and obesity. 
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Figure 5.2 - Diagram flow of the included studies for physical activity. 
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The mean AMSTAR score1 and standard deviation (SD) for the included articles of 
obesity was 6.9 SD (6.1) and 5.7 (4.5) for physical activity (stacked graph, Appendix 
A.3). Tables 5.1 and 5.2 presents a detailed summary of the systematic reviews used 
in this review to grade the evidence for obesity and physical activity during the past 
5 years. 
 
Grey literature 
 
Publications from the following institutions were searched for relevant information: 
 
- Australian Department of Health 
- Australian Institute of Health and Welfare 
- Australian State Government Health departments 
- Cancer Institute NSW 
- Cancer Council NSW 
- World Cancer Research Fund Continuous Update Project 
- International Agency for Research on Cancer reports 
- National Health Service (NHS) UK 
- Cancer Research UK 
- Health Canada 
- Canadian Cancer Society 
- NZ Ministry of Health 
- The Canadian Institutes of Health Research (CIHR) relevant to cancer. 
 
We conducted a desktop search was for relevant grey literature, finding 11 relevant 
systematic literature reviews from the World Cancer Research Fund (WCRF) 
Continuous Update Project and reports from the International Agency for Research 
on Cancer (IARC). In addition, we search the Aboriginal and Torres Strait Islander 
Health Bibliography online database to identify relevant material regarding cancer 
risk among Australian Indigenous populations.  
 
 
                                                 
1 Standard measure used to rate the quality of systematic reviews 
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Findings 
 
Question 1 (a): Obesity and cancer risk 
 
Overweight and obesity are described as the accumulation of excess adipose tissue 
with the capacity to impair health.(6) Both terms are usually defined in 
epidemiological studies by body mass index (BMI) status, which is derived from 
weight (kg) divided by the square of height (m). BMI status between 25 and 29.9 
kg/m2 defines those who are overweight and ≥30 kg/m2 defines those who are 
classified as obese. 
 
We conducted a search to appraise the evidence of association between excess 
adiposity and cancer risk; our search identified 73 systematic reviews and/or meta-
analyses that examined this association. The majority of articles focused on body 
mass index (BMI) as an overall assessment of body composition. The WHO 
suggested levels of risk for adults as follows: underweight <18.5 kg/m2, healthy 
weight range 18.5 - <25 kg/m2, overweight ≥25 - <30 kg/m2 and obese ≥30 kg/m2.(6) 
This tool provides a reasonable correlation with body fat percentage, which is about 
0.70 to 0.80.(7) Waist circumference and waist to hip ratio were other measures of 
adiposity used to assess the association with cancer risk, in particular with central 
obesity.(8) However, there were very few studies that allowed us to infer risk 
relationships with these measurements. Therefore, grading of the evidence was based 
on assessment of BMI as the most frequently reported exposure. In some studies, 
BMI was considered as a continuous measure, and in other studies and reviews BMI 
was a categorical exposure, comparing risk in the highest with the lowest category of 
BMI.   
 
Based on the available literature, there was convincing evidence obesity was 
associated with an increased risk of cancers of the colorectum, liver and thyroid 
among men and women.(9-23) In addition, obesity was convincingly associated with 
postmenopausal breast and uterine cancer in women and advanced prostate cancer 
incidence in men.(24-33) On the other hand, a reduced risk was observed for lung 
cancer regardless of gender; this obesity paradox may be due to confounding by 
smoking status, since it influences body weight and body composition.(19)  Evidence 
of a probable increase in incidence among both sexes was observed for 
123 
 
adenocarcinoma of the oesophagus, bladder, kidney and pancreatic cancer; and 
ovarian cancer in women.(26, 34-41) Possible evidence was noted for non-Hodgkin 
lymphoma, head and neck cancers and melanoma, particularly in men, and there was 
weak evidence for cervical cancer and leukaemia.(24, 41-46)  
 
There was convincing evidence for an association between obesity and increased 
mortality from colorectal cancer and probable evidence for prostate, pancreatic and 
breast cancer mortality.(30, 47-52) For the other cancer types of interest, it was not 
possible to draw a conclusion.   
 
Question 1 (b): Physical activity and cancer risk 
 
Physical activity is a broad concept described as any bodily movement using large 
skeletal muscles that results in energy expenditure.(53) It covers different domains 
including household, occupational, commuting and recreational physical activities. 
The WHO and Australian guidelines for health usually require at least 150 minutes 
per week of moderate-to-vigorous intensity physical activity.  
 
We identified 47 systematic reviews and/or meta-analysis to evaluate the association 
between physical activity (PA) and cancer risk. Different domains of physical 
activity were assessed although recreational or leisure time physical activity (LTPA) 
was most commonly examined. This is presumed to be the most relevant domain of 
physical activity, at least in many societies where levels of occupational, domestic 
and transport-related physical activity have reduced dramatically.(54, 55) The highest 
level of physical activity, fitness or objectively measured movement (through 
accelerometry) was compared with the lowest level of physical activity, 
cardiorespiratory fitness or movement. We observed PA was associated with 
convincing risk reductions for cancer incidence, without sex differences, for lung and 
colorectal cancers; and for breast cancer among female-specific cancers.(22, 56-61) We 
noted probable evidence of an inverse association for female-specific cancers such as 
uterine cancer.(32, 62) There was possible evidence for reduced risk of kidney, thyroid, 
bladder and pancreatic cancer among men and women, and possible evidence in the 
case of premenopausal breast cancer, particularly with vigorous activity, and weak 
evidence for cancers of the oesophagus, liver, non-Hodgkin lymphoma and 
ovaries.(16, 23, 31, 63-69)   
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Regarding mortality, there was convincing evidence for associations between PA and 
reduced cancer-specific mortality for breast and colorectal cancer and probable 
evidence for all-cause cancer mortality.(70-76) Additionally, possible evidence was 
found for a risk reduction of all-cause cancer mortality with high levels of 
cardiorespiratory fitness.(77) 
 
Question 2:  
 
We retrieved 256 unique publications on Aboriginality and culturally and 
linguistically diverse communities. Of these, no article reported on the association 
between the risk factors of interest and cancer in these populations. Most of the 
studies focused on cancer beliefs, attitudes towards screening, cancer care, health 
disparities, cancer experience and health care use. 
 
Aboriginal and Torres Strait Islander people comprise diverse populations across all 
Australian states and territories. The largest absolute number of Aboriginal 
Australians live in New South Wales and Queensland.(78) These populations have a 
higher prevalence of modifiable lifestyle risk factors for cancer2 compared with non-
indigenous Australians, as they are reported to be more likely to drink alcohol at 
dangerous levels, to smoke tobacco, be obese and be physically inactive than non-
indigenous Australians.(79) Additionally, the NSW Cancer Plan recognises 
communities who are at heightened risk of cancer and poor cancer-related outcomes. 
These communities include those who are culturally and linguistically diverse.(3) 
However, this Evidence Check could not assess the association between modifiable 
risk factors and cancer specifically in Aboriginal and Torres Strait Islander people 
and culturally and linguistically diverse communities since no systematic reviews or 
individual studies met the criteria of this review.  
 
Only one systematic review on Aboriginal risk factors was identified.(79) Despite the 
fact that the review did not meet the criteria, it is worth mentioning the findings due 
to the limited number of studies on potential risk factors and cancer outcomes in this 
population. Remote geographical location, Aboriginality and age less than 65 years 
were factors associated with increased risk of developing oesophageal, lung and liver 
                                                 
2 The key issue for cancer risk with Aboriginal adults is tobacco use, as smoking rates remain three to fourfold 
higher than amongst non-Aboriginal Australians – but this is outside the scope of this report  
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cancer compared with non-Aboriginal people. The review, examining studies to mid-
2014, noted that behavioural risk factors were rarely reported in relation to cancer 
risk in studies of Aboriginal people, with only one study examining alcohol and 
tobacco use.  
 
Based on the top ten languages spoken in NSW3, the incidence of liver cancer was 
higher in migrants from China, Italy and Vietnam among both sexes. Additionally, 
the incidence of liver cancer was higher for males from Egypt, Korea and the 
Philippines. There was an increased incidence of stomach cancer in migrants from 
China, Italy, Korea and Vietnam, while the incidence of thyroid cancer was greater 
in people from Lebanon and the Philippines regardless of sex. Cervical cancer was 
elevated in women from China, The Philippines and Vietnam.(80) With the exception 
of these cancer incident patterns, other cancers among migrant populations 
resembled the overall Australian rates.  
 
Question 3:  
 
There were very few studies that allowed the inference of cancer risk from lifetime 
exposure to the risk factors of interest. A systematic review that examined childhood 
obesity as a predictor of morbidity later in adulthood found that obesity at ages 7-11 
years was associated with increased risk for all cancers and liver cancer in men. 
Furthermore, the highest BMI in children 12 years of age and over compared with 
the lowest was associated with incidence of colon, ovarian and kidney cancer.(81) 
This study reported one-off exposure levels in childhood and not life-course 
exposure levels. Two reviews of adult weight gain reported increased risk of 
colorectal cancer for those participants who gained the most weight from early 
adulthood or middle age to older age compared with those whose weight was 
stable.(11, 82) Assessment of physical activity during different periods of life found 
physical activity performed at ages less than 25 years, between 25 to 50 years, or 
older than 50 years was associated with lower risk of breast cancer in women.(83) No 
                                                 
3  The languages used were the most commonly spoken at home in NSW according to the ABS 2016 Census, and 
comprised Mandarin, Arabic, Cantonese, Vietnamese, Greek, Italian, Filipino/Tagalog, Hindi, Spanish or 
Korean  
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study was identified to have assessed cancer risk modifications between different 
risk factors for cancer.  
 
Gaps in the evidence 
 
Evidence of lifestyle cancer risk factors mostly focused on risk factor exposure 
during the period before cancer diagnosis, with limited attention to these behaviours 
across the life course. Moreover, clustered risk behaviours were evaluated in very 
few reviews.(12, 73, 84) No review and/or meta-analyses targeted priority population 
groups (Aboriginal and Torres Strait Islander people, socioeconomically 
disadvantaged and rural communities; and culturally and linguistically diverse 
populations).     
 
Discussion 
 
Obesity and low levels of physical activity were associated with common cancers 
globally and in Australia. The existing epidemiological literature support the role that 
primary prevention approaches at the population level, such as assisting people to 
maintain a healthy weight and be physically active can considerably diminish the risk 
of developing and dying from cancer. This provides an updated evidence base for 
action in the primary prevention of cancer, as one component of an integrated cancer 
prevention strategy.  
 
 
Applicability 
 
These findings support the role of primary prevention interventions for maintaining 
and achieving a healthy weight and adequate levels of physical activity. These 
preventive strategies should target individuals in the general population as well as 
priority communities including Aboriginal and Torres Strait Islander people and 
culturally and linguistically diverse groups. While this review could not provide 
evidence for cancer risk from modifiable lifestyle factors for these subgroups, it is 
well reported that these priority populations have higher risks of developing some 
cancers, and worse cancer-related health outcomes than the general population.(3) 
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Conclusion 
 
Several of the common cancers in Australia are related to the lifestyle risk factors 
obesity and physical inactivity. The most consistent cancer risks across these lifestyle 
risk factors are for colorectal cancer, breast cancer and prostate cancer, but other 
cancers show moderate or strong associations with individual risk factors. This 
provides a rationale for investment in the primary prevention of cancer as part of an 
overall approach to cancer prevention, targeting the whole population. 
  
Evidence gaps exist for sub-populations, with no evidence for cancer risk for these 
lifestyle factors specifically among Aboriginal and Torres Strait Islander populations, 
or culturally and linguistically diverse groups. This lack of evidence should not 
impede or delay public health action, as many of these risks are likely to be similar to 
the evidence currently available, and hence efforts should focus on population 
intervention rather than further studies.  
 
Finally, the vast number of 120 systematic reviews and meta-analyses in the five-
year period covered in this Evidence Check indicate the plethora of replicated and 
overlapping evidence reviews, and it is timely to focus on influencing population 
awareness of these lifestyle risks rather than producing further distillations of the 
epidemiological evidence. Furthermore, there is a population health co-benefit from 
the promotion of awareness of these lifestyles risk factors, as it would also make a 
major contribution to reducing other non-communicable disease risk (especially to 
cardiovascular disease and diabetes prevention). 
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Table 5.1 - Summary for obesity. 
 
 
Source 
(Author, 
year) 
Study 
type 
(reviews) 
Population/ 
setting 
N (number of 
studies, 
number of 
participants) 
Intervention 
/comparator 
Outcomes 
Direction/ 
magnitude of 
effect 
Comment/ Notes 
Amstar 
score 
Level of evidence 
(Convincing, 
Probable, Possible 
and weak) 
All cancers 
Freisling, H. 
et al 
(2017)(84) 
Meta-
analysis 
of 
prospecti
ve 
studies.  
European 
participants 
from 
Denmark, 
Greece, the 
Netherlands, 
Spain, 
Germany, 
Northern 
Ireland and 
Norway. 
7 cohort 
studies 
participating 
in the 
CHANCES 
consortium. 
The study 
used data from 
43,419 male 
and female 
participants.  
Hazard ratio 
and 95% 
confidence 
intervals were 
calculated per 
one-unit 
increment of 
each indicator 
of adiposity.  
Incidence for obesity-related 
cancers (defined as 
postmenopausal female 
breast, colorectum, lower 
oesophagus, cardia stomach, 
liver, gallbladder, pancreas, 
endometrium, ovary and 
kidney). Increased risks 
were observed for a unit 
increment in body mass 
index (BMI) 1.11 (CI: 1.02–
1.21) and waist 
circumference (WC) 1.13 
(CI: 1.04–1.23). Suggestive 
for waist to hip ratio (WHR) 
1.15 (CI: 1.00–1.32). No 
statistical significance was 
found with hip 
circumference (HC) 1.09 
(CI: 0.98–1.21).   
BMI and WC 
were associated 
with increased 
risk of obesity-
related cancers. 
Height and weight 
were objectively 
measured in all but 
one study. BMI was 
examined as a 
measure of overall 
adiposity, whereas 
WC, HC and WHR 
were examined as 
measures of body 
fat distribution.  
N/A Convincing 
evidence for 
obesity-related 
cancers. 
Kyrgiou, M. 
et al 
(2017)(23) 
Umbrella 
review 
and meta-
A wide 
range of 
countries. 
507 unique 
studies; of 
them, 371 
The summary 
effects for 
cancer 
Risk estimates were similar 
between men and women per 
5-unit increase in BMI for 
BMI was most 
commonly 
associated with 
This review 
conducted a wide 
range of analyses to 
8/11 Convincing 
evidence for 
incidence of 
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analysis. (73.2%) had a 
cohort design, 
(26.4%) were 
case-control 
studies and two 
(0.4%) were 
cross-sectional 
studies. Total 
of 1,766,389 
participants. 
incidence and 
95% 
confidence 
intervals were 
calculated per 
increase in 
body mass 
index 
(5kg/m2), 
waist and hip 
circumference 
(10 cm), waist 
to hip ratio 
(0.1), weight 
(5 kg), and 
weight gain (1 
kg or 5 kg).  
oesophageal adenocarcinoma 
1.54 (CI: 1.41–1.67), 
oesophageal squamous cell 
0.63 (CI: 0.53–0.75), lung 
0.79 (CI: 0.73–0.85), kidney 
1.30 (CI: 1.23–1.36), non-
Hodgkin lymphoma 1.07 (CI: 
1.04–1.10), leukaemia 1.12 
(CI: 1.05–1.18) and thyroid 
1.23 (CI: 1.10–1.39). Cancer 
incidence of colon, rectal and 
melanoma was higher in men 
than women. The respective 
risks in men were 1.30 (CI: 
1.25–1.35), 1.09 (CI: 1.06–
1.13) and 1.17 (CI: 1.05–
1.30). Cancer incidence in 
women was significant for 
postmenopausal breast, in 
particular among never-users 
of menopausal therapy 1.13 
(CI: 1.09–1.17) and 
endometrial 1.54 (CI: 1.47–
1.61). Regarding cancer 
mortality, BMI was associated 
with death from prostate 1.15 
(CI: 1.06–1.25), endometrial 
1.46 (CI: 1.29–1.65) and non-
Hodgkin lymphoma 1.14 (CI: 
1.04–1.25).   
cancer risk 
except for 
oesophageal 
squamous cell 
and lung cancer. 
estimate the effect of 
different measures of 
adiposity on cancer 
risk, including 
estimation of 
prediction intervals 
(to account for 
heterogeneity), 
evaluation of excess 
significance (bias) 
and credibility 
ceiling (to account 
for potential 
methodological 
limitations). In 
addition, the 
evidence on the 
different outcomes 
was graded based on 
the P-values of the 
random effects.  
colorectal, liver, 
kidney, thyroid, 
lung, uterine and 
postmenopausal 
breast cancer. 
Probable evidence 
for oesophageal 
adenocarcinoma. 
Keum, N. et 
al (2015)(85) 
Meta-
analysis of 
prospective 
observation
Population 
consisted of 
people from 
North 
46 publications 
corresponding to 
50 studies. 
Risks 
associated 
with an 
increase in 
Linear analyses among non-
HRT users were associated 
with a 5 kg increase in adult 
weight gain for 
No effect was 
found for prostate 
(stratified by 
advanced or 
This meta-analysis 
examined 8 cancer 
sites (breast, prostate, 
colon, endometrium, 
6/11 There were very 
few studies from 
which to draw a 
conclusion. 
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al studies. America 
(US and 
Canada), 
Europe, 
China, Japan 
and 
Australia. 
adult weight 
gain (linear 
and nonlinear 
effects).  
postmenopausal breast 
(relative risk 1.11, 95% CI: 
1.08–1.13), endometrial (RR 
1.39, 95% CI: 1.29–1.49) and 
ovarian cancer (RR 1.13, 
95% CI: 1.03–1.23). Colon 
risk was associated with 
weight gain regardless of sex 
(RR 1.06, 95% CI: 1.03–
1.10). For the nonlinear 
effects, the highest weight 
compared with the lowest 
was significant for kidney 
cancer (RR 1.42, 95% CI: 
1.11–1.81).  
localised 
disease), thyroid 
and 
premenopausal 
breast cancer.  
ovary, pancreas, 
kidney and thyroid). 
Menopausal therapy 
(HRT) may obscure 
the effect of adiposity 
on female cancers. 
Thus, the primary 
analysis for 
postmenopausal 
cancers was 
conducted among 
non-HRT users. 
Weight gain was 
captured through self-
report in all the 
studies assessed. 
Conclusion: avoiding 
further weight gain 
throughout adulthood 
itself may confer 
protection against 
postmenopausal 
breast, endometrial 
and ovarian cancer as 
well as colon and 
kidney cancer.  
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Wang, J. et al 
(2016)(24) 
Systematic 
review 
and meta-
analysis. 
European-
Australian, 
Asia-Pacific, 
and North 
American 
populations. 
Most of the 
included 
articles were of 
prospective 
design. 
Estimates of 
relative risk 
(RR) per 5 
kg/m2 increase 
in BMI and 
cancer 
incidence. 
In males, a 5-unit increment 
in BMI was associated with: 
liver 1.21 (1.06–1.39), 
colorectal 1.13 (1.10–1.17), 
kidney 1.18 (1.06–1.31), 
thyroid 1.16 (1.04–1.28), 
oesophagus and gastric 1.11 
(1.03–1.19), pancreas 1.10 
(1.01-1.19) and prostate 1.03 
(1.01–1.05) cancer, whereas 
lung cancer was associated 
with a decreased risk 0.86 
(0.82–0.90). In females, the 
same magnitude of 
association was observed for 
liver, kidney, thyroid, 
colorectal, pancreas and lung 
cancer. Additionally, 
increased cancer risk was 
found for postmenopausal 
breast 1.11 (1.08–1.14) and 
premenopausal ovarian 1.10 
(1.05–1.16) cancer. 
  
Increased cancer 
risk for most of 
the cancers 
examined with 
the exception of 
lung cancer. No 
effect was 
observed for 
some cancers in 
women such as 
oesophagus and 
gastric, 
premenopausal 
breast and 
postmenopausal 
ovarian cancer. 
About half the 
studies included in 
this meta-analysis 
objectively 
calculated BMI. 
6/11 Convincing 
evidence for 
incidence of 
colorectal, liver, 
thyroid, lung, 
uterine and 
postmenopausal 
breast cancer. 
Probable evidence 
for oesophageal 
adenocarcinoma, 
kidney and 
pancreatic cancer. 
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Bladder 
Qin, Q. et al 
(2013)(34) 
Meta-
analysis 
of cohort 
studies. 
Mostly 
participants 
from Europe 
and the US. 
11 cohort 
studies 
fulfilled the 
criteria. 
Highest BMI 
group 
compared with 
the lowest. 
Obesity was associated with 
an increased risk for bladder 
cancer in men and women 
(RR 1.10, 95% CI: 1.06–
1.16). 
Increased cancer 
risk incidence. 
BMI was 
ascertained mainly 
by self-report. 
Subgroup analysis 
by geographical area 
shows the 
association between 
obesity and bladder 
cancer was more 
significant for 
studies conducted in 
the US than those 
conducted in 
Europe. 
7/11 
Probable evidence 
for cancer 
incidence.  
Sun, J. W. et 
al (2015)(35) 
Meta-
analysis 
of cohort 
studies. 
European, 
Australian, 
North 
American 
and Asian 
populations. 
15 cohort 
studies with 
14,201,500 
participants. 
Risks associated 
with BMI (linear 
and nonlinear 
effects).  
Compared with normal 
weight, RR of bladder 
cancer were 1.07 (95% CI: 
1.01–1.14) and 1.10 (95% 
CI: 1.06–1.14) for 
overweight and obese 
categories respectively. RR 
for each 5 kg/m2 increase in 
BMI was 1.04 (95% CI: 
1.01–1.07). 
Increased cancer 
risk. 
RRs were 
significant in studies 
conducted in Europe 
and North America 
more so than in 
Asia. No difference 
was observed when 
analysis was 
stratified by self-
reported BMI or 
measure. 
7/11 
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Breast 
Amadou, A. 
et al 
(2013)(86) 
Systematic 
review 
and dose–
response 
meta-
analysis. 
Women from 
the following 
ethnic groups: 
Caucasian 
(American or 
European), 
Asian and 
African 
(African–
American or 
from Africa). 
30 studies 
were included. 
Of them, 11 
were cohort 
studies. 
Risks 
associated 
with different 
anthropo-
metric 
measures 
(linear and 
nonlinear 
effects).  
Inverse association was 
significant among African and 
Caucasian women (increase 
by 5 kg/m2 of BMI) 0.95 
(95% CI: 0.91–0.98) and 0.93 
(95% CI: 0.91–0.95) 
respectively. On the other 
hand, a significant positive 
association was observed in 
Asian women 1.05 (95% CI: 
1.01–1.09). 
Risk appeared 
to differ by 
ethnicity. There 
was not a 
significant 
association 
between weight, 
HC or WC and 
premenopausal 
breast cancer 
risk. 
The analysis focused 
on anthropometric 
measures and the risk 
of premenopausal 
breast cancer in 
different ethnic 
groups. Linear risk 
was estimated by 
increase in 5 kg/m2 
of BMI, 0.1 of WHR 
and 10 cm of WC 
and HC.  
8/11 
Convincing 
evidence for 
incidence of 
postmenopausal 
breast cancer and 
probable evidence 
for breast cancer 
mortality. 
Chan, D. S. 
et al 
(2014)(49)  
Systematic 
review and 
meta-
analysis.  
A wide 
range of 
countries. 
However, 
most of the 
studies were 
based in 
North 
America or 
Europe. 
A total of 82 
follow-up 
studies 
assessed the 
relationship 
between BMI 
and mortality 
in women with 
breast cancer. 
Breast cancer 
mortality risks 
associated 
with BMI. 
Pre-diagnosis BMI was 
associated with breast cancer 
mortality. Obese or 
overweight women had RRs 
of 1.35 (1.24–1.47) and 1.11 
(1.06–1.17) respectively when 
compared with women with a 
healthy BMI. Additionally, 
BMI <12 months after 
diagnosis was associated with 
breast cancer mortality. The 
RR for obese women was 
1.25 (1.10–1.42) and 1.11 
(1.03–1.20) for overweight. 
No significant 
effect was found 
for BMI after 12 
months of 
diagnosis.  
There was no 
significant 
heterogeneity 
between pre- and 
postmenopausal 
breast cancer. Two 
co-authors reported 
personal fees from 
food makers and 
pharmaceutical 
companies. 
8/11 
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Chen, G. C. 
et al (2016)(7) 
Meta-
analysis of 
prospective 
studies. 
Mostly 
participants 
from Europe 
and the US. 
A total of 18 
publications 
were included 
in the analysis. 
Measures of 
central 
adiposity were 
used for 
increments of 
10 cm in WC 
and 0.1 in 
WHR.  
Increments in WC were 
associated with breast cancer 
incidence 1.06 (1.04–1.09). 
Besides, 0.1-unit increase of 
WHR was associated with 
postmenopausal cancer 1.07 
(95% CI: 1.01–1.14). 
No effects of 
WC or WHR 
were found on 
premenopausal 
cancer. 
The WHR-
postmenopausal BC 
association lost 
statistical significance 
after correcting for 
publication bias (RR 
1.06, 95% CI: 0.99–
1.13). Measurements 
of WC and WHR 
were based on self-
report.  
8/11 There were very few 
studies from which 
to draw a 
conclusion. 
Cheraghi, Z. 
et al 
(2012)(87) 
Meta-
analysis. 
Mostly 
participants 
from Europe 
and the US. 
50 studies 
were included 
in this meta-
analysis, of 
them 15 were 
prospective 
studies. 
Risks 
associated 
with BMI.  
BMI was associated with 
incidence of postmenopausal 
breast cancer. The estimated 
odds ratio from case-control 
studies was 1.21 (95% CI: 
1.08–1.34) and the risk ratio 
from cohort studies was 1.16 
(95% CI: 1.08–1.25).  
Overweight and 
obesity were not 
associated with 
premenopausal 
breast cancer. 
The results of both 
case-control studies 
and cohort studies 
showed that being 
overweight in the 
postmenopausal 
period slightly 
increased the risk of 
breast cancer.  
9/11 
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Munsell, M. 
F. et al 
(2014)(88) 
Meta-
analysis. 
Mostly 
participants 
from Europe 
and the US. 
57 studies 
fulfilled the 
criteria; of 
these 17 were 
cohort and 2 
RCT. 
Risk 
associated 
with different 
cut-offs of 
BMI.  
BMI of 25–29.9 kg/m2 and 
≥30 kg/m2 were associated 
with a reduced risk of 
premenopausal breast 
cancer. The respective RR 
were 0.95 (95% CI: 0.91–
1.00) and 0.83 (95% CI: 
0.75–0.91). On the other 
hand, a greater BMI was 
associated with increased 
risk of postmenopausal 
cancer; RR 1.10 (95% CI: 
1.06–1.13) for overweight 
and 1.18 (95% CI: 1.12–
1.25) for obese women. 
Increased risk of 
postmenopausal 
cancer with a 
higher BMI. 
Retrospective and 
prospective studies 
resulted in very 
similar estimates. 
6/11 
Convincing 
evidence for 
incidence of 
postmenopausal 
breast cancer and 
probable evidence 
for breast cancer 
mortality. 
Niraula, S. et 
al (2012)(50) 
Meta-
analysis. 
A wide 
range of 
countries. 
12 of the 21 
included 
studies were 
cohort studies. 
Mortality risks 
associated 
with different 
cut-offs of 
BMI. 
There was a higher 
likelihood of breast cancer 
mortality among obese 
women regardless of their 
menopausal status. 
Premenopausal: 1.23 (1.07–
1.42). Postmenopausal: 1.15 
(1.06–1.26). 
Increased risk of 
mortality. 
Body size was 
measured in 13 
studies. The 
combined HR was 
1.19 (95 % CI 1.10–
1.28) with no 
evidence of overall 
survival difference in 
the association with 
obesity. 
9/11 
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Colorectal 
Chen, Q. et 
al (2015)(89) 
Meta-
analysis.  
Participants 
from 
Canada, the 
US, Europe 
and 
Australia. 
5 out of 8 
studies were 
cohort studies. 
394,434 
people were 
assessed. 
Adult weight 
gain and risk 
of colorectal 
cancer (CRC). 
Comparison between the 
highest and lowest categories 
of adult weight gain produced 
the following RRs. CRC: 1.25 
(1.10–1.43), colon (CC): 1.30 
(1.14–1.49), rectal (RC): 1.27 
(1.02–1.58). There was a 
linear relationship between 
adult weight gain and risk of 
CRC, CC and RC. When 
analyses were stratified by sex, 
risks for men remained 
significant whereas in women 
they became insignificant. 
Increased risk in 
men.  
Adult weight gain 
was calculated as 
weight at baseline 
age minus 
weight in early 
adulthood 
(approximately 20 
years of age). 
7/11 Convincing 
evidence for 
cancer incidence 
and mortality. 
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Doleman, B. 
et al 
(2016)(46) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
18 prospective 
studies fulfilled 
the criteria. 
Assessment of 
risk for 
cancer-
specific 
mortality, 
cancer 
recurrence, 
and disease-
free survival 
after CRC 
diagnosis 
according to 
BMI reported 
in categories. 
Obese and underweight 
participants were both at a 
significantly increased risk of 
CRC mortality compared with 
normal weight participants. 
(RR 1.14, 95% CI: 1.05–1.24 
and 1.50, 95% CI: 1.20–1.87 
for obese and underweight 
respectively). Additionally, 
obese and underweight 
participants had worse disease-
free survival. The respective 
RRs were 1.07, 95% CI 1.01–
1.13 and 1.27, 95% CI 1.13–
1.43; and increased risk of 
recurrence RR 1.07, 95% CI 
1.02–1.13 for obese and RR 
1.13, 95% CI 1.05–1.21 for 
underweight patients.  
Increased risk of 
mortality for 
underweight and 
obese 
categories. 
All studies used 
World Health 
Organization 
(WHO) 
recommended BMI 
categories. 
However, the 
underweight group 
was slightly higher 
(<20 kg/m2). 
Overweight patients 
had no increased 
risk for any of the 
outcomes studied. 
9/11 
Convincing 
evidence for cancer 
incidence and 
mortality. 
Johnson, C. 
M. et al 
(2013)(90) 
Meta-
analysis. 
A wide 
range of 
countries. 
23 studies were 
included; 12 
were cohort 
studies. 
Estimates of 
RR per 8 
kg/m2 increase 
in BMI. 
A significant association 
between BMI and CRC 
incidence was observed per 8 
kg/m2 increment (RR 1.10, 
95% CI: 1.08–1.12). There 
was a gender variation, with 
the effect greater in men than 
in women. RR 1.29, 95% CI: 
1.26–1.34 among males. 
Increased cancer 
risk incidence. 
Study type was not 
a significant source 
of variation for the 
association between 
BMI and CRC risk. 
4/11 
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Karahalios, 
A. et al 
2015(81) 
Systematic 
review and 
meta-
analysis. 
Participants 
from 
Europe, the 
US and 
Australia. 
13 prospective 
studies fulfilled 
the criteria. 
Adult weight 
gain and risk 
of colorectal 
cancer. 
There was evidence of an 
increased risk of colorectal 
cancer incidence for the 
highest weight gain group 
compared with those in the 
reference group (hazard ratio 
(HR) 1.16, 95% CI: 1.08–
1.24). 
Increased cancer 
risk incidence. 
Change in weight or 
BMI was 
ascertained either 
from early 
adulthood to midlife 
or from midlife to 
older age. Studies 
that assessed change 
from midlife to 
older age had 
slightly lower 
hazard ratios 
compared with 
studies examining 
change from early 
adulthood to midlife 
(both were 
significant). 
8/11 There were very 
few studies from 
which to draw a 
conclusion. 
Lee, J. et al 
(2015)(47) 
Meta-
analysis of 
prospective 
cohort 
studies. 
Participants 
from 
Europe, the 
US, 
Australia 
and China.  
16 prospective 
cohort studies, 
which involved 
58,917 
individuals. 
Pre- and post-
diagnostic 
BMI with 
CRC 
mortality. 
Pre-diagnosis obesity 
was associated with increased 
colorectal cancer–specific 
mortality (RR 1.22, 95% CI: 
1.00–1.35). 
Increased risk of 
mortality for 
pre-diagnosis 
obesity. 
Pre-diagnosis 
underweight or 
overweight was not 
associated with 
colorectal cancer–
specific mortality. 
No association was 
found between 
post-diagnosis 
obesity and 
colorectal cancer–
specific mortality.  
8/11 
Convincing 
evidence for 
cancer incidence 
and mortality.  
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Ma, Y. et al 
(2013)(8) 
Systematic 
review of 
prospective 
studies. 
A wide 
range of 
countries. 
43 prospective 
studies with a 
total of 
9,000,000 
participants. 
Association 
between general 
obesity (BMI) 
or central 
obesity (WC) 
and the risk of 
colorectal 
cancer, 
comparing the 
highest and 
lowest 
categories. 
Obese participants were 
associated with increased 
CRC risk compared with 
individuals with a healthy 
BMI, RR 1.33 (95% C: 
1.25–1.42). Additionally, 
high (vs. low) WC levels 
were associated with 
increased risk. 1.46 (95% 
CI, 1.33–1.60). When only 
colon cancer incidence was 
assessed, the relationship 
between obesity and healthy 
BMI was 1.47 (95% CI: 
1.35–1.60); it was 1.15 (95% 
CI: 1.10–1.20) for rectal 
cancer. Results on WC 
levels in relation to colon 
cancer risk were 1.61 (95% 
CI: 1.42–1.84) for the 
highest vs. the lowest 
category and 1.35 (95% CI: 
1.11–1.63) for rectal cancer.  
Increased CRC 
risk with 
obesity. 
For studies 
conducted in 
Australia, the 
cancer risk from 
obesity vs. a 
healthy BMI was 
1.20 (95% CI: 
1.00–1.45); and 
1.51 (95% CI: 
1.22–1.87) for the 
highest WC 
compared with the 
lowest. The risk of 
CRC was slightly 
higher for men than 
women. 
9/11 
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Parkin, E. et 
al (2014)(9) 
Systematic 
review. 
Mostly 
participants 
from the US. 
32 prospective 
studies 
fulfilled the 
criteria. 
Assessment of 
the 
relationship 
between 
various 
measures of 
adiposity and 
mortality. 
Risk estimate per 5 kg/m2 
increment in pre-diagnosis 
BMI was significantly 
increased for men (1.19, 
95% CI: 1.14–1.25) but not 
for women (1.06, 95% CI: 
0.98–1.15). The cancer-
related mortality per 10 cm 
increase in WC was 1.20 and 
1.33 for each 10% increase 
in body fat (measured by 
electric impedance). Risk 
estimate per 5 kg/m2 
increment in pre-diagnosis 
BMI and overall survival 
were significantly increased 
for women (1.16, 95% CI: 
1.09–1.24) but not for men. 
Increased risk of 
mortality for 
pre-diagnosis 
obesity. 
No confidence 
intervals were 
provided for pre-
diagnostic WC and 
fat percentage. In 
summary, post-
diagnosis BMI did 
not have an effect 
on survival in 
studies using 
population-based 
databases. This is in 
contrast to the 
increased mortality 
noticed with pre-
diagnostic BMI. An 
author declared fees 
paid by a 
pharmaceutical 
company.  
7/11 Convincing 
evidence for 
cancer incidence 
and mortality. 
Schlesinger, 
S. et al 
(2015)(10) 
Systematic 
review and 
meta-
analysis.  
Participants 
from the US, 
Europe and 
Australia. 
13 studies 
fulfilled the 
criteria; of 
these 11 were 
cohort studies. 
Assessment of 
weight change 
from early or 
midlife 
adulthood to 
later adult 
years (high 
weight gain 
vs. stable 
weight). 
Individuals with high weight 
gain compared with 
individuals with stable 
weight had RR 1.22 (1.14–
1.30). In dose–response 
analysis, each 5 kg weight 
gain was associated with 
higher risk of CRC incidence 
RR 1.04 (1.02–1.05). 
Additionally, analyses of 
weight gain per 10, 15 and 20 
kg yielded the following risk 
of CRC 1.08 (95% CI: 1.04–
Increased cancer 
risk incidence. 
In stratified 
analyses by sex, 
weight gain was 
significantly 
associated with CC 
or RC risk in men 
but not in women. 
6/11 There were very 
few studies from 
which to draw a 
conclusion. 
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1.11), 1.12 (95% CI: 1.07–
1.17) and 1.16 (95% CI: 
1.09–1.23) respectively. 
  
Wu, S. et al 
(2014)(48) 
Meta-
analysis. 
A wide 
range of 
countries. 
29 prospective 
studies fulfilled 
the criteria. 
Estimation of 
the association 
between 
overweight or 
obesity with 
overall survival 
(OS). 
Analyses showed an 
increased mortality among 
obese patients (HR 1.10, 95% 
CI: 1.06–1.15), but not 
among overweight patients 
(HR 0.92 95% CI: 0.86–
1.00). 
Increased risk of 
mortality for 
obesity. 
Stratified analyses 
of pre-diagnostic 
and around-
treatment BMI 
showed a positive 
association between 
obesity and 
mortality. No effect 
was observed in 
post-treatment 
BMI. Obesity 
conferred a 
significantly worse 
OS for CRC 
patients irrespective 
of gender. 
8/11 Convincing 
evidence for 
cancer incidence 
and mortality. 
Oesophageal  
Fahey, P. P. 
et al 
(2015)(91) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
5 studies 
fulfilled the 
criteria; 2 
were cohort 
studies. 
Estimation of 
the association 
between BMI 
and mortality 
from 
oesophageal 
cancer. 
Risk of death for participants 
who were overweight or 
obese against those with a 
healthy BMI. The risk for 
oesophageal squamous cell 
carcinoma (OSCC) was 0.80 
(0.67–0.95) and for 
oesophageal adenocarcinoma 
(OAC) 0.80 (0.68–0.95). 
No effect of 
obesity on the 
outcome. 
When the 
overweight group 
was dissociated 
from the obese no 
decreased risk was 
found for obesity 
alone; OSCC HR 
1.05 (95% CI: 0.76–
1.46), and for OAC 
HR 0.85 (95% CI: 
0.68–1.06). 
7/11 Probable evidence 
for incidence of 
OAC.  
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Singh, S. et 
al (2013)(92) 
Systematic 
review and 
meta-
analysis. 
Participants 
from the US, 
Europe and 
Australia. 
6 observational 
studies fulfilled 
the criteria; 3 
were cohort 
studies. 
Estimation of 
the association 
between (OAC) 
incidence and 
central 
adiposity 
(comparing the 
highest and 
lowest). 
Central adiposity was 
associated with a higher risk 
of OAC (2.51, 95% CI: 
1.54–4.06), compared with 
normal body habitus. BMI 
was also associated with 
increased risk, in particular 
obese vs. healthy BMI (2.45, 
95% CI: 1.84–3.28). 
Increased cancer 
risk incidence. 
The effect of 
central adiposity 
was independent of 
BMI. 
9/11 
Probable evidence 
for incidence of 
OAC. 
Turati, F. et 
al (2013)(93) 
Meta-
analysis. 
A wide 
range of 
countries. 
22 observational 
studies fulfilled 
the criteria; 10 
were prospective 
studies. 
Estimation of 
the association 
between 
(OAC) 
incidence and 
different 
levels of BMI. 
Overweight and obesity 
were associated with an 
increased risk of cancer; the 
respective risks were 1.87 
(1.61–2.17) and 2.73 (2.16–
3.46).  
Increased cancer 
risk. 
No substantial 
differences were 
observed across sex 
and geographic 
areas. 
6/11 
Head and Neck *No meta-analysis or systematics review were found. Thus, a literature search on large prospective studies was conducted for this group of cancers. 
Gaudet, M. 
M. et al 
(2015)(42) 
Pooled 
analysis 
of cohort 
data. 
A wide 
range of 
countries. 
Data were 
pooled from 
20 cohort 
studies with 
1,941,300 
participants. 
Associations 
between 
anthropo-
metric 
measures and 
head and neck 
cancer (HNC). 
Associations with waist 
circumference (WC) and 
waist-to-hip ratio (WHR) 
were significant. HR for 5 
cm increment in WC was 
1.04, 95% CI 1.03–1.05; and 
1.07, 95% CI 1.05–1.09 per 
0.1-unit increase in WHR 
after adjustments for BMI.  
Increased cancer 
risk with 
measurements 
of central 
adiposity.  
The association with 
obesity defined by 
BMI differed by 
smoking status. An 
increased risk was 
observed among 
never-smokers 1.40 
(1.08–1.81) whereas a 
reduced risk was 
noticed in current 
smokers 0.58 (0.47–
0.72).  
N/A Weak 
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Gaudet, M. 
M et al 
(2012)(94) 
Cancer 
Prevention 
Study-II 
cohort and 
the 
Nutrition 
cohort. 
Participants 
from the US. 
Mortality data 
were used 
from 
1,059,153 
participants 
and incident 
analysis from 
150,262. 
Associations 
between 
different 
levels of BMI 
and head and 
neck cancer 
(HNC) 
incidence and 
mortality. 
BMI was not associated with 
incidence of HNC. On the 
other hand, overweight or 
obesity were associated with 
a reduced risk for mortality.  
Overweight or 
obese 
participants had 
a diminished 
risk of 
mortality. 
For cancer 
incidence, BMI was 
not related to the 
outcome even in 
stratified analysis 
by smoking status. 
N/A Weak 
Liver 
Chen, Y. et al 
(2012)(11) 
Meta-
analysis. 
Most of the 
studies were 
conducted in 
Asia. 
26 prospective 
studies were 
included with a 
study 
population of 
9,053,369 
participants. 
Associations 
between 
different 
levels of BMI 
and liver 
cancer 
incidence.  
Overweight and obesity 
were associated with an 
increased risk of cancer; the 
respective risks were 1.18 
(1.06–1.31) and 1.83 (1.59–
2.11). For populations with 
liver diseases (hepatitis C 
and cirrhosis), the 
association with obesity was 
between 2 and 3-fold higher. 
Increased cancer 
risk incidence. 
Most of the studies 
calculated BMI from 
objective measures. 
For stratified analysis, 
the association with 
obesity is stronger in 
males than in females. 
(Males: RR 1.91 
(1.51–2.41) vs. 
(females: RR 1.55 
(1.30–1.85).  
6/11 Convincing 
evidence for cancer 
incidence. 
Rui, R. et al 
(2012)(12) 
Meta-
analysis. 
Most of the 
studies were 
conducted in 
Asia. 
8 prospective 
studies met the 
inclusion 
criteria with 
1,779,471 
individuals. 
Associations 
between 
different 
levels of BMI 
and liver 
cancer 
incidence.  
Overweight and obesity 
were associated with an 
increased risk of cancer; the 
risk for overweight was 1.02 
95% CI: 1.02–1.03; 1.35 
95% CI: 1.24–1.47 for obese 
≥30; and 2.22 95% CI: 1.74–
2.83 for obese ≥35. 
Increased cancer 
risk with 
increasing BMI. 
Most of the studies 
calculated BMI 
from objective 
measures. 
7/11 
Convincing 
evidence for cancer 
incidence. 
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Wang, Y. et 
al (2012)(13) 
Meta-
analysis. 
A wide 
range of 
countries. 
21 studies 
fulfilled the 
criteria. Of 
them, 18 were 
prospective 
studies. 
Estimates of 
RR per 5 
kg/m2 increase 
in BMI. 
A 5-unit increment in BMI 
was associated with cancer 
incidence 1.39 (95% CI: 
1.25–1.55). Likewise, BMI 
was associated with 
mortality 1.27 (1.05–1.53). 
Increased cancer 
risk (incidence 
and mortality) 
with a 5-unit 
increment in 
BMI. 
Individuals with 
liver disease 
(hepatitis C and 
cirrhosis) had 
higher risks than 
the average 
population. 
7/11 
Lung 
Duan, P. et al 
(2015)(18) 
Systematic 
review and 
meta-
analysis. 
A wide range 
of countries. 
However, most 
of the studies 
were based in 
North 
America. 
29 prospective 
studies fulfilled 
the criteria with 
a total of 
7,253,941 
participants. 
Associations 
between 
different 
levels of BMI 
and lung 
cancer 
incidence.  
Obesity was inversely 
associated with cancer, the 
risk for BMI ≥30 was 0.91 
(95%CI: 0.85–0.98) and 
0.81 (95% CI: 0.72–0.91) 
for BMI ≥35 kg/m2. 
Overweight or 
obese 
participants had 
a decreased risk 
of cancer 
incidence. 
The effects of 
obesity on lung 
cancer risk were 
consistent regardless 
of smoking status. 
9/11 Convincing 
evidence for cancer 
incidence. 
Gupta, A. et 
al (2016)(17) 
Systematic 
review and 
meta-
analysis. 
A wide range 
of countries. 
14 prospective 
studies, 
comprising 
3,008,137 
participants. 
Associations 
between 
different 
levels of BMI 
and lung 
cancer 
mortality. 
A significantly lower lung 
cancer–related mortality was 
observed in overweight (HR 
0.76; 95% CI: 0.68–0.85) or 
obese individuals (HR 0.68, 
95% CI: 0.57–0.81). 
Overweight or 
obese 
participants had 
a diminished 
risk of 
mortality. 
The association was 
observed across 
sex, smoking status 
and geographical 
region. 
8/11 Convincing 
evidence for cancer 
incidence. 
 145 
 
Hidayat, K. 
et al 
(2016)(95) 
Systematic 
review and 
meta-
analysis. 
Most of the 
studies were 
conducted in 
the US. 
6 prospective 
cohort studies 
with a total of 
831,535 
participants. 
Estimation of 
the association 
between lung 
cancer 
incidence and 
central 
adiposity 
measures. 
Each 10 cm increase in WC 
and 0.1-unit increase in 
WHR were associated with 
cancer risk; the respective 
risks were RR 1.10, 95% CI: 
1.04–1.17 and 1.05, 95% CI: 
1.00–1.11. RRs for highest 
vs. lowest categories of WC 
and WHR were 1.32 (95% 
CI: 1.13–1.54) and 1.10 
(95% CI: 1.00–1.23). 
Higher cancer 
incidence with 
increased 
measurement of 
central 
adiposity. 
All studies 
concerning the 
association with WC 
were adjusted for 
BMI and the effect 
estimates were similar 
by smoking status. 
Almost all of the 
included studies were 
conducted in women. 
Thus, the findings 
might not be 
applicable to men. 
9/11 There were very few 
studies to draw a 
conclusion 
Shen, N. et al 
(2017)(19) 
Meta-
analysis. 
Participants 
from the US, 
Europe, 
China, New 
Zealand and 
Australia. 
15 prospective 
studies with a 
total of 
15,191,571 
individuals. 
Estimates of 
RR per 5 
kg/m2 increase 
in BMI and 
mortality. 
A 5 kg/m2 unit increase in 
BMI was associated with a 
lower risk of lung cancer 
mortality (0.94, 95% CI: 
0.92–0.96). 
Decreased 
cancer risk 
mortality with a 
5-unit increment 
in BMI. 
There was no effect 
modification 
observed on the 
basis of sex, 
smoking status or 
study location. 
9/11 Convincing 
evidence for cancer 
incidence. 
 Yang, Y. et 
al (2013)(20) 
Meta-
analysis.  
Most of the 
studies were 
conducted in 
the US and 
Europe. 
31 studies were 
included, of 
them, 20 were 
prospective. 
Associations 
between BMI 
and lung 
cancer 
incidence.  
Overweight and obesity 
were associated with a 
decreased risk of cancer; the 
risk for overweight was 0.74 
(95% CI: 0.68–0.80) and for 
obesity 0.71 (95% CI: 0.62–
0.80) compared with a 
healthy BMI. 
  
Participants with 
a high BMI had a 
diminished risk 
of cancer 
incidence. 
The association did 
not change with 
stratification by 
sex, smoking status, 
study population, 
study design or 
BMI measurement 
method. 
6/11 Convincing 
evidence for cancer 
incidence. 
 146 
 
Melanoma 
Sergentanis, 
T. N. et al 
(2013)(43) 
Meta-
analysis. 
Participants 
from 
Europe, the 
US and 
Australia. 
21 observational 
studies fulfilled 
the criteria. Of 
them, 10 were 
prospective 
studies. 
Associations 
between BMI 
and melanoma 
incidence.  
Among males, the effect 
estimate was 1.31 (95% CI: 
1.18–1.45) for overweight and 
1.31 (95% CI: 1.19–1.44) for 
obese compared with 
participants with a healthy 
BMI. Among females, no 
significant association was 
documented. 
Overweight or 
obese 
participants had 
an increased 
risk of 
malignant 
melanoma. 
The evidence is 
more apparent 
among males. 
6/11 Weak. 
Ovarian 
Aune, D. et 
al (2015)(38) 
Meta-
analysis.  
Participants 
from Europe 
and the US. 
28 prospective 
studies were 
identified. 
Associations 
between 
different 
adiposity 
measures and 
ovarian 
cancer. 
BMI, BMI during early 
adulthood (age 18–29 years) 
and WC were associated with 
ovarian cancer incidence. The 
summary RRs were 1.07 (CI: 
1.03–1.11) for a 5 kg/m2 
increment in BMI, 1.12 (CI: 
1.05–1.20) for a 5-unit 
increase in BMI during early 
adulthood and 1.06 (CI: 1.00–
1.12) for a 10 cm increase in 
WC. 
  
Increased cancer 
risk with 
increasing BMI 
and WC. 
There was evidence 
of a nonlinear 
association, with risk 
increasing from BMI 
about 28 kg/m2 and 
above. Additionally, 
no effect from 
weight gain, WHR or 
HC was observed. 
6/11 
Probable evidence 
for cancer incidence. 
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Bae, H. S et 
al (2014)(96) 
Systematic 
review and 
meta-
analysis. 
Mostly 
participants 
from Europe 
and the US. 
17 cohort 
studies. 
Associations 
between 
timing of BMI 
and ovarian 
cancer 
mortality. 
Obesity in adolescence and 5 
years prior to ovarian cancer 
diagnosis were associated 
with poor survival. Obesity 
in adolescence was 1.67 (CI: 
1.29–2.16); obesity 5 years 
pre-diagnosis was 1.35 (CI: 
1.03–1.76).  
Higher cancer 
mortality with 
increased BMI. 
No effect was seen 
on mortality for 
BMI at diagnosis.  
7/11 
Collaborative 
Group on 
Studies of 
Ovarian, 
Cancer 
(2012)(97) 
Meta-
analysis. 
A wide 
range of 
countries. 
47 studies; 17 
were cohort 
studies.  
Associations 
between BMI 
and ovarian 
cancer 
incidence. 
RR for ovarian cancer per 5 
kg/m2 unit increase in BMI 
was 1.10 (CI: 1.07–1.13) in 
never-users of menopausal 
therapy; and 0.95 (CI: 0.92–
0.99) in ever-users. 
Additionally, a BMI ≥30 
was associated with 
increased risk 1.13 (CI: 
1.06–1.20). 
Increased cancer 
risk. 
For BMI, there was 
significant 
heterogeneity for 
menopausal 
therapy. 
6/11 
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Liu, Z. et al 
(2015)(98) 
Meta-
analysis. 
Most of the 
studies were 
conducted in 
Europe and 
the US. 
26 observational 
studies, of which 
13 were cohort 
studies. 
Associations 
between 
different 
levels of BMI 
and ovarian 
cancer 
incidence.  
Overweight and obesity 
were associated with an 
increased risk of cancer; the 
risk for overweight was 1.07 
(95% CI: 1.02–1.12) and for 
obesity 1.28 (95% CI: 1.16–
1.41) compared with a 
healthy BMI. 
Increased cancer 
risk. 
When stratifying for 
menopausal status, 
overweight and 
obesity were 
associated with an 
increased risk of 
ovarian cancer in the 
premenopausal 
period (overweight 
1.31, 95% CI: 1.04–
1.65; obesity 1.50, 
95% CI: 1.12–2.00). 
However, no 
statistically 
significant 
association was 
observed in the 
postmenopausal 
period.  
7/11 
Probable evidence 
for cancer incidence. 
Poorolajal, J. 
et al 
(2014)(39) 
Meta-
analysis. 
Participants 
from Japan, 
the US, 
Europe and 
Australia. 
19 studies met 
the inclusion 
criteria; 10 
were cohort 
studies. 
Associations 
between 
different 
levels of BMI 
and ovarian 
cancer 
incidence.  
Obesity was associated with 
an increased risk for ovarian 
cancer (RR 1.27, 95% CI: 
1.19–1.35). 
Increased cancer 
risk. 
The pooled estimate 
combined 
premenopausal and 
postmenopausal 
periods since there 
was no evidence of 
heterogeneity. 
8/11 
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Protani, M. 
M. et al 
(2012)(99) 
Systematic 
review and 
meta-
analysis. 
Mostly 
participants 
from Europe 
and the US. 
20 cohort 
studies; of 
them 3 were 
of women 
with ovarian 
cancer 
participating 
in randomised 
trials. 
Associations 
between BMI 
and ovarian 
cancer 
mortality. 
Obese women showed 
poorer ovarian cancer 
survival compared with 
women with a healthy BMI 
(1.17, 95% CI: 1.03–1.34). 
When BMI was examined 
continuously, a 5-unit 
increase in BMI was not 
statistically significant (1.15, 
95% CI: 0.95-1.39). 
Increased cancer 
mortality. 
This estimate did not 
vary appreciably 
when analyses were 
restricted to studies 
where BMI was 
measured before 
diagnosis, or at the 
time of diagnosis or 
chemotherapy.  
6/11 Probable evidence 
for cancer 
incidence. 
Pancreatic 
Alsamarrai, 
A. et al 
(2014)(100) 
Systematic 
review and 
meta-
analysis. 
Mostly from 
Sweden, the 
US and 
Japan. 
26 prospective 
studies with a 
total population 
of 2,848,968. 
Associations 
between BMI 
and pancreatic 
cancer 
incidence. 
A high BMI ≥25 was not 
associated with risk (1.30, 
95% CI: 0.90–1.87).   
No effect. Overweight and 
obesity were not 
dissociated. 
9/11 
Probable evidence 
for cancer incidence 
and mortality. 
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Aune, D et al 
(2012)(37) 
Systematic 
review and 
meta-
analysis. 
Most of the 
studies were 
conducted in 
Europe and 
the US. 
29 prospective 
studies with a 
total population 
of 5,037,555 
participants. 
Associations 
between 
different 
adiposity 
measures and 
pancreatic 
cancer incidence 
and mortality. 
A 5-unit increment in BMI 
was associated with cancer 
incidence (1.10, 95% CI 
1.07–1.14). Additionally, 
measures of central 
adiposity were associated 
with increased risk. A 10 cm 
increase in WC was 1.11 
(95% CI: 1.05–1.18); and 
1.19 (95% CI: 1.09–1.31) 
for a 0.1-unit increment in 
WHR. On the other hand, a 
5-unit increment in BMI was 
not associated with mortality 
(1.16, 95% CI: 0.98–1.36). 
Increased cancer 
risk. 
Results were 
similar when 
stratified by gender 
and geographic 
location. There was 
evidence that the 
association between 
BMI and pancreatic 
cancer mortality 
was nonlinear, the 
risk was most 
pronounced above a 
BMI of 35. 
7/11 
Majumder, K 
et al 
(2016)(101) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
13 prospective 
cohort studies 
with a total 
population of 
3,434,737 
participants. 
Associations 
between pre-
diagnostic 
BMI and 
pancreatic 
mortality. 
Overweight and obesity 
were associated with an 
increased mortality; the risk 
for overweight was 1.06 
(95% CI: 1.02–1.11) and for 
obesity 1.31 (95% CI: 1.20–
1.42) compared with a 
healthy BMI. 
Increased cancer 
risk. 
In subgroup analysis, 
obesity was 
associated with 
increased mortality 
in Western 
populations (1.32, 
95% CI: 1.22–1.42) 
but not in Asia-
Pacific populations 
(0.98, 95% CI: 0.76–
1.27); the latter 
analysis consisted of 
only 2 studies. 
11/11 
Probable evidence 
for cancer incidence 
and mortality. 
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Shi, Y. Q. et 
al (2016)(102) 
Meta-
analysis.  
Mostly 
participants 
from Europe 
and the US. 
10 prospective 
studies.  
Association 
between BMI 
and survival.  
Pre-diagnostic obesity was 
associated with poorer 
survival; HR 1.29 (95% C: 
1.17–1.41). A dose–response 
analysis showed an 
increased risk of death of 
1.11 (95% CI: 1.05–1.18) 
for every 5 kg/m2 increase in 
pre-diagnostic BMI. 
Increased risk of 
mortality, 
particularly with 
high pre-
diagnostic BMI. 
BMI at diagnosis 
was not associated 
with cancer 
mortality. 
8/11 
Prostate 
Discacciati, 
A. et al 
(2012)(28)  
Meta-
analysis.  
Mostly 
participants 
from Europe 
and the US. 
13 prospective 
studies with a 
total of 
1,033,009 
subjects. 
Association 
between BMI 
and risk of 
localised and 
advanced 
prostate 
cancer. 
There was an inverse 
relationship between BMI 
and localised prostate 
cancer; RR 0.94 (95% CI: 
0.91–0.97) for every 5 kg/m2 
increase. For advanced 
disease, the relationship with 
BMI was 1.09 (95% CI: 
1.02–1.16) for every 5 kg/m2 
increase). 
Increased risk 
with advanced 
disease. 
Subgroup analyses 
stratified by 
ethnicity (known 
risk factor for this 
cancer) yielded 
similar risk for 
BMI. 
7/11 Convincing 
evidence for 
incidence of 
advanced prostate 
and probable for 
mortality. 
Markozannes
, G. 
(2016)(103) 
Umbrella 
review 
and 
meta-
analysis. 
A wide 
range of 
countries. 
46 meta-
analyses. 
Association 
between BMI 
and risk of 
localised and 
advanced 
prostate 
cancer. 
A 5 kg/m2 unit increase in 
BMI was associated with 
higher risk of prostate cancer 
mortality and advanced 
disease; the respective RR 
were 1.11 (95% CI: 1.06–
1.17) and 1.08 (95% CI: 
1.04–1.12). On the other 
hand, a 5 kg/m2 unit increase 
was associated with a 
reduced risk of low-grade 
prostate cancer.   
Increased cancer 
risk for mortality. 
This umbrella 
review ranked the 
evidence based on 
p-values. 
N/A 
Convincing 
evidence for 
incidence of 
advanced prostate 
and probable for 
mortality. 
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Zhong, S. et 
al (2016)(51) 
Meta-
analysis. 
A wide 
range of 
countries. 
38 studies were 
included; 37 
were cohort 
studies. 
Association 
between BMI 
and survival.  
An increment of 5 kg/m2 in 
pre-diagnosis BMI was 
associated with higher 
prostate cancer mortality 
(1.15, 95% CI: 1.07–1.23). 
Additionally, overweight 
and obesity were associated 
with mortality; the risk for 
overweight was 1.14 (95% 
CI: 1.06–1.22) and for 
obesity 1.33 (95% CI: 1.22–
1.45) compared with a 
healthy BMI.  
Increased cancer 
risk for 
mortality. 
No effect was seen 
with post-diagnosis 
BMI and cancer 
mortality. 
8/11 
Zhang, X. et 
al (2015)(29) 
Meta- 
analysis. 
Participants 
from 
Europe, the 
US and 
Australia. 
17 cohort 
studies. 
Association 
between BMI 
and mortality.  
Obesity was significantly 
correlated with an increased 
risk of aggressive prostate 
cancer (Gleason score 
between 7 and 10); 1.14 
(95% CI: 1.04–1.25). And 
also for prostate cancer 
mortality; 1.24 (95% CI: 
1.15–2.33).   
Increased risk 
with advanced 
disease. 
Obesity was not 
significantly 
correlated with PC 
incidence. There 
was no evidence of  
heterogeneity 
among the studies.  
6/11 Convincing 
evidence for 
incidence of 
advanced prostate 
and probable for 
mortality. 
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Kidney  
Choi, Y. et al 
(2013)(104) 
Meta-
analysis. 
Most of the 
studies were 
conducted in 
Europe and 
the US. 
20 prospective 
studies were 
included. 
Association 
between BMI 
and survival 
from renal cell 
carcinoma 
(most 
common 
cancer). 
Higher BMI was 
significantly associated with 
improved overall survival 
(HR 0.57, 95% CI: 0.43–
0.76), comparing the highest 
with the lowest BMI. 
Decreased 
cancer risk 
mortality. 
This study did not 
specify when BMI 
was calculated — 
most likely after 
diagnosis since the 
study focused on 
survival after 
nephrectomy 
(removal of the 
kidney). Also, 
publication bias was 
significant.  
6/11 Probable evidence 
for cancer incidence. 
Golabek, T. 
et al 
(2016)(105) 
Systematic 
review. 
A wide 
range of 
countries. 
20 prospective 
studies fulfilled 
the inclusion 
criteria; there 
were 8,716,689 
subjects. 
Association 
between BMI 
and cancer 
incidence and 
survival.  
A positive relationship 
between BMI and renal 
cancer risk was reported in 9 
studies in men and 10 in 
women; a modest 
association was described in 
1 study for both sexes and 
no association was reported 
in 3 studies of women and 
men. 3 studies reported 
higher risk for kidney cancer 
death in obese women.  
Increased cancer 
risk. 
This review did not 
summarise the 
information about 
mortality in men. 
N/A 
Probable evidence 
for cancer incidence. 
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Wang, F. et 
al (2014)(36) 
Meta-
analysis. 
A wide 
range of 
countries. 
However, 
most of the 
studies were 
based in 
North 
America or 
Europe. 
21 prospective 
studies with a 
total of 
9,080,052 
participants. 
Associations 
between 
different 
levels of BMI 
and risk of 
cancer. 
Overweight and obesity 
were associated with an 
increased incidence of 
cancer; the risk for 
overweight was 1.28 (95% 
CI: 1.24–1.33) and for 
obesity 1.77 (95% CI: 1.68–
1.87) compared with a 
healthy BMI. 
Increased cancer 
risk. 
The risk of kidney 
cancer incidence 
was slightly higher 
in Asian 
populations. Dose–
response analysis 
showed an 
increased risk of 
1.04 (95% CI: 
1.04–1.05) for each 
1 kg/m2 increase in 
BMI. 
6/11 
Thyroid 
Ma, J. et al 
(2015)(14) 
Meta-
analysis. 
A wide 
range of 
countries. 
32 
observational 
studies; of 
these, 24 were 
cohort. The 
total sample 
was 12,620,676 
subjects.   
Associations 
between 
obesity and 
risk of cancer. 
Obesity was associated with 
a significantly increased risk 
of thyroid cancer (RR 1.33, 
95% CI: 1.24–1.42). 
Increased cancer 
risk. 
In stratified 
analysis, the 
increased risk was 
observed regardless 
of sex, smoking 
status and ethnicity. 
8/11 Convincing 
evidence for cancer 
incidence. 
 155 
 
Schmid, D. et 
al (2015)(106) 
Meta-
analysis.  
A wide 
range of 
countries. 
21 observational 
studies fulfilled 
the criteria; 13 
were cohort 
studies. 
Associations 
between 
different 
levels of BMI 
and risk of 
cancer. 
Overweight and obesity 
were associated with an 
increased incidence of 
cancer; the risk for 
overweight was 1.25 (95% 
CI: 1.11–1.41) and for 
obesity 1.55 (95% CI: 1.21–
1.99) compared with a 
healthy BMI. 
Increased cancer 
risk. 
Obesity was 
significantly 
positively related to 
the following 
histological types: 
papillary, follicular 
and anaplastic; and 
inversely related to 
medullary thyroid 
cancer. The 
association between 
obesity and cancer in 
men was not 
significant in 
stratified analysis. 
7/11 
Convincing 
evidence for cancer 
incidence. 
Zhao Z,G. et 
al (2015)(16)  
Meta-
analysis. 
Participants 
from Korea, 
Norway, 
Sweden, 
Austria and 
the US. 
7 prospective 
studies met the 
inclusion 
criteria with a 
total of 
8,099,411 
participants. 
Associations 
between 
different 
levels of BMI 
and risk of 
cancer. 
Overweight and obesity 
were associated with an 
increased incidence of 
cancer; the risk for 
overweight was 1.13 (95% 
CI: 1.04–1.22), and for 
obesity 1.29 (95% CI: 1.18–
1.41) compared with a 
healthy BMI. 
Increased cancer 
risk. 
Obesity was 
associated with 
cancer risk among 
men and women. 
9/11 
Uterine 
Aune, D. et 
al (2015)(26) 
Systemat
ic review 
and 
meta-
analysis.  
Mostly 
participants 
from Europe 
and the US. 
32 prospective 
studies were 
included with 
a total 
population of 
6,445,402 
subjects. 
Associations 
between 
different 
adiposity 
measures and 
cancer 
incidence. 
A 5 kg/m2 unit increment in 
BMI was associated with 
increased risk of uterine 
cancer incidence and 
mortality; 1.54 (95% CI: 
1.47–1.61) and 1.45 (95% 
CI: 1.30–1.63 respectively. 
Increased cancer 
risk. 
There was evidence 
that the association 
between BMI and 
endometrial 
cancer was 
nonlinear, with risk 
increasing more 
10/11 
Convincing for 
incidence of uterine 
cancer 
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Each 5-unit BMI increase 
from BMI at age 18–25 
years was associated with 
cancer incidence (1.45, 95% 
CI: 1.28–1.64). Weight gain 
between age 18–20 and 
baseline showed a 5 kg 
increase in weight gain was 
also associated with cancer 
incidence (1.16, 95% CI: 
1.12–1.20). The risk of 
developing uterine cancer 
was increased by 1.27 (95% 
CI: 1.17–1.39) and 1.21 
(95% CI: 1.13–1.29) per 
every 10 cm increment in 
WC or 0.1 unit of WHR.  
noticeably for BMI 
over 25 kg/m2. In 
addition, the 
association of BMI 
was stronger among 
never-users of 
menopausal therapy 
that ever-users, 
although the effect 
was significant for 
both groups. No 
heterogeneity was 
seen for 
menopausal status. 
Jenabi, E. et 
al (2015)(27) 
Meta-
analysis. 
Mostly 
participants 
from Europe 
and the US. 
40 studies were 
included. Of 
them, 20 were 
cohort studies, 
involving 
32,281,242 
participants. 
Associations 
between 
different 
levels of BMI 
and risk of 
cancer. 
Overweight and obesity 
were associated with an 
increased incidence of 
cancer; the risk for 
overweight was 1.34 (95% 
CI: 1.20–1.48) and for 
obesity 2.54 (95% CI: 2.27–
2.81) in cohort studies.  
Increased cancer 
risk. 
There was 
substantial 
heterogeneity 
among cohort and 
case-control 
studies, with 
stronger effects in 
case-control 
studies. 
9/11 
Secord, A. A. 
et al 
(2016)(107) 
Systematic 
review and 
meta-
analysis 
A wide 
range of 
countries. 
18 prospective 
studies fulfilled 
the criteria. 
Associations 
between 
different 
levels of BMI 
and mortality. 
Obesity was only associated 
with mortality for values 
greater than 40 kg/m2 (1.66, 
95% CI: 1.10–2.51). 
Increased risk of 
death for 
participants with 
obesity grade 
III. 
No effects of 
obesity were seen 
for values below 
40. 
5/11 
Convincing 
evidence for cancer 
incidence. 
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 Zhang, Y. et 
al (2014)(108) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
However, 
most of the 
studies were 
based in 
North 
America. 
18 studies 
fulfilled the 
criteria; 7 
were cohort 
studies. 
Associations 
between 
different 
levels of BMI 
and cancer 
incidence. 
Overweight and obesity 
were associated with an 
increased incidence of 
cancer, the risk for 
overweight was 1.32 (95% 
CI: 1.16–1.50) and for 
obesity 2.54 (95% CI: 2.11–
3.06). 
Increased cancer 
risk. 
Subgroup analyses 
showed the positive 
associations were 
independent of 
study design, 
geographic 
locations, alcohol 
use, smoking habit 
and menopausal 
therapy. 
  
9/11 
Cervical 
Poorolajal, J. 
et al 
(2016)(44) 
Meta-
analysis. 
A wide 
range of 
countries. 
9 studies were 
included; 2 
were cohort 
studies. The 
total sample 
consisted of 
128,233 
participants. 
Associations 
between 
different 
levels of BMI 
and cancer 
incidence. 
The pooled analysis of 
cohort studies yielded a 
significant association with 
overweight but not with 
obesity. RR for overweight 
was 1.10 (95% CI: 1.03–
1.17).  
Increased cancer 
risk. 
No evidence of 
heterogeneity was 
detected. However, 
effects estimates 
were reported based 
on study design. The 
quality of the 
different studies 
ranged from low to 
moderate. 
Drawbacks: limited 
number of studies. 
10/11 Weak.  
Non-Hodgkin Lymphoma (NHL) there were no systematic reviews or meta-analysis identified during the literature search. Thus, large prospective studies were examined 
Patel, A. V. 
et al 
(2013)(41) 
Prospective 
cohort. 
Cancer 
Prevention 
Study-II 
Nutrition 
Cohort (US). 
152,423 men 
and women 
with 15 years 
of follow-up. 
Associations 
between 
different 
levels of BMI 
and cancer 
incidence. 
Obese individuals (BMI ≥30 
kg/m2) had higher risk of 
NHL incidence (HR 1.23, 
95% CI: 1.08–1.40) compared 
with participants with a 
healthy BMI (18.5–25 kg/m2). 
Increased cancer 
risk incidence of 
DLBCL and T-
cell lymphoma. 
The subtypes 
included in the 
analysis were 
all B-cell lymphoid 
neoplasms and T-
cell lymphoid 
N/A Weak.  
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However, the effect of the 
association was significant 
only in men when stratified 
analysis was performed. 
Regarding histological 
subsites, obesity was 
significantly associated with 
diffuse large B-cell 
lymphoma (DLBCL) and T-
cell lymphoma among men 
and women. 
neoplasms. 
Bertrand, K. 
A. et al 
(2013)(109) 
Prospective 
cohorts. 
The Health 
Professional
s Follow-up 
Study and 
the 
Nurses’ 
Health 
Study. 
46,390 men 
and 116,794 
women. 
Associations 
between 
different 
levels of BMI 
at different 
stages in life 
and cancer 
incidence. 
Middle adult BMI was 
associated with all NHL; a 5-
unit increase in BMI in men 
increased the risk of NHL 
1.13 (95% CI: 1.00–1.29). On 
the other hand, no effect was 
observed among women. 
BMI at young adulthood and 
adolescent somatotype was 
positively associated with all 
NHL in men and all NHL, 
DLBCL and follicular 
lymphoma (FL) in women. 
Increased cancer 
risk, in 
particular with 
early lifetime 
BMI. 
Although some 
differences in risk 
estimates were 
noted for men and 
women, there was 
no clear pattern of 
differences in 
associations and no 
statistical evidence 
of heterogeneity in 
effects by sex. 
N/A Weak. 
Grey literature 
Lauby-
Secretan, 
Béatrice et al 
(2016)(25) 
Body Fatness and Cancer — Viewpoint 
of the IARC Working Group. 
Associations 
between 
different 
levels of BMI 
and cancer 
incidence. 
The highest BMI category (vs. 
a healthy BMI) has been 
associated with these cancers: 
oesophagus (adenocarcinoma) 
RR 4.8 (3.0–7.7); colon and 
rectum 1.8 (1.3–2.5); liver 1.8 
(1.6–2.1); pancreas 1.5 (1.2–
1.8); corpus uteri 7.1 (6.3–
8.1); ovary 1.1 (1.1–1.2); 
Increased risk.    N/A IARC stated 
“there is sufficient 
level of evidence” 
for the 
aforementioned 
cancers. 
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kidney (renal-cell) 1.8 (1.7–
1.9). A 5 kg/m2 unit increment 
in BMI was associated with 
increased risk of thyroid 1.1 
(1.0-1.1) and breast 
(postmenopausal) 1.1 (1.1-
1.2).  
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2017)(30)  
Breast cancer: We identified 183 
publications from 181 studies that 
examined BMI during adulthood. 
Associations 
between 
different 
adiposity 
measures and 
cancer 
incidence. 
BMI was positively associated 
with breast cancer risk 
(summary RR per 5kg/m2 1.07 
(95% CI: 1.04–1.11). 
However, this risk differs by 
menopausal status. A 
protective effect was observed 
per 5-unit increase in BMI in 
premenopausal women and an 
increased risk was seen in 
postmenopausal women. The 
respective risks were: 0.93 
(0.90–0.97) and 1.12 (1.09–
1.15). Weight gain (from ages 
18–25 years to study 
baseline/recent follow-up) was 
associated with increased risk 
of postmenopausal cancer. Per 
5 kg of weight gain, risk 
increases 1.06 (1.05–1.08). 
Each 10 cm increment in WC 
was positively associated with 
postmenopausal breast cancer 
risk. RRs were 1.11 (95% CI: 
1.09–1.13).  
Increased risk 
for measures of 
general and 
central 
adiposity. 
No significant 
association was 
found with breast 
cancer mortality. 
BMI at early 
adulthood (age 18–
<30 years) was 
significantly 
inversely associated 
with any breast 
cancer risk. The 
effect of the 
association between 
weight gain and 
world regions was 
significant although 
the risk was slightly 
higher in Asian 
populations. 
N/A   
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World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2015)(110)  
Oesophageal cancer: 16 studies were 
included in the dose-response meta-
analysis. 
Associations 
between 
different 
adiposity 
measures and 
cancer 
incidence. 
There was an increased risk 
of oesophageal 
adenocarcinoma (OAC) with 
BMI whereas a protective 
effect was observed with 
squamous cell carcinoma. 
The respective RRs were 1.48 
(1.35–1.62) and 0.64 (0.56–
0.73). Additionally, increased 
risk for OAC was observed 
with weight gain and WC; 
risk increases 1.15 (1.09–
1.22) per 5kg increment in 
weight gain and 1.34 (1.17–
1.52) per 10 cm increase in 
WC.  
Increased risk 
for measures of 
general and 
central 
adiposity. 
Risks of 
oesophageal 
adenocarcinoma did 
not vary by sex or 
world regions. 
N/A   
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2017)(21)  
Colorectal cancer: 27 studies were 
identified after the 2010 SLR. 
Associations 
between 
different 
adiposity 
measures and 
cancer 
incidence. 
BMI was associated with 
cancer from any site of the 
colorectum. A 5kg/m2 
increase was associated with 
a risk of 1.07 (1.05–1.09) for 
colon and 1.02 (1.01–1.04) 
for rectal cancer. Colorectal 
cancer risk also increased 
with higher WC and WHR. 
Increased risk 
for measures of 
general and 
central 
adiposity. 
The association of 
BMI with 
colorectal cancer 
risk was slightly 
higher in men than 
in women. In 
addition, the effect 
of BMI was similar 
across different 
world regions. 
N/A   
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World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2014)(111)  
Bladder cancer: 22 studies were 
identified. 
Associations 
between 
different 
adiposity 
measures and 
cancer 
incidence. 
A 5kg/m2 unit increment in 
BMI was associated with 
increased risk (1.03, 95% 
CI: 0.97–1.09).  
No effect. Risk for BMI 
appears to be 
heterogeneous by 
geographic location 
with a significant 
increased risk for 
Asian population 
(RR 1.20, 1.01–
1.42).  
N/A   
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2012)(31)  
Endometrial cancer: 34 studies were 
identified. 
Associations 
between 
different 
adiposity 
measures and 
cancer 
incidence. 
A 5kg/m2 unit increment in 
BMI was associated with 
increased risk (1.50, 95% 
CI: 1.42–1.59). Higher BMI 
at ages 18–25 years was 
associated with increased 
risk (1.42, 95% CI: 1.22–
1.66) per 5 kg/m2 unit 
increment. Additionally, 
measures of central 
adiposity were associated 
with increased risk.  
Increased risk 
for measures of 
general and 
central 
adiposity. 
The increased risk 
of endometrial 
cancer was found 
among women who 
have used 
menopausal therapy 
or never-users, 
although the risk 
was higher among 
never-users.  
N/A   
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2015)(40)  
Kidney cancer: 28 studies were included.  Associations 
between 
different 
adiposity 
measures and 
cancer 
incidence and 
mortality. 
A 5kg/m2 unit increment in 
BMI was associated with 
increased incidence (1.30, 
95% CI: 1.25–1.35) and 
mortality (1.32, 95% CI: 
1.01–1.71). For weight gain 
RR per 5kg was 1.11 (95% 
CI: 1.07–1.14). Measures of 
central adiposity were 
associated with increased 
risk. 
Increased risk 
for measures of 
general and 
central 
adiposity. 
Risks were similar 
among men and 
women. 
N/A   
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World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2013)(45)  
Ovarian cancer: 26 prospective studies 
were included. 
Associations 
between 
different 
adiposity 
measures and 
cancer 
incidence. 
A 5kg/m2 unit increment in 
BMI was associated with 
increased risk (1.06, 95% 
CI: 1.02–1.11). For weight 
gain, RR per 5kg of weight 
was 1.05 (95% CI: 1.02–
1.07). 
Increased cancer 
risk. 
In stratified 
analyses by 
menopausal status 
effects were 
similar. 
N/A   
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2015)(22)  
Liver cancer: 15 studies were included. Associations 
between 
different 
adiposity 
measures and 
cancer 
incidence. 
A 5kg/m2 unit increment in 
BMI was associated with 
increased risk (1.30, 95% 
CI: 1.16–1.46). 
Increased cancer 
risk. 
Risks were similar 
among men and 
women. 
N/A   
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2014)(32)  
Prostate cancer: 64 studies were 
included. 
Associations 
between 
different 
adiposity 
measures and 
cancer 
incidence. 
There was no evidence of 
association between BMI 
and total prostate cancer. 
However, when analyses 
were conducted by subtypes 
a 5kg/m2 increment in BMI 
was associated with fatal 
cancer (RR 1.11, 1.06–17). 
Likewise, weight gain was 
not associated with total 
cancer but it was with fatal 
(1.03, 95% CI: 1.01–1.06) 
per 5kg increase in weight.  
No effect with 
total cancer. 
Risk were only 
significant for fatal 
prostate cancer. 
N/A   
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Life stages - Childhood ** there was only one systematic review, examining childhood obesity and the likelihood of developing cancer in adulthood. 
Llewellyn, A. 
et al 
(2016)(80) 
Systematic 
review and 
meta-
analysis.  
Participants 
from 
England, 
Scotland, 
Denmark, 
Israel and 
Norway. 
Approximately 
231,268 
participants.  
Associations 
between 
childhood 
obesity and 
development 
of cancer later 
in life. 
Childhood obesity between 
ages 7 and 11 years was 
associated with increased 
risk for ‘all cancers’ (1.14, 
1.00–1.29) and liver cancer 
among men (1.27, 1.11–
1.45). In analyses for 
children aged 12 and over, 
the highest BMI (compared 
with the lowest) was 
associated with liver cancer 
in men and women, colon 
cancer incidence and 
mortality, ovarian cancer 
and kidney cancer.  
Increased risk.  No effect was 
detected for breast 
cancer. The study 
concluded that the 
ability of childhood/ 
adolescent BMI 
measurement to 
predict adult 
morbidities was poor. 
The inception of most 
of the studies was 
around the 50s. 
7/11 Possible. 
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Table 5.2 - Summary for physical activity. 
 
 
Source 
(Author, 
year) 
Study type 
(reviews) 
Population 
/setting 
N (number of 
studies, number 
of participants) 
Intervention/ 
comparator 
Outcomes Direction/ 
magnitude of 
effect 
Comment/ Notes Amstar 
score 
Level of evidence 
(Convincing, 
Probable, Possible 
and weak) 
All cancers 
Kyu, H. H. 
et al 
(2016)(73) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
52 prospective 
studies. 
Effects of 
physical 
activity (PA) 
and cancer 
risk. 
The highest vs. the lowest 
category of PA was 
associated with a reduced 
risk for breast and colon 
cancer; the respective risks 
were 0.86 (0.83–0.90) and 
0.79 (0.74–0.85). 
Reduced risk. Higher levels of 
total PA were 
associated with 
lower risk of breast 
and colon cancer. 
9/11 Convincing 
evidence for 
cancer incidence 
of the colorectum 
and breast. 
Ballard-
Barbash, R. 
(2012)(112) 
Systematic 
review. 
Participants 
from the US, 
Europe, 
China and 
Australia. 
27 studies; most 
of these studies 
were designed 
as either follow-
up studies of 
healthy cohorts 
or follow-up 
studies of case 
subjects from 
case-control 
studies. 
Effects of PA 
and cancer 
survivorship. 
When comparing the highest 
with the lowest category of 
activity, 4 studies found no 
association between PA and 
breast cancer–specific 
mortality; 7 studies reported 
non–statistically significant 
decreased risks and 6 studies 
observed a statistically 
significant decreased risk. 
Additionally, there was little 
evidence of effect 
modification by menopausal 
status, tumour stage and 
hormone receptor status. For 
other cancers, there were 6 
articles on colorectal cancer; 
of these, 3 studies found PA 
Reduced risk For the purpose of 
the review, cancer 
survivor was defined 
according to the 
National Cancer 
Institute Office of 
Cancer Survivorship 
as “a person who is 
diagnosed with 
cancer from the onset 
of their diagnosis 
through the balance 
of his or her life”. 
The authors 
concluded that “there 
is fairly consistent 
evidence that 
physical activity 
N/A Convincing 
evidence for 
colorectal and 
breast cancer 
mortality. 
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after diagnosis was 
associated with statistically 
significant reduced risks, 
with indication of a dose–
response relationship. 1 
article on prostate cancer 
found significant risk 
reduction, and 2 articles on 
ovarian cancer found no 
association. 
either before or after 
breast cancer 
diagnosis is 
associated with a 
reduction in breast 
cancer–specific 
mortality”. 
Li, T. et al 
(2016)(69) 
Meta-
analysis. 
Participants 
from North 
America, 
Asia and 
Europe. 
71 cohort 
studies. 
Association 
between PA 
and cancer 
mortality. 
Individuals who 
participated in the highest 
PA level had reduced risks 
for cancer mortality in the 
general population (0.83, 
95% CI: 0.79–0.87) and 
among cancer survivors 
(0.78, 95% CI: 0.74–0.84). 
Reduced risk. In the general 
population, a 
minimum of 2.5 
h/week of moderate-
intensity activity led 
to a significant 13% 
reduction in cancer 
mortality. 
Additionally, a 
greater protective 
effect occurred in 
cancer survivors 
undertaking PA post-
diagnosis vs. pre-
diagnosis. Effects for 
the general 
population by sex did 
not differ. However, 
among cancer 
survivors, effects 
were only significant 
among women. 
9/11 Probable 
evidence for all 
cancer-cause 
mortality. 
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 Li, Y. et al 
(2016)(70) 
Systematic 
review and 
meta-
analysis. 
Participants 
from the US, 
China, Japan 
and Europe. 
32 prospective 
studies. 
Association 
between pre-
diagnosis PA 
and all cancer 
mortality. 
Relative risk of all cancer 
mortality was 0.80 (95% 
CI: 0.76–0.85) for highest 
vs. lowest PA group. 
Reduced risk.   8/11 Probable 
evidence for all 
cancer-cause 
mortality. 
Liu, L. et al 
(2016)(113) 
Systematic 
review and 
meta-
analysis. 
Participants 
from North 
America, 
Asia and 
Europe. 
126 prospective 
studies.  
Effects of PA 
and cancer 
risk. 
Compared with the lowest 
level of leisure time 
physical activity (LTPA), 
the highest level had lower 
cancer risk (0.90, CI: 0.88–
0.92). Participants who met 
the average guidelines of 
PA recommended by the 
WHO had reduced cancer 
risks (0.93, CI: 091–0.95). 
Reduced risk. Sub-analyses 
indicated a similar 
cancer risk 
reduction for LTPA 
in males and 
females. In 
stratified analysis 
by cancer type, 
LTPA reduced the 
risk for breast 
cancer and colon 
cancer. 
9/11 Possible. 
Schmid, D. 
et al 
(2015)(76) 
Systematic 
review and 
meta-
analysis. 
Participants 
from the US, 
Finland and 
Japan. 
6 cohort studies 
with a total 
population of 
71,654 
individuals. 
Association 
between 
physical 
fitness or 
cardio-
respiratory 
fitness and 
cancer 
mortality. 
Compared with low 
cardiorespiratory fitness 
(CRF), intermediate levels 
were associated with a 
decreased risks of total 
cancer mortality (0.80, CI: 
0.67–0.97) and high levels 
were associated with even 
lower risks (0.55, CI: 0.47–
0.65). 
Reduced risk. Cardiorespiratory 
fitness showed a 
strong inverse 
association with 
total cancer 
mortality. 
8/11 Possible evidence 
for all cancer-
cause mortality. 
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Shi, Y. et al 
(2015)(114) 
Systematic 
review and 
meta-
analysis. 
Participants 
from Europe 
and China. 
30 
observational 
studies, of 
these, 10 were 
cohort. 
Effects of PA 
(household) 
and cancer 
risk. 
In cohort studies, the 
highest category of 
activity, compared with the 
lowest, was associated with 
reduced cancer risk (0.92, 
0.87–0.97). In stratified 
analysis by sex, the 
association was only 
significant for women 
(0.78, 0.69–0.88).  
Reduced risk. Study participants 
were mostly women 
in cohort studies. 
9/11 There were very 
few studies on 
household PA to 
draw a conclusion 
Schmid, D. 
et al 
(2014)(115) 
Systematic 
review and 
meta-
analysis. 
Participants 
from North 
America, 
Australia, 
China and 
Europe. 
23 prospective 
studies with a 
total 
population of 
49,095 
subjects. 
Pre-and post-
diagnosis PA 
in relation to 
cancer 
mortality 
among breast 
or colorectal 
cancer 
survivors. 
Among breast cancer and 
colorectal survivors, the 
highest level of pre-
diagnosis PA, compared 
with the lowest, was 
associated with reduced 
total mortality and death 
from breast or colon 
cancer. The respective RRs 
were 0.77 (0.69–0.88), 0.77 
(0.66–0.90) and 0.75 
(0.62–0.91). Additionally, 
post-diagnosis PA was also 
related to total mortality 
from breast or colorectal 
cancer. Breast or CRC 
survivors who increased 
their PA by any level from 
pre- to post-diagnosis 
diminished their total risk 
of mortality (RR 0.61, 
0.46–0.80) compared with 
those who did not change 
their behaviour.   
Reduced risk. The association 
between pre- or 
post-diagnosis PA 
and total mortality 
among breast 
cancer survivors did 
not differ according 
to BMI, 
menopausal status, 
or tumour oestrogen 
receptor status. 
However, 
postmenopausal 
women who 
engaged in PA had 
better cancer-
specific survival 
than premenopausal 
women. 
7/11 Convincing 
evidence for 
colorectal and 
breast cancer 
mortality. 
 168 
 
Bladder 
Keimling, 
M. et al 
(2014)(63) 
Systematic 
review and 
meta-
analysis. 
Participants 
from North 
America, 
Europe and 
Asia. 
15 studies; 11 
were cohort 
studies. 
Association 
between 
physical 
activity (PA) 
and bladder 
cancer 
incidence. 
In cohort studies, the 
highest category of PA, 
compared with the lowest, 
was associated with 
reduced cancer risk (0.89, 
0.80–1.00).  
Reduced risk. In stratified 
analysis, 
association was 
only significant for 
women. 
7/11 Weak. 
Non-Hodgkin Lymphoma 
Jochem, C. 
et al 
(2014)(66) 
Systematic 
review and 
meta-
analysis. 
Participants 
from North 
America and 
Europe. 
25 studies; 17 
were cohort 
studies. 
The 
associations 
between 
physical 
activity (PA) 
and subtype-
specific 
haematologic 
cancer 
incidence. 
In cohort studies, the 
highest category of PA, 
compared with the lowest, 
had no effect on the risk of 
non-Hodgkin lymphoma 
(0.93, 0.83–1.04) or 
leukaemia (0.91, 0.74–
1.12).  
Null. When combining 
the effect of case-
control and cohort 
studies, PA was 
associated with 
non-Hodgkin 
lymphoma 0.91 
(0.82–1.00). 
6/11 Weak. 
Breast 
Fontein, D. 
B. et al 
(2013)(116) 
Systematic 
review. 
Mostly from 
the US. 
17 studies, of 
which, 13 were 
prospective, 2 
were 
randomised 
controlled 
studies and 2 
were case-
control studies. 
Association 
between 
physical 
activity (PA) 
and cancer 
mortality after 
a breast cancer 
diagnosis. 
Pre-diagnostic PA led to a 
significantly better overall 
cancer survival in 5 out of 
11 studies. Regarding 
breast cancer–specific 
survival, risk was 
significantly lower in 3 out 
of 5 studies that assessed 
this outcome. 
Reduced risk.  Most studies 
demonstrate that 
PA has a positive 
effect on overall 
survival and breast 
cancer–specific 
survival. 
N/A Convincing 
evidence for 
cancer incidence 
and mortality. 
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Goncalves, 
A. K. et al 
(2014)(117) 
Systematic 
review. 
Participants 
from North 
America and 
Europe. 
21 studies; 7 
were cohort 
studies. 
Association 
between PA 
and cancer 
risk. 
In cohort studies, the 
highest category of 
activity, compared with the 
lowest, was associated with 
lower risks (0.61, 0.59–
0.63). 
Reduced risk.   9/11 Convincing 
evidence for cancer 
incidence and 
mortality. 
Lahart, I. M. 
et al 
(2015)(83) 
Systematic 
review and 
meta-
analysis. 
Participants 
from North 
America, 
Australia, 
China and 
Europe. 
22 prospective 
cohort studies. 
Association 
between PA 
and breast 
cancer 
mortality. 
Highest level of self-
reported pre-diagnosis 
lifetime activity (compared 
with lowest level), more 
recent activity (<12 years) 
and pre- and post-
diagnostic activity were all 
associated with lower 
mortality risks. The 
respective RRs were 0.73 
(0.54–0.98), 0.84 (0.73–
0.97), 0.72 (0.56–0.91) and 
0.59 (0.45–0.78). 
Reduced risk. Meeting 
recommended PA 
guidelines post-
diagnosis yielded 
lower risks of breast 
cancer mortality 0.67 
(0.50–0.90). Effects 
in stratified analysis 
were stronger in 
women with BMI 
≥25 kg/m2 and 
postmenopausal 
survivors.  
9/11 
Pizot, C. et 
al (2016)(118) 
Meta-
analysis. 
Participants 
from North 
America, 
Japan, China 
and Europe. 
38 prospective 
studies. 
Association 
between PA 
and cancer 
risk incidence. 
Highest vs. lowest category 
of PA was associated with 
reduced cancer risk (0.88, 
0.85–0.90). In dose–
response analysis, steady 
reductions in risk were 
detected with increasing 
PA, without evidence for a 
threshold. 
Reduced risk. In stratified 
analysis, effects 
were not influenced 
by BMI or 
menopausal status. 
However, 
menopausal 
condition was 
unknown for 43% 
of women. On the 
other hand, risk 
reductions were 
only observed in 
7/11 
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women who had 
never used 
menopausal 
therapy.  
Wu, Y. et al 
(2013)(119) 
Meta-
analysis. 
Participants 
from the US, 
China, Japan 
and Europe. 
31 prospective 
studies. 
Association 
between PA 
and breast 
cancer risk. 
Highest vs. lowest category 
of PA was associated with 
reduced cancer risk (0.88, 
0.85–0.91). Assessment of 
activity during different 
periods of life found PA 
performed <25 years, 25–
50 years, >50 years or 
during follow-up was 
associated with lower risk 
of breast cancer. 
Reduced risk. Similar effect size 
was found for 
different domains 
of PA 
(occupational, non-
occupational, 
recreational and 
household). The 
effect size was 
stronger for 
vigorous activity 
than for moderate 
activity. 
6/11 Convincing 
evidence for cancer 
incidence and 
mortality. 
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Zhong, S. et 
al (2014)(72) 
Meta-
analysis. 
Participants 
from North 
America, 
Australia, 
China and 
Europe. 
16 prospective 
studies.  
Association 
between PA 
and breast 
cancer 
mortality. 
Participants who engaged 
in any amount of PA vs. 
low levels before diagnosis 
had lower risk of breast 
cancer–specific mortality 
(0.82, 95% CI: 0.74–0.91). 
Reduced risk. Post-diagnosis PA 
yielded the same 
effect estimates on 
breast cancer–
specific mortality as 
pre-diagnostic PA. 
Stratified analysis 
showed a significant 
effect in women 
with a BMI ≥25 
kg/m2 but not in 
those with a BMI 
<25. 
8/11 
Colorectal 
Boyle, T. et 
al (2012)(59) 
Systematic 
review and 
meta-
analysis. 
Participants 
from the US, 
Europe, 
Japan and 
Australia. 
21 studies; 12 
were cohort 
studies. 
Association 
between 
physical 
activity (PA) 
and colon 
cancer risk by 
subsites. 
The most physically active 
individuals (vs. the least 
active) had similar reduced 
risks of proximal and distal 
colon cancer; the respective 
RRs were 0.73 (0.66–0.81) 
and 0.74 (0.68–0.80).  
Reduced risk. Risk did not differ 
by study design or 
sex. 
7/11 Convincing 
evidence for cancer 
incidence and 
mortality. 
Johnson, C. 
M. et al 
Meta-
analysis. 
A wide 
range of 
21 studies; 12 
were cohort 
PA score, which 
ranged from 1–5. 
There was a significant 
negative correlation 
Reduced risk. For cohort studies, 
the relative risk of 
4/11 
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(2013)(90) countries. studies. 1 was the lowest 
level and 5 the 
highest category 
of activity. 
between CRC risk and PA 
per increased score of 2 
standard deviations (RR 
0.88, 95% CI: 0.86–0.91). 
CRC was 0.91 
(95% CI: 0.88–
0.96). 
Je, Y. et al 
(2013)(120) 
Meta-
analysis. 
Participants 
from the US 
and 
Australia. 
7 cohort 
studies. 
Association 
between PA and 
colorectal (CRC) 
specific 
mortality. 
Individuals with high PA 
before diagnosis or after 
diagnosis vs. participants 
with low levels had 
reduced risks of CRC 
mortality; the respective 
RRs were 0.70 (0.56–0.87) 
and 0.65 (0.47–0.92).  
Reduced risk. Participants who 
engaged in any 
amount of PA 
before diagnosis or 
after diagnosis had 
a lower risk of 
dying from 
colorectal cancer. 
8/11 
Otto, S. J. et 
al (2015)(74) 
Systematic 
review and 
meta-
analysis. 
Participants 
from the US 
and 
Australia. 
4 cohort 
studies. 
Change over 
time in PA 
and its 
association 
with mortality 
in colorectal 
cancer 
patients. 
Increased PA post-
diagnosis was associated 
with reduced CRC-specific 
mortality (0.66, 0.49–0.83). 
However, increase in PA 
from pre-diagnosis to 5 
months post-diagnosis was 
not significant. 
Reduced risk. Survivors were 
defined according 
to the National 
Cancer Institute 
Office of Cancer 
Survivorship. 
9/11 Convincing 
evidence for cancer 
incidence and 
mortality. 
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Robsahm, T. 
E. et al 
(2013)(121) 
Systematic 
review and 
meta-
analysis. 
Participants 
from the US, 
Japan and 
Europe. 
11 cohort 
studies. 
Association 
between PA 
and colon 
cancer risk by 
subsites. 
Similar effect estimates 
were observed for proximal 
and distal colon; the RRs 
were 0.76 (0.70–0.83) and 
0.77 (0.71–0.83). No effect 
was detected for the 
association between PA 
and rectal cancer. 
Reduced risk. Different domains 
of PA were 
combined to 
estimate effect 
sizes. 
6/11 
Oesophageal 
Chen, Y. et 
al (2014)(65) 
Meta-
analysis. 
Participants 
from the US, 
Europe, 
Canada and 
Korea. 
7 studies; 3 
were cohort 
studies. 
Association 
between 
physical 
activity (PA) 
and risk of 
oesophageal 
cancer.  
Highest vs. lowest category 
of PA in cohort studies was 
associated with reduced 
cancer risk (0.78, 0.66–
0.92). 
Reduced risk. No significant 
difference was 
observed in 
subgroup analysis 
by sex.  
7/11 Weak. 
Fahey, P. P. 
et al 
(2015)(91) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
2 studies 
fulfilled the 
criteria. 
Estimation of 
the association 
between PA 
and mortality 
from 
oesophageal 
cancer. 
There was no effect 
observed from PA on risk 
of death for the highest 
category vs. the lowest 
(1.20, 95% CI: 0.91–1.58). 
Null. There were very 
few studies from 
which to properly 
assess this 
association. 
7/11 Weak 
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Singh, S. et 
al (2014)(33) 
Systematic 
review and 
meta-
analysis. 
Participants 
from the US, 
Europe and 
Korea. 
10 studies; 4 
were cohort 
studies. 
Association 
between PA 
and risk of 
oesophageal 
cancer.  
Highest vs. lowest category 
of PA in cohort studies was 
associated with reduced 
cancer risk (0.84, 0.71–
1.00).  
Marginal. Subgroup analysis 
found lower risk for 
oesophageal 
adenocarcinoma 
and no association 
was detected for 
squamous cell 
carcinoma.  
10/11 
Lung 
Brenner, D. 
R. et al 
(2016)(55) 
Meta-
analysis. 
Participants 
from the US, 
Europe and 
Asia. 
27 studies; 21 
were cohort 
studies. 
Association 
between 
physical 
activity (PA) 
and risk of 
lung cancer.  
Highest vs. lowest category 
of PA in cohort studies was 
associated with reduced 
cancer risk (0.79, 0.70–
0.89).  
Reduced risk. Effect estimates did 
not differ by study 
design, sex or 
histological type. 
Effects were 
significant for 
former and current 
smokers but not for 
non-smokers. 
6/11 Convincing 
evidence for 
cancer incidence. 
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Buffart, L. 
M. et al 
(2014)(56) 
Meta-
analysis. 
Participants 
from the US, 
Europe, 
Japan and 
Korea. 
18 studies; 12 
were cohort 
studies. 
Association 
between PA 
and risk of 
lung cancer. 
Moderate to high PA vs. 
low levels was associated 
with reduced risk (0.79, 
0.73–0.86) for cohort 
studies. 
Reduced risk. Similar effect 
estimates were 
observed for 
moderate or vigorous 
activity. Stratified 
analyses did not 
differ by sex or study 
design. Additionally, 
lower risks were 
observed in current 
smokers or former 
smokers but not in 
non-smokers. 
9/11 Convincing 
evidence for cancer 
incidence. 
  
  
Sun, J. Y. et 
al (2012)(57) 
Meta-
analysis. 
Participants 
from the US, 
Europe and 
Japan. 
14 prospective 
studies with a 
total of 
1,644,305 
subjects. 
Association 
between PA 
and risk of 
lung cancer. 
High and moderate levels of 
PA were associated with 
decreased risk of lung cancer 
compared with a low level of 
activity; for a high level of 
PA the RR was 0.77 (0.73–
0.81); it was 0.87 (0.83–
0.90) for moderate levels. 
Reduced risk. Effect estimates did 
not differ by sex. 
7/11 
Zhong, S. et 
al (2016)(58) 
Meta-
analysis. 
Participants 
from the US, 
Europe, 
Japan and 
Korea. 
18 studies; 12 
were cohort 
studies. 
Association 
between PA 
and risk of 
lung cancer. 
Highest vs. lowest category 
of PA in cohort studies was 
associated with reduced 
cancer risk (0.88, 0.83–
0.92).  
Reduced risk. Effect estimates did 
not differ by sex. In 
stratified analysis 
by smoking status, 
estimates were only 
significant in 
current and former 
smokers.  
9/11 
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Ovarian 
Zhong, S et 
al (2014)(67) 
Meta-
analysis. 
Participants 
from the US, 
Europe, 
Japan and 
Australia. 
19 studies; 9 
were cohort 
studies. 
Association 
between non-
occupational 
physical 
activity (PA) 
and risk of 
ovarian cancer. 
No association was found 
in cohort studies. 
Null. Effect estimates 
were significant for 
case-control 
studies. 
9/11 Weak  
Zhou, L. M. 
et al 
(2014)(68) 
Meta-
analysis. 
Participants 
from the US 
and Europe. 
6 studies; 3 
were cohort 
studies. 
Association 
between 
recreational 
PA and cancer 
risk. 
Cohort studies did not find 
association with cancer 
risk. 
Null. Pooled estimate of 
case-control and 
cohort studies was 
not significant. 
7/11 
Pancreatic 
Behrens, G. 
et al 
(2015)(64) 
Systematic 
review and 
meta-
analysis. 
Participants 
from North 
America, 
Asia and 
Europe. 
30 studies; 22 
were cohort 
studies. 
Association 
between 
physical 
activity (PA) 
and risk of 
pancreatic 
cancer. 
Highest vs. lowest category 
of PA in cohort studies was 
associated with reduced 
cancer risk (0.93, 0.88–
0.98). PA over time 
(maintained for 10 years) 
yielded a slightly lower RR 
of 0.86 (0.76–0.97). 
Reduced risk. Effect estimates did 
not differ by 
domains of PA.  
6/11 Possible evidence 
for cancer 
incidence. 
Farris, M. S. 
et al 
(2015)(122) 
Systematic 
review and 
meta-
analysis. 
Participants 
from North 
America, 
Asia and 
Europe. 
27 studies; 21 
were cohort 
studies. 
Association 
between leisure 
time physical 
activity (LTPA) 
and risk of 
pancreatic 
cancer. 
Highest vs. lowest category 
of PA in cohort studies was 
not associated with cancer 
risk. 
Null. LTPA was 
associated with 
cancer risk for the 
combined estimate 
of case-control and 
cohort studies 
(0.89, 0.83–0.96).  
8/11 
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Kidney 
Behrens, G. 
et al 
(2013)(62) 
Systematic 
review and 
meta-
analysis. 
Participants 
from the US, 
Europe and 
Asia. 
19 studies; 11 
were cohort 
studies. 
Association 
between 
physical 
activity (PA) 
and risk of 
kidney cancer. 
Highest vs. lowest category 
of PA in cohort studies was 
associated with lower 
cancer risk (0.89, 0.80–
0.99). 
Reduced risk. The summary RR 
estimate was not 
affected by PA 
domain, timing in 
life of PA, gender 
and study design.  
7/11 Possible evidence 
for cancer 
incidence. 
Prostate 
Markozannes
, G. et al 
(2016)(103) 
Umbrella 
review. 
A wide 
range of 
countries. 
5 meta-analyses 
focused on 
physical activity 
(PA) indices 
(total, 
occupational  
and 
recreational). 
Association 
between PA 
and risk of 
prostate 
cancer. 
No associations between 
PA and risk of any type of 
prostate cancer presented 
strong evidence. 
Null.   N/A Weak. 
Thyroid 
Schmid, D. 
et al 
(2013)(15) 
Systematic 
review and 
meta-
analysis. 
Participants 
from the US 
and Norway. 
7 out of 11 
studies were 
cohort studies.  
Association 
between 
physical 
activity (PA) 
and risk of 
thyroid cancer. 
Highest vs. lowest category 
of PA in cohort studies was 
associated with cancer risk 
(1.28, 1.01–1.63). 
Increased risk. Highest vs. lowest 
category of PA was 
not associated with 
cancer risk when 
case-control and 
cohort studies were 
combined. 
9/11 Possible evidence 
for cancer 
incidence. 
Uterine 
Keum, N. et 
al (2014)(123) 
Meta-
analysis. 
Participants 
from the US 
and Europe. 
20 studies, of 
which 10 were 
cohort studies. 
Association 
between 
physical activity 
(PA) and risk of 
uterine 
Highest vs. lowest category 
of PA in cohort studies was 
associated with lower 
cancer risk (0.85, 0.73–
0.98). 
Reduced risk.   7/11 Probable evidence 
for cancer 
incidence. 
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incidence. 
Schmid, D. 
et al 
(2015)(61) 
Meta-
analysis. 
Participants 
from the US 
and Europe. 
33 studies; 19 
were cohort 
studies. 
Association 
between PA 
and risk of 
uterine cancer 
incidence. 
Highest vs. lowest category 
of PA in cohort studies was 
associated with lower 
cancer risk 0.84 (0.78-
0.91). No significant 
associations were observed 
for PA during different 
periods of life and risk of 
cancer. 
Reduced risk. No evidence of 
heterogeneity 
between studies was 
observed. Effect 
estimates were similar 
across different PA 
domains (household, 
recreational and 
occupational) and 
intensity. 
 
  
7/11 
The following article was included from: The Physical Activity Collaboration of the National Cancer Institute’s Cohort Consortium based on the scarce literature for some cancer types 
Moore, S. C. 
et al 
(2016)(124) 
Pooled 
data. 
Participants 
from the US 
and Europe. 
12 prospective 
studies with a 
total of 1.4 
million people. 
Association 
between 
leisure time 
physical 
activity 
(LTPA) and 
risk of several 
cancer types. 
High vs. low levels of LTPA 
were associated with lower 
risks of 12 cancers: 
oesophageal 
adenocarcinoma, liver, lung, 
kidney, endometrial, myeloid 
leukaemia, myeloma, colon, 
head and neck, rectal, bladder 
and breast. LTPA was 
associated with higher risks 
of malignant melanoma 
(1.27, 1.16–1.40) and 
prostate cancer (1.05, 1.03–
1.08). 
Reduced risk. Adjustments for 
BMI attenuated the 
significant risk for 
liver and 
endometrial cancer.  
N/A   
Grey literature  
 179 
 
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2017)(30)  
Breast cancer: 23 publications from 17 
studies were identified. 
Associations 
between total 
physical 
activity (PA) 
and cancer 
incidence. 
Highest vs. lowest category 
of activity was associated 
with lower risk of 
postmenopausal breast 
cancer (0.87, 0.79–0.96). 
Similar risk effects were 
observed for occupational 
and recreational activity. 
Vigorous PA was inversely 
associated with 
premenopausal breast 
cancer risk (0.83, 0.73–
0.95) for the highest vs. the 
lowest activity level.  
Decreased risk. No association was 
observed for 
premenopausal 
breast cancer with 
total, recreational or 
occupational 
activity. 
N/A   
Associations 
between 
recreational 
activity at 
different ages 
and cancer 
incidence. 
For early adulthood periods, 
non-significant inverse 
associations were reported in 
three studies. 
        
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2015)(110)  
Oesophageal cancer: 5 studies (seven 
publications) assessed PA. 
Associations 
between PA 
and cancer 
incidence. 
Highest vs. lowest category 
of PA was not associated 
with cancer risk. 
Null. RR was not 
significant (0.85, 
0.72–1.01). 
N/A   
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World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2017)(21)  
Colorectal cancer (CRC): 15 out of 17 
published studies were included. 
Associations 
between total 
PA and cancer 
incidence. 
Total PA was inversely 
associated with CRC risk. 
RRs for the highest 
compared with the lowest 
levels were 0.81 (0.69–
0.95) for CRC and 0.80 
(0.72–0.88) for colon 
cancer. No significant 
association was observed 
for rectal cancer. 
Reduced risk. Highest vs. lowest 
category of 
recreational activity 
was also associated 
with lower risk of 
colon cancer (0.84, 
0.78–0.91). No 
association was 
detected for rectal 
cancer. 
N/A   
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2014)(111)  
Bladder cancer: 12 studies from 9 articles 
were included. 
Associations 
between PA 
and cancer 
incidence. 
Highest vs. lowest level of 
activity was not associated 
with cancer risk (0.94, 
0.83–1.06). 
Null.   N/A   
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2012)(31)  
Endometrial cancer: we identified 9 cohort 
studies on recreational activity and 5 on 
occupational PA. 
Associations 
between PA 
and cancer 
incidence. 
Occupational and 
recreational PA were 
associated with cancer risk. 
The respective RRs for the 
highest vs. the lowest PA 
levels were 0.79 (0.71–
0.88) and 0.73 (0.58–0.93). 
Reduced risk.   N/A   
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World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2015)(40)  
Kidney cancer: 4 studies were included.  Associations 
between PA 
and cancer 
incidence. 
No association was 
observed for the highest vs. 
the lowest level of 
recreational activity. RR 
0.84 (0.70–1.01). 
Null. Occupational 
activity was not 
associated with 
cancer risk either. 
N/A   
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2013)(45)  
Ovarian cancer: 2 studies were included. Associations 
between PA 
and cancer 
incidence. 
None of the identified 
studies reported a 
significant association 
between total PA levels 
and ovarian cancer risk. 
Null.   N/A   
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2015)(22)  
Liver cancer: 4 studies were included.  Associations 
between PA 
and cancer 
incidence. 
    There were very 
few studies from 
which to evaluate 
this association. 
N/A   
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Life stages: no systematic reviews or meta-analysis were found for PA during different life stages and cancer risk. No systematic reviews or 
meta-analysis were found for migrants, culturally and linguistically diverse communities or aboriginal populations.  
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2014)(32)  
Prostate cancer: 19 publications from 12 
studies were included. 
Associations 
between PA 
and cancer 
incidence. 
The highest vs. lowest level 
of occupational activity 
was associated with lower 
cancer risk (0.87, 0.80–
0.95). 
Reduced risk. Total PA or 
recreational activity 
were not associated 
with cancer risk. 
N/A   
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CHAPTER 6  
 
“FAT BUT FIT” IN THE CANCER, LIFESTYLE AND 
EVALUATION OF RISK STUDY   
 
 
 
 
 
 
 
In the previous chapter, an Evidence Check was conducted linking the role of body 
fatness and physical activity in cancer outcomes. This chapter will expand on the “fat 
but fit” hypothesis and cancer risk. Although physical activity has been reported to 
modify disease risk in obese individual with high levels of activity or fitness, this 
phenomenon has not been investigated in the field of cancer research. This chapter 
provides the first of three peer-reviewed papers published. This analysis used data 
from the CLEAR, an Australian case-control study. Nunez C, Bauman A, Egger S, 
Sitas F, Nair-Shalliker V. Obesity, physical activity and cancer risks: Results 
from the Cancer, Lifestyle and Evaluation of Risk Study (CLEAR). Cancer 
Epidemiology. 2017; 47:56-63. A more detail description of the CLEAR study is 
provided in appendix B.1 
 
 
 
 
 
 
 
 
  
 
 
 
195 
Obesity, physical activity and cancer risks: Results from the 
Cancer, Lifestyle and Evaluation of Risk Study (CLEAR) 
 
Abstract 
 
Introduction: Physical activity (PA) has been associated with lower risk of 
cardiovascular diseases, but the evidence linking PA with lower cancer risk is 
inconclusive. We examined the independent and interactive effects of PA and obesity 
using body mass index (BMI) as a proxy for obesity, on the risk of developing 
prostate (PC), postmenopausal breast (BC), colorectal (CRC), ovarian (OC) and 
uterine (UC) cancers.  
 
Methods: We estimated odds ratios (OR) and 95% confidence intervals (CI), 
adjusting for cancer specific confounders, in 6,831 self-reported cancer cases and 
1,992 self-reported cancer-free controls from the Cancer Lifestyle and Evaluation of 
Risk Study, using unconditional logistic regression.  
 
Results: For women, BMI was positively associated with UC risk; specifically, obese 
women (BMI  30kg/m2) had nearly twice the risk of developing UC compared to 
women with healthy-BMI range (<25kg/m2) (OR = 1.99; CI: 1.31–3.03). For men, 
BMI was also positively associated with the risk of developing any cancer type, CRC 
and PC. In particular, obese men had 37% (OR = 1.37; CI: 1.11–1.70), 113% (OR = 
2.13; CI: 1.55–2.91) and 51% (OR = 1.51; CI: 1.17-1.94) higher risks of developing 
any cancer, CRC and PC respectively, when compared to men with healthy-BMI 
range (BMI <25kg/m2). Among women, PA was inversely associated with the risks 
of CRC, UC and BC. In particular, the highest level of PA (versus nil activity) was 
associated with reduced risks of CRC (OR = 0.60; CI: 0.44–0.84) and UC (OR = 
0.47; CI: 0.27–0.80). Reduced risks of BC were associated with low (OR = 0.66; CI: 
0.51–0.86) and moderate (OR = 0.72; CI: 0.57–0.91) levels of PA. There was no 
association between PA levels and cancer risks for men. We found no evidence of an 
interaction between BMI and PA in the CLEAR study.  
 
Conclusion: These findings suggest that PA and obesity are independent cancer risk 
factors.  
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Introduction 
 
Epidemiological evidence suggests that obesity may increase the risk of developing 
cancers of the gallbladder, pancreas, liver, oesophageal adenocarcinoma, colorectal, 
postmenopausal breast, ovary, endometrium, kidney and advanced stage of prostate 
cancer.(1) In 2012, it was estimated that 3.6% of all new adult cancer cases, which 
was equivalent to approximately 481,000 of all new cancer cases, was attributable to 
being overweight and obese globally.(2) The World Health Organization (WHO) has 
projected that, approximately 2.3 billion adults will be overweight and that at least 
700 million adults will be obese, by 2015,(3) with high prevalence of obesity 
predominantly in countries with high human development index. This rising trend 
and its impact on cancer risk, is a major concern, worldwide.  
 
Conversely, inverse associations have been documented between physical activity 
(PA) and cancer risk.(4) There is strong evidence to support an inverse association 
between PA and colon cancer risk,(5) but there is only moderate evidence to support 
an association for breast, endometrial, pancreas and lung.(6–9) and weak evidence to 
support an association for prostate and ovarian cancers.(10,11) PA may protect against 
the development of cancer in multiple ways specific to each cancer type, although 
the exact mechanisms, by which PA may reduce cancer risk, are unknown. Physical 
activity is known to alter hormone metabolism, reduce oxidative stress, improve 
immune function, decrease inflammation, regulate insulin levels, and enhance lipid 
metabolism, all of which have an underlying pathway associated with cancer 
development.(6) The specific effects of PA on cancer risk may work independently of 
each other or synergistically, varying by cancer type.  
 
The interaction between PA and obesity has been observed in active obese 
individuals who have lower incidence of cardiometabolic diseases and mortality 
rates, compared to inactive non-obese individuals.(12,13) However, the interaction 
between PA and BMI on cancer risks is unclear.(14–19) It is of public health 
importance to gain clarity on these risk factors in order to promote healthy lifestyles 
and reduce cancer incidence. Therefore, the purpose of this study is to assess the 
independent effects of PA, body mass index (BMI) as a proxy for obesity and, to 
examine the interaction between BMI and PA, on the risks of developing prostate 
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(PC), postmenopausal breast (BC), uterine (UC), ovarian (OC) and colorectal (CRC) 
cancers. 
 
Methods 
 
Study population 
 
The Cancer, Lifestyle and Evaluation of Risk study (CLEAR) is an all cancer case-
control study based in New South Wales (NSW), Australia. Participants aged 18 
years and above were recruited between 2006 and 2014. Eligible cases were 
participants with a self-reported incident cancer identified through multiple clinical 
databases; those with a prior cancer diagnosis, except for non-melanocytic cancer, 
were excluded. Controls were cancer-free spouses of cases, excluding non-
melanocytic skin cancer. An analysis linking CLEAR participants to NSW cancer 
registry found that cancer cases were highly likely to correctly self-report their 
cancer diagnosis positive predictive value (PPV >90%).(20) As data linkage with the 
NSW cancer registry is only updated to 2010, we used all self-reported cancer cases 
and cancer free controls from the CLEAR study, for this analysis. CLEAR study 
design and validity have been addressed comprehensively elsewhere;(20) and has 
produced a number of high-quality peer-reviewed publications.(21,22) The CLEAR 
study design was approved by St. Vincent’s Hospital Human Research Ethics 
Committee (HREC 07/SVH/106, 20.12.07) and the current research analysis was 
approved by the New South Wales (NSW) Population & Health Services Research 
Ethics Committee (HREC/14/CIPHS/36; HREC/11/CIPHS/52). CLEAR recruited 
10,796 participants, of whom 8,556 were cases and 2,240 controls. We excluded 
1,973 due to diagnosis of melanoma, missing age, age of diagnosis 18 years, invalid 
height, weight or calculated BMI and missing study factors or covariates of interest. 
The current complete case analysis includes 8,823 participants (6,831 self-reported 
cancer cases of any type and 1,992 self-reported cancer free controls). Details are 
shown in Appendix B.2. 
 
Cases 
 
For the individual cancer types examined in this study, cases included participants 
with a self-reported cancer diagnoses for colorectal, uterine, ovarian, breast and 
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prostate cancer regardless of stage at diagnosis. Analysis on breast cancer cases was 
limited to only postmenopausal women; those whose age were 53 years or had 
bilateral oophorectomy were considered as postmenopausal as described by 
Salagame et al.(21) For the “any cancer” group, cases included participants with any 
cancer type (including those with individual cancer types outlined above) except 
melanoma as the association of physical activity with melanoma might be mediated 
by ultraviolet (UV) sun exposure and increased risk of sunburn(4) (Appendix B.2). 
 
Controls 
 
Controls were cancer-free partners (except, for self-report of cutaneous keratinocyte 
cancers) of cases in this study; they were sex matched to cases as this analysis was 
cancer sex specific. 
 
Data collection  
 
Participants signed a consent form prior completion of a standardised questionnaire 
for both cases and controls. Information for this analysis was collected on 
sociodemographic characteristics and ethnicity, educational attainment, personal and 
parental history of cancer for the most common types of cancer (breast, bowel, lung, 
prostate, ovarian and melanoma), anthropometric measures, medical history, 
reproductive history, physical activity, alcohol consumption and smoking status. 
 
Data analysis 
 
Exposure Variables 
 
Body mass index (BMI; expressed in kg/m2) was derived from self-reported weight 
(kg) before cases’ diagnosis or partners’ diagnosis for controls, and height (m). 
Participants who reported being shorter than 100 cm, taller than 240 cm, weighing  
35 kg or 270 kg, or with a calculated BMI of <15 kg/m2 or >50 kg/m2, were 
excluded from the analysis. All remaining participants were categorised into the 
following groups recommended by the World Health Organization (WHO): those 
with a BMI <25kg/m2,  25 to <30 and  30kg/m2 were grouped as Healthy Range 
BMI, Overweight and Obese respectively.(23) All participants were asked about their 
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level of vigorous and less vigorous PA lasting for 20 minutes or more, in a normal 
week, prior to their or their partner’s diagnosis of cancer. Vigorous PA represented 
exercises which made people breathe harder such as netball, squash, jogging, 
aerobics and vigorous swimming. Less vigorous PA represented exercises which did 
not make people breath harder, such as walking, light gardening, swimming and lawn 
bowls. The purpose of the clause “normal week” in the question was to diminish the 
possible effect of recent illness on reported PA.(24) Participants’ responses to their 
weekly vigorous and less vigorous activity (never, once a week, 2–3 times a week, 
4–6 times a week, 1/day and >1/day) were cross tabulated to derive ranked categories 
that reflect incremental PA patterns of behaviour. (i) Nil activity were those who 
never did vigorous activity combined with less vigorous activity no more than 2–3 
times/week, or did vigorous activity 1/week combined with less vigorous activity no 
more than 1 time/week, (ii) Low activity were those who did vigorous activity 1 
time/week combined with less vigorous activity 2–3 times/week, or did vigorous 
activity 2–3 times/week combined with less vigorous activity less than 2–3 
times/week, (iii) Moderate activity were those who did vigorous activity 4–6 
times/week combined with less vigorous activity no more than 4–6 times/week, or 
less vigorous activity 4–6 times/ week combined with vigorous activity no more than 
4–6 times/ week, and (iv) High activity were those who did vigorous activity at least 
once/day and/or any combination of less vigorous activity. Details on how these 
groups were derived are displayed in Appendix B.3. 
 
Confounder variables 
 
Confounders of the effects of interest for each cancer type in this study, were 
selected on the basis of published evidence and this is shown in Appendix B.4. 
Partner- matching at the design stage was simply to provide CLEAR with a source of 
controls, not as a method for adjusting for certain confounders. Age adjustment and 
all other confounder adjustments were conducted through multivariable regression 
analysis. Variables included were: age at diagnosis for cases or partner’s diagnosis 
for controls (continuous variable), education (no school–high school, certificate-
diploma and university or higher), region of birth (Australia or overseas), place of 
residence was derived from the Accessibility Remoteness Index of Australia (ARIA 
plus) (major cities, inner regional, and outer-remote or very remote), smoking status 
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(current, never and former-those who quit smoking 5 year prior cancer diagnosis or 
partner’s diagnosis), weekly alcohol consumption in women and men was derived 
from median of drinkers (0, 1 - <6, and  6 drinks for women) and (0, 1 - <10 and  
10 for men), history of breast, bowel or prostate screening excluding all tests done 
in the year prior diagnosis in cases (no, yes and do not know only in PC and controls) 
and parental history of cancer. Additionally, in women, the following variables were 
included: use of hormonal contraceptives (never-no vs ever-yes) and hysterectomy 
(no, yes). 
 
Statistical analysis 
 
Relative risks of cancer were estimated by odds ratios (ORs) and 95% confidence 
intervals, using unconditional logistic regression. When performing the different 
analyses, the ratio case to control was on average 1 to 4 for CRC, OC and UC in 
women and 1 to 1.8 for CRC in men. On the other hand, the ratio was slightly higher 
for cases in any cancer combined, BC in women and PC in men. This was a complete 
case analysis that excluded participants with missing data on study factors or other 
covariates; this type of analysis provides valid estimates when data are missing 
completely at random.(25) ORs were estimated for men and women separately with 
the lowest categories of physical activity (nil activity) and BMI (healthy-range) used 
as the referent groups. Univariable modelling was initially used to identify potential 
risk factors for each cancer type in these data; variables identified as potential 
confounders that change any point estimates related to the effects of PA or BMI by 
more than 10% were retained in the final models, using a backward stepwise 
approach. Analysis of BC risks adjusting for parity and age at first birth did not 
appreciable change odds ratios estimates, and thus were not included in the final 
model. The effects of PA were adjusted for BMI in the final models and vice versa. 
In additional sensitivity analyses, potential residual confounding of the effects of PA 
from BMI (and vice versa) were assessed by fine categorization of the potential 
confounder and, separately, by treating it continuously; exclusion of underweight 
(BMI <18.5kg/m2) participants from healthy-BMI was also performed. Interaction 
between PA and BMI was assessed by adding interaction terms to regressions 
models where appropriate. Analyses were performed using SAS software, version 
9.4. SAS institute Inc, Cary, NC. 
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Results 
 
Socio-demographic and behavioural characteristics are shown in Table 6.1. Amongst 
women, UC cases were more likely to report a higher body mass index than their 
respective controls whereas any cancer case, CRC, postmenopausal BC and UC 
cases were more likely to be physically inactive. Among men, any cancer case and 
CRC were more likely to report a higher BMI. 
 
BMI was positively associated with risks of UC among women and any cancer, CRC 
and PC among men; Table 6.2. In particular, obese women were almost twice as 
likely to be diagnosed with UC than women with healthy-range BMI (OR = 1.99; CI: 
1.31–3.03). Obese men were 113% and 51% more likely to be diagnosed with CRC 
(OR = 2.13; CI: 1.55–2.91) and PC (OR = 1.51; CI: 1.17–1.94) respectively, 
compared to men with healthy-range BMI. Among women, there was evidence of an 
association between PA levels and risks of CRC, UC and BC; Table 6.2. In 
particular, women who engaged in high levels of activity were 40% less likely to be 
diagnosed with CRC (OR = 0.60; CI: 0.44–0.84) and 53% less likely to be diagnosed 
with UC (OR = 0.47; CI: 0.27–0.80), compared to women who engaged in nil 
activity. Women who engaged in low and moderate levels of PA were 34% (OR = 
0.66; CI: 0.51–0.86) and 28% (OR = 0.72; CI: 0.57–0.91) less likely to be diagnosed 
with BC, respectively, compared to those who engaged in nil activity. There was no 
evidence of an association between PA and cancer risks for any of the cancer types in 
men. Sensitivity analyses suggest that the main results are relatively robust to 
possible residual confounding from PA on the effect of BMI and vice versa 
(Appendix B.5). In addition, inclusion of missing covariates in the final model did 
not substantially change odd ratios estimates (Appendix B.6). Overall, 143 of the 
8,823 (1.4%) participants had a BMI of less than 18.5 kg/m2. A sensitivity analysis 
excluding these participants from analysis did not appreciably change odds ratio 
estimates. When assessing the interactive effects of BMI and PA on cancer risks, 
there was no evidence of an interaction between these two variables in these data. 
(Figures 6.1 and 6.2).  
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Table 6.1 - Characteristics of study participants in the CLEAR study, New South Wales, Australia. 
 
 
Characteristics in 
Women 
Any cancer a Control CRC Control BC Control b UC Control c OC Control d 
N 3845 1024 422 1031 1381 828 155 771 151 967 
Mean age (years) 56.3 58.3 60.8 58.3 61.1 62.5 60.8 56.9 58.4 58.0 
Education (%) P-value 0.001 P-value 0.09 P-value 0.004 P-value 0.47 P-value 0.24 
No school or high school 45.0 50.5 54.6 50.5 48.0 54.0 45.1 46.8 43.7 49.7 
Certificate or diploma 23.9 23.9 18.7 23.9 24.0 24.0 22.2 25.2 23.8 24.1 
University or higher 31.1 25.6 26.7 25.6 28.0 22.0 32.7 28.0 32.5 26.2 
Region of Birth (%) P-value 0.02 P-value 0.37 P-value 0.01 P-value 0.26 P-value 0.09 
Australia 72.5 76.0 73.9 76.1 71.3 76.0 70.3 74.7 68.9 75.4 
Overseas 27.5 24.0 26.1 23.9 28.7 24.0 29.7 25.3 31.1 24.6 
Place of residence (%) P-value <.0001 P-value 0.0004 P-value <.0001 P-value 0.05 P-value 0.09 
Major cities 63.9 54.0 63.4 53.9 63.2 51.5 57.8 55.3 60.9 53.8 
Inner regional 25.5 27.7 25.9 27.8 27.5 29.9 31.8 26.6 27.2 27.5 
Outer, remote or very 
remote 
10.6 18.3 10.7 18.3 9.3 18.6 10.4 18.1 11.9 18.7 
Smoking status (%) P-value 0.0003 P-value 0.0006 P-value 0.28 P-value 0.005 P-value 0.009 
Never 60.6 66.8 56.4 66.9 65.0 68.2 66.5 79.9 55.0 67.3 
Former 24.3 22.3 28.0 22.2 24.4 22.5 22.0 13.6 27.5 21.9 
Current 15.1 10.9 15.6 10.9 10.6 9.3 11.5 6.5 17.5 10.8 
Alcoholic drink/week P-value 0.002 P-value 0.008 P-value 0.05 P-value 0.0003 P-value 0.23 
0 42.5 36.4 44.8 36.6 43.1 37.8 48.4 33.7 36.7 35.8 
1 - <6 25.7 27.9 25.6 32.0 25.3 26.7 29.0 28.3 34.0 28.5 
≥6 31.8 35.7 29.6 31.4 31.6 35.5 22.6 38.0 29.3 35.7 
History of screening  P-value <.0001 P-value 0.32   
Yes - - 29.7 44.0 88.3 89.7 - - - - 
No - - 70.3 56.0 11.7 10.3 - - - - 
Parental history of 
cancer (%) 
P-value 0.26 P-value 0.13 P-value 0.0003  P-value 0.25 
Any cancer 33.4 31.6 - - - - - - - - 
Breast - - - - 11.8 7.0 - - 9.5 6.9 
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Colorectal - - 12.6 9.9 - - - - - - 
Ovarian - - - - - - - - 2.7 2.8 
Oral Contraceptive   P-value 0.14 P-value <.0001 P-value 0.009 
Yes - - - - 82.9 85.2 71.1 87.2 78.1 86.3 
No - - - - 17.1 14.8 28.9 12.8 21.9 13.7 
Hysterectomy     P-value <.0001 
Yes - - - - - - - - 47.0 21.4 
No - - - - - - - - 53.0 78.6 
Body Mass Index (%) P-value 0.53 P-value 0.89 P-value 0.81 P-value <.0001 P-value 0.10 
Healthy range 44.8 44.7 43.4 44.7 40.4 41.7 38.7 48.0 43.7 44.7 
Overweight 31.1 32.6 33.4 32.6 33.2 33.0 24.5 32.0 27.2 33.4 
Obese 24.1 22.7 23.2 22.7 26.4 25.3 36.8 20.0 29.1 21.9 
Physical activity level 
(%) 
P-value 0.002 P-value 0.0002 P-value 0.01 P-value 0.007 P-value 0.46 
Nil 31.4 25.7 36.0 25.5 31.8 25.6 35.5 23.2 29.1 24.7 
Low 19.8 23.1 16.3 23.2 18.4 21.6 20.0 24.3 18.5 23.5 
Moderate 26.0 28.6 28.0 28.6 25.3 28.2 29.0 29.4 30.5 29.0 
High 22.8 22.6 19.7 22.7 24.5 24.6 15.5 23.1 21.9 22.8 
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Characteristics 
In Men 
Any cancer 
a Control CRC Control PC Control 
N 2986 968 532 977 1280 974 
Mean age (years) 61.8 57.7 62.2 57.8 65.0 57.7 
Education (%) P-value <.0001 P-value <.0001 P-value <.0001 
No school or high 
school 
52.9 43.6 55.9 43.7 52.1 43.8 
Certificate or 
diploma 
20.4 20.5 20.3 20.4 21.7 20.5 
University or 
higher 
26.7 35.9 23.8 35.9 26.2 35.7 
Region of Birth 
(%) 
P-value 0.59 P-value 0.46 P-value 0.75 
Australia 71.9 72.8 71.1 72.8 73.5 72.9 
Overseas 28.1 27.2 28.9 27.2 26.5 27.1 
Place of 
residence (%) 
P-value 0.0003 P-value 0.06 P-value 0.004 
Major cities 62.3 56.7 62.9 56.8 59.2 56.8 
Inner regional 24.3 30.7 25.3 30.7 24.9 30.5 
Outer, remote or 
very remote 
13.4 12.6 11.8 12.5 15.9 12.7 
Smoking status 
(%) 
P-value <.0001 P-value <.0001 P-value 0.02 
Never 44.4 54.7 42.1 54.6 49.4 54.7 
Former 37.8 33.8 39.7 33.9 39.2 33.7 
Current 17.8 11.5 18.2 11.5 11.4 11.6 
Alcoholic 
drinks/week 
P-value 0.0002 P-value 0.03 P-value 0.01 
0 23.0 19.8 21.4 19.7 22.7 19.8 
1 - <10 32.8 39.0 32.3 39.1 33.1 39.1 
≥ 10 44.2 41.2 46.3 41.2 44.2 41.1 
History of 
screening 
 P-value <.0001 P-value <.0001 
Yes - - 27.8 42.5 76.7 37.0 
No - - 72.2 57.5 22.1 59.4 
Do not know - - - - 1.2 3.6 
Parental history 
of cancer (%) 
P-value 0.02 P-value 0.04 P-value <.0001 
Any cancer 35.7 31.5 - -   
Colorectal - - 13.7 10.2   
Prostate - - - - 16.5 9.0 
Body mass index 
(%) 
P-value 0.02 P-value <.0001 P-value 0.08 
Healthy range 28.1 30.9 23.5 30.9 27.2 31.0 
Overweight 46.2 47.8 44.9 47.8 48.8 47.8 
Obese 25.7 21.3 31.6 21.3 24.0 21.2 
Physical activity 
level (%) 
P-value 0.70 P-value 0.38 P-value 0.37 
Nil 24.3 23.5 26.1 23.8 21.4 23.4 
Low 19.9 21.5 18.1 21.3 19.8 21.6 
Moderate 26.9 27.2 26.1 27.0 28.8 27.2 
High 28.9 27.8 29.7 27.9 30.0 27.8 
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CRC = Colorectal cancer, BC = postmenopausal breast cancer, UC = Uterine 
cancer, OC = Ovarian cancer and PC = Prostate cancer.  
 
a Any cancer includes all cancers in the CLEAR study except melanoma. 
b Postmenopausal females cancer free were only included as controls. 
c Cancer free females without history of hysterectomy; 307 women were excluded. 
d Cancer free females without history of bilateral oophorectomy; 85 women were 
excluded.  
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Table 6.2 - ODDS RATIOS AND 95% CI OF CANCER RISK ACCORDING TO BMI AND PA LEVELS IN WOMEN AND MEN FROM THE 
CLEAR STUDY. 
 
 
Adjusted Odds Ratios (95% CI) 
 Body Mass Index Physical Activity Levels 
Cancer 
type 
Healthy 
range 
Ca/ 
Co 
Overweight Ca/ 
Co 
Obese Ca/ 
Co 
Nil Ca/ 
Co 
Low Ca/ 
Co 
Moderate Ca/ 
Co 
High Ca/ 
Co 
Women 
Any 
cancer 
a 
1.00 
(Reference) 
1724/
458 
1.03 
(0.87-1.21) 
1196/
334 
1.12 
(0.93-1.35) 
 
925/ 
232 
1.00 
(Reference) 
1206/ 
263 
0.70 
(0.57-0.85) 
761/ 
237 
0.77 
(0.64-0.93) 
999/ 
293 
0.87 
(0.71-1.06) 
 
879/ 
231 
P-value 0.49, P-Trend 0.25 P-value 0.003, P-Trend 0.18 
BC 
b 1.00 
(Reference) 
558/ 
345 
1.07 
(0.87-1.30) 
459/ 
273 
1.04 
(0.83-1.30) 
 
364/ 
210 
1.00 
(Reference) 
439/ 
212 
0.66 
(0.51-0.86) 
254/ 
179 
0.72 
(0.57-0.91) 
349/ 
233 
0.80 
(0.63-1.02) 
 
339/ 
204 
P-value 0.82, P-Trend 0.66 P-value 0.007, P-Trend 0.08 
CRC 
c 1.00 
(Reference) 
183/ 
461 
1.01 
(0.77-1.32) 
141/ 
336 
0.88 
(0.65-1.20) 
 
98/ 
234 
1.00 
(Reference) 
152/ 
263 
0.53 
(0.38-0.74) 
69/ 
239 
0.69 
(0.52-0.93) 
118/ 
295 
0.60 
(0.44-0.84) 
 
83/ 
234 
P-value 0.66, P-Trend 0.47 P-value 0.0006, P-Trend 0.005 
UC 
d 1.00 
(Reference) 
60/ 
370 
0.84 
(0.54-1.31) 
38/ 
247 
1.99 
(1.31-3.03) 
 
57/ 
154 
1.00 
(Reference) 
55/ 
179 
0.59 
(0.36-0.98) 
31/ 
187 
0.69 
(0.44-1.09) 
45/ 
227 
0.47 
(0.27-0.80) 
 
24/ 
178 
P-value 0.004, P-Trend 0.003 P-value 0.03, P-Trend 0.01 
OC 
e 1.00 
(Reference) 
66/ 
432 
0.77 
(0.50-1.19) 
41/ 
323 
1.22 
(0.78-1.91) 
 
44/ 
212 
1.00 
(Reference) 
44/ 
239 
0.75 
(0.45-1.27) 
28/ 
227 
1.01 
(0.63-1.61) 
46/ 
280 
0.91 
(0.55-1.51) 
 
33/ 
221 
P-value 0.17, P-Trend 0.55 P-value 0.67, P-Trend 0.98 
Men 
Any 
cancer 
f 
1.00 
(Reference) 
839/ 
299 
1.08 
(0.91-1.29) 
1379/
463 
1.37 
(1.11-1.70) 
 
768/ 
206 
1.00 
(Reference) 
725/ 
228 
0.98 
(0.79-1.23) 
594/ 
208 
0.99 
(0.81-1.23) 
803/ 
263 
1.04 
(0.84-1.28) 
 
864/ 
269 
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P-value 0.01, P-Trend 0.004 P-value 0.95, P-Trend 0.69 
CRC 
g 1.00 
(Reference) 
125/ 
302 
1.29 
(0.98-1.69) 
239/ 
467 
2.13 
(1.55-2.91) 
 
168/ 
208 
1.00 
(Reference) 
139/ 
232 
0.97 
(0.69-1.36) 
96/ 
208 
1.00 
(0.74-1.37) 
139/ 
264 
1.15 
(0.84-1.56) 
 
158/ 
273 
P-value<.0001, P-trend<.0001 P-value 0.72, P-Trend 0.37 
PC 
h 1.00 
(Reference) 
348/ 
302 
1.22 
(0.99-1.51) 
625/ 
466 
1.51 
(1.17-1.94) 
 
307/ 
206 
1.00 
(Reference) 
274/ 
228 
0.98 
(0.73-1.30) 
254/ 
210 
1.09 
(0.84-1.43) 
368/ 
265 
1.10 
(0.84-1.43) 
 
384/ 
271 
P-value 0.006, P-Trend 0.001 P-value 0.76, P-Trend 0.36 
 
a The ﬁnal model of PA in any cancer was adjusted for: age, alcohol, hysterectomy and BMI, whereas the ﬁnal model of BMI was 
adjusted for age, alcohol, hysterectomy, smoking status, place of residence, use of oral contraceptive and PA. 
 b The ﬁnal model of PA in BC was adjusted for: age and BMI, whereas the ﬁnal model of BMI was adjusted for age and PA. 
c The ﬁnal model of PA in CRC was adjusted for: age and BMI, whereas the ﬁnal model of BMI was adjusted for: age, smoking status, 
alcohol and PA. 
 d The ﬁnal model of PA in UC was adjusted for: age, alcohol and BMI, whereas the ﬁnal model of BMI was for age and PA. 
e The ﬁnal model of PA in OC was adjusted for: age, hysterectomy and BMI, whereas the ﬁnal model of BMI was adjusted for: age, 
place of residence, use of oral contraceptives, hysterectomy and PA. 
f The ﬁnal model of PA in any cancer was adjusted for: age, prostate screening, bowel screening and BMI, whereas the ﬁnal model of 
BMI was adjusted for: age, smoking status, alcohol and PA. 
g The ﬁnal model of PA in CRC was adjusted for: age, bowel screening and BMI, whereas the ﬁnal model of BMI was adjusted for: 
age, smoking status, alcohol and PA. 
h The ﬁnal model of PA in PC was adjusted for: age, prostate screening and BMI, whereas the ﬁnal model of BMI was adjusted for age 
and PA. 
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Figure 6.1 - Adjusted odds ratios for the joint effects between BMI and PA. 
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Figure 6.2 - Adjusted odds ratios for the joint effects between BMI and PA.
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Discussion 
 
In this case control study, obesity was positively associated with UC risk in women; 
and in men, it was positively associated with risks of CRC and PC. Our findings also 
showed that PA was inversely associated with risks of CRC, UC and BC in women 
but not in men. There was no evidence for an interaction between PA and BMI on 
cancer risk in any sex specific cancer types, in the CLEAR study.  
 
The increased cancer risk observed among obese individuals compared to healthy-
BMI category in our study is consistent with recent meta-analyses; Zhang et al.(26) 
reported that obese women had a two-fold increased risk of developing uterine 
cancer. Ma et al.(27) also observed a pooled RRs for CRC of 33% increased risk when 
comparing obese with the healthy category. Although this review did not assess CRC 
risk independently by sex, Chen et al.(28) in their meta-analysis of adult weight gain 
and colorectal cancer concluded that the evidence between adult weight gain and 
increased risk of CRC is stronger among men than among women; pooled RR in men 
1.65 (95%, CI: 1.42–1.92) whereas the pooled RR in women was 1.07 (95%, CI: 
0.95–1.20). Discacciati et al.(29) found that BMI was positively associated with a 9% 
increased risk for advanced PC but not for localised PC; this finding was also 
corroborated by The World Cancer Research Fund International (WCRF) in their 
latest update of PC.(30)  
 
The WCRF and the American Institute for Cancer Research (AICR)(31) found in their 
meta-analysis a significant 20% risk reduction of colon cancer for high versus low 
intensity recreational activity. Similarly, Wolin et al.(5) found a 25% risk reduction of 
colon cancer for the most active compared to the least active. These observations 
correspond with our findings. We also observed significant risk reductions of CRC 
associated with low and moderate PA compared to the lowest level, with evidence of 
a dose response between increasing levels of PA and decreasing CRC risk in women. 
In a review of physical activity and gynaecological cancers,(10) Cust AE reported that 
PA probably protects against the onset of endometrial cancer and this risk reduction 
was estimated to be around 20–30% for those women who engage in high PA 
compared to those with the lowest levels. This conclusion is broadly consistent with 
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our finding of a halving of risk among women in the highest category of PA 
compared to the lowest. In addition, we found evidence of a dose-response 
relationship between increasing PA and diminishing UC risk. The role of PA in BC 
prevention has been reviewed by Lynch et al.(32) In this review, the average risk 
reduction when comparing the highest versus the lowest level of physical activity 
was 25%. This reduced risk was even greater among postmenopausal women 
(around 31%). Our results showed that low to moderate PA levels decreased post-
menopausal BC risk; high levels of PA also reduced this cancer risk although the 
effect was not statistically significant. Leitzmann revised the role of physical activity 
and PC risk.(11) In this review, the strength of the association between PA and risk of 
PC was weak, based on the existing epidemiological evidence. The average risk 
reduction was 9% when comparing high versus low levels of PA. We did not find an 
association between PA levels and PC risks.  
 
Significant interactions between PA and obesity have been reported in observational 
prospective studies, assessing all-cause mortality, cardiovascular diseases and type 2 
diabetes.(33–35) These studies have suggested that the benefits of PA can counteract 
the detrimental effects associated with obesity. To our knowledge there is one case-
control study that reported a significant interaction between PA and BMI on cancer 
risk.(14) This study assessed lifetime history of PA in different domains and the risk 
of colon cancer. The reported significant interaction was only observed between 
lifetime history of commuting PA and BMI. We cannot fully compare our results 
with this study as we only have data on a point in time assessment of PA. Besides, 
our study may have been under-powered to detect such effects based on the wide 
confidence intervals in Figures. 6.1 and 6.2.(36) We did not find evidence of cancer 
risk modification between PA-BMI interactions in the CLEAR study.  
 
A major strength of our study is the generalizability of data collected on BMI and PA 
to the reported in the NSW population. The 2010 New South Wales Population 
Health Survey(37) reported 21% of its population were obese, and this is comparable 
to the 21.9% of the control participants in CLEAR who reported being obese. This 
survey also reported that 55.2% of its adult population undertook physical activity 
for a total of at least 150 minutes per week over 5 separate occasions. This estimation 
is consistent with the CLEAR control population, where it was estimated to be 
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50.3%. Additionally, information collected on these risk factors to examine its effect 
on cancer risk, was not limited to a single cancer, but instead was applied to a range 
of cancers. A limitation of this study is recall bias where participants may have 
unknowingly recalled incorrect information before their diagnosis. This study is also 
prone to social desirability bias, which is the tendency for an individual to respond to 
questions in a favorable manner. As a consequence, overweight and obese 
individuals may intentionally underestimate their weight and overestimate their 
PA.(38–40) However, self-reported BMI and PA have been validated in the Australian 
setting, reporting excellent agreement for BMI and acceptable test-rest validity for 
the two-question assessment of PA; thus, minimising the potential for social 
desirability bias of these variables.(38,39) In addition, selective recall bias of cancer 
patients to report BMI and PA levels might not be likely as physical inactivity and 
high body mass index are not well known risk factors in the general population.(14,41) 
Another limitation of the CLEAR study is that the outcome (cancer) was self-
reported; however, available data from NSW Cancer Registry linked to CLEAR 
study showed that the accuracy of self-report per cancer type was good based on the 
positive predictive value (PPV). The PPVs values for the verification of self-reported 
cancer types were above 95% for 6 of the most common cancers.(20)  
 
Conclusion  
 
These data suggest that PA and BMI are independent risk factors for some cancers. 
Therefore, these results underline the public health importance of separately 
encouraging physical activity as well as weight loss to have a greater impact on 
cancer prevention. The interactive effects of BMI and PA on cancer risks are worth 
further assessing in prospective studies. 
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CHAPTER 7 
 
 “FAT BUT FIT” IN THE 45 AND UP STUDY   
 
 
 
 
 
 
 
 
 
In the previous chapter, the “fat but fit” was assessed in an Australian case-control 
study. This chapter will examine the “fat but fit” in a prospective Australian cohort 
study, with emphasis only on cancers of the colon and rectum as there is consistent 
evidence from epidemiological studies that physical activity and body fatness are 
associated with risk. This chapter presents the peer-review paper that was published, 
using data from the large Australian population-based cohort, the “45 and Up” study. 
Nunez C, Nair-Shalliker V, Egger S, Sitas F, Bauman A. Physical activity, 
obesity and sedentary behaviour and the risks of colon and rectal cancers in the 
45 and up study. BMC Public Health. 2018; 18(1):325. A more detail description 
of the 45 and Up study is provided in appendix C.1 
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Physical activity, obesity and sedentary behaviour and the 
risks of colon and rectal cancers in the 45 and up study 
 
Abstract 
 
Introduction: Obesity and physical activity (PA) are predictors of colon (CC) and 
rectal (RC) cancers. Prolonged sitting is also emerging as a potential predictor for 
these cancers. Little knowledge exists about the interactive effects of obesity, PA and 
prolonged sitting on cancer risk. This analysis assessed independent and interactive 
effects of PA, body mass index (BMI) and sitting time on CC and RC risks. 
 
Methods: This analysis used data from a prospective study of 226,584 participants 
aged 45 years and over in New South Wales (NSW), Australia, who joined the 45 
and Up study between 2006 and 2009. Baseline data were linked with data relating to 
mortality, cancer registration, hospital admission and Department of Human Services 
to December 2010. Multivariable Cox regression was used to estimate adjusted 
hazard ratios (referred to as relative risks, RRs) and 95% confidence intervals (Cis). 
Statistical significance was defined as p <0.05. 
 
Results: There were 846 and 369 ascertained cases of CC and RC. BMI was 
positively associated with CC risk (p = 0.003, P-trend = 0.0006) but not with RC. CC 
risk was increased in participants in the highest BMI quartile (≥29.4 - ≤50 kg/m2) 
compared to the lowest (15 - <23.6 kg/m2), (RR = 1.32, 95% CI: 1.08–1.63). PA was 
associated with CC risk (p = 0.02) but not with RC. Specifically, CC risk was lower 
in individuals partaking in any amount of vigorous activity (time/week) compared to 
participants with no engagement (RR = 0.78, 95% CI: 0.65–0.93). Sitting time was 
not associated with CC or RC. We found no evidence of interactive effects of PA, 
BMI and prolonged sitting on cancer risk. 
 
Conclusion: This evidence suggests that a healthy weight and vigorous activity are 
essential to reduce CC risk since these factors may be independent of each other. 
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Introduction 
 
Colorectal cancer (CRC), defined as cancer of the colon or rectum, is the  third most 
common cancer globally, accounting for almost 1.4 million new cases annually. 
Considerable variation  in its incidence is observed across world regions;(1) the 
highest reported incidence occurred in Australia and New Zealand (age-standardised 
rates of 44.8 and 32.2 per 100,000 in men and women respectively) and the lowest in 
Western Africa (4.5 and 3.8 per 100,000) in 2012.(1) The burden of CRC increases 
with the embracement of unhealthy lifestyle choices. Therefore, a substantial number 
of cases could be preventable by changing these behaviours.(2) 
 
High body fatness, defined as having a body mass index (BMI) greater than 25 
kg/m2, has been classified as a confirmed predictor associated with increased risk of 
colon and rectal cancers.(3, 4) In Australia, the prevalence of overweight (BMI 25 to 
29.9 kg/m2) and obesity (BMI ≥30 kg/m2) has increased over time from 56% in 1995 
to 63% in 2015, being higher in men (70%) than in women (56%).(5) Conversely, 
physical activity (PA) has also been established as a predictor associated with a 
reduced risk of colon cancer (CC), but its association with rectal cancer (RC) 
remains inconclusive.(3) Physical inactivity, defined as insufficient levels to meet 
physical activity guidelines was estimated to be around 44.5% amongst the adult 
Australian population during the period 2014–15.(5) Despite the well-known 
association of PA with CC, the dose of activity required to diminish risk has not been 
determined. Australia’s Physical Activity Guidelines for adults currently recommend 
at least 150 min of moderate activity or 75 min of vigorous activity weekly.  
 
Moreover, interactions between these specific risk factors and cancer risk have been 
less studied.(6) Some epidemiological evidence suggest that PA has the potential to 
counteract the detrimental effects of obesity; in those studies, physically active 
individuals had a reduced risk of cardiometabolic outcomes regardless of BMI.(7) 
Two population-based case-control studies observed that commuting or leisure time 
physical activity (LTPA) significantly altered the risk related to a high body fatness 
on CC although neither study assessed adherence to PA guidelines in negating this 
effect on cancer risk.(8, 9)  
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Sedentary behavior is not synonymous with physical inactivity.(10) It mostly 
represents prolonged sitting which is ubiquitous in present-day societies, particularly 
in high income countries.(11) In recent years, this behaviour has emerged as an 
additional potential risk factor associated with adverse cardiometabolic profile, 
premature mortality and various types of cancer including CRC.(12) The increased 
cancer risk associated with sedentary behaviour has been found to be independent of 
PA where the deleterious health consequences of too much sitting persist even after 
adjusting for the possible confounding effects of PA.(10)  
 
The current analysis examined the independent effects of BMI, as a proxy for body 
fatness, intensity of PA according to guidelines and sitting time on CC and RC risks. 
We also assessed the interactions between (i) BMI and PA, (ii) sitting time and PA; 
and (iii) BMI and sitting time, on the risks of developing CC and RC in The Sax 
Institute’s 45 and Up Study. 
 
Methods 
 
Study design, setting and subjects 
 
The Sax Institute’s 45 and Up Study is a prospective, population-based cohort study 
in the state of New South Wales (NSW), Australia. The study was established to 
investigate different relationships between a wide range of exposures and health 
outcomes in the ageing population; details of the study design, sampling method and 
baseline data collection have been published elsewhere.(13) Eligible participants were 
randomly sampled from the general population of NSW through the Department of 
Human Services (formerly Medicare Australia) enrolment database, which provides 
near complete coverage of the population. A sex-specific baseline questionnaire was 
mailed to potential study participants who joined the study by completing the 
questionnaire and signing a consent for routine linkage of their health records to 
administrative databases. 267,014 men and women aged 45 years and over were 
recruited between January 2006 and December 2009.(13) For the purpose of this 
analysis, we used 45 and Up baseline data and record linkage data from the NSW 
Cancer Registry (NSWCR), Admitted Patient Data Collection (APDC) which are 
records of patients’ services provided by hospitals in NSW, Medicare Benefits 
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Schedule (MBS) a list of the Medicare services subsidised by the Australian 
government, Pharmaceutical Benefits Scheme (PBS) and Registry of Birth Deaths 
Marriages (RBDM). The 45 and Up Study was approved by the University of New 
South Wales Human Research Ethics Committee and this analysis was approved by 
the New South Wales Population and Health Services Research Ethics Committee 
(HREC/14/CIPHS/54). The use of MBS and PBS data was approved by the 
Department of Health and Ageing Departmental Ethics Committee. 
 
Identification of cases 
 
Linkage of the 45 and Up cohort data to the MBS and PBS data was conducted by 
the Sax Institute, using a unique identifier that was supplied to the Department of 
Human Services for the acquisition of the respective data. Incident cases of CC and 
RC and dates of diagnoses were obtained through probabilistic linkage from the 
NSWCR by the New South Wales Centre for Health Record Linkage (CHeRel) for 
all cancer registrations until the 31st of December 2010. Notification of new cancer 
cases is required under the Public Health Act 2010 by pathology laboratories, 
hospitals, radiotherapy and medical oncology departments. The International 
Classification of Diseases for Oncology 3rd edition was used to classify incident 
cases of CC (C18) and RC which included cancers of the rectosigmoid junction 
(C19–20).(14) 
 
Data collection 
 
Baseline questionnaire collected self-reported information on age, height, weight, 
educational attainment, country of birth, medical history, parental history of cancer 
and personal health behaviours, including: PA, weekly alcohol intake, smoking 
status, diet and daily time spent sitting.  
 
Exposure variables 
 
Assessment of body mass index 
 
Body mass index, expressed in kg/m2, was derived from self-reported weigh (kg) and 
height (m) at baseline. These questions were phrased as “how tall are you without 
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shoes” and “about how much do you weigh”. Consistent with established methods, 
participants who reported extreme values for height being shorter than 100 cm, taller 
than 240 cm, weighing ≤35 kg or ≥270 kg, or with a calculated BMI of <15 kg/m2 
were excluded from the analysis due to the increased probability of measurement 
error.(15) All remaining participants were categorised according to baseline BMI 
quartiles since BMI risk may be more fine grained that the broad World Health 
Organization (WHO) categories;(15) we examined actual distribution of BMI in the 
sample as: 15 to <23.6 (reference), ≥23.6 to <26.2, ≥26.2 to <29.4 and ≥29.4 to 
50 kg/m2. Participants, for whom BMI was not possible to be estimated due to 
missing values of weight or height, were categorised as “unknown”. 
 
Assessment of physical activity 
 
In the baseline questionnaire, PA was measured with items from the Active Australia 
Survey (AAS),(16) which has been shown to have acceptable reliability and 
validity.(17) All participants were asked the weekly frequency and time spent on (i) 
walking, (ii) moderate and (iii) vigorous activity that lasted at least 10 min. Moderate 
activity included activities such as gentle swimming, social tennis, vigorous 
gardening or work around the house; while vigorous activity comprised activities that 
made participants breathe harder or puff and pant such as jogging, cycling, aerobics, 
competitive tennis, but not household chores or gardening. Time spent on walking 
and moderate activity were combined as the former is a form of the latter to derive 
groups according to PA guidelines; zero activity (reference), >0 to <150 and 
≥150 min/week. Time spent on vigorous activity was categorised as zero activity 
(reference), >0 to <75 and ≥75 min/week. Participants who did not report their 
activity level were classified as “unknown”. 
 
Assessment of sitting time 
 
Sitting time was based on participants’ response to the question “About how many 
hours in each 24-hour day do you usually spend sitting”. Responses were categorised 
according to quartiles of the number of hours spent sitting in a 24-h period. The 
respective quartiles were 0 to <3 (reference), 3 to <5, 5 to <8 or ≥8 h/day. Those 
participants who did not answer this question were classified as “unknown”. 
 
  
 223 
Confounders 
 
Potential confounders of CC and RC risks were selected on the basis of published 
evidence(3) which included: sex (female or male), birth cohorts (1920s, 1930s, 1940s, 
1950s or 1960s), educational attainment (no school certificate or other qualifications,  
school or intermediate certificate, higher school or leaving certificate, trade-
apprenticeship, certificate-diploma or university degree-higher), region of birth 
(Australia or overseas), smoking status (never, former-those who quit smoking 5 year 
prior baseline or current), weekly alcohol consumption acquired from quartiles of 
drinkers (0, 1–3, 4–6, 7–13 or ≥14 drinks/week), adherence to the Australian 
guidelines of fruit and vegetable defined as consuming more than 2 serves of fruit 
and 5 serves of vegetable a day (yes or no), weekly consumption of processed meat 
based on tertiles (0, 1, or ≥2 servings/week), quartiles of weekly intake of red meat 
(< 2, 2, 3 or ≥4 servings/week), weekly consumption of fibre derived from frequency 
of brown, wholemeal bread and cereal intake (<7, 7–13, 14–20 or ≥21 
servings/week), prevalence of diabetes mellitus (yes or no) identified by using 
diagnostic codes in APDC data, claims for glycosylated haemoglobin (HbA1c) in 
MBS data and claims for diabetes medication in PBS data (Anatomical Therapeutic 
Chemical Classification System (ATC) A10) as described in the validation of self-
report diabetes and linked data in this cohort;(18) aspirin use (yes or no) outlined as 
having taken this medication for most of the last 4 weeks, history of colorectal 
testing (tested less than three 3 years ago, tested more than 3 years ago or never)(19) 
and parental history of CRC (yes or no). 
 
Statistical analysis 
 
Multivariable Cox regression was used to estimate adjusted hazard ratios (referred to 
as relative risks, RRs) and 95% confidence intervals (Cis). Statistical significance 
was defined as p <0.05 for BMI, PA or sitting time, using age as the underlying time 
variable. Participants were censored if they died, were diagnosed with other cancers 
or were alive at the end of follow up period (31 of December 2010), whichever came 
first. RRs were estimated for both men and women combined since there was no 
evidence of effect modification by sex. 
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We examined potential two-way interactions between BMI, sitting time and PA on 
CC and RC risks by adding appropriate interaction terms to the models. The 
proportional hazard assumptions of the Cox regression models were assessed by 
Wald tests of covariates through log-time interactions. Sensitivity analyses were 
performed by excluding: (i) participants with BMI <18.5 kg/m2 from the lowest BMI 
category because weight loss and therefore very low BMI may be due to an 
undiagnosed cancer; and (ii) removing participants who self-reported poor health 
status at baseline or those who were diagnosed during the first 6 months to reduce the 
potential impact of reverse causality. Statistical analyses were performed using SAS 
software, version 9.4; SAS institute Inc., Cary, NC. 
 
Results 
 
Of 267,014 baseline questionnaire respondents, 40,430 were excluded from these 
analyses due to data linkage errors (n = 58), having a prevalent cancer other than 
non-melanocytic skin cancer prior to recruitment (n = 24,167) or extreme values for 
height, weight and/or calculated BMI (n = 16,205).(20) After exclusions, a total of 
226,584 participants remained for these analyses. There were 846 incident cases of 
CC and 369 RC diagnosed between 2006 and December 2010. Mean follow-up was 
2.7 years, ranging from 0.0 to 5.5 years. The mean age at recruitment was 62.0 years 
(age range 45.0 to 106.2 years). 
 
After exclusions, 61.5% of 226,584 reported having a BMI greater than 25 kg/m2 
with a higher prevalence in men than in women. Of these, 26.1% did not meet 
guidelines of moderate activity with women being more likely to adhere to 
guidelines; and 59.0% did not meet guidelines of vigorous activity with men being 
more likely to achieve 75 min/week. Men were more likely to spend more than 8 h a 
day on sedentary pursuits than women. Compared to the lowest BMI quartile, the 
highest quartile was, on average, younger, more socially disadvantaged, Australian 
born, less likely to be current smoker and more likely to report less healthy eating 
habits (more likely to consume processed and red meat; and a low level of dietary 
fibre) and to have been diagnosed as diabetic. Compared to participants who reported 
sitting <3 h/day, those who sat 8+ hours/day were younger, least socially 
disadvantaged, did not adhere to fruit and vegetable guidelines and consumed more 
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processed meat. Participants who adhered to guidelines of moderate PA (≥150 
min/week) or vigorous activity (≥75 min/week) compared to those who did not were 
younger, least socially disadvantaged, less likely to be current smokers and had 
lower prevalence of diabetes (Tables 7.1 and 7.2).  
 
Increasing BMI was associated with increased CC risk (p = 0.003 and p-
trend = 0.0006) (Table 7.3); participants with a BMI ≥29.4 - ≤50 kg/m2 had a 32% 
increased CC risk compared to participants with a BMI 15 - <23.6 kg/m2 (RR = 1.32, 
95% CI: 1.08–1.63). Although diabetes might be an intermediate outcome on the 
causal pathway between BMI and disease risk,(21) further adjustments with diabetes 
had little influence on the final outcome, thus it was not included in these analyses 
(data not shown). Sensitivity analysis excluding underweight participants from the 
lowest BMI group did not appreciably change any effects of relative risk of neither 
CC nor RC. 
 
Of the 2 types of activities, only vigorous activity was associated with CC (Table 
7.3). Participants who engaged in any amount of vigorous activity/week had 22% 
lower risk of developing CC compared to participants who did not perform this type 
of activity. The respective RR was 0.78 95% CI: 0.65–0.93 with no evidence of a 
dose response relationship. 
 
Risk of CC was not associated with sitting time (p = 0.55) or moderate activity 
(p = 0.17) (Table 7.3). Additionally, RC risk was not associated with BMI (p = 0.20), 
sitting time (p = 0.65), moderate activity (p = 0.77) or vigorous activity (p = 0.11) 
(Table 7.4). Sensitivity analysis excluding participants who self-reported poor health 
status at baseline or those participants who were diagnosed within the first 6 months 
did not substantially change any effects of relative risks for either CC or RC risk 
(data not shown). No significant interactions between PA and BMI, sitting time and 
PA or BMI and sitting time were evident on CC or RC risks in these analyses (p-
values greater than 0.10) (Figures. 7.1 and 7.2). 
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Table 7.1 - Characteristics of study participants according to BMI and sitting time. 
 
 
  BMI Kg/m2 (%) Sitting time hours a day (%) 
Characteristic 15-<23.6 
≥23.6-
<26.2 
≥26.2-
<29.4 
≥29.4-
50 
Unknown 0-<3 3-<5 5-<8 8+ Unknown 
Total 56,275 54,765 57,130 57,205 1,209 31,458 60,710 64,980 52,927 16,509 
Male 
18,437 
(33%) 
27,633 
(50%) 
31,662 
(55%) 
26,372 
(46%) 
551 
(46%) 
13,357 
(42.5%) 
27,054 
(44.6%) 
29,959 
(46.1%) 
27,654 
(52.3%) 
6,631 
(40.2%) 
Mean Age 65.3 63.6 62.4 61.1 64.9 62.7 63.6 63.6 60.6 67.3 
Education 
University 
degree or higher 
5,507 
(30.5%) 
8,255 
(30.3%) 
7,991 
(25.6%) 
5,196 
(20.0%) 
124 
(22.9%) 
2,586 
(19.7%) 
5,302 
(19.9%) 
7,697 
(26.0%) 
10,437 
(38.2%) 
1,051 
(16.5%) 
Region of birth 
Australia  
12,372 
(67.1%) 
19,562 
(70.8%) 
23,510 
(74.3%) 
20,258 
(76.8%) 
357 
(64.8%) 
9,779 
(73.2%) 
19,907 
(73.6%) 
21,901 
(73.1%) 
19,725 
(71.3%) 
4,747 
(71.6%) 
Smoking status 
Current 
3,187 
(17.4) 
3,480 
(12.7%) 
3,959 
(12.6%) 
3,847 
(14.7%) 
74 
(13.5%) 
1,937 
(14.6%) 
3,807 
(14.2%) 
3,976 
(13.4%) 
3,746 
(13.6%) 
1,081 
(16.4%) 
Alcohol consumption (drinks/week) 
14 or more 
4,467 
(24.7%) 
7,737 
(28.4%) 
9,565 
(30.6%) 
7,734 
(29.8%) 
131 
(24.8%) 
3,882 
(29.6%) 
7,917 
(29.7%) 
8,534 
(28.8%) 
7,703 
(28.1%) 
1,598 
(25.3%) 
Adherence to fruit and vegetable guidelines 
No 
14,880 
(82.1%) 
22,133 
(81.2%) 
25,475 
(81.6%) 
20,960 
(80.7%) 
456 
(83.4%) 
10,586 
(80.4%) 
21,432 
(80.2%) 
23,843 
(80.6%) 
22,956 
(84.1%) 
5,087 
(79.4%) 
Consumption of processed meat (servings/week) 
2 or more 
6,412 
(34.8%) 
10,220 
(37.0%) 
12,952 
(40.9%) 
12,144 
(46.1%) 
217 
(39.4%) 
5,105 
(38.2%) 
10,722 
(39.6%) 
12,239 
(40.9%) 
11,569 
(41.8%) 
2,310 
(34.8%) 
Intake of red meat (servings/week) 
4 or more 
7,162 
(40.3%) 
11,248 
(41.9%) 
13,770 
(44.7%) 
12,164 
(47.4%) 
227 
(42.9%) 
5,549 
(42.8%) 
11,611 
(44.1%) 
13,062 
(44.7%) 
11,713 
(43.4%) 
2,636 
(43.2%) 
  
 227 
Consumption of fibre (servings/week) 
21 or more 
6,369 
(35.7%) 
8,818 
(32.7%) 
8,894 
(28.8%) 
6,911 
(26.9%) 
145 
(27.1%) 
3,902 
(30.0%) 
8,440 
(32.0%) 
9,331 
(31.8%) 
7,700 
(28.5%) 
1,764 
(28.7%) 
Diabetes Mellitus 
Yes 
1,546 
(8.4%) 
2,681 
(9.7%) 
3,993 
(12.6%) 
5,956 
(22.6%) 
134 
(24.3%) 
1,694 
(12.7%) 
3,627 
(13.4%) 
4,141 
(13.8%) 
3,578 
(12.9%) 
1,270 
(19.2%) 
Aspirin Use 
Yes 
4,047 
(21.9%) 
6,340 
(22.9%) 
7,861 
(24.8%) 
7,326 
(27.8%) 
157 
(28.5%) 
3,151 
(23.6%) 
6,828 
(25.2%) 
7,732 
(25.8%) 
6,185 
(22.4%) 
1,835 
(27.7%) 
History of colorectal testing 
Never 
8,850 
(49.3%) 
12,611 
(46.7%) 
14,467 
(46.6%) 
12,878 
(49.9%) 
281 
(52.0%) 
6,432 
(49.2%) 
12,653 
(47.8%) 
13,452 
(45.8%) 
13,296 
(49.0%) 
3,254 
(51.7%) 
Parental history of CRC 
Yes 
1821 
(9.9%) 
2,800 
(10.1%) 
3,280 
(10.4%) 
2,647 
(10.0%) 
48 
(8.7%) 
1,327 
(9.9%) 
2,698 
(10.0%) 
3,131 
(10.5%) 
2,858 
(10.3%) 
582 
(8.8%) 
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Table 7.2 - Characteristics of study participants according to time spent on moderate and 
vigorous activity. 
 
 
 
 
 
 
 
  Moderate (%) Vigorous (%) 
Characteristic 0 
>0-149 
minutes 
≥ 150 
minutes 
Unknown 0 
>0-<74 
minutes 
≥ 75 
minutes 
Unknown 
Total 11,727 47,304 159,715 7,838 98,308 35,293 53,120 39,863 
Male 
5,559 
(47.4%) 
23,621 
(49.9%) 
72,004 
(45.1%) 
3,471 
(44.3%) 
42,526 
(43.3%) 
18,201 
(51.6%) 
26,637 
(50.1%) 
17,291 
(43.4%) 
Mean Age 64.8 62.2 62.9 65.0 64.0 60.4 59.5 68.2 
Education 
University 
degree or 
higher 
913 
(16.9%) 
6,601 
(28.4%) 
19,053 
(26.8%) 
506 
(15.3%) 
9,762 
(23.3%) 
5,820 
(32.3%) 
8,961 
(34.0%) 
2,530 
(15.1%) 
Region of birth 
Australia  
4,035 
(72.6%) 
16,787 
(71.1%) 
52,792 
(73.3%) 
2,445 
(70.4%) 
30,882 
(72.6%) 
13,472 
(74.0%) 
19,593 
(73.6%) 
12,112 
(70.1%) 
Smoking status 
Current 
1,118 
(20.3%) 
3,498 
(14.9%) 
9,353 
(13.1%) 
578 
(16.8%) 
6,676 
(15.8%) 
2,273 
(12.6%) 
3,068 
(11.6%) 
2,530 
(14,7%) 
Alcohol consumption (drinks/week) 
14 or more 
1,336 
(24.6%) 
5,695 
(24.5%) 
21,750 
(30.5%) 
853 
(26.2%) 
11,703 
(27.8%) 
5,046 
(28.0%) 
7,873 
(29.8%) 
5,012 
(30.1%) 
Adherence to fruit and vegetable guidelines 
No 
4,638 
(85.0%) 
19,632 
(84.6%) 
56,917 
(80.0%) 
2,717 
(81.0%) 
34,749 
(82.8%) 
14,809 
(82.5%) 
20,929 
(79.6%) 
13,417 
(79.2%) 
Consumption of processed meat (servings/week) 
2 or more 
2,270 
(40.8%) 
9,284 
(39.3%) 
29,172 
(40.5%) 
1,219 
(35.1%) 
17,793 
(41.8%) 
7,253 
(39.9%) 
10,333 
(38.8%) 
6,566 
(38.0%) 
Intake of red meat (servings/week) 
4 or more 
2,389 
(45.0%) 
9,583 
(41.9%) 
31,206 
(44.4%) 
1,393 
(43.3%) 
18,841 
(45.5%) 
7,709 
(43.4%) 
10,544 
(40.5%) 
7,477 
(45.5%) 
Consumption of fibre (servings/week) 
21 or more 
1,227 
(22.9%) 
5,872 
(25.6%) 
23,162 
(32.9%) 
876 
(27.3%) 
12,375 
(29.8%) 
5,270 
(29.6%) 
8,361 
(32.0%) 
5,131 
(31.2%) 
Diabetes Mellitus 
Yes 
1,192 
(21.4%) 
3,572 
(15.1%) 
9,009 
(12.5%) 
537 
(15.5%) 
6,973 
(16.4%) 
1,878 
(10.3%) 
2,358 
(8.9%) 
3,101 
(17.9%) 
Aspirin Use 
Yes 
1,507 
(27.1%) 
5,632 
(23.8%) 
17,795 
(24.7%) 
797 
(23.0%) 
11,351 
(26.7%) 
3,944 
(21.7%) 
5,223 
(19.6%) 
5,213 
(30.2%) 
History of colorectal testing 
Never 
2,974 
(54.9%) 
11,718 
(50.9%) 
32,586 
(46.1%) 
1,809 
(54.8%) 
20,141 
(48.3%) 
8,489 
(47.5%) 
12,515 
(47.8%) 
7,942 
(47.5%) 
Parental history of CRC 
Yes 
524 
(9.4%) 
2,328 
(9.8%) 
7,460 
(10.4%) 
284 
(8.2%) 
4,171 
(9.8%) 
1,964 
(10.8%) 
2,893 
(10.9%) 
1,568 
(9.1%) 
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Table 7.3 - Cox proportional hazards of incident CC according to BMI, sedentary behaviour 
and types of physical activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Events No person-
years 
Age-adjusted 
HR 
Multivariable 
HR(1) 
BMI Kg/m2  
  
15-<23.6 195 154,782 1.00 1.00 
≥23.6-<26.2 188 150,904 0.99 (0.81-1.21) 0.90 (0.73-1.12) 
≥26.2-<29.4 223 156,854 1.13 (0.93-1.37) 1.12 (0.91-1.38) 
≥29.4-50  232 156,109 1.18 (0.98-1.43) 1.32 (1.08-1.63) 
Unknown 8 3273 1.94 (0.96-3.94) 2.21 (1.09-4.49) 
P-value(a)    0.003 
P-trend(b)    0.0006 
Sitting hours/day    
0-<3 105 87,149 1.00 1.00 
3-<5 228 167,892 1.13 (0.90-1.42) 0.98 (0.77-1.25) 
5-<8 267 178,262 1.24 (0.99-1.56) 1.12 (0.88-1.42) 
8+ 165 143,987 0.95 (0.75-1.22) 1.02 (0.79-1.32) 
Unknown 81 44,633 1.51 (1.13-2.02) 0.92 (0.67-1.28) 
P-value(a)    0.55 
P-trend(b)    0.88 
Moderate activity 
minutes/week 
 
  
None 52 30,194 1.00 1.00 
>0-149 175 137,275 0.73 (0.54-1.00) 1.08 (0.76-1.54) 
150 or more 583 433,966 0.78 (0.58-1.03) 1.25 (0.90-1.74) 
Unknown 36 20,487 1.01 (0.66-1.55) 1.09 (0.65-1.82) 
P-value(a)    0.17 
P-trend(b)    0.76 
Vigorous activity 
minutes/week 
  
 
None 423 270,374 1.00 1.00 
Any amount:(*) 220 248,354 0.56 (0.48-0.66) 0.78 (0.65-0.93) 
>0-74 97 102,607 0.60 (0.48-0.75) 0.78 (0.61-0.98) 
75 or more 123 145,747 0.54 (0.44-0.66) 0.78 (0.63-0.97) 
Unknown 203 103,194 1.26 (1.07-1.49) 0.98 (0.81-1.18) 
P-value(a)    0.02 
P-trend(b)    0.11 
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(1) Multivariable models adjusted for: birth cohort, sex, education, BMI, sitting time, 
time spent on moderate and vigorous activity, smoking, alcohol, country of birth, 
guidelines of fruit and vegetables, weekly intake of processed food, red meat and 
fibre, aspirin, parental history of CRC and history of colorectal testing.  
 
(a) ‘P-value’ for each variable corresponds to a test of whether all HRs = 1 
 
(b) ‘P-trend’ is for test of linear association in the log hazard scale and obtained by 
substituting the categorical versions of covariates in the Cox model with 
continuous or ordinal versions where appropriate 
 
‘Unknown’ category was excluded from the estimation of P-values and P-trends. 
 
(*) The “any amount” category was derived by combining the “> 0–74” and “75 or 
more” and the HR for “any amount” was estimated by fitting a separate multivariate 
model. 
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Table 7.4 - Cox proportional hazards of incident RC according to BMI, sedentary behaviour 
and types of physical activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Events 
No person-
years 
Age-adjusted 
HR 
Multivariable 
HR(1) 
BMI Kg/m2    
15-<23.6 93 154,782 1.00 1.00 
≥23.6-<26.2 93 150,905 1.03 (0.77-1.37) 0.84 (0.62-1.14) 
≥26.2-<29.4 87 156,855 0.92 (0.69-1.24) 0.73 (0.54-1.00) 
≥29.4-50 93 156,110 0.99 (0.74-1.32) 0.76 (0.55-1.04) 
Unknown n.p 3,273 1.52 (0.48-4.81) 0.89 (0.22-3.62) 
P-value(a)    0.20 
P-trend(b)    0.12 
Sitting hours/day    
0-<3 50 87,149 1.00 1.00 
3-<5 100 167,893 1.04 (0.74-1.46) 1.03 (0.72-1.48) 
5-<8 111 178,263 1.09 (0.78-1.52) 1.10 (0.77-1.57) 
8+ 72 143,988 0.87 (0.61-1.25) 0.90 (0.61-1.32) 
Unknown 36 44,633 1.41 (0.92-2.16) 1.07 (0.66-1.74) 
P-value(a)    0.65 
P-trend(b)    0.40 
Moderate activity 
minutes/week 
   
None 20 30,195 1.00 1.00 
>0-149 77 102,607 0.85 (0.52-1.39) 0.85 (0.51-1.43) 
150 or more 252 433,967 0.88 (0.56-1.38) 0.93 (0.57-1.51) 
Unknown 20 20,487 1.47 (0.79-2.73) 1.17 (0.57-2.38) 
P-value(a)    0.77 
P-trend(b)    0.21 
Vigorous activity 
minutes/week 
   
None 163 270,375  1.00 
>0-74 53 102,607 0.86 (0.63-1.17) 0.98 (0.71-1.36) 
75 or more 58 145,748 0.66 (0.49-0.89) 0.70 (0.50-0.98) 
Unknown 95 103,194 1.52 (1.18-1.96) 1.34 (1.01-1.79) 
P-value(a)    0.11 
P-trend(b)    0.78 
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(1) Multivariable models adjusted for: birth cohort, sex, education, BMI, sitting time,
time spent on moderate and vigorous activity, smoking, alcohol, country of birth,
guidelines of fruit and vegetables, weekly intake of processed food, red meat and
fibre, aspirin use, parental history of CRC and history of colorectal testing.
(a) ‘P-value’ for each variable corresponds to a test of whether all HRs = 1.
(b) ‘P-trend’ is for test of linear association in the log hazard scale and obtained by
substituting the categorical versions of covariates in the Cox model with continuous
or ordinal versions where appropriate.
‘Unknown’ category was excluded from the estimation of P-values and P-trends. 
n.p Not publishable because of small number, confidentiality or ethical concerns
about the data.
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Figure 7.1 – Adjusted hazard ratios and 95% CI for the interaction between BMI-
PA, Sitting time-PA; and BMI-Sitting time on CC risk.
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Figure 7.2 – Adjusted hazard ratios and 95% CI for the interaction between BMI-
PA, Sitting time-PA; and BMI-Sitting time on RC risk.  
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≥150
>0 - <150
0
Sitting a day ≥8h
≥150
>0 - <150
0
1.00 (Referent)
0.96 (0.46-2.01)
1.22 (0.60-2.48)
1.00 (0.46-2.18)
1.00 (Referent)
0.85 (0.45-1.59)
0.78 (0.41-1.48)
0.51 (0.24-1.09)
1.00 (Referent)
0.76 (0.34-1.67)
1.46 (0.72-2.96)
1.17 (0.55-2.51)
1.00 (Referent)
1.85 (0.81-4.22)
1.05 (0.44-2.50)
1.17 (0.49-2.79)
P-interaction 0.23
 BMI 15 - <23.6
Sitting hours a day
<3
≥3 - <5
≥5 - <8
≥8
BMI ≥23.6 - <26.2
<3
≥3 - <5
≥5 - <8
≥8
BMI ≥26.2 - <29.4
<3
≥3 - <5
≥5 - <8
≥8
BMI ≥29.4 - ≤50
<3
≥3 - <5
≥5 - <8
≥8
.5 1 2 4 10
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Discussion 
This is the first analysis to our knowledge that examined the independent and 
interactive effects of PA based on the Australian recommended guidelines, BMI and 
sitting time on CC and RC risks. In this Australian cohort, BMI and vigorous activity 
were independent predictors for CC risk where individuals with a BMI ≥29.4 kg/m2 
were at higher risk of developing CC than those in the lowest. Also, individuals who 
engaged in any amount of vigorous activity were at lower risk of developing CC than 
those who did not partake in this activity. We found no evidence of interactions 
between any of the study variables assessed and CC or RC risk. 
In a recent assessment of observational studies on body fatness and cancer risk, the 
International Agency for Research on Cancer reported a 30% increased likelihood of 
developing CRC in those individuals in the highest evaluated BMI compared to the 
lowest.(4) However, dissociation between colon and rectal cancers was not 
considered. Some evidence indicate that the aetiology of these two cancers may 
differ.(14) For instance, a recent meta-analysis of prospective studies observed a 47% 
increased risk of CC and only 15% for RC when contrasting the highest category of 
BMI against the lowest.(22) In our analysis, we found that the highest BMI group was 
similarly associated with an increased risk of CC but not with RC. The lack of 
association between BMI and RC in our analysis is concordant with a previous 
prospective Australian study.(23) 
There is convincing evidence to support a protective role of PA in CC risk. A recent 
meta-analysis of prospective studies reported a 23% risk reduction for CC when 
comparing the most active to the least active in the PA spectrum.(24) However, this 
protective effect of PA on CC risk was based on a combined measure of moderate to 
vigorous activity (MVPA) without considering the individual type of activity.(25, 26, 27, 
28, 29, 30) This grouping makes it difficult to determine if intensity and duration are 
relevant for reducing cancer risk.(31) Very few observational studies have assessed 
the effects of different types of PA on CC risk.(32, 33, 34, 35) A prospective study among 
Japanese reported a significant risk reduction in CC in men who walked more than 
1 h a day, but not in women.(35) Moreover, a prospective cohort documented that 
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vigorous activity decreased CC risk in men but not in women.(34) On the other hand, 
we found that any amount of vigorous activity reduced CC risk irrespective of sex. 
This discrepancy in findings might have occurred due to the low number of female 
cases accrued (fewer than 50) in the studies by Takahashi et al.(35) or Lee et al.,(34) 
while our study had a relatively large number of CC cases for both genders. Also, 
vigorous physical activity is different from walking as there is a much higher energy 
expenditure in vigorous activity than walking. 
The role of PA on rectal cancer risk is less clear as no association has consistently 
been observed.(32) A recent meta-analysis of prospective studies reported no change 
in risk.(26) To our knowledge, there are only three studies that have examined this 
association by types of PA with RC risk.(32, 34, 36) Of them, only a population-based 
case-control study observed a decreased risk with lifetime vigorous activity.(32) We 
found no evidence for a relationship between PA and RC risk. 
Sedentary behaviour has been proposed as an independent risk factor in colorectal 
carcinogenesis.(10, 37) A recent meta-analysis of prospective studies reported a 27% 
increased risk for CC and 6% for RC when comparing the highest amount of sitting 
to the lowest.(37) However, moderate heterogeneity was observed, reflecting the 
variability between studies in measuring and categorising this complex behaviour. 
The different domains of sedentary behaviour include recreation (TV viewing and 
computer use), workplace sitting and commuting.(12) We did not find any association 
between total sitting time and the risks of CC or RC nor did we find evidence of two-
way interactions with PA or BMI. 
The elucidation of the interaction between BMI and PA in terms of cancer risk is of 
public health interest since these risk factors tend to be related, and have been shown 
to interact in the context of cardiovascular disease risk.(7, 38) Emerging evidence from 
case-control studies proposes that PA might offset CC risk related to a high BMI.(8, 9) 
Only four studies have reported the assessment of the interaction between BMI and 
PA on CC risk. Of them, two prospective studies reported no significant 
interactions(14, 27) while two case-control studies detected significant interactions 
between high levels of lifetime commuting activity or long-term vigorous activity 
and BMI.(8, 9) We did not observe a significant interaction between PA and BMI on 
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either CC or RC risk. Additionally, our measurement of PA is not comparable to 
those used in the case-control studies as the questionnaire only assessed current and 
not lifetime activity. Consistent with our results, we recently reported no evidence of 
interaction between BMI and current PA on CRC risk in a case-control study.(39) The 
nature of this interaction does not depend on the scale used as presence on one scale 
(additive or multiplicative) will also be present on the other scale.(40) 
Major strengths of this analysis are the prospective nature of the study design, the 
large cohort sample size of 226,584 participants that provided reasonable statistical 
power to detect an effect of the exposure variables on cancer risk; and the linkages of 
the questionnaire data to deaths records, cancer registry and administrative data. A 
limitation is the relatively short-term follow-up (mean 2.7 years) for cancer incidence 
which can, depending on the outcome, lead to a low number of cases and imprecise 
effect estimates. In this study, however, a large number of incident cases for both CC 
(n = 846) and RC (n = 369) were accrued during the follow-up period. Another 
potential limitation is that exposure variables were ascertained by self-report. 
Nevertheless, BMI and PA have been validated. For instance, a subsample of the 45 
and UP cohort showed a strong correlation between self-reported and measured BMI 
(r = 0.95)(20) and the AAS questionnaire possesses a reliability which ranges from 
0.56 to 0.64 and validity estimated around 0.52.(41) Furthermore, vigorous activity 
tends to be better reported by participants than other categories of recreational PA.(41) 
Any misclassification of the exposure variables collected before the diagnosis of 
cancer would most likely have resulted in attenuated estimates of effects.(27) Finally, 
while we did not find evidence of two-way interactions, confidence intervals for 
interaction variable categories within were wide, perhaps suggesting limited 
statistical power to detect such interactions.(42)  
Conclusion 
This analysis supports the importance of independently adhering to vigorous 
guidelines of physical activity as well as achieving and maintaining a healthy BMI. 
Future research using other cohort studies is needed to confirm the absence of 
interaction between PA and BMI. 
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CHAPTER 8 
 
 “FAT BUT FIT” IN THE COPENHAGEN MALE 
STUDY 
 
 
 
 
 
 
 
 
 
 
In the previous chapter, the “fat but fit” was assessed in a large Australian cohort 
study. This chapter will assess the “fat but fit” in a prospective Danish cohort study, 
using objective measures of physical activity and body mass index. This chapter also 
provides a peer-review paper that was published. This study used the Copenhagen 
Male cohort, a long-term follow up of over 5000 mid-aged Danish men. Nunez C, 
Clausen J, Jensen MT, Holtermann A, Gyntelberg F, Bauman A. Main and 
interactive effects of physical activity, fitness and body mass in the prevention of 
cancer from the Copenhagen Male Study. Scientific Reports-Nature. 
2018;8(1):11780. A more detail description of the Copenhagen Male Study is 
provided in appendix D.1 
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Main and interactive effects of physical activity, fitness and 
body mass in the prevention of cancer from the Copenhagen 
Male Study (CMS) 
 
Abstract 
 
Little knowledge exists about the role of cardiorespiratory fitness (CRF) or its 
interaction with excess adiposity determined by body mass index (BMI) in cancer 
prevention. A total of 5,128 middle-aged men, without a history of cancer at baseline 
in 1970–71, were examined for subsequent incidence and mortality of several cancer 
types. Participants’ data were linked with cancer registration and mortality data to 
March 2017. During 47 years of follow-up, a total of 1,920 incident cases and 1,638 
cancer-related deaths were ascertained. BMI, particularly obesity, was associated 
with (i) incidence and (ii) mortality from respiratory/thoracic cancers; and (iii) all 
cancer-cause mortality. The respective adjusted hazard ratios (HRs) were: (i) 0.51 
(95% CI: 0.32–0.79), (ii) 0.48 (95% CI: 0.30–0.75) and (iii) 0.73 (95% CI: 0.59–
0.89) when compared obese men (BMI ≥30 kg/m2) to men with healthy-BMI 
(<25 kg/m2). Increasing CRF was inversely associated with incidence and mortality 
of respiratory/thoracic cancers, HRs 0.78 (95% CI: 0.67–0.90) and 0.73 (95% CI: 
0.63–0.84) respectively; and all cancer-cause incidence 0.92 (95% CI: 0.86–0.98) 
and mortality 0.85 (95% CI: 0.79–0.91). Physical activity (PA) was not associated 
with most outcomes. We found no evidence of interactions between CRF or PA and 
BMI on cancer risk. This evidence suggests that midlife CRF is associated with 
lowered risk of cancer incidence and mortality with no evidence of cancer risk 
modification by BMI. 
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Introduction 
Cancer is a prominent cause of morbidity and mortality worldwide, accounting for 14 
million new cases and 8 million deaths in 2012;(1) of which, 7.4 million incident 
cases and 4.6 million cancer-related deaths occurred in men. Higher incidence rates 
were reported in OECD nations whereas higher mortality was documented in 
developing countries.(1) Globally, the highest incidence rate amongst men and 
women was reported in Denmark, age-standardised 338 per 100.000 people in 
2012,(2) with 1 in 3 cancers being potentially preventable though modification of 
lifestyle risk factors.(3) 
 
Lifestyle modifications are promising strategies to reduce cancer risk. High body 
mass, defined as having a body mass index (BMI) of 25 kg/m2 or greater, may 
increase cancer risk resulting in higher incidence and death.(4) The increased 
prevalence of overweight and obesity has virtually spread to every country. In 2014, 
69.2% of Danish males were either overweight or obese;(5) this rise in excess body 
mass is a major concern as there is sufficient evidence for an associated increased 
risk for 13 types of cancer, including esophageal adenocarcinoma, gastric cardia, 
colorectum, liver, gallbladder and pancreatic cancers.(6) 
 
Conversely, physical activity (PA) has consistently been linked to a decreased risk of 
colon cancer, is probably associated with reduced risks of postmenopausal breast and 
endometrial cancer; and less consistent with other types of cancer.(7) This lack of 
association may be hampered due to imprecise measurement of this complex and 
multifaceted behavior,(8) which is usually determined through self-report in most 
epidemiological studies.(9) Cardiorespiratory fitness (CRF), an objective attribute of 
repetitive training activities and of genetics, is measured by the maximal oxygen 
uptake (VO2 max) required by the body during sustained physical exertion.
(10) Thus, 
CRF provides the most accurate population measure of regular fitness.(11) However, 
little is known about its impact on cancer prevention, as very few studies have 
examined this objective measurement of PA with the most common incident cancers 
in men.(10, 12-14) Furthermore, the possible pre-diagnostic role of CRF in cancer 
specific mortality has not been fully explored.(15) 
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Although PA and high body mass are considered independent risk factors for some 
types of cancer,(7, 16) the interaction between these two determinants and cancer 
outcomes has not been well investigated using objective measures of PA.(10) Disease 
risk modification has been documented in several epidemiological studies of all-
cause mortality and cardiometabolic outcomes; in those studies, obese individuals 
with high levels of PA or fitness had lower cardiometabolic risk or better survival 
compared to inactive or unfit individuals with a healthy BMI.(17) This phenomenon is 
also known as “fat but fit”.(18) Nevertheless, cancer risk modification still remains to 
be investigated. 
 
The current prospective study examined main and interactive effects of PA, fitness 
and BMI on the incidence and mortality of different cancer groups in the 
Copenhagen Male Study. 
 
Methods 
Study design, setting and subjects 
 
The Copenhagen Male Study (CMS) is a prospective cohort study of middle-aged 
men employed in large private or public workplaces in Copenhagen, Denmark. This 
study was established to assess the relationship between PA or CRF and coronary 
heart disease in relatively healthy men. Details of the study design, sampling method, 
data collection and examination have been published elsewhere.(19) 6,125 eligible 
men aged between 39 to 61 years were invited to participate; of them, 5,245 provided 
informed consent to participate in the study and underwent a medical examination, 
which consisted of a short interview by a physician based on prior completion of a 
standardized questionnaire, measurement of blood pressure, height, weight and 
CRF.(19) Recruitment was conducted between 1970 and 1971 and the estimated 
response rate was 86 per cent. In 1985–1986, 3,260 men completed a questionnaire 
to update exposures, lifestyle and disease diagnosis. For the purpose of this analysis, 
we used data collected at baseline (1970–71) and second wave (1985–86) from the 
CMS study and record linkage data from the Danish Cancer Registry and the Danish 
Register of Causes of Death. This analysis was approved by the steering committee 
  
 246 
of the Copenhagen Male Study and was conducted in accordance with relevant 
guidelines and regulations.  
 
Identification of cases 
 
For the individual cancer types examined in this analysis, incident cancers were 
identified and dates of diagnoses obtained through linkage to data from the Danish 
Cancer Registry for all cancer registrations until the 22nd of March 2017. This cancer 
registry is population-based and contains records for all incident malignant 
neoplasms in the Danish population from 1943 onwards. Although reporting to the 
cancer registry has been mandatory since 1987, the prior voluntary system ensured 
completeness and high-quality data based on multiple reports from different sources, 
including hospitals, treatment, follow-up of cancer patients and death certificates.(20) 
Mortality data were obtained from the Danish Register of Causes of Death, which 
includes individual data on all deaths among Danish, Greenlanders and Faroese 
residents dying in Denmark, Greenland or the Faroe Islands.(21) Cancer incidence and 
mortality were coded to 3 digits using any of the International Classification of 
Diseases (ICD) 8–10; the following codes were used for PC 185/C61, CRC 153-
154.1/C18-20, oral/digestive 140-159/C00-26, respiratory/intrathoracic 160-163/ 
C30-39, genito-urinary 185-189/C60-68, other cancers 170-184,190-209/C40-
58,C69-96; and all cancers combined except melanoma and other malignant 
neoplasms of skin 140-209/C00-96. Skin cancers were excluded as the association 
with PA might be confounded by ultraviolet (UV) sun exposure and increased risk of 
sunburn.(22) 
 
Data collection 
 
Questionnaires collected self-reported information on age, occupation, parental 
history of coronary heart disease, hypertension, diabetes mellitus, personal medical 
history and health behaviours, including: PA, daily alcohol intake and smoking 
habits. SES was derived from Svalastoga’s system which is based on educational 
attainment and job profile.(23) 
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Exposure variables 
 
Assessment of body mass index 
 
Body mass index was calculated at baseline and second wave from measured weight 
and height, dividing weight in kilograms by the square of height in meters (kg/m2). 
Height and weight were ascertained with the subject wearing light clothing and 
shoes; 2 centimetres were deducted from the height and 2 kilograms from weight.(19) 
Participants with extreme measures of BMI (<15 kg/m2 or >50 kg/m2) were excluded 
from the analysis to reduce the probability of measurement error.(24) All remaining 
participants were categorised into the recommended BMI categories by WHO; those 
with a BMI <25 kg/m2 (Healthy), ≥25 kg/m2 to <30 kg/m2 (Overweight) and 
≥30 kg/m2 (Obese) as time-varying exposures. Missing values of BMI were imputed 
using the method of Last Observation Carry Forward (LOCF)(25) since baseline BMI 
and a re-measurement years later are highly correlated 0.90.(26) Underweight 
participants (BMI <18.5 kg/m2) were combined with the healthy group as this 
number was too small to influence observed associations (n = 27). The category 
corresponding to the lowest BMI was used as the reference group. 
 
Assessment of physical activity 
 
Physical activity was assessed at baseline and second wave with a closed-ended 
question in the respective questionnaires as “How much physical activity do you 
believe you do” almost nothing (reference), some or a lot as time varying exposure. 
This question was developed by Finn Gyntelberg as there was no reliable or valid PA 
question at the time of inception or follow-up.(19) The lowest group of PA was used 
as the reference. 
 
Assessment of Cardiorespiratory fitness 
 
Cardiorespiratory fitness was determined only at baseline, using an indirect method 
of VO2 max. This approach relies on heart rate, work load from a bicycle ergometer 
and the Åstrand nomogram.(19) Heart rate was measured during a submaximal bicycle 
work in a steady state with the aid of a stethoscope and a stopwatch. The loads used 
were 100, 150 and 200 watts. One, two or in a few cases three different loads were 
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used. The chosen load for each case was determined from weight and age of the 
subject or heart rate during the first minute of the test. The examination was 
supervised by an experienced physician with the assistance of trained nurses.(19) The 
effect of CRF in statistical analysis was obtained per 10 ml/kg/min increase in VO2 
max so as to obtain reasonable-sized risk estimates. 
 
Confounders 
 
Potential confounders for cancer incidence and mortality included: birth cohort 
obtained from date of birth (1910s, 1920s or 1930s), smoking status (never, former 
or current) and grams of tobacco a day (current tobacco smoking was calculated from 
information about the number of cigarettes, cheroots or cigars, or the weight of pipe 
tobacco smoked daily. One cigarette was taken as equivalent to 1 g of tobacco, one 
cheroot as 3 g and one cigar as 4 g), alcohol consumption (2 or less, 3–5, or 6 units 
a day), diabetes (yes or no), systolic and diastolic blood pressure, history of acute 
myocardial infarction (AMI) (yes or no) and SES (low, middle or high). Most of the 
selected confounders were incorporated as time-varying risk factors with the 
exception of AMI and SES. 
 
Statistical methods 
 
Analyses were conducted separately for PC, CRC and cancer groupings. Adjusted 
hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for cancer 
incidence and cause-specific mortality, using Cox regression with age as the 
underlying time scale. Time-varying risk factor analysis was conducted for BMI and 
self-reported PA and fixed baseline risk factor for CRF. For cancer incidence, 
participants were censored if they died, were diagnosed with other cancers or were 
alive at the end of follow up period, whichever came first. For cancer mortality, 
participants were censored if they died from other causes or were alive at the end of 
follow-up. 
 
We examined potential two-way interactions between (i) BMI and PA, and (ii) BMI 
and CRF, on cancer outcomes by adding appropriate interaction terms into the 
respective models. Based on the nature of the interaction, the multiplicative scale 
was used as presence of interaction on this scale will also be present on the additive 
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scale.(27) Furthermore, the proportional hazard assumptions of the Cox regression 
models were assessed by Wald tests of covariates through log-time interactions. 
Sensitivity analyses were also performed by excluding: (i) underweight (BMI 
<18.5 kg/m2) participants from the lowest BMI category and (ii) the first ten years of 
follow-up to reduce the potential impact of reverse causality. Statistical analyses 
were performed using R version 3.4.0. 
 
Results 
 
Of 5,245 participants included in the examination, 117 were excluded due to a 
history of cancer other than non-melanocytic skin cancer prior to recruitment (n = 78) 
or did not perform the exercise test (n = 39). After exclusions, a total of 5,128 
participants remained for analysis. There were 391 incident cases of prostate cancer 
(PC), colorectal cancer (CRC) (n = 299), oral/digestive (n = 546), respiratory/intra-
thoracic (n = 455), genito-urinary (n = 571), other cancers (n = 348) and all-cancers 
combined (n = 1,920). Additionally, there were 253 deaths due to PC, CRC (n = 218), 
oral/digestive (n = 446), respiratory/intrathoracic (n = 482), genito-urinary (n = 380), 
other cancers (n = 322) and all-cancers combined (n = 1638). Mean follow-up was 
29.7 years, ranging from 0.3 to 44.1 years. The mean age at recruitment was 48.8 
years (age range 39.0 to 61.0 years). 
 
Baseline socio-demographic and lifestyle characteristics are shown for BMI, PA and 
CRF in Table 8.1 Participants in the highest BMI category (≥30 kg/m2) compared to 
the lowest (<25 kg/m2), were more likely to be older, of higher social class, to report 
more units of alcohol per day, to have higher mean systolic and diastolic blood 
pressure; and less likely to be current smokers. Compared to participants who 
reported almost no PA, those who reported a lot were more likely to be of higher 
social class, less likely to drink large quantities of alcohol and to have lower mean 
diastolic blood pressure. Participants who had high fitness levels compared to those 
with low fitness, were more likely to be younger, current smokers and to consume 
more grams of tobacco, less likely to drink large amounts of alcohol and to have 
much lower mean systolic and diastolic blood pressure.  
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BMI was associated with incidence and mortality of respiratory/thoracic cancers and 
all cancer-cause mortality (Tables 8.2 and 8.3). Participants with a BMI ≥30 kg/m2 
had a 49% and 52% decreased risk of being diagnosed and dying from 
respiratory/thoracic cancers respectively, when compared to participants with a BMI 
<25 kg/m2. Additionally, participants categorised as obese had a 27% risk reduction 
of all cancer-cause mortality compared to participants with a healthy range BMI. 
Sensitivity analyses excluding underweight participants from the healthy BMI 
category did not appreciably change any effects of relative risk of neither incidence 
nor mortality (Appendices C.1-C.2). 
 
PA was only related to genitourinary cancer incidence in sensitivity analysis; those 
participants who reported a lot of PA had a 25% decreased risk. The respective HR 
was 0.75 (95% CI: 0.57–0.99). Additionally, CRF was associated with reduced 
incidence and mortality of respiratory/thoracic cancers; and all cancers combined 
(Tables 8.2–8.3). Lower risks were noted for developing respiratory/thoracic cancers; 
and all-cancers combined per 10 ml/kg/min increase in VO2 max; the respective HRs 
were 0.78 (95% CI: 0.67–0.90) and 0.92 (95% CI: 0.86–0.98). Besides, a 
10 ml/kg/min increase in VO2 max was associated with a 27% and 15% decreased 
risk of respiratory and thoracic cancer mortality; and all cancer-cause mortality. 
Sensitivity analysis excluding the first ten years of follow-up did not substantially 
change any effects of relative risks for the different study variables (Appendices C.1-
C.2). 
 
In this cohort, 2.1% or 35 individuals were identified to be “fat but fit”, based on a 
BMI ≥30 kg/m2 and a high CRF (36–78 ml/kg/min). A p-value below 0.1 may be an 
acceptable cut-off for interactions.(28) Overall, no significant interactions were 
evident between BMI and CRF or BMI and PA on cancer risk. Figures 8.1, 8.2, 8.3 
and 8.4 show the interactions between BMI-CRF and the interactions between BMI-
PA are portrayed in the Appendices C.3, C.4, C.5 and C.6.  
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Table 8.1 - Baseline characteristics of participants in the CMS according to BMI, self-reported PA and CRF. 
 
 BMI Kg/m2 Physical activity Cardiorespiratory fitness ml/kg/min* 
Characteristic <25 ≥25-<30 ≥30 
Almost 
nothing 
Some A lot 
Low 
(15-29) 
Moderate 
(30-35) 
High 
(36-78) 
 n= 2455 (%) n= 2328 (%) n= 336 (%) n= 887 (%) n= 3687 (%) n= 554 (%) n= 1736 (%) n= 1733 (%) n= 1659 (%) 
Birth cohort          
1910s 714 (29.1) 793 (34.1) 129 (38.4) 274 (30.9) 1,187 (32.2) 180 (32.5) 755 (43.5) 548 (31.6) 338 (20.4) 
1920s 1,542 (62.8) 1,404 (60.3) 196 (58.3) 548 (61.8) 2,262 (61.4) 335 (60.5) 927 (53.4) 1,061 (61.2) 1,157 (69.7) 
1930s 199 (8.1) 131 (5.6) 11 (3.3) 65 (7.3) 238 (6.4) 39 (7.0) 54 (3.1) 124 (7.2) 164 (9.9) 
Socioeconomic Status 
Low 497 (20.3) 333 (14.3) 23 (6.8) 179 (20.2) 641 (17.4) 35 (6.3) 268 (15.5) 285 (16.5) 302 (18.2) 
Middle 766 (31.2) 600 (25.8) 75 (22.3) 289 (32.6) 1,044 (28.4) 112 (20.3) 508 (29.3) 484 (28.0) 453 (27.3) 
High 1,189 (48.5) 1,392 (59.9) 238 (70.9) 419 (47.2) 1,997 (54.2) 406 (73.4) 956 (55.2) 962 (55.5) 904 (54.5) 
Smoking status          
Never 194 (7.9) 214 (9.2) 34 (10.1) 76 (8.5) 307 (8.3) 61 (11.0) 147 (8.5) 148 (8.5) 149 (9.0) 
Former 397 (16.2) 506 (21.7) 81 (24.1) 171 (19.3) 711 (19.3) 102 (18.4) 377 (21.7) 347 (20.0) 260 (15.7) 
Current 1,864 (75.9) 1,608 (69.1) 221 (65.8) 640 (72.2) 2,669 (72.4) 391 (70.6) 1,212 (69.8) 1,238 (71.5) 1,250 (75.3) 
Mean grams of 
tobacco per day 
(s.d) 
14.7 (11.2) 13.6 (12.0) 12.4 (11.5) 14.7 (12.1) 14.0 (11.5) 13.4 (11.6) 13.3 (11.5) 13.9 (11.6) 15.1 (11.8) 
Alcohol (units/day)          
2 or less 2,092 (85.2) 1,826 (78.4) 212 (63.1) 695 (78.4) 2,999 (81.3) 444 (80.2) 1,318 (75.9) 1,426 (82.3) 1,394 (84.1) 
3- 5 308 (12.5) 406 (17.5) 97 (28.9) 141 (15.9) 576 (15.6) 95 (17.1) 339 (19.5) 245 (14.1) 228 (13.7) 
6 or more 55 (2.3) 96 (4.1) 27 (8.0) 51 (5.7) 112 (3.1) 15 (2.7) 79 (4.6) 62 (3.6) 37 (2.2) 
Diabetes          
Yes 22 (0.9) 16 (0.7) 5 (1.5) 12 (1.4) 27 (0.7) 4 (0.7) 21 (1.2) 11 (0.6) 11 (0.7) 
Previous AMI          
Yes 36 (1.5) 28 (1.2) 1 (0.3) 14 (1.6) 49 (1.3) 2 (0.4) 30 (1.7) 26 (1.5) 9 (0.5) 
Mean Systolic BP 
(s.d) 
131.8 (18.2) 137.0 (19.3) 144.8 
(21.9) 
135.8 (19.7) 135.0 (19.3) 133.9 (18.9) 142.1 (20.6) 134.3 (18.1) 128.5 (16.5) 
Mean Diastolic BP 
(s.d) 
80.5 (10.9) 84.9 (11.5) 90.4 (12.9) 84.4 (12.2) 83.1 (11.5) 82.0 (11.7) 86.6 (12.4) 82.9 (11.1) 79.8 (10.4) 
(%) correspond to column percent, AMI: acute myocardial infarction. BP: blood pressure in mmHg. (s.d): standard deviation. * The cut-offs low, moderate and 
high were obtained from tertiles of the actual distribution of CRF in this cohort. 
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Table 8.2 - Adjusted hazard ratios (HR) and 95% confidence intervals (CI) for cancer incidence according to time-varying BMI and PA; and 
baseline CRF in the CMS. 
 
 
  BMI Kg/m2 HR (95% CI) * Physical Activity HR (95% CI) * CRF* 
Cancer type Events <25 ≥25-<30 ≥30 P-valueA 
Almost 
nothing 
Some A lot 
P-
valueA 
10 ml/kg/min 
(VO2 max) 
P-valueA 
Prostate 391 1.00 
1.06 
(0.85-1.31) 
0.84 
(0.53-1.32) 
0.56 1.00 
0.78 
(0.57-1.08) 
0.78 
(0.56-1.09) 
0.29 
1.02 
(0.88-1.19) 
0.75 
Colorectal 299 1.00 
1.07 
(0.84-1.37) 
0.68 
(0.40-1.15) 
0.20 1.00 
1.17 
(0.79-1.73) 
1.06 
(0.70-1.59) 
0.60 
0.94 
(0.79-1.12) 
0.48 
Oral and 
digestive 
546 1.00 
1.10 
(0.91-1.33) 
0.99 
(0.71-1.39) 
0.54 1.00 
1.23 
(0.93-1.63) 
1.01 
(0.74-1.36) 
0.15 
0.90 
(0.79-1.03) 
0.13 
Respiratory 
and thoracic 
455 1.00 
0.87 
(0.71-1.06) 
0.51 
(0.32-0.79) 
0.01 1.00 
0.92 
(0.69-1.22) 
0.81 
(0.59-1.10) 
0.31 
0.78 
(0.67-0.90) 
0.001 
Genito-
urinary 
571 1.00 
1.05 
(0.87-1.25) 
0.85 
(0.59-1.22) 
0.48 1.00 
0.83 
(0.64-1.08) 
0.77 
(0.58-1.01) 
0.15 
1.05 
(0.93-1.18) 
0.47 
Other cancer 348 1.00 
0.98 
(0.78-1.24) 
1.06 
(0.69-1.61) 
0.94 1.00 
1.17 
(0.81-1.67) 
1.05 
(0.72-1.53) 
0.55 
0.93 
(0.79-1.09) 
0.35 
All-cancers 1,920 1.00 
1.00 
(0.91-1.11) 
0.83 
(0.68-1.00) 
0.12 1.00 
1.01 
(0.87-1.16) 
0.88 
(0.75-1.03) 
0.10 
0.92 
(0.86-0.98) 
0.01 
 
* Multivariable model adjusted for: birth decades, smoking and grams of tobacco a day, alcohol, SES, systolic blood pressure, 
diastolic blood pressure, previous AMI, diabetes and the other study variables. (All covariates are time-dependent except for birth 
decade, previous AMI, SES and CRF).  
 
A ‘P-value’ for each variable corresponds to a test of whether all HRs = 1. 
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Table 8.3 - Adjusted hazard ratios (HR) and 95% confidence intervals (CI) for cancer death according to time-varying BMI and PA; and baseline 
CRF in the CMS. 
 
 
  BMI Kg/m2 HR (95% CI) * Physical Activity HR (95% CI) * CRF* 
Cancer type Events <25 ≥25-<30 ≥30 
P-
valueA 
Almost 
nothing 
Some A lot 
P-
valueA 
10 ml/kg/min 
(VO2 max) 
P-
valueA 
Prostate 253 1.00 
1.04 
(0.79-1.36) 
0.72 
(0.40-1.28) 
0.43 1.00 
0.77 
(0.51-1.15) 
0.81 
(0.53-1.22) 
0.44 
1.02 
(0.85-1.23) 
0.80 
Colorectal 218 1.00 
0.89 
(0.67-1.18) 
0.63 
(0.34-1.15) 
0.30 1.00 
0.96 
(0.63-1.48) 
0.85 
(0.54-1.34) 
0.66 
0.91 
(0.74-1.11) 
0.35 
Oral and 
digestive 
446 1.00 
0.96 
(0.78-1.18) 
0.91 
(0.63-1.31) 
0.84 1.00 
1.12 
(0.83-1.51) 
0.82 
(0.59-1.13) 
0.22 
0.89 
(0.77-1.03) 
0.12 
Respiratory 
and thoracic 
482 1.00 
0.92 
(0.75-1.11) 
0.48 
(0.30-0.75) 
0.005 1.00 
0.95 
(0.72-1.25) 
0.81 
(0.60-1.09) 
0.23 
0.73 
(0.63-0.84) 
<0.001 
Genito-
urinary 
380 1.00 
0.97 
(0.78-1.20) 
0.72 
(0.45-1.15) 
0.38 1.00 
0.98 
(0.69-1.40) 
0.99 
(0.69-1.41) 
0.99 
0.97 
(0.83-1.13) 
0.67 
Other cancer 322 1.00 
0.78 
(0.61-0.99) 
0.75 
(0.47-1.18) 
0.10 1.00 
1.27 
(0.86-1.88) 
1.16 
(0.77-1.75) 
0.44 
0.86 
(0.73-1.01) 
0.07 
All-cancers 1,638 1.00 
0.91 
(0.82-1.02) 
0.73 
(0.59-0.89) 
0.007 1.00 
1.00 
(0.86-1.17) 
0.88 
(0.75-1.04) 
0.13 
0.85 
(0.79-0.91) 
<0.001 
 
* Multivariable model adjusted for: birth decades, smoking and grams of tobacco a day, alcohol, SES, systolic blood pressure, 
diastolic blood pressure, previous AMI, diabetes and the other study variables. (All covariates are time-dependent except for birth 
decade, previous AMI, SES and CRF).  
 
A ‘P-value’ for each variable corresponds to a test of whether all HRs = 1. 
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Figure 8.1 - Multivariable model adjusted for: birth decades, smoking and grams of tobacco a day, alcohol, SES, systolic blood pressure, 
diastolic blood pressure, previous AMI, diabetes, physical activity, BMI, CRF and interaction between BMI-CRF. 
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Figure 8.2 - Multivariable model adjusted for: birth decades, smoking and grams of tobacco a day, alcohol, SES, systolic blood pressure, 
diastolic blood pressure, previous AMI, diabetes, physical activity, BMI, CRF and interaction between BMI-CRF. 
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Figure 8.3 - Multivariable model adjusted for: birth decades, smoking and grams of tobacco a day, alcohol, SES, systolic blood pressure, 
diastolic blood pressure, previous AMI, diabetes, physical activity, BMI, CRF and interaction between BMI-CRF. 
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Figure 8.4 - Multivariable model adjusted for: birth decades, smoking and grams of tobacco a day, alcohol, SES, systolic blood pressure, 
diastolic blood pressure, previous AMI, diabetes, physical activity, BMI, CRF and interaction between BMI-CRF. 
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Discussion 
In this Danish cohort, BMI and CRF were independent predictors of cancer risk in 
men. Reduced risks of respiratory/thoracic cancer incidence and mortality; and all 
cancer-cause mortality were noticed for participants with BMI ≥30 kg/m2 compared 
to participants with a healthy BMI (<25 kg/m2). Increasing levels of CRF also 
lowered cancer risk incidence and mortality of respiratory/thoracic cancers; and all-
cancers combined. Self-reported PA was not associated with most outcomes 
assessed. Additionally, we detected no evidence of interaction between the effects of 
BMI and PA or CRF on cancer risk. Testing the “fat but fit” concept was difficult in 
this cohort because obesity was not associated with higher risks of cancer. Obesity is 
usually a marker of social inequality in developed countries and these disparities are 
known to influence the burden of cancer.(29) However, in this early epidemiological 
study, obese participants were from high socioeconomic status (SES), and thus they 
might have different health-risk behaviour profiles, which may explain the reduced 
risk associated with obesity.(29) Additionally, confounding by smoking (smokers 
were thinner) could be another possible reason for the reduced risk observed for 
obesity.(30)  
 
The International Agency for Research on Cancer (IARC) working group on body 
mass reported that there is sufficient evidence for a positive association between 
obesity and some gastro-intestinal cancers, with the highest risk for esophageal 
adenocarcinoma and the lowest for colorectum or gallbladder.(6) Additionally, this 
group reported limited evidence for fatal PC and inadequate evidence for lung cancer 
(LC).(6) A reduced risk of LC has been reported with obesity in a fairly recent 
systematic review and meta-analysis.(30) In our study, we also observed that obesity 
conferred lower risk of respiratory/thoracic cancers. Possible explanations for this 
obesity paradox include (i) confounding by smoking status since this behaviour 
influences body weight and body composition; and (ii) storage, mobilisation, and 
metabolism of carcinogen DNA adducts by the adipose tissue.(30) 
 
Ambivalence still persists in the association of BMI with cancer mortality.(26) Most 
studies on cancer-related death have observed an increased risk from all-cancer 
combined or CRC in men with obesity compared to their healthy BMI 
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counterparts.(26, 31) The elevated risk for all-cancers combined has been documented 
around 10% and 32% for CRC.(26) In a recent meta-analysis of nearly 4 million 
participants from different world regions, a BMI of 25 kg/m2 or greater was 
associated with increased all-cancer cause mortality in a log-linear manner which did 
not differ across each region.(32) The increased risk of cancer death was 10% for 
overweight, 31% for obesity grade I (BMI ≥30 to <35 kg/m2), 57% for obesity grade 
II (BMI ≥35 to <40 kg/m2) and 96% for obesity grade III (BMI ≥40 to <60 kg/m2).(32) 
Mortality relationships with PC or other types of cancer are less consistent with 
conflicting results.(26, 31, 33, 34) 
 
Considerable evidence exists for a protective role of PA in lowering the risk of some 
types of cancer, particularly with colon cancer (CC).(35) The World Cancer Research 
Fund (WCRF) and IARC have described the association between PA and LC as 
suggestive.(7) Nevertheless, a recent review of the literature suggests that the majority 
of studies support a role of PA in reducing LC incidence by 20–50% in men;(36) and 
proposes a weak inverse association of PA and PC with an average risk reduction of 
10%.(37) Studies assessing CRF and cancer incidence have reported lower risks of 
LC or CC in participants with high levels of CRF compared to the lowest; the 
respective reduced risk were 55% and 44%.(12, 14) However, the association with PC 
has produced inconsistent findings; an earlier analysis from an American cohort 
study reported a reduction of 74%(38) while subsequent analysis observed an 
increased risk which ranges from 22% to 74%.(10, 14) Our data suggest that increasing 
CRF levels lower cancer risk incidence of respiratory/thoracic cancers; and all-
cancers combined. 
 
Pre-diagnostic CRF was associated with a decreased risk of respiratory/thoracic 
cancer mortality; and all cancer-cause mortality even after adjusting for BMI levels; 
this shows that the apparent protection is not explained by adiposity as was 
previously suggested for several types of cancer.(7) We did not find evidence for a 
beneficial effect of PA or fitness on mortality for other clinical cancer groups. 
Genetics and habitual PA behaviour are considered the main determinants of CRF. 
Although the reported correlation between PA and CRF ranges from 60 to 70%,(39) 
this study suggests that CRF may be a better predictor of regular vigorous activity 
than subjective self-report measures on cancer outcomes. Additionally, PA captured 
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by self-report was broad-ranging and the generic question used in this analysis may 
have introduced measurement error mis-classification, attenuating the observed 
association with cancer outcomes.(40) 
 
In 2011, cancer as a single entity was the leading cause of death globally and 20 
million new cancer cases are projected by 2025.(1) Therefore, the elucidation of the 
interaction between body mass and levels of PA or CRF on cancer outcomes is of 
public health interest because these independent lifestyle factors contribute 
independently to the burden of cancer.(1) Very few studies have examined this 
interaction on cancer incidence, providing contradictory results.(10, 41-46) Four 
observational studies have focused on CC;(41-44) of them, only two case-control 
studies detected a significant interaction, reporting that high levels of PA offset risks 
among those with the highest BMI.(43, 44) Two studies appraised this interaction on 
LC risk;(45, 46) of which, a case-control study reported a significant interaction.(45) The 
authors noticed lower risk in healthy BMI or overweight individuals with high levels 
of activity but the same observation was not detected in obese individuals. Regarding 
prostate cancer, one prospective study noted a significant interaction where obese 
individuals with moderate or high levels of CRF offset obesity risks.(10) Case-control 
studies were more likely to report significant interactions than other epidemiological 
designs. To our knowledge, the interaction between BMI and PA on all cancer 
mortality has been assessed in one study, finding no significant interaction.(47) We 
found no evidence of interaction between BMI and levels of PA or CRF on cancer 
incidence or mortality. Despite yielding significant p-values for CRC and genito-
urinary cancer mortality, stratified effect sizes were not significant. These spurious 
statistical interactions may have emerged from categorization of CRF and BMI in 
accordance with established values, producing unequal observations across different 
stratum or inappropriate median splits.(48, 49) 
 
This analysis has several strengths and limitations. Among its strengths are the 
prospective nature of the study design, the linkages of questionnaire data to deaths 
records and cancer registry; the long follow-up period, which was sufficient to allow 
the ascertainment of a large number of cancer end points and the objective 
assessment of physical fitness (CRF) which is not usually feasible in large studies. A 
limitation is that changes in health-related fitness could not be assessed since CRF 
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was only collected at baseline. Additionally, CRF was estimated using an indirect 
method of VO2 max. However, this measurement is known to have a high correlation 
of 0.87 compared to more direct methods of estimating VO2 max.
(23) Finally, 
confidence intervals of two-way interactions were wide within strata, perhaps 
suggesting limited statistical power to detect such interactions.(28) 
 
Conclusion 
 
Findings from this study underline the importance of improving and maintaining 
high CRF, which can be achieved through a minimum of 150 minutes a week of 
moderate to vigorous intensity activity, to reduce cancer risk, but this factor does not 
interact with obesity. 
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CHAPTER 9 
 
CONCLUSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter summarises the results observed across the epidemiological studies 
utilised in this thesis, examining the interaction of physical activity, obesity and 
cancer risk; and their public health implications. It also acknowledges the limitations 
of the research methods and highlights areas that require further research.  
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Concluding Remarks 
 
Summary of findings 
 
Although evidence is accumulating regarding an association between obesity and 
physical inactivity as independent risk factors for cancer, little is known about the 
effects of high levels of physical activity on attenuating the increased cancer risk 
usually observed with obesity.(1, 2) Given the high prevalence of obesity globally and 
in Australia,(3, 4) research is scarce on the “fat but fit” hypothesis in the cancer field. 
Thus, the broad aims of this thesis were to assess the main and interactive effects 
between physical activity and obesity on different cancer types and outcomes, using 
multiple datasets in a series of epidemiological studies. Chapter 1 highlighted the 
need for embarking upon this thesis while chapter 2, 3 provided background 
information on excess adiposity, physical activity and their possible underlying 
cancer risk. The implicated pathways involve sex steroid hormones, regulation of 
insulin, bioavailability of insulin growth factor (IGF-1), inflammation and the 
immune function.(5, 6) Chapter 4 comprehensively reviewed the “fat but fit” 
hypothesis in the cardiovascular context and provided biological mechanisms 
through which physical activity might modify cancer risk in individuals with a high 
body mass independently of weight loss. Chapter 5 presented the most up to date 
evidence for an association between obesity and physical activity with cancer risk as 
a foundation for cancer preventive strategies in New South Wales (NSW), Australia. 
Chapters 6 to 8 (published papers) and Appendix E (preliminary DANHES analysis) 
evaluated the independent role of excess body fatness, physical activity or 
cardiorespiratory fitness when measured, and examined the “fat but fit” hypothesis 
on several cancer outcomes.  
 
The “fat but fit” hypothesis originated nearly 20 years ago when it was observed that 
high levels of cardiorespiratory fitness (CRF) attenuated the detrimental effects 
associated with obesity on the risk of all-cause or cardiovascular mortality in the 
Aerobics Center Longitudinal Study (ACLS).(7) This conclusion was drawn from 
analyses of more than 20.000 men who were followed up for an average of 8 years 
stratified by body mass index (BMI) or body fat percentage (BF%) and fitness 
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levels.(8, 9) In those analyses, men with a BMI greater than 30 kg/m2 or a body fat 
percent greater than 21.7% who were also fit had lower risks of death from 
cardiovascular outcomes or all-cause than unfit individuals irrespective of their BMI 
or BF%. Although this observation was initially noticed in fit men, these findings 
have been documented in physically active men and women.(10, 11) Since inception of 
this hypothesis, more than 50 studies have assessed it, with most studies focusing on 
mortality outcomes and cardiometabolic diseases. The general consensus of those 
“fat but fit” studies is that high levels of physical activity or fitness appear to offset 
some of the obesity-risks associated with all-cause and cardiovascular mortality and 
diminish risk of some cardiometabolic outcomes (Chapter 4). Testing this hypothesis 
with respect to cancer outcomes was the central focus of this thesis.    
 
In this thesis, obesity or the highest category of BMI was associated with cancer risk 
compared to a healthy BMI or the lowest BMI reference. This association was 
observed in the studies in this thesis. For instance, in the CLEAR study (case-
control), a BMI 30 kg/m2 increased the risk for uterine cancer in women; and any 
cancer combined, prostate and colorectal cancer in men. These associations occurred 
in a dose-response manner since tests for trends were all significant (P-trend less than 
0.05). On the other hand, the effects of obesity were not significant on the risks of 
breast, colorectal or ovarian cancer in female-specific malignancies in this study. In 
cohort studies, in particular in the preliminary analysis of DANHES, increases in 
BMI per kg/m2 elevated the risks of breast cancer, uterine and any cancer combined 
in women; and colon and any cancer in men. Conversely a unit increase in BMI 
marginally diminished the risk of lung cancer in women. Additionally, no 
associations were noticed for female colon cancer and cancers of the lung or prostate 
in men. The effects of body mass in a cohort of only men (Copenhagen Males Study) 
found that obesity reduced the risk of respiratory and thoracic cancer incidence and 
mortality as well as all-cancer cause mortality. Possible explanations for the 
contradictory decreased risk associated with obesity and lung cancer or respiratory 
cancers include: (i) confounding by smoking and (ii) storage, mobilisation, and 
metabolism of carcinogen-DNA adducts in the adipose tissue.(12) Given the 
discrepancies in findings of colon cancer amongst men and women, the risk for this 
malignancy was particularly assessed in a large cohort study of more than 225,000 
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participants. This analysis assessed fine gradation of BMI in order to evaluate cancer 
risk in more detail than the broad World Health Organization (WHO) categories, 
noting that a BMI 29.4 kg/m2 increased the risk of colon cancer among both sexes. 
However, the same association was not observed for rectal cancer. Although the use 
of established BMI categories may enable comparisons between studies and facilitate 
decision making in the clinical setting,(13) the lowest value (29.4 kg/m2) within the 
higher data binning of BMI in the 45 and UP study basically equates to the minimal 
value suggested by WHO to define obesity, allowing for comparability; and the 32% 
increased risk of colon cancer observed in this study generally agree with the 
reported risk by leading cancer authorities.(1) The main effects of BMI on cancer 
risks in men and women in this thesis are summarised in Tables 9.1 and 9.2. 
 
Physical activity (PA) behaviour was captured by validated instruments across the 
studies used in this thesis with the purpose of providing exposures of public health 
significance. In the CLEAR study, PA was cross tabulated from vigorous and less 
vigorous activities. In the 45 and Up study, groups of activity were created based on 
guidelines of PA and in the Danish cohorts, PA was ranked in categories that reflect 
incremental PA patterns of this behaviour. As a result, PA was associated with lower 
risk of cancer; the main effects of PA and CRF on cancer risks are summarised in 
Tables 9.3 and 9.4. High levels of PA in women in the CLEAR study reduced the 
risk of uterine cancer whereas low or moderate PA decreased the risks of any cancer 
combined and breast cancer. Besides, any level of PA diminished the risk of 
colorectal cancer in females. In the DANHES cohort study, light or moderate to 
vigorous PA (MVPA) was negatively associated with female lung cancer and any 
cancer combined. In the 45 and UP study, meeting recommended guidelines of PA, 
in particular vigorous activity, reduced risk of colon cancer in both sexes. 
Conversely, PA was not associated with male-specific cancers, namely prostate, 
genito-urinary and other cancers in Danish cohorts or CLEAR study. However, a 10 
ml/kg/min increase in VO2max or CRF reduced cancer risk incidence and mortality 
of respiratory and thoracic cancers; and all-cancer sites combined in males in the 
Copenhagen Males Study.  
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Table 9.1 - Summary table of the effects of BMI on cancer risk in women, using different epidemiological studies in this thesis. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cancer type 
CLEAR study (case-control) 
3,845 cases and 1,024 controls 
(Chapter 6) 
45 and UP study (prospective cohort) 
Participants 121,929 
(Chapter 7) 
Danish Health Examination 
Survey 
(prospective cohort) 
Participants: 40,915 
(Appendix E) 
Women Healthy 
<25 
Overweight 
25-<30 
Obese 
30kg/m2 
<23.6 23.6-<26.2 26.2-<29.4 29.4 Kg/m2 Increase in a unit of BMI 
(Kg/m2) 
Any cancer 1.00 1.03 
(0.87-1.21) 
1.12 
(0.93-1.35) 
- - - - 1.01 (1.00-1.02) 
Breast 1.00 1.07 
(0.87-1.30) 
1.04 
(0.83-1.30) 
- - - - 1.02 (1.01-1.03) 
Colorectal 1.00 1.01 
(0.77-1.32) 
0.88 
(0.65-1.20) 
- - - - - 
Colon - - - 1.00 0.90 
(0.73-1.12) 
1.12 
(0.91-1.38) 
1.32 
(1.08-4.49) 
1.01 (0.98-104) 
Rectal - - - 1.00 0.84 
(0.62-1.14) 
0.73 
(0.54-1.00) 
0.76 
(0.55.-1.04) 
- 
Uterine 1.00 0.84 
(0.54-1.31) 
1.99 
(1.31-3.03) 
- - - - 1.06 (1.03-1.09) 
Ovarian 1.00 0.77 
(0.50-1.19) 
1.22 
(0.78–1.91) 
- - - - - 
Lung - - - - - - - 0.95 (0.92-0.99) 
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Table 9.2 - Summary table of the effects of BMI on cancer risk in males, using different epidemiological studies in this thesis. 
 
Cancer type 
CLEAR study 
(case-control) 
2,986 cases and 968 controls 
(Chapter 6) 
45 and UP study 
(prospective cohort) 
Participants 104,655 
(Chapter 7) 
Copenhagen Male Study 
(prospective cohort) 
Participants 5,128 
(Chapter 8) 
Danish Health 
Examination Survey 
(prospective cohort) 
Participants 28,173 
(Appendix E) 
Men Healthy 
<25 
Overweight 
25-<30 
Obese 
30kg/m2 
<23.6 23.6-
<26.2 
26.2-
<29.4 
29.4 
Kg/m2 
Healthy 
<25 
Overweight 
25-<30 
Obese 
30kg/m2 
Increase in a unit of 
BMI (Kg/m2) 
Any cancer 1.00 1.08 
(0.91-1.29) 
1.37 
(1.11-1.70) 
- - - - 1.00 1.00 
(0.91-1.11) 
0.83 
(0.68-1.00) 
1.01 (1.00-1.03) 
Colorectal 1.00 1.29 
(0.98-1.69) 
2.13 
(1.55-2.91) 
- - - - 1.00 1.07 
(0.84-1.37) 
0.68 
(0.40-1.15) 
- 
Colon - - - 1.00 0.90 
(0.73-1.12) 
1.12 
(0.91-1.38) 
1.32 
(1.08-4.49) 
- - - 1.04 (1.00-1.07) 
Rectal - - - 1.00 0.84 
(0.62-1.14) 
0.73 
(0.54-1.00) 
0.76 
(0.55-1.04) 
- - - - 
Prostate 1.00 1.22 
(0.99-1.51) 
1.51 
(1.17-1.94) 
- - - - 1.00 1.06 
(0.85-1.31) 
0.84 
(0.53-1.32) 
1.01 (0.99-1.03) 
Oral and 
digestive 
- - - - - - - 1.00 1.10 
(0.91-1.33) 
0.99 
(0.71-1.39) 
- 
Respiratory 
and Thoracic 
- - - - - - - 1.00 0.87 
(0.71-1.06) 
0.51 
(0.32-0.79) 
- 
Genito-
urinary 
- - - - - - - 1.00 1.05 
(0.87-1.25) 
0.85 
(0.59-1.22) 
- 
Other 
cancers 
- - - - - - - 1.00 0.98 
(0.78-1.24) 
1.06 
(0.69-1.61) 
- 
Lung - - - - - - - - - - 0.98 (0.95-1.03) 
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Regarding the “fat but fit”, no interactions between body mass index and PA or CRF 
were observed on the different cancer outcomes presented here as the interactions 
were not significant (>0.10) and the graphical assessment did not show an evident 
risk reduction. This thesis investigated the “fat but fit” in several epidemiological 
studies including a case control study and three cohort studies. Although two P-
interactions were found to be significant for mortality from colorectal and genito-
urinary cancer in the Copenhagen Male Study, graphic display of stratified effect 
sizes were not significant for either type of cancer; the spurious significant 
interactions may have been attributed to categorisation which led to unequal 
observations across strata or inappropriate median split.(14, 15) Absence of interaction 
means that there is no clear evidence for the “fat but fit” hypothesis applicable to the 
cancer field. This suggests that physical activity and body fatness are likely 
independent cancer risk factors, and based on the findings from this thesis, high 
levels of physical activity could not be recommended to offset cancer risks posed by 
obesity. A summary of the statistical P-interactions is displayed in Table 9.5. 
 
Significance of the findings 
 
Clinical recommendations increasingly recognise the effects of excess body fatness 
and physical inactivity on cancer risk.(16-18) The World Cancer Research Fund and the 
Clinical Oncology Society of Australia promote and advocate for a healthy body 
weight and adherence to physical activity guidelines for primary and tertiary cancer 
prevention.(16-18) Nevertheless, many physicians do not counsel their patients about 
the importance of weight management and meeting the recommended levels of 
physical activity.(19) On the other hand, lay people are not well aware of the dangers 
associated with these behaviours. For instance, a survey conducted in 2016 by 
Cancer Council NSW found that 40% of residents in the state do not relate 
overweight or obesity with cancer risk. Likewise, only 26% of people associate 
physical inactivity with higher risks of cancer.(20) Therefore, more efforts are needed 
to increase knowledge in both lay and medical communities about the importance of 
weight control and meeting physical activity guidelines to impact cancer risk.  
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Table 9.3 - Summary table of the effects of PA levels on cancer risk in women, using different epidemiological studies in this thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cancer type 
CLEAR study (case-control) 
3,845 cases and 1,024 controls 
(Chapter 6) 
45 and UP study 
(prospective cohort) 
Minutes of vigorous PA 
Participants 121,929 
(Chapter 7) 
Danish Health Examination Survey 
(prospective cohort) 
Participants: 40,915 
(Appendix E) 
Women Nil Low Moderate High None >0-74 75 or more Inactive light MVPA 
Any cancer 1.00 0.70 
(0.57-0.85) 
0.77 
(0.64-0.93) 
0.87 
(0.71-1.06) 
- - - 1.00 0.94 
(0.83-1.07) 
0.85 
(0.76-1.00) 
Breast 1.00 0.66 
(0.51-0.86) 
0.72 
(0.57-0.91) 
0.80 
(0.63-1.02) 
- - - 1.00 1.06 
(0.87-1.31) 
0.84 
(0.64-1.09) 
Colorectal 1.00 0.53 
(0.38-0.74) 
0.69 
(0.52-0.93) 
0.60 
(0.44-0.84) 
- - -    
Colon - - - - 1.00 0.78 
(0.65-0.93) 
0.78 
(0.61-0.98) 
1.00 0.99 
(0.66-1.48) 
1.07 
(0.64-1.79) 
Rectal - - - - 1.00 0.98 
(0.71-1.36) 
0.70 
(0.50-0.98) 
   
Uterine 1.00 0.59 
(0.36-0.98) 
0.69 
(0.44-1.09) 
0.47 
(0.27-0.80) 
- - - 1.00 0.90 
(0.58-1.40) 
0.82 
(0.46-1.44) 
Ovarian 1.00 0.75 
(0.45-1.27) 
1.01 
(0.63-1.61) 
0.91 
(0.55-1.51) 
- - - - - - 
Lung - - - - - - - 1.00 0.65 
(0.45-0.95) 
0.43 
(0.24-0.78) 
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Table 9.4 - Summary table of the effects of PA levels or CRF on cancer risk in men, using different epidemiological studies in this thesis. 
Cancer 
type 
CLEAR study 
(case-control) 
2,986 cases and 968 controls 
(Chapter 6)  
45 and UP study 
(prospective cohort) 
Minutes of vigorous PA 
Participants 104,655 
(Chapter 7) 
Copenhagen Male 
Study 
(prospective cohort) 
Participants 5,128 
(Chapter 8) 
Danish Health Examination Survey 
(prospective cohort) 
Participants 28,173 
(Appendix E) 
Men Nil Low Moderate High None >0-74 75 or more Increased in CRF 
per 10 ml/kg/min 
Inactive light MVPA 
Any cancer 1.00 0.98 
(0.79-1.23) 
0.99 
(0.81-1.23 
1.04 
(0.84-1.28) 
- - - 0.92 
(0.86-0.98) 
1.00 1.00 
(0.88-1.14) 
1.07 
(0.92-1.24) 
Colorectal 1.00 0.97 
(0.69-1.36) 
1.00 (0.74-
1.37) 
1.15 
(0.84-1.28) 
- - - 0.94 
(0.79-1.12) 
- - - 
Colon - - - - 1.00 0.78 
(0.65-0.93) 
0.78 
(0.61-0.98) 
- 1.00 1.07 
(0.72-1.58) 
0.88 
(0.55-1.40) 
Rectal - - - - 1.00 0.98 
(0.71-1.36) 
0.70 
(0.50-0.98) 
- - - - 
Prostate 1.00 0.98 
(0.73-1.30) 
1.09 
(0.84-1.43) 
1.10 
(0.84-1.43) 
- - - 1.02 
(0.88-1.19) 
1.00 1.15 
(0.92-1.43) 
1.22 
(0.96-1.55) 
Oral and 
digestive 
- - - - - - - 0.90 
(0.79-1.03) 
- - - 
Respiratory 
and 
Thoracic 
- - - - - - - 0.78 
(0.67-0.90) 
- - - 
Genito-
urinary 
- - - - - - - 1.05 
(0.93-1.18) 
- - - 
Other 
cancers 
- - - - - - - 0.93 
(0.79-1.09) 
- - - 
Lung - - - - - - - - 1.00 0.70 
(0.48-1.03) 
0.81 
(0.51-1.29) 
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Table 9.5 - Summary table of the statistical interaction, testing the “fat but fit” hypothesis on cancer risk in men and women, using different epidemiological 
studies in this thesis. 
 
 
 
 
 
Cancer type 
CLEAR study 
(case-control) 
6,831cases and 1,992 
controls 
(Chapter 6) 
45 and UP study 
(prospective cohort) 
Minutes of vigorous 
PA 
Participants 
226,584 
(Chapter 7) 
Copenhagen Male Study 
(prospective cohort) 
Participants 5,128 
(Chapter 8) 
Danish Health 
Examination 
Survey (prospective 
cohort) 
Participants 69,088 
(Appendix E) 
 Men Women Men Women Men 
(incidence) 
Men 
(mortality) 
Men Women 
Any cancer 0.81 0.12 - - 0.41 0.34 0.81 0.79 
Colorectal 0.27 0.13 - - 0.50 0.07 - - 
Colon - - 0.65 0.65 - - 0.74 0.22 
Rectal - - 0.96 0.96 - - - - 
Prostate 0.45 - - - 0.83 0.20 0.89 - 
Oral and 
digestive 
- - - - 0.94 0.42 - - 
Respiratory 
and Thoracic 
- - - - 0.41 0.81 - - 
Genito-urinary - - - - 0.69 0.04 - - 
Other cancers - - - - 0.26 0.74 - - 
Lung - - - - - - 0.93 0.80 
Breast - 0.16 - - - - - 0.31 
Uterine - 0.37 - - - - - 0.76 
Ovarian - 0.25 - - - - - - 
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“Fat but fit” has often been reported to be associated with cardio-metabolic 
outcomes; (21-24) and despite that malignant neoplasms and cardio-metabolic diseases 
might share risk factors and basic molecular pathways which overlap 
considerably.(25) These two aetiologies appear to be epidemiologically distinct since 
evidence from this thesis supports that PA or CRF alone do not appear to be 
sufficient to offset the detrimental effects of obesity-associated cancer risk. Thus, the 
public health “fat but fit” message does not seem to apply in the cancer field. In 
addition, this thesis validates that cancer-preventive efforts to maintain a healthy 
weight and adequate levels of physical activity or fitness are required as these two 
determinants seem to act independently on different cancer outcomes. 
 
Limitations of the research 
 
In epidemiological research, randomised controlled trials (RCTs) are recognised as 
the “gold standard” to grade the evidence and formulate recommendations because 
results from experimental studies are most internally valid.(26) Findings from this 
thesis are based on observational epidemiological data in particular a case-control 
study and three cohort studies. Although physical activity and body mass index were 
independently associated with cancer outcomes, this correlation does not probe 
causation as confounding restricts the inference of valid causal associations in all 
observational studies.(27) Additionally, statistical measures of association do not 
explain the number of ways in which the exposure might cause disease,(27) in 
particular with cancers, as they usually present slow-onset and the exposures 
examined in this thesis were collected at or near cancer diagnoses with the exception 
of the Copenhagen Male Study.  
 
Intrinsic methodological concerns of observational studies include selection bias, 
which is defined as a distortion of the exposure on the outcome that differs among 
those who decided to participate compared to those who did not.(28) This 
misrepresentation of the study population occurs from methods used to select 
subjects and from factors influencing their participation.(28) Selection bias is also 
more common in case-control studies than in cohort studies.(29) However, this type of 
bias might have been minimised in the Cancer, Lifestyle and Evaluation of Risk 
Study (CLEAR) due to the recruitment of the spouse as a control since cases and 
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control may share exposures of interest.(30) Another concern in epidemiological 
studies is the generalisability of findings from cohort studies with low response rates. 
Although these studies are not representative of the population of interest, effect 
estimates are not biased since representativeness is not indispensable to yield reliable 
estimates of risk.(31) Besides, the main effects estimates of PA or BMI and cancer 
risk observed in this thesis were in the same general direction and magnitude as those 
reported by leading cancer reviews.(1, 18, 32)  Although the practice of public health 
requires the best available level of evidence, RCTs are not always suitable to 
examine cancer risk factors due to ethical considerations and feasibility (long follow-
up periods for cancer onset and budgetary constraints).(26) Thus, observational 
studies, predominantly cohort studies, can effectively provide policy-relevant 
epidemiological evidence that cannot be acquired from RCTs in a real life setting.(33) 
 
Another type of bias is information bias. This systematic error arises from the 
implemented methods to gather data from the exposure and outcome in a study.(34) 
Self-report, through the use of questionnaires, was the approach utilised to capture 
physical activity and body mass. Data obtained by subjective methods is prone to 
social desirability and recall bias and this may influence the precision of the effect of 
physical activity or excess adiposity on cancer risk.(26, 34) Social desirability occurs 
when a participant selects responses they perceive as more socially acceptable rather 
than being reflective of their true behaviour.(35) Study participants might therefore 
over-report their engagement in different domains of physical activity and under-
report their BMI. Validation studies of objective and subjective measures of BMI, in 
the studied populations of this thesis, found that both men and women often 
overestimated their height and underestimated their weight.(36, 37) However, the 
correlation between BMI derived from self-report and directly measured has shown 
to be high and reliable for categorising study participants in order to assess risks 
associated with overweight and obesity(36) Additionally, most of the studies in this 
thesis used established measures of physical activity which had previously been 
validated to minimise bias.(38, 39) Recall bias is the differential reporting between 
cases and controls;(40) cancer cases may be more motivated to probe their memories 
than controls for plausible causes, reporting their exposures more exhaustively than 
controls. This type of bias is more likely in case control designs.(40) Prospective 
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cohort studies are less prone to this bias since BMI or physical activity habits are 
collected before the occurrence of cancer.(26)  
 
A limitation of the assessment of the “fat but fit” hypothesis was the possible low 
statistical power of each study used to detect an interaction since none was 
particularly designed to examine interactions. An interaction analysis requires a 
larger sample size to guarantee that an effect is accurately present in comparison to 
overall effects.(41) Besides, study power and simple size are also affected by the 
amount of measurement error of the different exposure variables. It has been 
documented that studies utilising imprecise study factors; such as physical activity, 
need a much larger sample than those studies with more accurate measures.(41) This 
proposes that precise exposure measurement is needed to overcome the limitation of 
sample size. However, in one of the studies in this thesis, objective measures of 
cardiorespiratory fitness were used to assess the “fat but fit” hypothesis and no 
evidence of interaction between fitness and obesity was observed. 
 
Accurate diagnoses of cancer are required in cancer-prevention research with cancer 
registries being the most accurate source of information.(42) Three out of four studies 
in this thesis used cancer registry data. However, the case control study (CLEAR) 
showed an association between self-reported cancer and physical activity or body 
mass index; although this is not ideal, the acquisition of registry data is not always 
possible and self-report may be a reasonable proxy to cancer registry data, providing 
that the accuracy of such data are known.(42) Based on the 20% of CLEAR 
participants that were available for verification against the NSW cancer registry, the 
positive predictive value (PPV) confirmed accuracy of self-report around 95% for 
most of the cancers assessed in Chapter 6 with the exception of ovarian cancer (PPV 
of 76%). 
 
Another limitation, which warrant interpretation of the cancer mortality results 
observed in the Copenhagen Males Study, was the lack of adjustment of stage of 
cancer diagnosis in the multivariable models since it has been found that cancer 
staging or tumour characteristics could influence mortality after cancer diagnosis.(43) 
Additionally, staging of cancer was less well-developed in 1970s and 80s so early 
incident  cancer in CMS may not have been clearly staged. 
 280 
 
Implications for future research 
 
Assessment of the interaction between physical activity and body fatness “fat but fit” 
is particularly important to cancer prevention as it could guide the implementation of 
public health strategies in order to reduce the burden of cancer. Findings from this 
thesis do not support the “fat but fit” hypothesis and cancer. The results suggest that 
physical activity and body mass are independent risk factors associated with cancer 
risk. Therefore, the promotion of a healthy body weight in addition to adequate levels 
of activity are recommended to impact on cancer risk but that physical activity may 
not offset obesity-related risks. This thesis broadens the knowledge base for 
decision-making in the field of cancer prevention.  
 
Questions of public health interest were addressed. Notwithstanding these findings, 
research across the continuum of cancer is needed. A vital area of cancer research 
which demands more investigation is the timing of these behavioural factors over 
susceptible periods of life and life course.(26) Additionally, further exploration of 
clustering of health-related behaviours and cancer risk may be informative since this 
approach provides the most effective public health interventions to improve risk 
factors than unconnected interventions targeting single behaviours.(44) Given that 
cancer patients are surviving longer and might be more likely to develop a second 
malignancy;(45) little is known about the role of physical activity, excess body fatness 
and “fat but fit” in cancer recurrence and second malignancies. The American Cancer 
Society defines cancer recurrence as a neoplasm detected after treatment or after a 
period of time when a patient was considered cancer-free.(46) Second malignancies or 
second primary cancers is a concept that applies to pre-existing treated or untreated 
malignancies which are not as a result of metastasis nor recurrence.(47) Therefore, 
more research in cancer survivorship is required to provide recommendations for 
physical activity, weight control and their possible additive or synergistic effects 
with treatment.     
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Epidemiological evidence from several cardiometabolic and all-cause mortality 
studies indicates that not all obese individuals are negatively affected by their extra 
weight, in particular if they are physically active or fit (“fat but fit”). However, this 
observation may not be relevant in the cancer field as the excess cancer risk of 
obesity was not eliminated or attenuated by physical activity or fitness levels. 
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Executive Summary 
  
Background / Purpose of the Evidence Check  
 
Modification of cancer-related lifestyle risk factors is an important part of cancer prevention. 
After excluding tobacco and sun exposure, the most important modifiable determinants of 
cancer incidence are: unhealthy weight, unhealthy dietary choices and physical inactivity.(1) In 
Australia, the prevalence of these unhealthy behaviours is high and continues to rise. Data 
from the National Health Survey (NHS) 2014–15(2) estimated that among adults 63% were 
either overweight or obese, 46% did not meet the minimum recommended levels of physical 
activity to achieve health benefits4, 95% did not meet a minimum of two daily serves of fruit 
and five or more serves of vegetables, and 17% exceeded the recommended two standard 
drinks of alcohol consumption a day. The focus of this rapid review is to identify up-to-date 
and available evidence (published 2012–2017) to determine if there is convincing evidence to 
link obesity, physical inactivity, major dietary guidelines and alcohol intake to the risks of the 
leading cancers in Australia.  
 
Evidence Check questions  
 
This literature review aimed to address the following questions: 
 
Question 1: What is the evidence for the association between cancer risk and the 
following (primary prevention) risk factors? 
(a) Overweight and obesity  
(b) Physical activity 
(c) Diet 
(d) Alcohol consumption. 
 
Question 2: What is the evidence for the above-mentioned risk factors on cancer risk in 
priority populations? 
 
Question 3: What is the evidence for life-course exposure to these risk factors on cancer 
risk? 
 
Summary of methods 
 
We took a primary prevention focus for this review, indicating the influence of these risk 
factors on cancer risk in people free of cancer at the outset or not at especially high risk of 
cancer. We did not focus on the cancer risks attributable to comorbidity, such as diabetes, but 
focused on four major primary prevention risk factors for non-communicable diseases 
(NCDs); three of these (physical inactivity, unhealthy diet and alcohol use) were defined by 
the World Health Organization (WHO)(3), to which we added overweight and obesity as a risk 
factor. We excluded tobacco use as this is reviewed elsewhere. Outcomes were the most 
common cancers in NSW. The peer-reviewed literature was systematically examined for 
relevant literature across four major databases: Medline, Scopus, PsycINFO and Cochrane 
                                                 
4 More than 150 minutes/week of moderate intensity physical activity or 75 min/week of vigorous physical activity or equivalent 
combinations of moderate–vigorous activity are required to meet the threshold for health (WHO 2010)  
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Database of Systematic Reviews. The review was limited to recent systematic reviews and/or 
meta-analyses published between 2012 and 2017. Additionally, grey literature was included 
from leading authorities and agencies concerned with cancer prevention and control, 
including World Cancer Research Fund (WCRF) and the International Agency for Research 
on Cancer (IARC).  
 
For the purpose of this Evidence Check, we used the following definitions to characterise the 
different risk factors:  
 
Overweight and obesity are described as the accumulation of excess adipose tissue with the 
capacity to impair health.(4) Both terms are usually defined in epidemiological studies by body 
mass index (BMI) status, which is derived from weight (kg) divided by the square of height 
(m). BMI status between 25 and 29.9 kg/m2 defines those who are overweight and ≥30 kg/m2 
defines those who are classified as obese.  
 
Physical activity is a broad concept described as any bodily movement using large skeletal 
muscles that results in energy expenditure.(5) It covers different domains including household, 
occupational, commuting and recreational physical activities. The WHO and Australian 
guidelines for health usually require at least 150 minutes per week of moderate-to-vigorous 
intensity physical activity.  
 
Diet or ‘healthy eating’ refers to the five food groups recommended in the Australian 
Dietary Guidelines for health and wellbeing.(6) Specific nutrients, nutrient groups or 
micronutrients in food were not assessed in this review as the issues surrounding 
micronutrients and cancer risk are complex and may not provide broad-based behavioural 
guidance for cancer prevention.  
 
Alcohol was defined as any beverage containing ethanol, and in epidemiological studies is 
usually measured as grams of ethanol per day/week or alcoholic drinks per day/week. 
 
 
Evidence grading 
 
We adapted existing frameworks to classify the strength of the evidence reported in these 
observational studies. Evidence is reported by gender, and the relationships between risk 
factors and cancers are categorised as ‘convincing’ evidence, ‘probable’, ‘possible’ and 
‘weak’. We graded the evidence according to the number of systematic reviews we identified 
and their quality. A more detailed description is given in Appendix A.1. A subsequent 
component of this work examines any evidence for cancer risk for (i) subgroups, particularly 
Aboriginal and Torres Strait Islander populations and specific culturally and linguistically 
diverse groups that are priority populations in relation to the NSW Cancer Plan, and (ii) life-
course exposure.  
 
 
Key findings  
 
The findings below summarise the Evidence Check of reviews on risk factors and cancer risk 
between 2012 and 2017. Only ‘convincing’ and ‘probable’ evidence is included in the 
Executive Summary since current evidence indicates a supportive association and these are 
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the cancers where primary preventive strategies could have a substantive impact on cancer 
prevention.  
 
Question 1: 
 
(a) Overweight and obesity 
 
Most of the studies, which examined the association between excess adiposity and cancer, 
used BMI as a proxy for adiposity as a continuous variable, or in some instances as a 
categorical variable. BMI comparisons were made between those in the overweight or obese 
category and those in the acceptable or underweight range. The studies that assessed waist 
circumference were included but were too few to identify specific risk relationships, so BMI 
was the primary measure used. Based on the available literature, there was convincing 
evidence that obesity increased cancer incidences of the colorectum, liver and thyroid and 
reduced the incidence of lung cancer among both men and women.(7-21) Additionally, obesity 
was convincingly associated with increased incidence of female postmenopausal breast and 
uterine cancer, and advanced prostate cancer in males.(22-31) There was probable evidence that 
increased incidence was observed in oesophageal, bladder, kidney and pancreatic cancers 
among both sexes, and ovarian cancer in women.(24, 32-40)  
 
There was convincing evidence for an association between obesity and increased mortality 
from colorectal cancer and probable evidence for an association between obesity and 
increased mortality from prostate, pancreatic and breast cancers.(28, 41-46) 
 
(b) Physical activity 
 
Most of the literature compared the highest level of physical activity (PA) or fitness or 
objectively measured movement (through accelerometry) against the lowest level of physical 
activity, fitness or movement. There was convincing evidence for an inverse association 
between PA and cancer incidence for lung and colorectal cancers in both sexes, and breast 
cancer among female-specific cancers.(20, 47-52) There was probable evidence for an inverse 
association between PA and uterine cancer in women.(30, 53) 
 
There was convincing evidence that PA reduced cancer-specific mortality for breast and 
colorectal cancer and probable evidence that PA reduced all-cause cancer mortality.(54-60) 
 
(c) Diet 
 
There was no convincing evidence of a link between diet and incidence of any cancer type. 
There was probable evidence that fruit and vegetable intake reduced lung and bladder cancer 
incidence and that dairy intake decreased the risk of colorectal cancer, in both men and 
women.(20, 61-66) Moreover, there was probable evidence that risk of female breast cancer was 
reduced with fibre and fruit intake whereas we observed an increased risk with red meat 
consumption.(29, 67-69)  
 
There was convincing evidence of an inverse association between all-cause cancer mortality 
and wholegrain intake and probable evidence of an inverse association between all-cause 
cancer mortality and high fibre intake, in both sexes.(65, 70-74)  
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 (d) Alcohol consumption 
 
We covered various types of alcoholic drinks such as any alcohol, beer, wine and spirits. Most 
of the literature compared multiple categories of alcohol consumption such as ‘light’, 
‘moderate’ and ‘heavy’ drinking with either ‘non-drinking’ or ‘non- and occasional drinking’. 
There was convincing evidence that increasing levels of alcohol consumption increased 
incidence of colorectal, liver and female breast cancers. There was probable evidence for an 
increased risk of head and neck cancer, pancreatic cancer (especially at levels of consumption 
greater than approximately 30 g ethanol/day) and melanoma.(20, 21, 29, 75-80) There was also 
convincing evidence that alcohol consumption is associated with a decreased risk of kidney 
cancer (the association was more consistent in women than in men).(40, 75, 81-83) Irrespective of 
the categories used for alcohol consumption, a reduced risk of renal cancer remained; further, 
when levels of alcohol were examined continuously per 10 gram increase in intake, the 
significant risk reduction was still apparent. 
 
There was probable evidence that alcohol consumption was associated with an increased risk 
of colorectal, liver and female breast cancer mortality.(21, 75, 84-86) 
 
Question 2:  
 
This Evidence Check could not assess the association between the modifiable risk factors of 
interest and priority populations including Australian Aboriginal and culturally and 
linguistically diverse populations living in Australia since no systematic reviews or individual 
studies met the criteria to be included in the current report.  
 
We identified only one systematic review of risk factors and Aboriginal populations.(87) 
Despite the fact that the review did not meet the criteria, it is worth mentioning the findings 
due to the limited number of studies on potential risk factors and cancer outcomes in this 
population; remote geographical location, Aboriginality and age less than 65 years were 
factors associated with increased risk of developing oesophageal, lung and liver cancer 
compared with non-Aboriginal Australians.  
 
Based on the top 10 languages spoken in NSW5, cancer incidence of liver, stomach and 
thyroid was higher for migrants from China, Egypt, Italy, Korea, Lebanon, the Philippines 
and Vietnam.(88) Although this study was published outside the time frame used in this 
Evidence Check (the decade 2007–2017), it was included to define the cancer risks of the 
non-English-speaking residents of NSW, as it is the most recent publication on this topic. 
Apart from these associations, cancer incidence patterns resembled those of the Australian-
born population when comparing migrants residing in NSW based on their language spoken 
at home. 
 
Most of the unique studies that we retrieved on Aboriginal and Torres Strait Islander people 
and culturally and linguistically diverse populations in Australia focused on cancer beliefs, 
attitudes towards screening, cancer care, health disparities, cancer experience and healthcare 
use, and therefore were not relevant to this Evidence Check.  
                                                 
5 Based on the ABS 2016 Census for NSW residents, the leading countries of birth were UK, China, India, New Zealand, 
Philippines, Vietnam, Lebanon, South Korea, Italy and South Africa, and for languages spoken at home, Mandarin, Arabic, 
Cantonese, Vietnamese, Greek, Italian, Tagalog, Hindi, Spanish, Korean 
http://profile.id.com.au/australia/language?WebID=100 . 
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Question 3:  
 
Very few studies drew inferences between lifetime exposure to the risk factors of interest and 
cancer risk. A systematic review that examined childhood obesity as a predictor of morbidity 
in adulthood found obesity at ages 7–11 years was associated with increased risk for all 
cancers and liver cancer in men. Furthermore, the highest BMI in children 12 years and over 
compared with the lowest was associated with incidence of colon, ovarian and kidney 
cancer.(89) This study reported single exposure levels in childhood and not life-course 
exposure levels. Two reviews of adult weight gain reported increased risk of colorectal cancer 
for participants who gained the most weight from early adulthood or middle age to older age 
compared with those whose weight was stable.(9, 90) Lifetime consumption of alcohol was 
assessed in one review reporting an increased risk of female breast cancer and colorectal 
cancer.(76) Assessment of physical activity during different periods of life found physical 
activity performed at any age — namely, less than 25 years, between 25 and 50 years or older 
than 50 years — was associated with lower risk of breast cancer in women.(91) 
 
Gaps in the evidence 
 
Evidence of lifestyle cancer risk factors mostly focused on risk factor exposure during the 
period before cancer diagnosis, with limited attention paid to these behaviours across the life 
course. Studies of risk factors in people with or after a cancer diagnosis were excluded as 
these were secondary/tertiary prevention studies. Further, clustered risk behaviours were 
evaluated in very few reviews.(10, 57, 92) No review and/or meta-analysis targeted priority 
population groups (Aboriginal and Torres Strait Islander people; and culturally and 
linguistically diverse populations).  
 
Discussion of key findings   
 
Question 1:  
 
Obesity, physical inactivity, unhealthy diet and alcohol consumption were associated with an 
increased risk of common cancers, globally and in Australia. The existing epidemiological 
literature supports the role of primary prevention approaches at the population level, such as 
the message that maintaining a healthy weight, being physically active and consuming a 
healthy diet (including limiting alcohol consumption) can considerably diminish the risk of 
developing and dying of cancer.  
 
Question 2:  
 
Although there is very limited data of potential risk factors and cancer outcomes in priority 
populations in NSW, primary cancer prevention strategies should be implemented as 
linguistically diverse communities may adopt lifestyles comparable to the host country, 
resulting in cancer patterns that are similar to the Australian-born population.(88) In addition, 
Aboriginal and Torres Strait Islander people and culturally and linguistically diverse groups 
have been identified as possessing a higher risk for some cancers, and poorer cancer-related 
outcomes.(93)  
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Question 3: 
  
Further studies are needed to examine the associations between life-course exposure to risk 
factors and cancer outcomes in order to help define public health policy for primary cancer 
prevention in Australia. 
 
Applicability 
 
These findings support the role of primary prevention interventions to help people achieve 
and maintain a healthy weight, undertake sufficient physical activity and eat a healthy diet 
while limiting their alcohol intake. These preventive strategies should target the general 
population and also priority communities including Aboriginal and Torres Strait Islander 
people and culturally and linguistically diverse groups since they have been identified as 
having higher risks of developing cancer and worse cancer-related health outcomes than the 
general population.(93) 
 
Conclusion 
 
These findings reaffirm the need for cancer prevention efforts, and for raising awareness of 
the cancer-related risks of lifestyle behaviours in the Australian population. Cancer prevention 
efforts could usefully focus on influencing unhealthy lifestyle-related behaviours that are 
substantial contributors to cancer in Australia. 
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Background 
 
Modification of cancer-related lifestyle risk factors is an important part of cancer prevention, 
as a recent report suggests one in three cancers is associated with lifestyle factors and thus 
may be preventable.(94) With the exclusion of tobacco exposure, the three most important 
modifiable determinants of cancer incidence are physical activity, maintaining a healthy 
weight and a healthy diet; however, alcohol will be included in this review as it is a core risk 
factor for non-communicable diseases, partly mediated through cancer risk.  
 
Data from the Australian Bureau of Statistics (ABS) Australian National Health Survey 
(NHS) 2014–15(2) estimated unhealthy behaviours in the Australian population and reported 
that among adults older than 65, 44.7% did not achieve the recommended 30 minutes of 
moderate physical activity on most days of the week. Additionally, 45.5% of adults aged 18–
64 years did not engage in the minimum recommended level of physical activity. The NHS 
also assessed rates of overweight and obesity, estimating the prevalence of being overweight 
or obese at 35.5% and 27.9% respectively. More than 17% of adults exceeded the 
recommended guidelines of daily alcohol consumption (two standard drinks per day), whereas 
44% of adults had exceeded the single occasion risk threshold of more than four standard 
drinks at least once in the previous year. Further, the NHS reported that 94.9% of Australians 
did not meet a minimum of two daily serves of fruit and five or more serves of vegetables. 
 
Given the high prevalence of these unhealthy behaviours in the Australian population; the 
objective of this Evidence Check is to identify the most up-to-date available evidence linking 
physical activity, diet, overweight and obesity, and alcohol consumption to cancer risk. 
 
Notwithstanding the fact that the burden of cancer affects society as a whole, there are priority 
populations with heightened susceptibility to these risk factors. Priority populations in 
Australia include, although are not limited to, Aboriginal and Torres Strait Islander people, 
culturally and linguistically diverse populations, socioeconomically disadvantaged people and 
rural and remote communities.(93) These population groups may be more likely to report 
unhealthy behaviours and lifestyles and consequently may be at increased risk of developing 
cancer.(93)  
 
The purpose of this Evidence Check was to examine the evidence that is currently available in 
order to answer the following questions: 
 
1. What is the evidence for the association between cancer risk and the following risk 
factors? 
(a) Overweight and obesity  
(b) Physical activity 
(c) Diet 
(d) Alcohol consumption.  
 
What is the evidence for the above-mentioned risk factors on cancer risk in priority 
populations? 
 
What is the evidence for life-course exposure to these risk factors on cancer risk? 
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Methods  
 
Peer review literature 
 
We reviewed academic literature to identify the association of these primary prevention risk 
factors and cancer incidence or mortality across the life course (pregnancy, childhood, 
adolescence, adulthood and lifetime) with a sub-focus on priority groups. We reported 
associations overall and, where possible, stratified by sex. 
 
The methodology for the literature search is outlined below. Initially we confined our 
searches to systematic reviews or meta-analyses, but used large-scale single epidemiological 
studies if there were insufficient studies in any search within subgroups. 
 
We conducted searches of the relevant academic literature published in English between 2012 
and 2017 in key research databases including Cochrane, Medline, Scopus and PsycINFO. We 
used the search terms shown below for each risk factor. Note that for cancer types, we 
included the most commonly occurring cancer types in NSW, namely cancers of the prostate 
and oesophagus, colorectal cancer, melanoma, lung, head and neck, breast and uterine 
cancers, lymphoma, leukaemia, thyroid, bladder, ovarian, kidney, pancreatic and liver 
cancers. In addition, we included cervical cancer and non-Hodgkin lymphoma based on the 
greater burden of those cancers on Aboriginal populations. Additional search terms were 
included for culturally and linguistically diverse populations (see Appendix A.2.1). 
 
For overweight and obesity  
 
Primary search (of the overall global literature) 
• Cancer.mp OR exp neoplasms/ OR neoplasms/ep, et [Epidemiology, Etiology/ 
aetiology] OR neoplasms/ OR tumor.mp OR carcino*.mp OR Onco* OR 
neoplasms/ep [epidemiology] OR Neoplasms/pc [Prevention & Control] 
• AND 
• Overweight.mp OR obesity.mp OR high BMI OR body mass index OR WC OR 
waist circumference OR body fatness 
• Systematic reviews OR meta-analysis (OR review). 
 
Secondary search (which produced literature relevant to specific demographic subgroups but 
NOT unique to a group) The same above-mentioned strategy was used in addition to: 
- AND 
- Migrant* OR culturally diverse OR ethnic* OR Aboriginal OR Indigenous OR 
Oceanic ancestry group. 
 
And then to further determine life stages, we included the following: 
 
- AND 
- Pregnancy OR gestation OR childhood OR adolescence OR adult* OR life. 
 
A paucity of identified information redirected the focus of the research to any specific large 
population cohort studies that could be identified in the area; failing this, we sought case-
control studies in the specific sub-areas. This also applied to other risk factors in relation to 
population subgroups. 
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For physical activity  
 
The same approach as above was used but for: 
- Physical activity.mp OR physical activities.mp OR exercise/ OR motor activity. 
 
A paucity of information redirected the focus of the research to large population cohort 
studies.  
 
For diet  
 
The emphasis was on diet as recommended in the Australian Dietary Guidelines. The same 
approach as above was used but for:  
- Fruit.mp OR vegetable* OR fibre.mp OR dietary fib* OR fruit fib* OR vegetable fib* 
OR cereal fib* OR processed meat OR red meat OR grain* OR whole grain.mp OR 
cereal* OR cereal grains OR breakfast cereal6 OR saturated fat.mp OR exp nutrition/ 
OR exp food intake/ or exp food OR exp diets/ OR vegetable.mp OR lean meat.mp 
OR dairy products OR DASH diet OR dietary pattern* OR exp diets/ OR 
Mediterranean diet.mp OR Western diet OR healthy eating index.mp OR dietary 
inflammatory index.mp. 
 
A paucity of information in this area also redirected the research focus to consider large 
population cohort studies.  
 
For alcohol 
 
The same approach as above was used but for: 
- Alcohol.mp OR beer OR wine OR spirits OR drinking OR excessive drinking OR 
binge. 
 
Evidence grading 
 
The quality of the different systematic reviews and/or meta-analyses was assessed using the 
Assessment of Multiple Systematic Reviews (AMSTAR). This tool consists of 11 item 
criteria; each criterion is given a score of 1 if it is met, or a score of 0 if the criterion is not 
met, is unclear, or is not applicable.(95) An overall score was then calculated adding the 
individual item scores. An AMSTAR of 8 to 11 is considered high quality, 4 to 7 is medium 
and 0 to 3 is low quality. 
 
One of the main objectives of this Evidence Check was to classify the evidence regarding the 
association of obesity, physical activity, diet and alcohol consumption with cancer risk. We 
created a grading system to guide and inform policy strategies. Our classification of evidence 
as ‘convincing’, ‘probable’, ‘possible’ and ‘weak’ was slightly adapted from the World 
Cancer Research Fund’s criteria for judging the evidence (Appendix A.1). For practical public 
health interventions, efforts to reduce the burden of cancer should be implemented where the 
evidence is at convincing or probable levels since current evidence indicates a strong enough 
supportive association to guide practice. Possible evidence indicates some associations with 
                                                 
6 As a major source of dietary fibre 
  
 
 
DOCUMENT1 | SAX INSTITUTE 297 
the risk factor, but caution should be applied in using this evidence in practice, and weak 
evidence indicates limited capacity for use in practice. 
 
Included studies 
 
The initial search strategy retrieved 4643 records; after duplicates were removed, 4502 unique 
articles remained and were screened by the reviewing team, who excluded 4027 as irrelevant 
for this Evidence Check. A total of 475 full text articles were assessed for eligibility and this 
rapid review comprises 247 systematic reviews and/or meta-analyses. A flowchart of the 
literature selection process is included as Appendix A.2. 
 
The mean AMSTAR score7 and standard deviation (SD) for the included articles on obesity 
was 6.9 SD (6.1), 5.7 (4.5) for physical activity, 9.8 (6.8) for diet and 4.3 (2.7) for alcohol 
(stacked graph, Appendix A.3). A summary table of the AMSTAR scores for the included 
studies is attached as Appendix A.4 in the detailed presentation of all systematic reviews used 
in this evidence synthesis. 
 
Grey literature 
Publications from the following institutions were searched for relevant information: 
- Australian Department of Health  
- Australian Institute of Health and Welfare 
- Australian state government health departments 
- Cancer Institute NSW 
- Cancer Council NSW 
- World Cancer Research Fund Continuous Update Project 
- International Agency for Research on Cancer reports 
- National Health Service (NHS) UK 
- Cancer Research UK 
- Health Canada 
- Canadian Cancer Society 
- NZ Ministry of Health 
- The Canadian Institutes of Health Research (CIHR) relevant to cancer. 
 
We conducted a desktop search for relevant grey literature, finding 11 systematic literature 
reviews from the World Cancer Research Fund (WCRF) Continuous Update Project and 
reports from the International Agency for Research on Cancer (IARC). In addition, we 
searched the Aboriginal and Torres Strait Islander Health Bibliography online database to 
identify relevant material regarding cancer risk among Australian Indigenous populations.  
 
 
 
  
                                                 
7 Standard measure used to rate the quality of systematic reviews 
  
 
 
DOCUMENT1 | SAX INSTITUTE 298 
Findings 
 
Question 1 (a): Obesity and cancer risk  
 
We conducted a search to appraise the evidence of association between excess adiposity and 
cancer risk; our search identified 73 systematic reviews and/or meta-analyses that examined 
this association. The majority of articles focused on body mass index (BMI) as an overall 
assessment of body composition. The WHO suggested levels of risk for adults as follows: 
underweight <18.5 kg/m2, healthy weight range 18.5–<25 kg/m2, overweight ≥25–<30 kg/m2 
and obese ≥30 kg/m2.(4) This tool provides a reasonable correlation with body fat percentage, 
which is about 0.70 to 0.80.(96) Waist circumference and waist to hip ratio were other 
measures of adiposity used to assess the association with cancer risk, in particular with central 
obesity.(97) However, there were very few studies that allowed us to infer risk relationships 
with these measurements. Therefore, grading of the evidence was based on assessment of 
BMI as the most frequently reported exposure. In some studies, BMI was considered as a 
continuous measure, and in other studies and reviews BMI was a categorical exposure, 
comparing risk in the highest with the lowest category of BMI.  
 
Based on the available literature, there was convincing evidence obesity was associated with 
an increased risk of cancers of the colorectum, liver and thyroid among men and women.(7-21) 
In addition, obesity was convincingly associated with postmenopausal breast and uterine 
cancer in women and advanced prostate cancer incidence in men.(22-31) On the other hand, a 
reduced risk was observed for lung cancer regardless of gender; this obesity paradox may be 
due to confounding by smoking status, since it influences body weight and body 
composition.(17) Evidence of a probable increase in incidence among both sexes was observed 
for adenocarcinoma of the oesophagus, and bladder, kidney and pancreatic cancer; and 
ovarian cancer in women.(24, 32-38, 40) Possible evidence was noted for non-Hodgkin lymphoma, 
head and neck cancers and melanoma, particularly in men, and there was weak evidence for 
cervical cancer and leukaemia.(22, 39, 40, 98-101)  
 
There was convincing evidence for an association between obesity and increased mortality 
from colorectal cancer and probable evidence for prostate, pancreatic and breast cancer 
mortality.(28, 41-46) For the other cancer types of interest, it was not possible to draw a 
conclusion.   
 
Question 1 (b): Physical activity and cancer risk  
 
We identified 47 systematic reviews and/or meta-analyses to evaluate the association between 
physical activity (PA) and cancer risk. Different domains of physical activity were assessed 
although recreational or leisure time physical activity (LTPA) was most commonly examined. 
This is presumed to be the most relevant domain of physical activity, at least in many 
societies where levels of occupational, domestic and transport-related physical activity have 
reduced dramatically.(102, 103) The highest level of physical activity, fitness or objectively 
measured movement (through accelerometry) was compared with the lowest level of physical 
activity, cardiorespiratory fitness or movement. We observed PA was associated with 
convincing risk reductions for cancer incidence, without sex differences, for lung and 
colorectal cancers; and for breast cancer among female-specific cancers.(20, 47-52) We noted 
probable evidence of an inverse association for female-specific cancers such as uterine 
cancer.(30, 53) There was possible evidence for reduced risk of kidney, thyroid, bladder and 
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pancreatic cancer among men and women, and possible evidence in the case of 
premenopausal breast cancer, particularly with vigorous activity, and weak evidence for 
cancers of the oesophagus, liver, non-Hodgkin lymphoma and ovaries.(14, 21, 29, 104-110) 
 
Regarding mortality, there was convincing evidence for associations between PA and reduced 
cancer-specific mortality for breast and colorectal cancer and probable evidence for all-cause 
cancer mortality.(54-60) Additionally, possible evidence was found for a risk reduction of all-
cause cancer mortality with high levels of cardiorespiratory fitness.(111) 
 
Question 1 (c): Diet and cancer risk  
 
Seventy-five articles included in this Evidence Check appraised the association of diet with 
cancer risk; a healthy diet may be a pivotal behaviour in the prevention of carcinogenesis.(112) 
The NSW Healthy Eating and Active Living Strategy endorses the Australian Dietary 
Guidelines as these are evidence-based recommendations of foods needed for health and 
wellbeing.(113) The guidelines recommend Australians eat a wide range of nutritious foods 
from the five food groups including vegetables, fruit, grain, dairy products and lean meats.(113) 
This review did not focus on the effect of micronutrients in isolation as this approach 
minimises the complexity of diet when translating dietary guidelines to the public.(114) 
 
There was no convincing evidence of an association between diet and incidence of any type of 
cancer. We observed a probable risk reduction for lung and bladder cancer with fruit and 
vegetable intake; and for colorectal cancer with dairy intake.(20, 61-66) These findings did not 
differ between men and women. Additionally, we found probable evidence of a reduced risk 
of breast cancer with fibre and fruit intake but an increased risk with red meat consumption in 
women.(29, 67-69) There was possible evidence that fruit consumption may reduce the risk of 
oesophageal, colorectal and pancreatic cancer while vegetable intake may decrease the risk of 
colorectal, breast (in women) and prostate (in men) cancer.(20, 31, 67, 115, 116) We noted a possible 
increased risk of pancreatic, colorectal, oesophageal, breast and prostate cancer with a high 
intake of processed meat, a finding noted in IARC reports as well.(69, 78, 117-119) The association 
of saturated fat with cancer risk is weak based on current literature.(120, 121)  
 
There was convincing evidence of a reduction in all-cause cancer mortality with wholegrain 
intake and probable evidence with a high intake of fibre; these associations were not modified 
by sex.(65, 70-74) A possible decrease in cancer-specific mortality was noted for bladder and 
lung cancer with fruit and vegetable intake; and an increase in all-cause cancer mortality was 
observed for adherence to a ‘Western diet’, defined in most reviews as a dietary pattern 
characterised by a high intake of red and processed meat, refined grains, sweets and desserts, 
and high-fat dairy products, with low consumption of fruit and vegetables.(122)  
 
Question 1 (d): Alcohol and cancer risk  
 
Fifty-two articles covered the association between alcohol intake and cancer. The most 
common types of alcoholic drinks consumed include beers and ciders followed by wines and 
liquors (spirits).(123) The ethanol content of these drinks varies within each group; for instance, 
beers contain between 3% and 7% alcohol whereas wine contains between 9% and 15 per 
cent. The concentration of alcohol is higher in spirits, where it ranges from 35% to 50% or 
higher.(123) In this Evidence Check, we covered the most common types of alcoholic drinks 
(beer, wine and spirits). Most of the literature compared multiple categories of alcohol 
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consumption, such as ‘light’, ‘moderate’ and ‘heavy’ drinking, with either ‘non-drinking’ or 
‘non- and occasional drinking’. There was not a consistent definition of each category of 
alcohol intake, as these were derived within specific populations. However, light drinking was 
often defined as ≤ 1 drink/day and moderate drinking often as ≤ 2 drinks/day. Heavy drinking 
was the most variable, with definitions ranging from at least 24 grams of ethanol per day to 
values of 50 grams or more per day. The number of grams of ethanol in a drink also varied 
between studies, with values of 12, 12.5 and 15 grams used. Regarding cancer incidence, 
there was convincing evidence that alcohol consumption is associated with an increased risk 
of colorectal cancer, liver cancer and female breast cancer, and probable evidence for an 
increased risk of head and neck cancer, pancreatic cancer (especially at levels of consumption 
greater than approximately 30 g ethanol/day) and melanoma.(20, 21, 29, 75-80) There was also 
convincing evidence that alcohol consumption is associated with a decreased risk of kidney 
cancer (sometimes the association was more consistent in women than in men).(40, 75, 81-83) 
Different levels of alcohol consumption were assessed in relation to renal cancers, including 
light, moderate and high levels vs. the lowest level; all the studies found a reduced risk 
irrespective of how these categories were defined. Additionally, when levels of alcohol were 
examined continuously per 10 g increase in intake, the significant risk reduction was still 
apparent. 
 
Regarding mortality, there was probable evidence that alcohol consumption is associated with 
an increased risk of colorectal, liver and female breast cancer mortality. (75, 84-86) There was a 
weak association between alcohol intake and cancer of the bladder, leukaemia or lymphoma 
and cervical or uterine cancer among female-specific cancers.(75, 124-126)  
 
Question 2:  
 
We retrieved 256 unique publications on Aboriginality and culturally and linguistically 
diverse communities. Of these, no article reported on the association between the risk factors 
of interest and cancer in these populations. Most of the studies focused on cancer beliefs, 
attitudes towards screening, cancer care, health disparities, cancer experience and healthcare 
use. 
 
Aboriginal and Torres Strait Islander people comprise diverse populations across all 
Australian states and territories. The largest absolute number of Aboriginal Australians live in 
NSW and Queensland.(127) These populations have a higher prevalence of modifiable lifestyle 
risk factors for cancer8 compared with non-indigenous Australians, as they are reported to be 
more likely to drink alcohol at dangerous levels, to smoke tobacco, be obese and be 
physically inactive than non-indigenous Australians.(87)  Additionally, the NSW Cancer Plan 
recognises communities who are at heightened risk of cancer and poor cancer-related 
outcomes. These communities include those who are culturally and linguistically diverse.(93) 
However, this Evidence Check could not assess the association between modifiable risk 
factors and cancer specifically in Aboriginal and Torres Strait Islander people and culturally 
and linguistically diverse communities since no systematic reviews or individual studies met 
the criteria of this review.  
 
Only one systematic review on Aboriginal risk factors was identified.(87) Despite the fact that 
the review did not meet the criteria, it is worth mentioning the findings due to the limited 
                                                 
8 The key issue for cancer risk with Aboriginal adults is tobacco use, as smoking rates remain three to four times higher than 
among non-Aboriginal Australians — but this is outside the scope of this report 
  
 
 
DOCUMENT1 | SAX INSTITUTE 301 
number of studies on potential risk factors and cancer outcomes in this population. Remote 
geographical location, Aboriginality and age less than 65 years were factors associated with 
increased risk of developing oesophageal, lung and liver cancer compared with non-
Aboriginal people. The review, examining studies to mid-2014, noted that behavioural risk 
factors were rarely reported in relation to cancer risk in studies of Aboriginal people, with 
only one study examining alcohol and tobacco use.  
 
Based on the top 10 languages spoken9 in NSW, the incidence of liver cancer was higher in 
migrants from China, Italy and Vietnam among both sexes. Additionally, the incidence of 
liver cancer was higher for males from Egypt, Korea and the Philippines. There was an 
increased incidence of stomach cancer in migrants from China, Italy, Korea and Vietnam, 
while the incidence of thyroid cancer was greater in people from Lebanon and the Philippines 
regardless of sex. Cervical cancer was elevated in women from China, the Philippines and 
Vietnam.(88) With the exception of these cancer incidence patterns, other cancers among 
migrant populations resembled the overall Australian rates. The result of our search on 
culturally and linguistically diverse populations is described in Appendix A.2.1 and 
demonstrates that no culturally and linguistically diverse-specific studies were identified that 
could be included in this Evidence Check.  
 
Question 3:  
 
There were very few studies that allowed the inference of cancer risk from lifetime exposure 
to the risk factors of interest. A systematic review that examined childhood obesity as a 
predictor of morbidity later in adulthood found that obesity at ages 7–11 years was associated 
with increased risk for all cancers and liver cancer in men. Furthermore, the highest BMI in 
children 12 years of age and over compared with the lowest was associated with incidence of 
colon, ovarian and kidney cancer.(89) This study reported one-off exposure levels in childhood 
and not life-course exposure levels. Two reviews of adult weight gain reported increased risk 
of colorectal cancer for those participants who gained the most weight from early adulthood 
or middle age to older age compared with those whose weight was stable.(9, 90) Lifetime 
consumption of alcohol was assessed in one review that reported an increased risk of female 
breast cancer and colorectal cancer.(76) Assessment of physical activity during different 
periods of life found physical activity performed at ages less than 25 years, between 25 and 
50 years, or older than 50 years was associated with a lower risk of breast cancer in 
women.(91) 
 
Gaps in the evidence 
 
Evidence of lifestyle cancer risk factors mostly focused on risk factor exposure during the 
period before cancer diagnosis, with limited attention to these behaviours across the life 
course. Moreover, clustered risk behaviours were evaluated in very few reviews.(10, 57, 92) No 
review and/or meta-analyses targeted priority population groups (Aboriginal and Torres Strait 
Islander people, socioeconomically disadvantaged and rural communities; and culturally and 
linguistically diverse populations). 
                                                 
9 The languages used were the most commonly spoken at home in NSW according to the ABS 2016 Census, and comprised 
Mandarin, Arabic, Cantonese, Vietnamese, Greek, Italian, Filipino/Tagalog, Hindi, Spanish and Korean  
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Discussion/synthesis of findings 
 
Obesity, low levels of physical activity, unhealthy diet and moderate and heavy alcohol 
drinking were associated with the common cancers globally and in Australia. The existing 
epidemiological literature supports the role that primary prevention approaches at the 
population level, such as assisting people to maintain a healthy weight, be physically active, 
limit alcohol consumption and consume a healthy diet, can considerably diminish the risk of 
developing and dying from cancer. This provides an updated evidence base for action in the 
primary prevention of cancer, as one component of an integrated cancer prevention strategy.  
 
Applicability 
 
These findings support the role of primary prevention interventions for maintaining and 
achieving a healthy weight, adequate levels of physical activity and a healthy diet while 
limiting alcohol consumption. These preventive strategies should target individuals in the 
general population as well as priority communities including Aboriginal and Torres Strait 
Islander people and culturally and linguistically diverse groups. While this review could not 
provide evidence for cancer risk from modifiable lifestyle factors for these subgroups, it is 
well reported that these priority populations have higher risks of developing some cancers, 
and worse cancer-related health outcomes than the general population.(93) 
 
Conclusion 
 
Several of the common cancers in Australia are related to the lifestyle risk factors obesity, 
physical inactivity, unhealthy diet and alcohol consumption. The most consistent cancer risks 
across these four lifestyle risk factors are for colorectal cancer, breast cancer and prostate 
cancer, but other cancers show moderate or strong associations with individual risk factors. 
This provides a rationale for investment in the primary prevention of cancer as part of an 
overall approach to cancer prevention, targeting the whole population.  
 
Evidence gaps exist for sub-populations, with no evidence for cancer risk for these lifestyle 
factors specifically among Aboriginal and Torres Strait Islander populations, or culturally and 
linguistically diverse groups. This lack of evidence should not impede or delay public health 
action, as many of these risks are likely to be similar to the evidence currently available, and 
hence efforts should focus on population intervention rather than further studies.  
 
Finally, the vast number of nearly 250 systematic reviews and meta-analyses in the five-year 
period covered in this Evidence Check indicate the plethora of replicated and overlapping 
evidence reviews, and it is timely to focus on influencing population awareness of these 
lifestyle risks rather than producing further distillations of the epidemiological evidence. 
Furthermore, there is a population health co-benefit from the promotion of awareness of these 
lifestyle risk factors, as it would also make a major contribution to reducing other non-
communicable disease risks (especially to cardiovascular disease and diabetes prevention). 
  
 
 
DOCUMENT1 | SAX INSTITUTE 303 
References 
 
1. Kushi LH, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera EV, et al. 
American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: 
reducing the risk of cancer with healthy food choices and physical activity. [Summary for 
patients in CA Cancer J Clin. 2012 Jan–Feb;62(1):68–9; PMID: 22237783]. CA: a Cancer 
Journal for Clinicians. 2012;62(1):30–67. 
2. Australian Bureau of Statistics. National Health Survey First Results. Australia 2014–15. 
2015. 
3. http://www.who.int/gho/ncd/risk_factors/en/ World Health Organization, Geneva. 
4. Organization WH. Obesity: preventing and managing the global epidemic: report of a 
WHO consultation on obesity, Geneva, 3–5 June 1997. 1998. 
5. Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical 
fitness: definitions and distinctions for health-related research. Public health reports. 
1985;100(2):126. 
6. NSW Healthy Eating and Active Living Strategy: Preventing overweight and obesity in 
New South Wales 2013–2018. 
7. Ma Y, Yang Y, Wang F, Zhang P, Shi C, Zou Y, et al. Obesity and risk of colorectal 
cancer: a systematic review of prospective studies. PLoS ONE [Electronic Resource]. 
2013;8(1):e53916. 
8. Parkin E, O'Reilly DA, Sherlock DJ, Manoharan P, Renehan AG. Excess adiposity and 
survival in patients with colorectal cancer: a systematic review. Obesity Reviews. 
2014;15(5):434–51. 
9. Schlesinger S, Lieb W, Koch M, Fedirko V, Dahm CC, Pischon T, et al. Body weight gain 
and risk of colorectal cancer: a systematic review and meta-analysis of observational studies. 
Obesity Reviews. 2015;16(7):607–19. 
10. Chen Y, Wang X, Wang J, Yan Z, Luo J. Excess body weight and the risk of primary liver 
cancer: an updated meta-analysis of prospective studies. European Journal of Cancer. 
2012;48(14):2137–45. 
11. Rui R, Lou J, Zou L, Zhong R, Wang J, Xia D, et al. Excess body mass index and risk of 
liver cancer: a nonlinear dose-response meta-analysis of prospective studies. PLoS ONE 
[Electronic Resource]. 2012;7(9):e44522. 
12. Wang Y, Wang B, Shen F, Fan J, Cao H. Body mass index and risk of primary liver 
cancer: a meta-analysis of prospective studies. Oncologist. 2012;17(11):1461–8. 
13. Ma J, Huang M, Wang L, Ye W, Tong Y, Wang H. Obesity and risk of thyroid cancer: 
evidence from a meta-analysis of 21 observational studies. Medical Science Monitor. 
2015;21:283–91. 
14. Schmid D, Behrens G, Jochem C, Keimling M, Leitzmann M. Physical activity, diabetes, 
and risk of thyroid cancer: a systematic review and meta-analysis. European Journal of 
Epidemiology. 2013;28(12):945–58. 
15. Zhao ZG, Guo XG, Ba CX, Wang W, Yang YY, Wang J, et al. Overweight, obesity and 
thyroid cancer risk: a meta-analysis of cohort studies. Journal of International Medical 
Research. 2012;40(6):2041–50. 
16. Gupta A, Majumder K, Arora N, Mayo HG, Singh PP, Beg MS, et al. Premorbid body 
mass index and mortality in patients with lung cancer: A systematic review and meta-analysis. 
Lung Cancer. 2016;102:49–59. 
17. Duan P, Hu C, Quan C, Yi X, Zhou W, Yuan M, et al. Body mass index and risk of lung 
cancer: Systematic review and dose-response meta-analysis. Scientific Reports. 
2015;5:16938. 
  
 
 
DOCUMENT1 | SAX INSTITUTE 304 
18. Shen N, Fu P, Cui B, Bu CY, Bi JW. Associations between body mass index and the risk 
of mortality from lung cancer: A dose-response PRISMA-compliant meta-analysis of 
prospective cohort studies. Medicine. 2017;96(34):e7721. 
19. Yang Y, Dong J, Sun K, Zhao L, Zhao F, Wang L, et al. Obesity and incidence of lung 
cancer: a meta-analysis. International Journal of Cancer. 2013;132(5):1162–9. 
20. World Cancer Research Fund International Systematic Literature Review. The 
Associations between Food, Nutrition and Physical Activity and the risk of Colorectal Cancer. 
Continuous Update Project Report: WCRF; 2017. 
21. World Cancer Research Fund International Systematic Literature Review. The 
Associations between Food, Nutrition and Physical Activity and the risk of Liver Cancer. 
Continuous Update Project Report: WCRF; 2015. 
22. Kyrgiou M, Kalliala I, Markozannes G, Gunter MJ, Paraskevaidis E, Gabra H, et al. 
Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ. 
2017;356:j477. 
23. Wang J, Yang DL, Chen ZZ, Gou BF. Associations of body mass index with cancer 
incidence among populations, genders, and menopausal status: A systematic review and meta-
analysis. Cancer Epidemiology. 2016;42:1–8. 
24. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body 
Fatness and Cancer—Viewpoint of the IARC Working Group. New England Journal of 
Medicine. 2016;375(8):794–8. 
25. Aune D, Navarro Rosenblatt DA, Chan DS, Vingeliene S, Abar L, Vieira AR, et al. 
Anthropometric factors and endometrial cancer risk: a systematic review and dose-response 
meta-analysis of prospective studies. Annals of Oncology. 2015;26(8):1635–48. 
26. Jenabi E, Poorolajal J. The effect of body mass index on endometrial cancer: a meta-
analysis. Public Health. 2015;129(7):872–80. 
27. Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and 
advanced prostate cancer—a dose-response meta-analysis of prospective studies. Annals of 
Oncology. 2012;23(7):1665–71. 
28. Zhang X, Zhou G, Sun B, Zhao G, Liu D, Sun J, et al. Impact of obesity upon prostate 
cancer-associated mortality: A meta-analysis of 17 cohort studies. Oncology Letters. 
2015;9(3):1307–12. 
29. World Cancer Research Fund International Systematic Literature Review. The 
Associations between Food, Nutrition and Physical Activity and the risk of Breast Cancer. 
Continuous Update Project Report: WCRF; 2017. 
30. World Cancer Research Fund International Systematic Literature Review. The 
Associations between Food, Nutrition and Physical Activity and the risk of Endometrial 
Cancer. Continuous Update Project Report: WCRF; 2013. 
31. World Cancer Research Fund International Systematic Literature Review. The 
Associations between Food, Nutrition and Physical Activity and the risk of Prostate Cancer. 
Continuous Update Project Report: WCRF; 2014. 
32. Singh S, Devanna S, Edakkanambeth Varayil J, Murad MH, Iyer PG. Physical activity is 
associated with reduced risk of esophageal cancer, particularly esophageal adenocarcinoma: a 
systematic review and meta-analysis. BMC Gastroenterology. 2014;14:101. 
33. Qin Q, Xu X, Wang X, Zheng XY. Obesity and risk of bladder cancer: a meta-analysis of 
cohort studies. Asian Pacific Journal of Cancer Prevention: Apjcp. 2013;14(5):3117–21. 
34. Sun JW, Zhao LG, Yang Y, Ma X, Wang YY, Xiang YB. Obesity and risk of bladder 
cancer: a dose-response meta-analysis of 15 cohort studies. PLoS ONE [Electronic Resource]. 
2015;10(3):e0119313. 
  
 
 
DOCUMENT1 | SAX INSTITUTE 305 
35. Wang F, Xu Y. Body mass index and risk of renal cell cancer: a dose-response meta-
analysis of published cohort studies. International Journal of Cancer. 2014;135(7):1673–86. 
36. Aune D, Greenwood DC, Chan DS, Vieira R, Vieira AR, Navarro Rosenblatt DA, et al. 
Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-
linear dose-response meta-analysis of prospective studies. Annals of Oncology. 
2012;23(4):843–52. 
37. Aune D, Navarro Rosenblatt DA, Chan DS, Abar L, Vingeliene S, Vieira AR, et al. 
Anthropometric factors and ovarian cancer risk: a systematic review and nonlinear dose-
response meta-analysis of prospective studies. International Journal of Cancer. 
2015;136(8):1888–98. 
38. Poorolajal J, Jenabi E, Masoumi SZ. Body mass index effects on risk of ovarian cancer: a 
meta- analysis. Asian Pacific Journal of Cancer Prevention: Apjcp. 2014;15(18):7665–71. 
39. World Cancer Research Fund International Systematic Literature Review. The 
Associations between Food, Nutrition and Physical Activity and the risk of Ovarian Cancer. 
Continuous Update Project Report: WCRF; 2014. 
40. World Cancer Research Fund International Systematic Literature Review. The 
Associations between Food, Nutrition and Physical Activity and the risk of Kidney Cancer. 
Continuous Update Project Report: WCRF; 2015. 
41. Doleman B, Mills KT, Lim S, Zelhart MD, Gagliardi G. Body mass index and colorectal 
cancer prognosis: a systematic review and meta-analysis. Techniques in Coloproctology. 
2016;20(8):517–35. 
42. Lee J, Meyerhardt JA, Giovannucci E, Jeon JY. Association between body mass index 
and prognosis of colorectal cancer: a meta-analysis of prospective cohort studies. [Erratum 
appears in PLoS One. 2016;11(1):e0147456; PMID: 26765168]. PLoS ONE [Electronic 
Resource]. 2015;10(3):e0120706. 
43. Wu S, Liu J, Wang X, Li M, Gan Y, Tang Y. Association of obesity and overweight with 
overall survival in colorectal cancer patients: a meta-analysis of 29 studies. Cancer Causes & 
Control. 2014;25(11):1489–502. 
44. Chan DSM, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, et al. Body 
mass index and survival in women with breast cancer—systematic literature review and meta-
analysis of 82 follow-up studies. Annals of Oncology. 2014;25(10):1901–14. 
45. Niraula S, Ocana A, Ennis M, Goodwin PJ. Body size and breast cancer prognosis in 
relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Research 
& Treatment. 2012;134(2):769–81. 
46. Zhong S, Yan X, Wu Y, Zhang X, Chen L, Tang J, et al. Body mass index and mortality 
in prostate cancer patients: a dose-response meta-analysis. Prostate Cancer and Prostatic 
Diseases. 2016;19(2):122–31. 
47. Brenner DR, Yannitsos DH, Farris MS, Johansson M, Friedenreich CM. Leisure-time 
physical activity and lung cancer risk: A systematic review and meta-analysis. Lung Cancer. 
2016;95:17–27. 
48. Buffart LM, Singh AS, van Loon EC, Vermeulen HI, Brug J, Chinapaw MJ. Physical 
activity and the risk of developing lung cancer among smokers: a meta-analysis. Journal of 
Science and Medicine in Sport. 2014;17(1):67–71. 
49. Sun JY, Shi L, Gao XD, Xu SF. Physical activity and risk of lung cancer: a meta-analysis 
of prospective cohort studies. Asian Pacific Journal of Cancer Prevention: Apjcp. 
2012;13(7):3143–7. 
50. Zhong S, Ma T, Chen L, Chen W, Lv M, Zhang X, et al. Physical Activity and Risk of 
Lung Cancer: A Meta-analysis. Clinical Journal of Sport Medicine. 2016;26(3):173–81. 
  
 
 
DOCUMENT1 | SAX INSTITUTE 306 
51. Boyle T, Keegel T, Bull F, Heyworth J, Fritschi L. Physical activity and risks of proximal 
and distal colon cancers: a systematic review and meta-analysis. Journal of the National 
Cancer Institute. 2012;104(20):1548–61. 
52. Robsahm TE, Aagnes B, Hjartåker A, Langseth H, Bray FI, Larsen IK. Body mass index, 
physical activity, and colorectal cancer by anatomical subsites: a systematic review and meta-
analysis of cohort studies. European Journal of Cancer Prevention. 2013;22(6):492–505. 
53. Schmid D, Behrens G, Keimling M, Jochem C, Ricci C, Leitzmann M. A systematic 
review and meta-analysis of physical activity and endometrial cancer risk. European Journal 
of Epidemiology. 2015;30(5):397–412. 
54. Li T, Wei S, Shi Y, Pang S, Qin Q, Yin J, et al. The dose-response effect of physical 
activity on cancer mortality: findings from 71 prospective cohort studies. British Jounal of 
Sports Medicine. 2016;50(6):339–45. 
55. Li Y, Gu M, Jing F, Cai S, Bao C, Wang J, et al. Association between physical activity 
and all cancer mortality: Dose-response meta-analysis of cohort studies. International Journal 
of Cancer. 2016;138(4):818–32. 
56. Schmid D, Leitzmann M. Association between physical activity and mortality among 
breast cancer and colorectal cancer survivors: a systematic review and meta-analysis. Annals 
of Oncology. 2014;25(7):1293–311. 
57. Zhong S, Jiang T, Ma T, Zhang X, Tang J, Chen W, et al. Association between physical 
activity and mortality in breast cancer: a meta-analysis of cohort studies. European Journal of 
Epidemiology. 2014;29(6):391–404. 
58. Kyu HH, Bachman VF, Alexander LT, Mumford JE, Afshin A, Estep K, et al. Physical 
activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic 
stroke events: systematic review and dose-response meta-analysis for the Global Burden of 
Disease Study 2013. BMJ. 2016;354:i3857. 
59. Otto SJ, Korfage IJ, Polinder S, van der Heide A, de Vries E, Rietjens JA, et al. 
Association of change in physical activity and body weight with quality of life and mortality 
in colorectal cancer: a systematic review and meta-analysis. Supportive Care in Cancer. 
2015;23(5):1237–50. 
60. Je Y, Jeon JY, Giovannucci EL, Meyerhardt JA. Association between physical activity 
and mortality in colorectal cancer: a meta-analysis of prospective cohort studies. International 
Journal of Cancer. 2013;133(8):1905–13. 
61. Vieira AR, Abar L, Vingeliene S, Chan DS, Aune D, Navarro-Rosenblatt D, Stevens C, 
Greenwood D, Norat T. Fruits, vegetables and lung cancer risk: a systematic review and 
meta-analysis. Annals of Oncology. 2016;27(1):81–96. 
62. Wang Y, Li F, Wang Z, Qiu T, Shen Y, Wang M. Fruit and vegetable consumption and 
risk of lung cancer: a dose-response meta-analysis of prospective cohort studies. Lung 
Cancer. 2015;88(2):124–30. 
63. Vieira AR, Vingeliene S, Chan DS, Aune D, Abar L, Navarro Rosenblatt D, Greenwood 
DC, Norat T. Fruits, vegetables, and bladder cancer risk: a systematic review and meta-
analysis. Cancer Medicine. 2015;4(1):136–46. 
64. Aune D, Lau R, Chan DS, Vieira R, Greenwood DC, Kampman E, Norat T. Dairy 
products and colorectal cancer risk: a systematic review and meta-analysis of cohort studies. 
Annals of Oncology. 2012;23(1):37–45. 
65. Kim YJ, Y. Dietary fibre intake and mortality from cardiovascular disease and all cancers: 
A meta-analysis of prospective cohort studies. Archives of cardiovascular diseases. 
2016;109(1):39–54. 
  
 
 
DOCUMENT1 | SAX INSTITUTE 307 
66. World Cancer Research Fund International Systematic Literature Review. The 
Associations between Food, Nutrition and Physical Activity and the risk of Bladder Cancer. 
Continuous Update Project Report: WCRF; 2015. 
67. Aune D. Chan DS, Vieira AR, Rosenblatt DN, Vieira R, Greenwood DC, Norat T. Fruits, 
vegetables and breast cancer risk: a systematic review and meta-analysis of prospective 
studies. Breast Cancer Research & Treatment. 2012;134(2):479–93. 
68. Aune D, Chan DS, Greenwood DC, Vieira AR, Rosenblatt DN, Vieira R, Norat T. Dietary 
fiber and breast cancer risk: a systematic review and meta-analysis of prospective studies. 
Annals of Oncology. 2012;23(6):1394–402. 
69. Guo J, Wei W, Zhan L. Red and processed meat intake and risk of breast cancer: a meta-
analysis of prospective studies. Breast Cancer Research & Treatment. 2015;151(1):191–8. 
70. Wei H, Gao Z, Liang R, Li Z, Hao H, Liu X. Whole-grain consumption and the risk of all-
cause, CVD and cancer mortality: a meta-analysis of prospective cohort studies. British 
Journal of Nutrition. 2016;116(3):514–25. 
71. Aune D, Keum N, Giovannucci E, Fadnes LT, Boffetta P, Greenwood DC, Tonstad S, 
Vatten LJ, Riboli E, Norat T. Whole grain consumption and risk of cardiovascular disease, 
cancer, and all cause and cause specific mortality: systematic review and dose-response meta-
analysis of prospective studies. BMJ. 2016;353:i2716. 
72. Benisi-Kohansal S, Saneei P, Salehi-Marzijarani M, Larijani B, Esmaillzadeh A. Whole-
grain intake and mortality from all causes, cardiovascular disease, and cancer: A systematic 
review and dose-response meta-analysis of prospective cohort studies. Advances in Nutrition. 
2016;7(6):1052–65. 
73. Chen GC, Tong X, Xu JY, Han SF, Wan, ZX, Qin, JB, Qin LQ. Whole-grain intake and 
total, cardiovascular, and cancer mortality: a systematic review and meta-analysis of 
prospective studies. American Journal of Clinical Nutrition. 2016;104(1):16472. 
74. Liu L, Wang S, Liu J. Fiber consumption and all-cause, cardiovascular, and cancer 
mortalities: a systematic review and meta-analysis of cohort studies. Molecular Nutrition & 
Food Research. 2015;59(1):139–46. 
75. Choi YJ, Myung SK, Lee JH. Light Alcohol Drinking and Risk of Cancer: A Meta-
analysis of Cohort Studies. Cancer Research & Treatment. 2017. 
76. Jayasekara H, MacInnis RJ, Room R, English DR. Long-Term Alcohol Consumption and 
Breast, Upper Aero-Digestive Tract and Colorectal Cancer Risk: A Systematic Review and 
Meta-Analysis. Alcohol Alcohol. 2016;51(3):315–30. 
77. Rota M, Pasquali E, Bellocco R, Bagnardi V, Scotti L, Islami F, et al. Alcohol drinking 
and cutaneous melanoma risk: a systematic review and dose-risk meta-analysis. British 
Journal of Dermatology. 2014;170(5):1021–8. 
78. International Agency for Research on Cancer. Personal habits and indoor combustions. 
Volume 100 E. A review of human carcinogens. IARC Monograph on the Evaluation of 
Carcinogenic Risks to Humans. 2012;100(Pt E):1–538. 
79. Wang YT, Gou YW, Jin WW, Xiao M, Fang HY. Association between alcohol intake and 
the risk of pancreatic cancer: a dose-response meta-analysis of cohort studies. BMC Cancer. 
2016;16:212. 
80. Turati F, Garavello W, Tramacere I, Pelucchi C, Galeone C, Bagnardi V, et al. A meta-
analysis of alcohol drinking and oral and pharyngeal cancers: results from subgroup analyses. 
Alcohol Alcohol. 2013;48(1):107–18. 
81. Song DY, Song S, Song Y, Lee JE. Alcohol intake and renal cell cancer risk: a meta-
analysis. British Journal of Cancer. 2012;106(11):1881–90. 
  
 
 
DOCUMENT1 | SAX INSTITUTE 308 
82. Bellocco R, Pasquali E, Rota M, Bagnardi V, Tramacere I, Scotti L, et al. Alcohol 
drinking and risk of renal cell carcinoma: results of a meta-analysis. Annals of Oncology. 
2012;23(9):2235–44. 
83. Xu X, Zhu Y, Zheng X, Xie L. Does beer, wine or liquor consumption correlate with the 
risk of renal cell carcinoma? A dose-response meta-analysis of prospective cohort studies. 
Oncotarget. 2015;6(15):13347–58. 
84. Gou YJ, Xie DX, Yang KH, Liu YL, Zhang JH, Li B, et al. Alcohol Consumption and 
Breast Cancer Survival: A Meta-analysis of Cohort Studies. Asian Pacific Journal of Cancer 
Prevention. 2013;14(8):4785–90. 
85. Cai S, Li Y, Ding Y, Chen K, Jin M. Alcohol drinking and the risk of colorectal cancer 
death: a meta-analysis. European Journal of Cancer Prevention. 2014;23(6):532-9. 
86. Turati F, Galeone C, Rota M, Pelucchi C, Negri E, Bagnardi V, et al. Alcohol and liver 
cancer: a systematic review and meta-analysis of prospective studies. Annals of Oncology. 
2014;25(8):1526–35. 
87. Castles S, Wainer Z, Jayasekara H. Risk factors for cancer in the Australian Aboriginal 
and Torres Strait Islander population: a systematic review. Australian Journal of Primary 
Health. 2016;22(3):190–7. 
88. Supramaniam R. Cancer incidence in New South Wales migrants, 1991 to 2001: New 
South Wales Cancer Council; 2006. 
89. Llewellyn A, Simmonds M, Owen C, Woolacott N. Childhood obesity as a predictor of 
morbidity in adulthood: a systematic review and meta‐analysis. Obesity reviews. 
2016;17(1):56–67. 
90. Karahalios A, English DR, Simpson JA. Weight change and risk of colorectal cancer: a 
systematic review and meta-analysis. American Journal of Epidemiology. 2015;181(11):832–
45. 
91. Wu Y, Zhang D, Kang S. Physical activity and risk of breast cancer: a meta-analysis of 
prospective studies. Breast Cancer Research & Treatment. 2013;137(3):869–82. 
92. Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical activity, risk of death and 
recurrence in breast cancer survivors: A systematic review and meta-analysis of 
epidemiological studies. Acta Oncologica. 2015;54(5):635–54. 
93. NSW Cancer Plan, Cancer Institute NSW, Sydney, April 2016. 
94. Whiteman DC, Webb PM, Green AC, Neale RE, Fritschi L, Bain CJ, et al. Cancers in 
Australia in 2010 attributable to modifiable factors: summary and conclusions. Australian and 
New Zealand Journal of Public Health. 2015;39(5):477–84. 
95. Sharif MO, Janjua-Sharif F, Ali H, Ahmed F. Systematic reviews explained: AMSTAR—
how to tell the good from the bad and the ugly. Oral Health and Dental Management. 
2013;12(1):9–16. 
96. Allison DB, Heo M, Fontaine KR, Hoffman DJ. Body weight, body composition and 
longevity. International Textbook of Obesity New York: J Wiley. 2001:31–48. 
97. Chen GC, Chen SJ, Zhang R, Hidayat K, Qin JB, Zhang YS, et al. Central obesity and 
risks of pre- and postmenopausal breast cancer: a dose-response meta-analysis of prospective 
studies. Obesity Reviews. 2016;17(11):1167–77. 
98. Patel AV, Diver WR, Teras LR, Birmann BM, Gapstur SM. Body mass index, height and 
risk of lymphoid neoplasms in a large United States cohort. Leukemia & lymphoma. 
2013;54(6):1221–7. 
99. Gaudet MM, Kitahara CM, Newton CC, Bernstein L, Reynolds P, Weiderpass E, et al. 
Anthropometry and head and neck cancer:a pooled analysis of cohort data. International 
Journal of Epidemiology. 2015;44(2):673–81. 
  
 
 
DOCUMENT1 | SAX INSTITUTE 309 
100. Sergentanis TN, Antoniadis AG, Gogas HJ, Antonopoulos CN, Adami HO, Ekbom A, et 
al. Obesity and risk of malignant melanoma: a meta-analysis of cohort and case-control 
studies. European Journal of Cancer. 2013;49(3):642–57. 
101. Poorolajal J, Jenabi E. The association between BMI and cervical cancer risk: a meta-
analysis. European Journal of Cancer Prevention. 2016;25(3):232–8. 
102. Pettee KK, Storti KL, Ainsworth BE, Kriska AM. Measurement of physical activity and 
inactivity in epidemiologic studies. Epidemiological methods in physical activity studies. 
2009:15–33. 
103. Schmid D, Leitzmann MF. Physical Activity Epidemiology.  Handbook of 
Epidemiology: Springer; 2014. p. 1927–2002. 
104. Behrens G, Leitzmann MF. The association between physical activity and renal cancer: 
systematic review and meta-analysis. British Journal of Cancer. 2013;108(4):798–811. 
105. Keimling M, Behrens G, Schmid D, Jochem C, Leitzmann MF. The association between 
physical activity and bladder cancer: systematic review and meta-analysis. British Journal of 
Cancer. 2014;110(7):1862–70. 
106. Behrens G, Jochem C, Schmid D, Keimling M, Ricci C, Leitzmann MF. Physical 
activity and risk of pancreatic cancer: a systematic review and meta-analysis. European 
Journal of Epidemiology. 2015;30(4):279–98. 
107. Chen Y, Yu C, Li Y. Physical activity and risks of esophageal and gastric cancers: a 
meta-analysis. PLoS ONE [Electronic Resource]. 2014;9(2):e88082. 
108. Jochem C, Leitzmann MF, Keimling M, Schmid D, Behrens G. Physical activity in 
relation to risk of hematologic cancers: a systematic review and meta-analysis. Cancer 
Epidemiology, Biomarkers & Prevention. 2014;23(5):833–46. 
109. Zhong S, Chen L, Lv M, Ma T, Zhang X, Zhao J. Nonoccupational physical activity and 
risk of ovarian cancer: a meta-analysis. Tumour Biology. 2014;35(11):11065–73. 
110. Zhou LM. Recreational physical activity and risk of ovarian cancer: a meta-analysis. 
Asian Pacific Journal of Cancer Prevention: Apjcp. 2014;15(13):5161–6. 
111. Schmid D, Leitzmann MF. Cardiorespiratory fitness as predictor of cancer mortality: a 
systematic review and meta-analysis. Annals of Oncology. 2015;26(2):272–8. 
112. Liu XW, Lin S, Yuan J, Yu, I.T. Dietary patterns and oesophageal squamous cell 
carcinoma: a systematic review and meta-analysis. British Journal of Cancer. 
2014;110(11):2785–95. 
113. NSW Healthy Eating and Active Living Strategy: Preventing overweight and obesity in 
New South Wales 2013–2018. 
114. Balter KM, Fondell E. The effect of dietary guidelines on cancer risk and mortality. 
Current Opinion in Oncology. 2012;24(1):90–102. 
115. Alsamarrai A, Das SL, Windsor JA, Petrov MS. Factors that affect risk for pancreatic 
disease in the general population: a systematic review and meta-analysis of prospective cohort 
studies. Clinical Gastroenterology & Hepatology. 2014;12(10):1635–44.e5; quiz e103. 
116. World Cancer Research Fund International Systematic Literature Review. The 
Associations between Food, Nutrition and Physical Activity and the risk of Oesophageal 
Cancer. Continuous Update Project Report: WCRF; 2016. 
117. Alexander D. L, Miller P. E, Mohamed, M. A. Red Meat and Colorectal Cancer: A 
Quantitative Update on the State of the Epidemiologic Science. Journal of the American 
College of Nutrition. 2015;34(6):521–43. 
118. Choi YS, Song S, Lee J.E. Consumption of red and processed meat and esophageal 
cancer risk: meta-analysis. World Journal of Gastroenterology. 2013;19(7):1020–9. 
  
 
 
DOCUMENT1 | SAX INSTITUTE 310 
119. Bylsma LCA, D. D. A review and meta-analysis of prospective studies of red and 
processed meat, meat cooking methods, heme iron, heterocyclic amines and prostate cancer. 
Nutrition Journal. 2015;14:125. 
120. Cao Y,Hou L, Wang, W. Dietary total fat and fatty acids intake, serum fatty acids and 
risk of breast cancer: A meta-analysis of prospective cohort studies. International Journal of 
Cancer. 2016;138(8):1894–904. 
121. Xu C, Han FF, Zeng XT, Liu TZ, Li S, Gao ZY. Fat Intake Is Not Linked to Prostate 
Cancer: A Systematic Review and Dose-Response Meta-Analysis. PLoS One. 
2015;10(7):e0131747. 
122. Lu PY, Shu L, Shen, S.S, Chen X.J, Zhang, X.Y. Dietary Patterns and Pancreatic Cancer 
Risk: A Meta-Analysis. Nutrients. 2017;9(1):05. 
123. World Cancer Research Fund / American Institute for Cancer Research. Food, Nutrition, 
Physical Activity, and the prevention of cancer: a Global Perspective. 2007. 
124. Rota M, Porta L, Pelucchi C, Negri E, Bagnardi V, Bellocco R, et al. Alcohol drinking 
and risk of leukemia-a systematic review and meta-analysis of the dose-risk relation. Cancer 
Epidemiology. 2014;38(4):339–45. 
125. Tramacere I, Pelucchi C, Bonifazi M, Bagnardi V, Rota M, Bellocco R, et al. Alcohol 
drinking and non-Hodgkin lymphoma risk: a systematic review and a meta-analysis. Annals 
of Oncology. 2012;23(11):2791–8. 
126. Zhou Q, Guo P, Li H, Chen XD. Does alcohol consumption modify the risk of 
endometrial cancer? A dose-response meta-analysis of prospective studies. Archives of 
Gynecology and Obstetrics. 2017;295(2):467–79. 
127. Tapia KA, Garvey G, Mc Entee M, Rickard M, Brennan P. Breast cancer in Australian 
Indigenous women: incidence, mortality, and risk factors. Asian Pacific journal of cancer 
prevention: APJCP. 2017;18(4):873. 
128. World Cancer Research Fund. Continuous Update Project Report: Diet, Nutrition, 
Physical Activity and Breast Cancer. WCRF; 2017. 
129. Freisling H, Arnold M, Soerjomataram I, O'Doherty MG, Ordonez-Mena JM, Bamia C, 
et al. Comparison of general obesity and measures of body fat distribution in older adults in 
relation to cancer risk: meta-analysis of individual participant data of seven prospective 
cohorts in Europe. British Journal of Cancer. 2017;116(11):1486–97. 
130. Keum N, Greenwood DC, Lee DH, Kim R, Aune D, Ju W, et al. Adult weight gain and 
adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. 
Journal of the National Cancer Institute. 2015;107(2). 
131. Amadou A, Ferrari P, Muwonge R, Moskal A, Biessy C, Romieu I, et al. Overweight, 
obesity and risk of premenopausal breast cancer according to ethnicity: a systematic review 
and dose-response meta-analysis. Obesity Reviews. 2013;14(8):665–78. 
132. Cheraghi Z, Poorolajal J, Hashem T, Esmailnasab N, Doosti Irani A. Effect of body mass 
index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis. 
PLoS ONE [Electronic Resource]. 2012;7(12):e51446. 
133. Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A. Body mass index 
and breast cancer risk according to postmenopausal estrogen-progestin use and hormone 
receptor status. Epidemiologic Reviews. 2014;36:114–36. 
134. Chen Q, Wang J, Yang J, Jin Z, Shi W, Qin Y, et al. Association between adult weight 
gain and colorectal cancer: a dose-response meta-analysis of observational studies. 
International Journal of Cancer. 2015;136(12):2880–9. 
135. Johnson CM, Wei C, Ensor JE, Smolenski DJ, Amos CI, Levin B, et al. Meta-analyses of 
colorectal cancer risk factors. Cancer Causes & Control. 2013;24(6):1207–22. 
  
 
 
DOCUMENT1 | SAX INSTITUTE 311 
136. Fahey PP, Mallitt KA, Astell-Burt T, Stone G, Whiteman DC. Impact of pre-diagnosis 
behavior on risk of death from esophageal cancer: a systematic review and meta-analysis. 
Cancer Causes & Control. 2015;26(10):1365–73. 
137. Singh S, Sharma AN, Murad MH, Buttar NS, El-Serag HB, Katzka DA, et al. Central 
adiposity is associated with increased risk of esophageal inflammation, metaplasia, and 
adenocarcinoma: a systematic review and meta-analysis. Clinical Gastroenterology & 
Hepatology. 2013;11(11):1399–412.e7. 
138. Turati F, Tramacere I, La Vecchia C, Negri E. A meta-analysis of body mass index and 
esophageal and gastric cardia adenocarcinoma. Annals of Oncology. 2013;24(3):609–17. 
139. Gaudet MM, Patel AV, Sun J, Hildebrand JS, McCullough ML, Chen AY, et al. 
Prospective studies of body mass index with head and neck cancer incidence and mortality. 
Cancer Epidemiology and Prevention Biomarkers. 2012:cebp. 0935.2011. 
140. Hidayat K, Du X, Chen G, Shi M, Shi B. Abdominal Obesity and Lung Cancer Risk: 
Systematic Review and Meta-Analysis of Prospective Studies. Nutrients. 2016;8(12):15. 
141. Bae HS, Kim HJ, Hong JH, Lee JK, Lee NW, Song JY. Obesity and epithelial ovarian 
cancer survival: a systematic review and meta-analysis. Journal of Ovarian Research. 
2014;7:41. 
142. Collaborative Group on Epidemiological Studies of Ovarian C. Ovarian cancer and body 
size: individual participant meta-analysis including 25,157 women with ovarian cancer from 
47 epidemiological studies. PLoS Medicine / Public Library of Science. 2012;9(4):e1001200. 
143. Liu Z, Zhang TT, Zhao JJ, Qi SF, Du P, Liu DW, et al. The association between 
overweight, obesity and ovarian cancer: a meta-analysis. Japanese Journal of Clinical 
Oncology. 2015;45(12):1107–15. 
144. Protani MM, Nagle CM, Webb PM. Obesity and ovarian cancer survival: a systematic 
review and meta-analysis. Cancer Prevention Research. 2012;5(7):901–10. 
145. Majumder K, Gupta A, Arora N, Singh PP, Singh S. Premorbid Obesity and Mortality in 
Patients With Pancreatic Cancer: A Systematic Review and Meta-analysis. Clinical 
Gastroenterology & Hepatology. 2016;14(3):355-68.e; quiz e32. 
146. Shi YQ, Yang J, Du P, Xu T, Zhuang XH, Shen JQ, et al. Effect of Body Mass Index on 
Overall Survival of Pancreatic Cancer: A Meta-Analysis. Medicine. 2016;95(14):e3305. 
147. Markozannes G, Tzoulaki I, Karli D, Evangelou E, Ntzani E, Gunter MJ, et al. Diet, 
body size, physical activity and risk of prostate cancer: An umbrella review of the evidence. 
European Journal of Cancer. 2016;69:61–9. 
148. Choi Y, Park B, Jeong BC, Seo SI, Jeon SS, Choi HY, et al. Body mass index and 
survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. 
International Journal of Cancer. 2013;132(3):625–34. 
149. Golabek T, Bukowczan J, Szopinski T, Chlosta P, Lipczynski W, Dobruch J, et al. 
Obesity and renal cancer incidence and mortality—a systematic review of prospective cohort 
studies. Annals of Agricultural & Environmental Medicine. 2016;23(1):37–43. 
150. Schmid D, Ricci C, Behrens G, Leitzmann MF. Adiposity and risk of thyroid cancer: a 
systematic review and meta-analysis. Obesity Reviews. 2015;16(12):1042–54. 
151. Secord AA, Hasselblad V, Von Gruenigen VE, Gehrig PA, Modesitt SC, Bae-Jump V, et 
al. Body mass index and mortality in endometrial cancer: A systematic review and meta-
analysis. Gynecologic Oncology. 2016;140(1):184–90. 
152. Zhang Y, Liu H, Yang S, Zhang J, Qian L, Chen X. Overweight, obesity and endometrial 
cancer risk: results from a systematic review and meta-analysis. International Journal of 
Biological Markers. 2014;29(1):e21–9. 
  
 
 
DOCUMENT1 | SAX INSTITUTE 312 
153. Bertrand KA, Giovannucci E, Zhang SM, Laden F, Rosner B, Birmann BM. A 
prospective analysis of body size during childhood, adolescence, and adulthood and risk of 
non-Hodgkin lymphoma. Cancer Prevention Research. 2013;6(8):864–73. 
154. Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano 
CM. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic 
review. Journal of the National Cancer Institute. 2012;104(11):815–40. 
155. Liu L, Shi Y, Li T, Qin Q, Yin J, Pang S, et al. Leisure time physical activity and cancer 
risk: evaluation of the WHO's recommendation based on 126 high-quality epidemiological 
studies. British Journal of Sports Medicine. 2016;50(6):372–8. 
156. Shi Y, Li T, Wang Y, Zhou L, Qin Q, Yin J, et al. Household physical activity and 
cancer risk: a systematic review and dose-response meta-analysis of epidemiological studies. 
Scientific Reports. 2015;5:14901. 
157. Schmid D, Leitzmann MF. Association between physical activity and mortality among 
breast cancer and colorectal cancer survivors: a systematic review and meta-analysis. Annals 
of Oncology. 2014;25(7):1293–311. 
158. Fontein DB, de Glas NA, Duijm M, Bastiaannet E, Portielje JE, Van de Velde CJ, et al. 
Age and the effect of physical activity on breast cancer survival: A systematic review. Cancer 
Treatment Reviews. 2013;39(8):958–65. 
159. Goncalves AK, Dantas Florencio GL, Maisonnette de Atayde Silva MJ, Cobucci RN, 
Giraldo PC, Cote NM. Effects of physical activity on breast cancer prevention: a systematic 
review. Journal of Physical Activity & Health. 2014;11(2):445–54. 
160. Pizot C, Boniol M, Mullie P, Koechlin A, Boniol M, Boyle P, et al. Physical activity, 
hormone replacement therapy and breast cancer risk: A meta-analysis of prospective studies. 
European Journal of Cancer. 2016;52:138–54. 
161. Wu Y, Zhang D, Kang S. Physical activity and risk of breast cancer: a meta-analysis of 
prospective studies. Breast Cancer Research & Treatment. 2013;137(3):869–82. 
162. Je Y, Jeon JY, Giovannucci EL, Meyerhardt JA. Association between physical activity 
and mortality in colorectal cancer: a meta-analysis of prospective cohort studies. International 
Journal of Cancer. 2013;133(8):1905–13. 
163. Robsahm TE, Aagnes B, Hjartaker A, Langseth H, Bray FI, Larsen IK. Body mass 
index, physical activity, and colorectal cancer by anatomical subsites: a systematic review and 
meta-analysis of cohort studies. European Journal of Cancer Prevention. 2013;22(6):492–505. 
164. Farris MS, Mosli MH, McFadden AA, Friedenreich CM, Brenner DR. The Association 
between Leisure Time Physical Activity and Pancreatic Cancer Risk in Adults: A Systematic 
Review and Meta-analysis. Cancer Epidemiology, Biomarkers & Prevention. 
2015;24(10):1462–73. 
165. Keum N, Ju W, Lee DH, Ding EL, Hsieh CC, Goodman JE, et al. Leisure-time physical 
activity and endometrial cancer risk: dose-response meta-analysis of epidemiological studies. 
International Journal of Cancer. 2014;135(3):682–94. 
166. Moore SC, Lee IM, Weiderpass E, Campbell PT, Sampson JN, Kitahara CM, et al. 
Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 
Million Adults. JAMA Internal Medicine. 2016;176(6):816–25. 
167. Bella F, Godos J, Ippolito A, Di Prima A, Sciacca S. Differences in the association 
between empirically derived dietary patterns and cancer: a meta-analysis. International 
Journal of Food Sciences & Nutrition. 2017;68(4):402–10. 
168. Bloomfield HE, Greer, N, Kane R, Wilt TJ. Effects on Health Outcomes of a 
Mediterranean Diet With No Restriction on Fat Intake: A Systematic Review and Meta-
analysis. Annals of Internal Medicine. 2016;165(7):491–500. 
  
 
 
DOCUMENT1 | SAX INSTITUTE 313 
169. Lippi G, Mattiuzzi C, Cervellin G. Meat consumption and cancer risk: a critical review 
of published meta-analyses. Critical Reviews in Oncology-Hematology. 2016;97:1–14. 
170. Makarem N, Nicholson J.M, Bandera EV, McKeown, NM, Parekh N. Consumption of 
whole grains and cereal fiber in relation to cancer risk: a systematic review of longitudinal 
studies. Nutrition Reviews. 2016;74(6):353–73. 
171. Potter J, Brown L, Williams R. L, Byles, J, Collins CE. Diet Quality and Cancer 
Outcomes in Adults: A Systematic Review of Epidemiological Studies. International Journal 
of Molecular Sciences. 2016;17(7):05. 
172. Schwedhelm C, Boening H, Hoffmann G, Aleksandrova K, Schwingshackl L. Effect of 
diet on mortality and cancer recurrence among cancer survivors: a systematic review and 
meta-analysis of cohort studies. Nutrition Reviews. 2016;74(12):737–48. 
173. Schwingshackl L, Hoffmann G. Adherence to Mediterranean diet and risk of cancer: an 
updated systematic review and meta-analysis of observational studies. Cancer Medicine. 
2015;4(12):1933–47. 
174. Wang X, Lin X, Ouyang, YY, Liu J, Zhao G, Pan A, Hu FB. Red and processed meat 
consumption and mortality: dose-response meta-analysis of prospective cohort studies. Public 
Health Nutrition. 2016;19(5):893–905. 
175. Wang X, Ouyang Y, Liu J, Zhu M, Zhao G, Bao W, Hu FB. Fruit and vegetable 
consumption and mortality from all causes, cardiovascular disease, and cancer: systematic 
review and dose-response meta-analysis of prospective cohort studies. BMJ. 2014;349:g4490. 
176. Aune D, Giovannucci E, Boffetta P, Fadnes LT, Keum N, Norat T, et al. Fruit and 
vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality—a 
systematic review and dose-response meta-analysis of prospective studies. International 
Journal of Epidemiology. 2017:dyw319. 
177. Wang C, Jiang H. Meat intake and risk of bladder cancer: a meta-analysis. Medical 
Oncology. 2012;29(2):848–55. 
178. Xu C, Zeng XT, Liu TZ, Zhang C, Yang ZH, Li S, Chen XY. Fruits and vegetables 
intake and risk of bladder cancer: a PRISMA-compliant systematic review and dose-response 
meta-analysis of prospective cohort studies. Medicine. 2015;94(17):e759. 
179. Yao B, Yan Y, Ye X, Fang H, Xu H, Liu Y, Li S, Zhao Y. Intake of fruit and vegetables 
and risk of bladder cancer: A dose-response meta-analysis of observational studies. Cancer 
Causes & Control. 2014;25(12):1645–58. 
180. Albuquerque RC, Baltar VT, Marchioni DM. Breast cancer and dietary patterns: a 
systematic review. Nutrition Reviews. 2014;72(1):1–17. 
181. Peng C, Luo WP, Zhang CX. Fruit and vegetable intake and breast cancer prognosis: a 
meta-analysis of prospective cohort studies. British Journal of Nutrition. 2017;117(5):737–49. 
182. Van den Brandt PA, Schulpen M. Mediterranean diet adherence and risk of 
postmenopausal breast cancer: results of a cohort study and meta-analysis. International 
Journal of Cancer. 2017;140(10):2220–31. 
183. Brennan SF, Woodside JV, Lunny PM, Cardwell CR, Cantwell MM. Dietary fat and 
breast cancer mortality: A systematic review and meta-analysis. Critical Reviews in Food 
Science & Nutrition. 2017;57(10):1999–2008. 
184. Xia H, Ma S, Wang S, Sun G. Meta-Analysis of Saturated Fatty Acid Intake and Breast 
Cancer Risk. Medicine. 2015;94(52):e2391. 
185. Magalhaes B, Peleteiro B, Lunet N. Dietary patterns and colorectal cancer: systematic 
review and meta-analysis. European Journal of Cancer Prevention. 2012;21(1):15–23. 
186. Shi Y, YU PW, Zeng DZ. Dose-response meta-analysis of poultry intake and colorectal 
cancer incidence and mortality. European Journal of Nutrition. 2015;54(2):243–50. 
  
 
 
DOCUMENT1 | SAX INSTITUTE 314 
187. Yu XF, Zou J, Dong J. Fish consumption and risk of gastrointestinal cancers: a meta-
analysis of cohort studies. World Journal of Gastroenterology. 2014;20(41):15398–412. 
188. Zhu B, Sun Y, Qi, L, Zhong R, Miao X. Dietary legume consumption reduces risk of 
colorectal cancer: evidence from a meta-analysis of cohort studies. Scientific Reports. 
2015;5:8797. 
189. Han YJ, Li J, Huang W, Fang Y, Xiao LN.: Liao, Z. E. Fish consumption and risk of 
esophageal cancer and its subtypes: a systematic review and meta-analysis of observational 
studies. European Journal of Clinical Nutrition. 2013;67(2):147–54. 
190. Jiang G, Li B, Liao X, Zhong C. Poultry and fish intake and risk of esophageal cancer: A 
meta-analysis of observational studies. Asia-Pacific Journal of Clinical Oncology. 
2016;12(1):e82–91. 
191. Salehi M, Moradi-Lakeh M, Salehi MH, Nojomi M, Kolahdooz F. Meat, fish, and 
esophageal cancer risk: a systematic review and dose-response meta-analysis. Nutrition 
Reviews. 2013;71(5):257–67. 
192. Zhu HC, Yang X, Xu, LP, Zhao LJ, Tao GZ, Zhang C, Qin Q, Cai J, Ma JX, Mao WD, 
Zhang XZ, Cheng H. Y, Sun, XC. Meat consumption is associated with esophageal cancer 
risk in a meat- and cancer-histological-type dependent manner. Digestive Diseases & 
Sciences. 2014;59(3):664–73. 
193. Bai HW, Qian YY, Shi BY, Li G, Fan Y, Wang Z, Yuan M, Liu LP. The association 
between fish consumption and risk of renal cancer: a meta-analysis of observational studies. 
PLoS ONE [Electronic Resource]. 2013;8(11):e81939. 
194. Yang Y, Zhang D, Feng N, Chen G, Liu J, Chen G, Zhu Y. Increased intake of 
vegetables, but not fruit, reduces risk for hepatocellular carcinoma: A meta-analysis. 
Gastroenterology. 2014;147(5):1031–42. 
195. Song J. Su H, Wang BL, Zhou YY, Guo LL. Fish consumption and lung cancer risk: 
systematic review and meta-analysis. Nutrition & Cancer. 2014;66(4):539–49. 
196. Sun Y, Liu Z, Li J, Li Z, Han J. A Healthy Dietary Pattern Reduces Lung Cancer Risk: A 
Systematic Review and Meta-Analysis. Nutrients. 2016;8(3):134. 
197. Yang WS, Wong MY, Vogtmann E, Tang RQ, Xie L, Yang YS, Wu QJ, Zhang W, 
Xiang YB. Meat consumption and risk of lung cancer: evidence from observational studies. 
Annals of Oncology. 2012;23(12):3163–70. 
198. Crane TE, Khulpateea BR, Alberts DS, Basen-Engquist K, Thomson, CA. Dietary intake 
and ovarian cancer risk: a systematic review. Cancer Epidemiology, Biomarkers & 
Prevention. 2014;23(2):255–73. 
199. Jiang PY, Jiang ZB, Shen KX, Yue Y. Fish intake and ovarian cancer risk: a meta-
analysis of 15 case-control and cohort studies. PLoS ONE [Electronic Resource]. 
2014;9(4):e94601. 
200. Hou R, Wu QJ, Gong TT, Jiang L. Dietary fat and fatty acid intake and epithelial ovarian 
cancer risk: evidence from epidemiological studies. Oncotarget. 2015;6(40):43099–119. 
201. Larsson SC, Crippa A, Orsini N, Wolk A, Michaelsson KMilk Consumption and 
Mortality from All Causes, Cardiovascular Disease, and Cancer: A Systematic Review and 
Meta-Analysis. Nutrients. 2015;7(9):7749–63. 
202. Wu QJ, Wu L, Zheng LQ, Xu X, Ji C, Gong TT. Consumption of fruit and vegetables 
reduces risk of pancreatic cancer: evidence from epidemiological studies. European Journal of 
Cancer Prevention. 2016;25(3):196–205. 
203. Zhao Z, Yin Z, Pu Z, Zhao Q. Association Between Consumption of Red and Processed 
Meat and Pancreatic Cancer Risk: A Systematic Review and Meta-analysis. Clinical 
Gastroenterology & Hepatology. 2017;15(4):486–93.e10. 
  
 
 
DOCUMENT1 | SAX INSTITUTE 315 
204. Yao X, Tian Z. Saturated, Monounsaturated and Polyunsaturated Fatty Acids Intake and 
Risk of Pancreatic Cancer: Evidence from Observational Studies. PLoS ONE [Electronic 
Resource]. 2015;10(6):e0130870. 
205. Aune D, Navarro Roseblatt D. A, Chan DS, Vieira AR, Vieira R, Greenwood DC, 
Vatten LJ, Norat T. Dairy products, calcium, and prostate cancer risk: a systematic review and 
meta-analysis of cohort studies. American Journal of Clinical Nutrition. 2015;101(1):87–117. 
206. Fabiani R, Minelli L, Bertarelli G, Bacci S. A Western Dietary Pattern Increases Prostate 
Cancer Risk: A Systematic Review and Meta-Analysis. Nutrients. 2016;8(10):12. 
207. Meng H, Hu W, Chen Z, Shen Y. Fruit and vegetable intake and prostate cancer risk: a 
meta-analysis. Asia-Pacific Journal of Clinical Oncology. 2014;10(2):133–40. 
208. Sheng T, Shen RL, Shao H, Ma TH. No association between fiber intake and prostate 
cancer risk: a meta-analysis of epidemiological studies. World Journal of Surgical Oncology. 
2015;13:264. 
209. Xu C, Han FF, Zeng XT, Liu TZ, Li S, Gao ZY. Fat Intake Is Not Linked to Prostate 
Cancer: A Systematic Review and Dose-Response Meta-Analysis. PLoS ONE [Electronic 
Resource]. 2015;10(7):e0131747. 
210. Wang J, Li X, Zhang D. Dairy Product Consumption and Risk of Non-Hodgkin 
Lymphoma: A Meta-Analysis. Nutrients. 2016;8(3):120. 
211. Zhao J, Lyu C, Gao J, Du L, Shan B, Zhang H, et al. Dietary fat intake and endometrial 
cancer risk: A dose response meta-analysis. Medicine. 2016;95(27):e4121. 
212. Jin M, Cai S, Guo J, Zhu Y, Li M, Yu Y, et al. Alcohol drinking and all cancer mortality: 
a meta-analysis. Annals of Oncology. 2013;24(3):807–16. 
213. Schwedhelm C, Boeing H, Hoffmann G, Aleksandrova K, Schwingshackl L. Effect of 
diet on mortality and cancer recurrence among cancer survivors: a systematic review and 
meta-analysis of cohort studies. Nutrition Reviews. 2016;74(12):737–48. 
214. Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, et al. Alcohol 
consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. 
British Journal of Cancer. 2015;112(3):580–93. 
215. Pelucchi C, Galeone C, Tramacere I, Bagnardi V, Negri E, Islami F, et al. Alcohol 
drinking and bladder cancer risk: a meta-analysis. Annals of Oncology. 2012;23(6):1586–93. 
216. Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, et al. Light alcohol 
drinking and cancer: a meta-analysis. Annals of Oncology. 2013;24(2):301–8. 
217. Seitz HK, Pelucchi C, Bagnardi V, La Vecchia C. Epidemiology and pathophysiology of 
alcohol and breast cancer: Update 2012. Alcohol Alcohol. 2012;47(3):204–12. 
218. Shield KD, Soerjomataram I, Rehm J. Alcohol Use and Breast Cancer: A Critical 
Review. Clinical and Experimental Research. 2016;40(6):1166–81. 
219. Mahabir S. Association between diet during preadolescence and adolescence and risk for 
breast cancer during adulthood. Journal of Adolescent Health. 2013;52(5 Suppl):S30–5. 
220. Simapivapan P, Boltong A, Hodge A. To what extent is alcohol consumption associated 
with breast cancer recurrence and second primary breast cancer?: A systematic review. 
Cancer Treatment Review. 2016;50:155–67. 
221. Chen J-Y, Zhu H-C, Guo Q, Shu Z, Bao X-H, Sun F, et al. Dose-Dependent Associations 
between Wine Drinking and Breast Cancer Risk—Meta-Analysis Findings. Asian Pacific 
Journal of Cancer Prevention. 2016;17(3):1221–33. 
222. Mourouti N, Kontogianni MD, Papavagelis C, Panagiotakos DB. Diet and breast cancer: 
a systematic review. International Journal of Food Science and Nutrition. 2015;66(1):1–42. 
223. Zeisser C, Stockwell TR, Chikritzhs T. Methodological biases in estimating the 
relationship between alcohol consumption and breast cancer: the role of drinker 
  
 
 
DOCUMENT1 | SAX INSTITUTE 316 
misclassification errors in meta-analytic results. Alcoholism, Clinical and Experimental 
Research. 2014;38(8):2297–306. 
224. Ali AM, Schmidt MK, Bolla MK, Wang Q, Gago-Dominguez M, Castelao JE, et al. 
Alcohol consumption and survival after a breast cancer diagnosis: a literature-based meta-
analysis and collaborative analysis of data for 29,239 cases. Cancer Epidemiology, 
Biomarkers & Prevention. 2014;23(6):934–45. 
225. Zhang C, Zhong M. Consumption of beer and colorectal cancer incidence: a meta-
analysis of observational studies. Cancer Causes & Control. 2015;26(4):549–60. 
226. Tramacere I, Pelucchi C, Bonifazi M, Bagnardi V, Rota M, Bellocco R, et al. A meta-
analysis on alcohol drinking and the risk of Hodgkin lymphoma. European Journal of Cancer 
Prevention. 2012;21(3):268–73. 
227. Prabhu A, Obi KO, Rubenstein JH. Systematic review with meta-analysis: race-specific 
effects of alcohol and tobacco on the risk of oesophageal squamous cell carcinoma. 
Alimentary Pharmacology & Therapeutics. 2013;38(10):1145–55. 
228. Jarl J, Gerdtham UG. Time pattern of reduction in risk of oesophageal cancer following 
alcohol cessation—a meta-analysis. Addiction. 2012;107(7):1234–43. 
229. Tramacere I, Pelucchi C, Bagnardi V, Rota M, Scotti L, Islami F, et al. A meta-analysis 
on alcohol drinking and esophageal and gastric cardia adenocarcinoma risk. Annals of 
Oncology. 2012;23(2):287–97. 
230. Rota M, Pasquali E, Scotti L, Pelucchi C, Tramacere I, Islami F, et al. Alcohol drinking 
and epithelial ovarian cancer risk. a systematic review and meta-analysis. Gynecologic 
Oncology. 2012;125(3):758–63. 
231. Yan-Hong H, Jing L, Hong L, Shan-Shan H, Yan L, Ju L. Association between alcohol 
consumption and the risk of ovarian cancer: a meta-analysis of prospective observational 
studies. BMC Public Health. 2015;15:223. 
232. Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: a summary review of 
meta-analytical studies. International Journal of Epidemiology. 2015;44(1):186–98. 
233. Rota M, Scotti L, Turati F, Tramacere I, Islami F, Bellocco R, et al. Alcohol 
consumption and prostate cancer risk: a meta-analysis of the dose-risk relation. European 
Journal of Cancer Prevention. 2012;21(4):350–9. 
234. Zhao J, Stockwell T, Roemer A, Chikritzhs T. Is alcohol consumption a risk factor for 
prostate cancer? A systematic review and meta-analysis. BMC Cancer. 2016;16:845. 
 
 
 
 
  
  
 
 
DOCUMENT1 | SAX INSTITUTE 317 
Appendices  
 
Appendix A.1 — Criteria for grading the evidence  
 
The following criteria were used for grading the evidence in this Evidence Check. They were 
adapted from the World Cancer Research Fund/ American Institute for Cancer Research 
(WCRF/AICR).(128) 
 
Convincing  
 
All the following criteria are essential: 
- Evidence from more than two systematic reviews and/or meta-analyses 
- More than half of the studies included in the review and/or meta-analysis are cohort 
studies 
- Reviews and/or meta-analyses are of medium-high to high quality (AMSTAR score of 
6 or greater) 
- Where there is a paucity of information, data will be used from leading authorities 
(WCRF) in cancer prevention or at least two independent cohort studies. 
  
Probable  
 
This classification is also important to justify efforts and strategies designed to diminish 
cancer risks; all of the following are mostly required: 
- Evidence from more than one systematic review and/or meta-analysis 
- More than half of the studies included in the review and/or meta-analysis are cohort 
studies 
- Reviews and/or meta-analyses are of medium-high to high quality (AMSTAR score of 
6 or greater) 
- Where there is a paucity of information, data will be used from leading authorities 
(WCRF) in cancer prevention or at least two independent cohort studies. 
 
Possible  
 
This classification is for evidence that is too limited to infer a convincing or probable 
judgement. However, there is a suggestive effect. 
 
Weak 
 
No conclusions can be drawn based on current evidence. 
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Appendix A.2 — Flowchart of the literature selection process 
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Appendix A.2.1 — Literature search for culturally and linguistically diverse populations  
 
 
The first search strategy identified studies that had terms of interest from a culturally and 
linguistically diverse perspective with risk factors and cancer terms; this search was confined 
to 2012–2017 and comprised the following terms:  
 
(Mandarin OR Arabic OR Cantonese OR Vietnamese OR Greek OR Italian OR Filipino OR 
Tagalog OR Hindi OR Spanish OR Korean OR language diversity OR transient and migrants 
OR culturally diverse OR diverse population OR Australia) 
AND 
Risk factor (obesity, physical activity, diet and alcohol) 
AND 
Neoplasm 
 
Using this strategy, we obtained 184 articles; 37 on obesity, 22 on alcohol, 49 on physical 
activity and 76 on diet. No article met the inclusion criteria for this Evidence Check. Almost 
all the studies on minority groups were performed in the US, with a few identified in Italy, 
Greece, Korea and Spain.  
 
The second approach was slightly different, to exclude the ‘risk factor’ terms and examine 
cancer studies in any of these culturally and linguistically diverse populations in Australia, 
again based on the common languages spoken at home. This strategy had the potential to 
increase the probability of finding more cancer studies, and then assessing their relevance to 
risk factors and to this Evidence Check. The search strategy (2012–2017) was: 
 
(Mandarin OR Arabic OR Cantonese OR Vietnamese OR Greek OR Italian OR Filipino OR 
Tagalog OR Hindi OR Spanish OR Korean OR language diversity OR transient and migrants 
OR culturally diverse OR diverse population) 
AND 
Australia 
AND 
Neoplasm 
 
This search strategy retrieved 173 unique Australian articles identified in Medline, Scopus 
and PsycINFO. No study examined the association with obesity, physical activity, diet or 
alcohol. Most of the studies focused on knowledge and attitudes, beliefs, cancer experience, 
health disparities, communication challenges and institutional mistrust. Hence no studies were 
relevant for inclusion from the culturally and linguistically diverse search.  
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Appendix A.3 — Stacked graph according to AMSTAR score by risk factors 
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Appendix A.4 — Summary tables of obesity and cancer risk 
 
Source 
(author, 
year) 
Study type 
(reviews) 
Population/ 
setting 
N (number of 
studies, 
number of 
participants) 
Intervention/ 
comparator 
Outcomes 
Direction/ 
magnitude of 
effect 
Comment/ notes 
Amstar 
score 
Level of evidence 
(convincing, 
probable, possible 
and weak) 
All cancers 
Freisling, H. 
et al 
(2017)(129) 
Meta-analysis 
of prospective 
studies.  
European 
participants 
from 
Denmark, 
Greece, the 
Netherlands, 
Spain, 
Germany, 
Northern 
Ireland and 
Norway. 
7 cohort 
studies 
participating 
in the 
CHANCES 
consortium. 
The study 
used data 
from 43,419 
male and 
female 
participants.  
Hazard ratio 
and 95% 
confidence 
intervals were 
calculated per 
one-unit 
increment of 
each indicator 
of adiposity.  
Incidence for obesity-
related cancers (defined as 
postmenopausal female 
breast, colorectum, lower 
oesophagus, cardia 
stomach, liver, gallbladder, 
pancreas, endometrium, 
ovary and kidney). 
Increased risks were 
observed for a unit 
increment in body mass 
index (BMI) 1.11 (CI: 
1.02–1.21) and waist 
circumference (WC) 1.13 
(CI: 1.04–1.23). 
Suggestive for waist to hip 
ratio (WHR) 1.15 (CI: 
1.00–1.32). No statistical 
significance was found 
with hip circumference 
(HC) 1.09 (CI: 0.98–1.21).  
BMI and WC 
were associated 
with increased 
risk of obesity-
related cancers. 
Height and weight 
were objectively 
measured in all but 
one study. BMI was 
examined as a 
measure of overall 
adiposity, whereas 
WC, HC and WHR 
were examined as 
measures of body fat 
distribution.  
N/A Convincing evidence 
for obesity-related 
cancers. 
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Kyrgiou, M. 
et al 
(2017)(22) 
Umbrella 
review and 
meta-analysis. 
A wide 
range of 
countries. 
507 unique 
studies; of 
them, 371 
(73.2%) had 
a cohort 
design, 
(26.4%) were 
case-control 
studies and 
two (0.4%) 
were 
cross-
sectional 
studies. Total 
of 1,766,389 
participants. 
The summary 
effects for 
cancer 
incidence and 
95% 
confidence 
intervals were 
calculated per 
increase in 
body mass 
index 
(5kg/m2), 
waist and hip 
circumference 
(10 cm), waist 
to hip ratio 
(0.1), weight 
(5 kg), and 
weight gain (1 
kg or 5 kg).  
Risk estimates were similar 
between men and women 
per 5-unit increase in BMI 
for oesophageal 
adenocarcinoma 1.54 (CI: 
1.41–1.67), oesophageal 
squamous cell 0.63 (CI: 
0.53–0.75), lung 0.79 (CI: 
0.73–0.85), kidney 1.30 (CI: 
1.23–1.36), non-Hodgkin 
lymphoma 1.07 (CI: 1.04–
1.10), leukaemia 1.12 (CI: 
1.05–1.18) and thyroid 1.23 
(CI: 1.10–1.39). Cancer 
incidence of colon, rectal 
and melanoma was higher in 
men than women. The 
respective risks in men were 
1.30 (CI: 1.25–1.35), 1.09 
(CI: 1.06–1.13) and 1.17 
(CI: 1.05–1.30). Cancer 
incidence in women was 
significant for 
postmenopausal breast, in 
particular among never-
users of menopausal therapy 
1.13 (CI: 1.09–1.17) and 
endometrial 1.54 (CI: 1.47–
1.61). Regarding cancer 
mortality, BMI was 
associated with death from 
prostate 1.15 (CI: 1.06–
1.25), endometrial 1.46 (CI: 
1.29–1.65) and non-
Hodgkin lymphoma 1.14 
BMI was most 
commonly 
associated with 
cancer risk except 
for oesophageal 
squamous cell 
and lung cancer. 
This review 
conducted a wide 
range of analyses to 
estimate the effect of 
different measures of 
adiposity on cancer 
risk, including 
estimation of 
prediction intervals 
(to account for 
heterogeneity), 
evaluation of excess 
significance (bias) 
and credibility 
ceiling (to account 
for potential 
methodological 
limitations). In 
addition, the 
evidence on the 
different outcomes 
was graded based on 
the P-values of the 
random effects.  
8/11 Convincing 
evidence for 
incidence of 
colorectal, liver, 
kidney, thyroid, 
lung, uterine and 
postmenopausal 
breast cancer. 
Probable evidence 
for oesophageal 
adenocarcinoma. 
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(CI: 1.04–1.25).  
Keum, N. et 
al (2015)(130) 
Meta-analysis 
of prospective 
observational 
studies. 
Population 
consisted of 
people from 
North 
America 
(US and 
Canada), 
Europe, 
China, Japan 
and 
Australia. 
46 publications 
corresponding 
to 50 studies. 
Risks 
associated 
with an 
increase in 
adult weight 
gain (linear 
and nonlinear 
effects).  
Linear analyses among non-
HRT users were associated 
with a 5 kg increase in adult 
weight gain for 
postmenopausal breast 
(relative risk 1.11, 95% CI: 
1.08–1.13), endometrial 
(RR 1.39, 95% CI: 1.29–
1.49) and ovarian cancer 
(RR 1.13, 95% CI: 1.03–
1.23). Colon risk was 
associated with weight gain 
regardless of sex (RR 1.06, 
95% CI: 1.03–1.10). For the 
nonlinear effects, the 
highest weight compared 
with the lowest was 
significant for kidney cancer 
(RR 1.42, 95% CI: 1.11–
1.81).  
No effect was 
found for prostate 
(stratified by 
advanced or 
localised 
disease), thyroid 
and 
premenopausal 
breast cancer.  
This meta-analysis 
examined 8 cancer 
sites (breast, prostate, 
colon, endometrium, 
ovary, pancreas, 
kidney and thyroid). 
Menopausal therapy 
(HRT) may obscure 
the effect of adiposity 
on female cancers. 
Thus, the primary 
analysis for 
postmenopausal 
cancers was 
conducted among 
non-HRT users. 
Weight gain was 
captured through self-
report in all the 
studies assessed. 
Conclusion: avoiding 
further weight gain 
throughout adulthood 
itself may confer 
protection against 
postmenopausal 
breast, endometrial 
and ovarian cancer as 
well as colon and 
kidney cancer. 
6/11 There were very 
few studies from 
which to draw a 
conclusion. 
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Wang, J. et 
al (2016)(23) 
Systematic 
review and 
meta-
analysis. 
European-
Australian, 
Asia-Pacific, 
and North 
American 
populations. 
Most of the 
included 
articles were of 
prospective 
design. 
Estimates of 
relative risk 
(RR) per 5 
kg/m2 increase 
in BMI and 
cancer 
incidence. 
In males, a 5-unit 
increment in BMI was 
associated with: liver 1.21 
(1.06–1.39), colorectal 
1.13 (1.10–1.17), kidney 
1.18 (1.06–1.31), thyroid 
1.16 (1.04–1.28), 
oesophagus and gastric 
1.11 (1.03–1.19), pancreas 
1.10 (1.01-1.19) and 
prostate 1.03 (1.01–1.05) 
cancer, whereas lung 
cancer was associated with 
a decreased risk 0.86 
(0.82–0.90). In females, 
the same magnitude of 
association was observed 
for liver, kidney, thyroid, 
colorectal, pancreas and 
lung cancer. Additionally, 
increased cancer risk was 
found for postmenopausal 
breast 1.11 (1.08–1.14) 
and premenopausal 
ovarian 1.10 (1.05–1.16) 
cancer. 
Increased cancer 
risk for most of 
the cancers 
examined with 
the exception of 
lung cancer. No 
effect was 
observed for 
some cancers in 
women such as 
oesophagus and 
gastric, 
premenopausal 
breast and 
postmenopausal 
ovarian cancer. 
About half the 
studies included in 
this meta-analysis 
objectively 
calculated BMI. 
6/11 Convincing 
evidence for 
incidence of 
colorectal, liver, 
thyroid, lung, 
uterine and 
postmenopausal 
breast cancer. 
Probable evidence 
for oesophageal 
adenocarcinoma, 
kidney and 
pancreatic cancer. 
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Bladder 
Qin, Q. et al 
(2013)(33) 
Meta-
analysis of 
cohort 
studies. 
Mostly 
participants 
from Europe 
and the US. 
11 cohort 
studies 
fulfilled the 
criteria. 
Highest BMI 
group 
compared with 
the lowest. 
Obesity was associated with 
an increased risk for bladder 
cancer in men and women 
(RR 1.10, 95% CI: 1.06–
1.16). 
Increased cancer 
risk incidence. 
BMI was 
ascertained mainly 
by self-report. 
Subgroup analysis 
by geographical area 
shows the 
association between 
obesity and bladder 
cancer was more 
significant for 
studies conducted in 
the US than those 
conducted in 
Europe. 
7/11 
Probable evidence 
for cancer 
incidence.  
Sun, J. W. 
et al 
(2015)(34) 
Meta-
analysis of 
cohort 
studies. 
European, 
Australian, 
North 
American 
and Asian 
populations. 
15 cohort 
studies with 
14,201,500 
participants. 
Risks associated 
with BMI (linear 
and nonlinear 
effects).  
Compared with normal 
weight, RR of bladder 
cancer were 1.07 (95% CI: 
1.01–1.14) and 1.10 (95% 
CI: 1.06–1.14) for 
overweight and obese 
categories respectively. RR 
for each 5 kg/m2 increase 
in BMI was 1.04 (95% CI: 
1.01–1.07). 
Increased cancer 
risk. 
RRs were 
significant in studies 
conducted in Europe 
and North America 
more so than in 
Asia. No difference 
was observed when 
analysis was 
stratified by self-
reported BMI or 
measure. 
7/11 
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Breast 
Amadou, 
A. et al 
(2013)(131) 
Systematic 
review 
and dose–
response 
meta-
analysis. 
Women from 
the following 
ethnic groups: 
Caucasian 
(American or 
European), 
Asian and 
African 
(African–
American or 
from Africa). 
30 studies 
were 
included. Of 
them, 11 
were cohort 
studies. 
Risks 
associated 
with different 
anthropo-
metric 
measures 
(linear and 
nonlinear 
effects).  
Inverse association was 
significant among African 
and Caucasian women 
(increase by 5 kg/m2 of BMI) 
0.95 (95% CI: 0.91–0.98) 
and 0.93 (95% CI: 0.91–
0.95) respectively. On the 
other hand, a significant 
positive association was 
observed in Asian women 
1.05 (95% CI: 1.01–1.09). 
Risk appeared 
to differ by 
ethnicity. There 
was not a 
significant 
association 
between weight, 
HC or WC and 
premenopausal 
breast cancer 
risk. 
The analysis focused 
on anthropometric 
measures and the risk 
of premenopausal 
breast cancer in 
different ethnic 
groups. Linear risk 
was estimated by 
increase in 5 kg/m2 of 
BMI, 0.1 of WHR 
and 10 cm of WC and 
HC.  
8/11 
Convincing 
evidence for 
incidence of 
postmenopausal 
breast cancer and 
probable evidence 
for breast cancer 
mortality. 
Chan, D. 
S. et al 
(2014)(44)  
Systematic 
review and 
meta-
analysis.  
A wide 
range of 
countries. 
However, 
most of the 
studies were 
based in 
North 
America or 
Europe. 
A total of 82 
follow-up 
studies 
assessed the 
relationship 
between 
BMI and 
mortality in 
women with 
breast 
cancer. 
Breast cancer 
mortality risks 
associated 
with BMI. 
Pre-diagnosis BMI was 
associated with breast cancer 
mortality. Obese or 
overweight women had RRs 
of 1.35 (1.24–1.47) and 1.11 
(1.06–1.17) respectively 
when compared with women 
with a healthy BMI. 
Additionally, BMI <12 
months after diagnosis was 
associated with breast cancer 
mortality. The RR for obese 
women was 1.25 (1.10–1.42) 
and 1.11 (1.03–1.20) for 
overweight. 
No significant 
effect was found 
for BMI after 12 
months of 
diagnosis.  
There was no 
significant 
heterogeneity 
between pre- and 
postmenopausal 
breast cancer. Two 
co-authors reported 
personal fees from 
food makers and 
pharmaceutical 
companies. 
8/11 
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Chen, G. 
C. et al 
(2016)(97) 
Meta-analysis 
of prospective 
studies. 
Mostly 
participants 
from Europe 
and the US. 
A total of 18 
publications 
were 
included in 
the analysis. 
Measures of 
central 
adiposity were 
used for 
increments of 
10 cm in WC 
and 0.1 in 
WHR.  
Increments in WC were 
associated with breast 
cancer incidence 1.06 
(1.04–1.09). Besides, 0.1-
unit increase of WHR was 
associated with 
postmenopausal cancer 
1.07 (95% CI: 1.01–1.14). 
No effects of 
WC or WHR 
were found on 
premenopausal 
cancer. 
The WHR-
postmenopausal BC 
association lost 
statistical significance 
after correcting for 
publication bias (RR 
1.06, 95% CI: 0.99–
1.13). Measurements 
of WC and WHR 
were based on self-
report. 
8/11 There were very 
few studies from 
which to draw a 
conclusion. 
Cheraghi, 
Z. et al 
(2012)(132) 
Meta-
analysis. 
Mostly 
participants 
from Europe 
and the US. 
50 studies 
were 
included in 
this meta-
analysis, of 
them 15 
were 
prospective 
studies. 
Risks 
associated 
with BMI.  
BMI was associated with 
incidence of postmenopausal 
breast cancer. The estimated 
odds ratio from case-control 
studies was 1.21 (95% CI: 
1.08–1.34) and the risk ratio 
from cohort studies was 1.16 
(95% CI: 1.08–1.25).  
Overweight and 
obesity were not 
associated with 
premenopausal 
breast cancer. 
The results of both 
case-control studies 
and cohort studies 
showed that being 
overweight in the 
postmenopausal 
period slightly 
increased the risk of 
breast cancer. 
9/11  
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Munsell, 
M. F. et al 
(2014)(133) 
Meta-
analysis. 
Mostly 
participants 
from Europe 
and the US. 
57 studies 
fulfilled the 
criteria; of 
these 17 
were cohort 
and 2 RCT. 
Risk 
associated 
with different 
cut-offs of 
BMI.  
BMI of 25–29.9 kg/m2 and 
≥30 kg/m2 were associated 
with a reduced risk of 
premenopausal breast 
cancer. The respective RR 
were 0.95 (95% CI: 0.91–
1.00) and 0.83 (95% CI: 
0.75–0.91). On the other 
hand, a greater BMI was 
associated with increased 
risk of postmenopausal 
cancer; RR 1.10 (95% CI: 
1.06–1.13) for overweight 
and 1.18 (95% CI: 1.12–
1.25) for obese women. 
Increased risk of 
postmenopausal 
cancer with a 
higher BMI. 
Retrospective and 
prospective studies 
resulted in very 
similar estimates. 
6/11  
 
 
 
 
 
 
 
 
Convincing 
evidence for 
incidence of 
postmenopausal 
breast cancer and 
probable evidence 
for breast cancer 
mortality. 
Niraula, S. 
et al 
(2012)(45) 
Meta-
analysis. 
A wide 
range of 
countries. 
12 of the 21 
included 
studies were 
cohort 
studies. 
Mortality risks 
associated 
with different 
cut-offs of 
BMI. 
There was a higher 
likelihood of breast cancer 
mortality among obese 
women regardless of their 
menopausal status. 
Premenopausal: 1.23 
(1.07–1.42). 
Postmenopausal: 1.15 
(1.06–1.26). 
Increased risk of 
mortality. 
Body size was 
measured in 13 
studies. The 
combined HR was 
1.19 (95 % CI 1.10–
1.28) with no 
evidence of overall 
survival difference in 
the association with 
obesity. 
9/11 
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Colorectal 
Chen, Q. et 
al 
(2015)(134) 
Meta-
analysis.  
Participants 
from 
Canada, the 
US, Europe 
and 
Australia. 
5 out of 8 
studies were 
cohort 
studies. 
394,434 
people were 
assessed. 
Adult weight 
gain and risk 
of colorectal 
cancer (CRC). 
Comparison between the 
highest and lowest categories 
of adult weight gain 
produced the following RRs. 
CRC: 1.25 (1.10–1.43), 
colon (CC): 1.30 (1.14–
1.49), rectal (RC): 1.27 
(1.02–1.58). There was a 
linear relationship between 
adult weight gain and risk of 
CRC, CC and RC. When 
analyses were stratified by 
sex, risks for men remained 
significant whereas in 
women they became 
insignificant. 
Increased risk in 
men.  
Adult weight gain 
was calculated as 
weight at baseline 
age minus 
weight in early 
adulthood 
(approximately 20 
years of age). 
7/11 Convincing 
evidence for 
cancer incidence 
and mortality. 
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Doleman, 
B. et al 
(2016)(41) 
Systematic 
review and 
meta-analysis. 
A wide 
range of 
countries. 
18 
prospective 
studies 
fulfilled the 
criteria. 
Assessment of 
risk for 
cancer-
specific 
mortality, 
cancer 
recurrence, 
and disease-
free survival 
after CRC 
diagnosis 
according to 
BMI reported 
in categories. 
Obese and underweight 
participants were both at a 
significantly increased risk 
of CRC mortality compared 
with normal weight 
participants. (RR 1.14, 95% 
CI: 1.05–1.24 and 1.50, 95% 
CI: 1.20–1.87 for obese and 
underweight respectively). 
Additionally, obese and 
underweight participants had 
worse disease-free survival. 
The respective RRs were 
1.07, 95% CI 1.01–1.13 and 
1.27, 95% CI 1.13–1.43; and 
increased risk of recurrence 
RR 1.07, 95% CI 1.02–1.13 
for obese and RR 1.13, 95% 
CI 1.05–1.21 for 
underweight patients.  
Increased risk of 
mortality for 
underweight and 
obese 
categories. 
All studies used 
World Health 
Organization 
(WHO) 
recommended BMI 
categories. 
However, the 
underweight group 
was slightly higher 
(<20 kg/m2). 
Overweight patients 
had no increased 
risk for any of the 
outcomes studied. 
9/11 
Convincing 
evidence for 
cancer incidence 
and mortality. 
Johnson, 
C. M. et al 
(2013)(135) 
Meta-
analysis. 
A wide 
range of 
countries. 
23 studies 
were 
included; 12 
were cohort 
studies. 
Estimates of 
RR per 8 
kg/m2 increase 
in BMI. 
A significant association 
between BMI and CRC 
incidence was observed per 
8 kg/m2 increment (RR 
1.10, 95% CI: 1.08–1.12). 
There was a gender 
variation, with the effect 
greater in men than in 
women. RR 1.29, 95% CI: 
1.26–1.34 among males. 
Increased cancer 
risk incidence. 
Study type was not 
a significant source 
of variation for the 
association between 
BMI and CRC risk. 
4/11 
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Karahalios 
A. et al 
2015(90) 
Systematic 
review and 
meta-analysis. 
Participants 
from 
Europe, the 
US and 
Australia. 
13 
prospective 
studies 
fulfilled the 
criteria. 
Adult weight 
gain and risk 
of colorectal 
cancer. 
There was evidence of an 
increased risk of colorectal 
cancer incidence for the 
highest weight gain group 
compared with those in the 
reference group (hazard 
ratio (HR) 1.16, 95% CI: 
1.08–1.24). 
Increased cancer 
risk incidence. 
Change in weight or 
BMI was 
ascertained either 
from early 
adulthood to midlife 
or from midlife to 
older age. Studies 
that assessed change 
from midlife to 
older age had 
slightly lower 
hazard ratios 
compared with 
studies examining 
change from early 
adulthood to midlife 
(both were 
significant). 
8/11 There were very 
few studies from 
which to draw a 
conclusion. 
Lee, J. et al 
(2015)(42) 
Meta-analysis 
of prospective 
cohort studies. 
Participants 
from 
Europe, the 
US, 
Australia 
and China.  
16 
prospective 
cohort 
studies, 
which 
involved 
58,917 
individuals. 
Pre- and post-
diagnostic 
BMI with 
CRC 
mortality. 
Pre-diagnosis obesity 
was associated with 
increased colorectal cancer–
specific mortality (RR 1.22, 
95% CI: 1.00–1.35). 
Increased risk of 
mortality for 
pre-diagnosis 
obesity. 
Pre-diagnosis 
underweight or 
overweight was not 
associated with 
colorectal cancer–
specific mortality. 
No association was 
found between 
post-diagnosis 
obesity and 
colorectal cancer–
specific mortality. 
8/11 
Convincing 
evidence for 
cancer incidence 
and mortality.  
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Ma, Y. et 
al (2013)(7) 
Systematic 
review of 
prospective 
studies. 
A wide 
range of 
countries. 
43 
prospective 
studies with a 
total of 
9,000,000 
participants. 
Association 
between general 
obesity (BMI) 
or central 
obesity (WC) 
and the risk of 
colorectal 
cancer, 
comparing the 
highest and 
lowest 
categories. 
Obese participants were 
associated with increased 
CRC risk compared with 
individuals with a healthy 
BMI, RR 1.33 (95% C: 
1.25–1.42). Additionally, 
high (vs. low) WC levels 
were associated with 
increased risk. 1.46 (95% 
CI, 1.33–1.60). When only 
colon cancer incidence was 
assessed, the relationship 
between obesity and 
healthy BMI was 1.47 
(95% CI: 1.35–1.60); it 
was 1.15 (95% CI: 1.10–
1.20) for rectal cancer. 
Results on WC levels in 
relation to colon cancer 
risk were 1.61 (95% CI: 
1.42–1.84) for the highest 
vs. the lowest category and 
1.35 (95% CI: 1.11–1.63) 
for rectal cancer.  
Increased CRC 
risk with 
obesity. 
For studies 
conducted in 
Australia, the 
cancer risk from 
obesity vs. a 
healthy BMI was 
1.20 (95% CI: 
1.00–1.45); and 
1.51 (95% CI: 
1.22–1.87) for the 
highest WC 
compared with the 
lowest. The risk of 
CRC was slightly 
higher for men than 
women. 
9/11 
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Parkin, E. 
et al 
(2014)(8) 
Systematic 
review. 
Mostly 
participants 
from the US. 
32 
prospective 
studies 
fulfilled the 
criteria. 
Assessment of 
the 
relationship 
between 
various 
measures of 
adiposity and 
mortality. 
Risk estimate per 5 kg/m2 
increment in pre-diagnosis 
BMI was significantly 
increased for men (1.19, 
95% CI: 1.14–1.25) but 
not for women (1.06, 95% 
CI: 0.98–1.15). The 
cancer-related mortality 
per 10 cm increase in WC 
was 1.20 and 1.33 for each 
10% increase in body fat 
(measured by electric 
impedance). Risk estimate 
per 5 kg/m2 increment in 
pre-diagnosis BMI and 
overall survival were 
significantly increased for 
women (1.16, 95% CI: 
1.09–1.24) but not for 
men. 
Increased risk of 
mortality for 
pre-diagnosis 
obesity. 
No confidence 
intervals were 
provided for pre-
diagnostic WC and 
fat percentage. In 
summary, post-
diagnosis BMI did 
not have an effect 
on survival in 
studies using 
population-based 
databases. This is in 
contrast to the 
increased mortality 
noticed with pre-
diagnostic BMI. An 
author declared fees 
paid by a 
pharmaceutical 
company.  
7/11 Convincing 
evidence for 
cancer incidence 
and mortality. 
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Schlesinger, 
S. et al 
(2015)(9) 
Systematic 
review and 
meta-analysis.  
Participants 
from the US, 
Europe and 
Australia. 
13 studies 
fulfilled the 
criteria; of 
these 11 
were cohort 
studies. 
Assessment of 
weight change 
from early or 
midlife 
adulthood to 
later adult 
years (high 
weight gain 
vs. stable 
weight). 
Individuals with high 
weight gain compared with 
individuals with stable 
weight had RR 1.22 (1.14–
1.30). In dose–response 
analysis, each 5 kg weight 
gain was associated with 
higher risk of CRC 
incidence RR 1.04 (1.02–
1.05). Additionally, 
analyses of weight gain per 
10, 15 and 20 kg yielded 
the following risk of CRC 
1.08 (95% CI: 1.04–1.11), 
1.12 (95% CI: 1.07–1.17) 
and 1.16 (95% CI: 1.09–
1.23) respectively. 
Increased cancer 
risk incidence. 
In stratified 
analyses by sex, 
weight gain was 
significantly 
associated with CC 
or RC risk in men 
but not in women. 
6/11 There were very 
few studies from 
which to draw a 
conclusion. 
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Wu, S. et 
al 
(2014)(43) 
Meta-
analysis. 
A wide 
range of 
countries. 
29 
prospective 
studies 
fulfilled the 
criteria. 
Estimation of 
the association 
between 
overweight or 
obesity with 
overall survival 
(OS). 
Analyses showed an 
increased mortality among 
obese patients (HR 1.10, 
95% CI: 1.06–1.15), but not 
among overweight patients 
(HR 0.92 95% CI: 0.86–
1.00). 
Increased risk of 
mortality for 
obesity. 
Stratified analyses 
of pre-diagnostic 
and around-
treatment BMI 
showed a positive 
association between 
obesity and 
mortality. No effect 
was observed in 
post-treatment 
BMI. Obesity 
conferred a 
significantly worse 
OS for CRC 
patients irrespective 
of gender. 
8/11 Convincing 
evidence for 
cancer incidence 
and mortality. 
Oesophageal  
Fahey, P. 
P. et al 
(2015)(136) 
Systematic 
review and 
meta-analysis. 
A wide 
range of 
countries. 
5 studies 
fulfilled the 
criteria; 2 
were cohort 
studies. 
Estimation of 
the association 
between BMI 
and mortality 
from 
oesophageal 
cancer. 
Risk of death for 
participants who were 
overweight or obese against 
those with a healthy BMI. 
The risk for oesophageal 
squamous cell carcinoma 
(OSCC) was 0.80 (0.67–
0.95) and for oesophageal 
adenocarcinoma (OAC) 
0.80 (0.68–0.95). 
No effect of 
obesity on the 
outcome. 
When the 
overweight group 
was dissociated 
from the obese no 
decreased risk was 
found for obesity 
alone; OSCC HR 
1.05 (95% CI: 0.76–
1.46), and for OAC 
HR 0.85 (95% CI: 
0.68–1.06). 
7/11 
Probable evidence 
for incidence of 
OAC.  
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Singh, S. 
et al 
(2013)(137) 
Systematic 
review and 
meta-analysis. 
Participants 
from the US, 
Europe and 
Australia. 
6 
observational 
studies 
fulfilled the 
criteria; 3 
were cohort 
studies. 
Estimation of 
the association 
between (OAC) 
incidence and 
central 
adiposity 
(comparing the 
highest and 
lowest). 
Central adiposity was 
associated with a higher 
risk of OAC (2.51, 95% 
CI: 1.54–4.06), compared 
with normal body habitus. 
BMI was also associated 
with increased risk, in 
particular obese vs. healthy 
BMI (2.45, 95% CI: 1.84–
3.28). 
Increased cancer 
risk incidence. 
The effect of 
central adiposity 
was independent of 
BMI. 
9/11 
Turati, F. 
et al 
(2013)(138) 
Meta-
analysis. 
A wide 
range of 
countries. 
22 
observational 
studies 
fulfilled the 
criteria; 10 
were 
prospective 
studies. 
Estimation of 
the association 
between 
(OAC) 
incidence and 
different 
levels of BMI. 
Overweight and obesity 
were associated with an 
increased risk of cancer; 
the respective risks were 
1.87 (1.61–2.17) and 2.73 
(2.16–3.46).  
Increased cancer 
risk. 
No substantial 
differences were 
observed across sex 
and geographic 
areas. 
6/11 Probable evidence 
for incidence of 
OAC. 
Head and Neck *No meta-analyses or systematic reviews were found. Thus, we conducted a literature search on large prospective studies for this group of cancers. 
Gaudet, M. 
M. et al 
(2015)(99) 
Pooled 
analysis of 
cohort data. 
A wide 
range of 
countries. 
Data were 
pooled from 
20 cohort 
studies with 
1,941,300 
participants. 
Associations 
between 
anthropo-
metric 
measures and 
head and neck 
cancer (HNC). 
Associations with waist 
circumference (WC) and 
waist-to-hip ratio (WHR) 
were significant. HR for 5 
cm increment in WC was 
1.04, 95% CI 1.03–1.05; 
and 1.07, 95% CI 1.05–
1.09 per 0.1-unit increase 
in WHR after adjustments 
for BMI.  
Increased cancer 
risk with 
measurements 
of central 
adiposity.  
The association with 
obesity defined by 
BMI differed by 
smoking status. An 
increased risk was 
observed among 
never-smokers 1.40 
(1.08–1.81) whereas a 
reduced risk was 
noticed in current 
smokers 0.58 (0.47–
0.72).  
N/A 
Weak. 
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Gaudet, M. 
M et al 
(2012)(139) 
Cancer 
Prevention 
Study-II 
cohort and the 
Nutrition 
cohort. 
Participants 
from the US. 
Mortality 
data were 
used from 
1,059,153 
participants 
and incident 
analysis 
from 
150,262. 
Associations 
between 
different 
levels of BMI 
and head and 
neck cancer 
(HNC) 
incidence and 
mortality. 
BMI was not associated 
with incidence of HNC. 
On the other hand, 
overweight or obesity were 
associated with a reduced 
risk for mortality.  
Overweight or 
obese 
participants had 
a diminished 
risk of 
mortality. 
For cancer 
incidence, BMI was 
not related to the 
outcome even in 
stratified analysis 
by smoking status. 
N/A 
Liver 
Chen, Y. et 
al 
(2012)(10) 
Meta-
analysis. 
Most of the 
studies were 
conducted in 
Asia. 
26 
prospective 
studies were 
included with 
a study 
population of 
9,053,369 
participants. 
Associations 
between 
different 
levels of BMI 
and liver 
cancer 
incidence.  
Overweight and obesity 
were associated with an 
increased risk of cancer; 
the respective risks were 
1.18 (1.06–1.31) and 1.83 
(1.59–2.11). For 
populations with liver 
diseases (hepatitis C and 
cirrhosis), the association 
with obesity was between 
2 and 3-fold higher. 
Increased cancer 
risk incidence. 
Most of the studies 
calculated BMI from 
objective measures. 
For stratified analysis, 
the association with 
obesity is stronger in 
males than in females. 
(Males: RR 1.91 
(1.51–2.41) vs. 
(females: RR 1.55 
(1.30–1.85). 
6/11 
Convincing 
evidence for 
cancer incidence. 
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Rui, R. et al 
(2012)(11) 
Meta-
analysis. 
Most of the 
studies were 
conducted in 
Asia. 
8 
prospective 
studies met 
the inclusion 
criteria with 
1,779,471 
individuals. 
Associations 
between 
different 
levels of BMI 
and liver 
cancer 
incidence.  
Overweight and obesity 
were associated with an 
increased risk of cancer; 
the risk for overweight was 
1.02 95% CI: 1.02–1.03; 
1.35 95% CI: 1.24–1.47 
for obese ≥30; and 2.22 
95% CI: 1.74–2.83 for 
obese ≥35. 
Increased cancer 
risk with 
increasing BMI. 
Most of the studies 
calculated BMI 
from objective 
measures. 
7/11 
Wang, Y. 
et al 
(2012)(12) 
Meta-
analysis. 
A wide 
range of 
countries. 
21 studies 
fulfilled the 
criteria. Of 
them, 18 
were 
prospective 
studies. 
Estimates of 
RR per 5 
kg/m2 increase 
in BMI. 
A 5-unit increment in BMI 
was associated with cancer 
incidence 1.39 (95% CI: 
1.25–1.55). Likewise, BMI 
was associated with 
mortality 1.27 (1.05–1.53). 
Increased cancer 
risk (incidence 
and mortality) 
with a 5-unit 
increment in 
BMI. 
Individuals with 
liver disease 
(hepatitis C and 
cirrhosis) had 
higher risks than 
the average 
population. 
7/11 
Lung 
Duan, P. et 
al (2015)(17) 
Systematic 
review and 
meta-analysis. 
A wide range 
of countries. 
However, most 
of the studies 
were based in 
North 
America. 
29 
prospective 
studies 
fulfilled the 
criteria with a 
total of 
7,253,941 
participants. 
Associations 
between 
different 
levels of BMI 
and lung 
cancer 
incidence.  
Obesity was inversely 
associated with cancer, the 
risk for BMI ≥30 was 0.91 
(95%CI: 0.85–0.98) and 
0.81 (95% CI: 0.72–0.91) 
for BMI ≥35 kg/m2. 
Overweight or 
obese 
participants had 
a decreased risk 
of cancer 
incidence. 
The effects of 
obesity on lung 
cancer risk were 
consistent regardless 
of smoking status. 
9/11 
Convincing 
evidence for 
cancer incidence. 
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Gupta, A. et 
al (2016)(16) 
Systematic 
review and 
meta-analysis. 
A wide range 
of countries. 
14 
prospective 
studies, 
comprising 
3,008,137 
participants. 
Associations 
between 
different 
levels of BMI 
and lung 
cancer 
mortality. 
A significantly lower lung 
cancer–related mortality 
was observed in 
overweight (HR 0.76; 95% 
CI: 0.68–0.85) or obese 
individuals (HR 0.68, 95% 
CI: 0.57–0.81). 
Overweight or 
obese 
participants had 
a diminished 
risk of 
mortality. 
The association was 
observed across 
sex, smoking status 
and geographical 
region. 
8/11 
Hidayat, 
K. et al 
(2016)(140) 
Systematic 
review and 
meta-analysis. 
Most of the 
studies were 
conducted in 
the US. 
6 
prospective 
cohort 
studies with 
a total of 
831,535 
participants. 
Estimation of 
the association 
between lung 
cancer 
incidence and 
central 
adiposity 
measures. 
Each 10 cm increase in 
WC and 0.1-unit increase 
in WHR were associated 
with cancer risk; the 
respective risks were RR 
1.10, 95% CI: 1.04–1.17 
and 1.05, 95% CI: 1.00–
1.11. RRs for highest vs. 
lowest categories of WC 
and WHR were 1.32 (95% 
CI: 1.13–1.54) and 1.10 
(95% CI: 1.00–1.23). 
Higher cancer 
incidence with 
increased 
measurement of 
central 
adiposity. 
All studies 
concerning the 
association with WC 
were adjusted for 
BMI and the effect 
estimates were similar 
by smoking status. 
Almost all of the 
included studies were 
conducted in women. 
Thus, the findings 
might not be 
applicable to men. 
9/11 There were very 
few studies from 
which to draw a 
conclusion. 
Shen, N. et 
al (2017)(18) 
Meta-
analysis. 
Participants 
from the US, 
Europe, 
China, New 
Zealand and 
Australia. 
15 
prospective 
studies with a 
total of 
15,191,571 
individuals. 
Estimates of 
RR per 5 
kg/m2 increase 
in BMI and 
mortality. 
A 5 kg/m2 unit increase in 
BMI was associated with a 
lower risk of lung cancer 
mortality (0.94, 95% CI: 
0.92–0.96). 
Decreased 
cancer risk 
mortality with a 
5-unit increment 
in BMI. 
There was no effect 
modification 
observed on the 
basis of sex, 
smoking status or 
study location. 
9/11 
Convincing 
evidence for 
cancer incidence. 
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 Yang, Y. et 
al (2013)(19) 
Meta-
analysis.  
Most of the 
studies were 
conducted in 
the US and 
Europe. 
31 studies 
were 
included, of 
them, 20 
were 
prospective. 
Associations 
between BMI 
and lung 
cancer 
incidence.  
Overweight and obesity 
were associated with a 
decreased risk of cancer; 
the risk for overweight was 
0.74 (95% CI: 0.68–0.80) 
and for obesity 0.71 (95% 
CI: 0.62–0.80) compared 
with a healthy BMI. 
Participants with 
a high BMI had a 
diminished risk 
of cancer 
incidence. 
The association did 
not change with 
stratification by 
sex, smoking status, 
study population, 
study design or 
BMI measurement 
method. 
6/11 
Melanoma 
Sergentanis, 
T. N. et al 
(2013)(100) 
Meta-
analysis. 
Participants 
from 
Europe, the 
US and 
Australia. 
21 
observational 
studies 
fulfilled the 
criteria. Of 
them, 10 were 
prospective 
studies. 
Associations 
between BMI 
and melanoma 
incidence.  
Among males, the effect 
estimate was 1.31 (95% CI: 
1.18–1.45) for overweight 
and 1.31 (95% CI: 1.19–
1.44) for obese compared 
with participants with a 
healthy BMI. Among 
females, no significant 
association was 
documented. 
Overweight or 
obese 
participants had 
an increased 
risk of 
malignant 
melanoma. 
The evidence is 
more apparent 
among males. 
6/11 Weak. 
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Ovarian 
Aune, D. et 
al (2015)(37) 
Meta-
analysis.  
Participants 
from Europe 
and the US. 
28 
prospective 
studies were 
identified. 
Associations 
between 
different 
adiposity 
measures and 
ovarian 
cancer. 
BMI, BMI during early 
adulthood (age 18–29 years) 
and WC were associated 
with ovarian cancer 
incidence. The summary 
RRs were 1.07 (CI: 1.03–
1.11) for a 5 kg/m2 
increment in BMI, 1.12 (CI: 
1.05–1.20) for a 5-unit 
increase in BMI during early 
adulthood and 1.06 (CI: 
1.00–1.12) for a 10 cm 
increase in WC. 
Increased cancer 
risk with 
increasing BMI 
and WC. 
There was evidence 
of a nonlinear 
association, with risk 
increasing from BMI 
about 28 kg/m2 and 
above. Additionally, 
no effect from 
weight gain, WHR or 
HC was observed. 
6/11 
Probable evidence 
for cancer 
incidence. 
Bae, H. S. 
et al 
(2014)(141) 
Systematic 
review and 
meta-analysis. 
Mostly 
participants 
from Europe 
and the US. 
17 cohort 
studies. 
Associations 
between 
timing of BMI 
and ovarian 
cancer 
mortality. 
Obesity in adolescence and 
5 years prior to ovarian 
cancer diagnosis were 
associated with poor 
survival. Obesity in 
adolescence was 1.67 (CI: 
1.29–2.16); obesity 5 years 
pre-diagnosis was 1.35 
(CI: 1.03–1.76).  
Higher cancer 
mortality with 
increased BMI. 
No effect was seen 
on mortality for 
BMI at diagnosis.  
7/11 
Collabora-
tive Group on 
Ovarian 
Studies 
(2012)(142) 
Meta-
analysis. 
A wide 
range of 
countries. 
47 studies; 
17 were 
cohort 
studies.  
Associations 
between BMI 
and ovarian 
cancer 
incidence. 
RR for ovarian cancer per 
5 kg/m2 unit increase in 
BMI was 1.10 (CI: 1.07–
1.13) in never-users of 
menopausal therapy; and 
0.95 (CI: 0.92–0.99) in 
ever-users. Additionally, a 
BMI ≥30 was associated 
with increased risk 1.13 
(CI: 1.06–1.20). 
Increased cancer 
risk. 
For BMI, there was 
significant 
heterogeneity for 
menopausal 
therapy. 
6/11 
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Liu, Z. et 
al 
(2015)(143) 
Meta-
analysis. 
Most of the 
studies were 
conducted in 
Europe and 
the US. 
26 
observational 
studies, of 
which 13 were 
cohort studies. 
Associations 
between 
different 
levels of BMI 
and ovarian 
cancer 
incidence.  
Overweight and obesity 
were associated with an 
increased risk of cancer; 
the risk for overweight was 
1.07 (95% CI: 1.02–1.12) 
and for obesity 1.28 (95% 
CI: 1.16–1.41) compared 
with a healthy BMI. 
Increased cancer 
risk. 
When stratifying for 
menopausal status, 
overweight and 
obesity were 
associated with an 
increased risk of 
ovarian cancer in the 
premenopausal 
period (overweight 
1.31, 95% CI: 1.04–
1.65; obesity 1.50, 
95% CI: 1.12–2.00). 
However, no 
statistically 
significant 
association was 
observed in the 
postmenopausal 
period. 
7/11 
Probable evidence 
for cancer 
incidence. 
Poorolajal, J. 
et al 
(2014)(38) 
Meta-
analysis. 
Participants 
from Japan, 
the US, 
Europe and 
Australia. 
19 studies 
met the 
inclusion 
criteria; 10 
were cohort 
studies. 
Associations 
between 
different 
levels of BMI 
and ovarian 
cancer 
incidence.  
Obesity was associated 
with an increased risk for 
ovarian cancer (RR 1.27, 
95% CI: 1.19–1.35). 
Increased cancer 
risk. 
The pooled estimate 
combined 
premenopausal and 
postmenopausal 
periods since there 
was no evidence of 
heterogeneity. 
8/11 
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Protani, M. 
M. et al 
(2012)(144) 
Systematic 
review and 
meta-analysis. 
Mostly 
participants 
from Europe 
and the US. 
20 cohort 
studies; of 
them 3 were 
of women 
with ovarian 
cancer 
participating 
in 
randomised 
trials. 
Associations 
between BMI 
and ovarian 
cancer 
mortality. 
Obese women showed 
poorer ovarian cancer 
survival compared with 
women with a healthy 
BMI (1.17, 95% CI: 1.03–
1.34). When BMI was 
examined continuously, a 
5-unit increase in BMI was 
not statistically significant 
(1.15, 95% CI: 0.95-1.39). 
Increased cancer 
mortality. 
This estimate did not 
vary appreciably 
when analyses were 
restricted to studies 
where BMI was 
measured before 
diagnosis, or at the 
time of diagnosis or 
chemotherapy.  
6/11 Probable evidence 
for cancer 
incidence. 
Pancreatic 
Alsamarrai, 
A. et al 
(2014)(115) 
Systematic 
review and 
meta-analysis. 
Mostly from 
Sweden, the 
US and 
Japan. 
26 prospective 
studies with a 
total 
population of 
2,848,968. 
Associations 
between BMI 
and pancreatic 
cancer 
incidence. 
A high BMI ≥25 was not 
associated with risk (1.30, 
95% CI: 0.90–1.87).   
No effect. Overweight and 
obesity were not 
dissociated. 
9/11 
Probable evidence 
for cancer 
incidence and 
mortality. 
Aune, D. et 
al (2012)(36) 
Systematic 
review and 
meta-analysis. 
Most of the 
studies were 
conducted in 
Europe and 
the US. 
29 
prospective 
studies with a 
total 
population of 
5,037,555 
participants. 
Associations 
between 
different 
adiposity 
measures and 
pancreatic 
cancer incidence 
and mortality. 
A 5-unit increment in BMI 
was associated with cancer 
incidence (1.10, 95% CI 
1.07–1.14). Additionally, 
measures of central 
adiposity were associated 
with increased risk. A 10 
cm increase in WC was 
1.11 (95% CI: 1.05–1.18); 
and 1.19 (95% CI: 1.09–
1.31) for a 0.1-unit 
increment in WHR. On the 
other hand, a 5-unit 
increment in BMI was not 
associated with mortality 
Increased cancer 
risk. 
Results were 
similar when 
stratified by gender 
and geographic 
location. There was 
evidence that the 
association between 
BMI and pancreatic 
cancer mortality 
was nonlinear, the 
risk was most 
pronounced above a 
BMI of 35. 
7/11 
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(1.16, 95% CI: 0.98–1.36). 
Majumder, 
K. et al 
(2016)(145) 
Systematic 
review and 
meta-analysis. 
A wide 
range of 
countries. 
13 
prospective 
cohort studies 
with a total 
population of 
3,434,737 
participants. 
Associations 
between pre-
diagnostic 
BMI and 
pancreatic 
mortality. 
Overweight and obesity 
were associated with an 
increased mortality; the 
risk for overweight was 
1.06 (95% CI: 1.02–1.11) 
and for obesity 1.31 (95% 
CI: 1.20–1.42) compared 
with a healthy BMI. 
Increased cancer 
risk. 
In subgroup analysis, 
obesity was 
associated with 
increased mortality 
in Western 
populations (1.32, 
95% CI: 1.22–1.42) 
but not in Asia-
Pacific populations 
(0.98, 95% CI: 0.76–
1.27); the latter 
analysis consisted of 
only 2 studies. 
11/11 
Probable evidence 
for cancer 
incidence and 
mortality.  
Shi, Y. Q. 
et al 
(2016)(146) 
Meta-
analysis.  
Mostly 
participants 
from Europe 
and the US. 
10 
prospective 
studies.  
Association 
between BMI 
and survival.  
Pre-diagnostic obesity was 
associated with poorer 
survival; HR 1.29 (95% C: 
1.17–1.41). A dose–
response analysis showed 
an increased risk of death 
of 1.11 (95% CI: 1.05–
1.18) for every 5 kg/m2 
increase in pre-diagnostic 
BMI. 
Increased risk of 
mortality, 
particularly with 
high pre-
diagnostic BMI. 
BMI at diagnosis 
was not associated 
with cancer 
mortality. 
8/11 
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Prostate 
Discacciati, 
A. et al 
(2012)(27)  
Meta-
analysis.  
Mostly 
participants 
from Europe 
and the US. 
13 
prospective 
studies with a 
total of 
1,033,009 
subjects. 
Association 
between BMI 
and risk of 
localised and 
advanced 
prostate 
cancer. 
There was an inverse 
relationship between BMI 
and localised prostate 
cancer; RR 0.94 (95% CI: 
0.91–0.97) for every 5 
kg/m2 increase. For 
advanced disease, the 
relationship with BMI was 
1.09 (95% CI: 1.02–1.16) 
for every 5 kg/m2 
increase). 
Increased risk 
with advanced 
disease. 
Subgroup analyses 
stratified by 
ethnicity (known 
risk factor for this 
cancer) yielded 
similar risk for 
BMI. 
7/11 
Convincing 
evidence for 
incidence of 
advanced prostate 
and probable for 
mortality. 
Markozannes, 
G. (2016)(147) 
Umbrella 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
46 meta-
analyses. 
Association 
between BMI 
and risk of 
localised and 
advanced 
prostate 
cancer. 
A 5 kg/m2 unit increase in 
BMI was associated with 
higher risk of prostate 
cancer mortality and 
advanced disease; the 
respective RR were 1.11 
(95% CI: 1.06–1.17) and 
1.08 (95% CI: 1.04–1.12). 
On the other hand, a 5 
kg/m2 unit increase was 
associated with a reduced 
risk of low-grade prostate 
cancer.  
Increased cancer 
risk for mortality. 
This umbrella 
review ranked the 
evidence based on 
p-values. 
N/A 
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Zhong, S. 
et al 
(2016)(46) 
Meta-
analysis. 
A wide 
range of 
countries. 
38 studies 
were 
included; 37 
were cohort 
studies. 
Association 
between BMI 
and survival.  
An increment of 5 kg/m2 in 
pre-diagnosis BMI was 
associated with higher 
prostate cancer mortality 
(1.15, 95% CI: 1.07–1.23). 
Additionally, overweight 
and obesity were 
associated with mortality; 
the risk for overweight was 
1.14 (95% CI: 1.06–1.22) 
and for obesity 1.33 (95% 
CI: 1.22–1.45) compared 
with a healthy BMI. 
Increased cancer 
risk for 
mortality. 
No effect was seen 
with post-diagnosis 
BMI and cancer 
mortality. 
8/11 
Convincing 
evidence for 
incidence of 
advanced prostate 
and probable for 
mortality. 
Zhang, X. 
et al 
(2015)(28) 
Meta- 
analysis. 
Participants 
from 
Europe, the 
US and 
Australia. 
17 cohort 
studies. 
Association 
between BMI 
and mortality.  
Obesity was significantly 
correlated with an increased 
risk of aggressive prostate 
cancer (Gleason score 
between 7 and 10); 1.14 
(95% CI: 1.04–1.25). And 
also for prostate cancer 
mortality; 1.24 (95% CI: 
1.15–2.33).  
Increased risk 
with advanced 
disease. 
Obesity was not 
significantly 
correlated with PCa 
incidence. There 
was no evidence of  
heterogeneity 
among the studies.  
6/11 
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Kidney  
Choi, Y. et 
al 
(2013)(148) 
Meta-
analysis. 
Most of the 
studies were 
conducted in 
Europe and 
the US. 
20 
prospective 
studies were 
included. 
Association 
between BMI 
and survival 
from renal cell 
carcinoma 
(most 
common 
cancer). 
Higher BMI was 
significantly associated 
with improved overall 
survival (HR 0.57, 95% 
CI: 0.43–0.76), comparing 
the highest with the lowest 
BMI. 
Decreased 
cancer risk 
mortality. 
This study did not 
specify when BMI 
was calculated — 
most likely after 
diagnosis since the 
study focused on 
survival after 
nephrectomy 
(removal of the 
kidney). Also, 
publication bias was 
significant. 
6/11 
Probable evidence 
for cancer 
incidence 
Golabek, 
T. et al 
(2016)(149) 
Systematic 
review. 
A wide 
range of 
countries. 
20 
prospective 
studies 
fulfilled the 
inclusion 
criteria; there 
were 
8,716,689 
subjects. 
Association 
between BMI 
and cancer 
incidence and 
survival.  
A positive relationship 
between BMI and renal 
cancer risk was reported in 
9 studies in men and 10 in 
women; a modest 
association was described 
in 1 study for both sexes 
and no association was 
reported in 3 studies of 
women and men. 3 studies 
reported higher risk for 
kidney cancer death in 
obese women. 
Increased cancer 
risk. 
This review did not 
summarise the 
information about 
mortality in men. 
N/A 
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Wang, F. 
et al 
(2014)(35) 
Meta-
analysis. 
A wide 
range of 
countries. 
However, 
most of the 
studies were 
based in 
North 
America or 
Europe. 
21 prospective 
studies with a 
total of 
9,080,052 
participants. 
Associations 
between 
different 
levels of BMI 
and risk of 
cancer. 
Overweight and obesity 
were associated with an 
increased incidence of 
cancer; the risk for 
overweight was 1.28 (95% 
CI: 1.24–1.33) and for 
obesity 1.77 (95% CI: 
1.68–1.87) compared with 
a healthy BMI. 
Increased cancer 
risk. 
The risk of kidney 
cancer incidence 
was slightly higher 
in Asian 
populations. Dose–
response analysis 
showed an 
increased risk of 
1.04 (95% CI: 
1.04–1.05) for each 
1 kg/m2 increase in 
BMI. 
6/11 Probable evidence 
for cancer 
incidence 
Thyroid 
Ma, J. et al 
(2015)(13) 
Meta-
analysis. 
A wide 
range of 
countries. 
32 
observational 
studies; of 
these, 24 were 
cohort. The 
total sample 
was 
12,620,676 
subjects.  
Associations 
between 
obesity and 
risk of cancer. 
Obesity was associated 
with a significantly 
increased risk of thyroid 
cancer (RR 1.33, 95% CI: 
1.24–1.42). 
Increased cancer 
risk. 
In stratified 
analysis, the 
increased risk was 
observed regardless 
of sex, smoking 
status and ethnicity. 
8/11 Convincing 
evidence for 
cancer incidence. 
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Schmid, D. 
et al 
(2015)(150) 
Meta-
analysis.  
A wide 
range of 
countries. 
21 
observational 
studies 
fulfilled the 
criteria; 13 
were cohort 
studies. 
Associations 
between 
different 
levels of BMI 
and risk of 
cancer. 
Overweight and obesity 
were associated with an 
increased incidence of 
cancer; the risk for 
overweight was 1.25 (95% 
CI: 1.11–1.41) and for 
obesity 1.55 (95% CI: 
1.21–1.99) compared with 
a healthy BMI. 
Increased cancer 
risk. 
Obesity was 
significantly 
positively related to 
the following 
histological types: 
papillary, follicular 
and anaplastic; and 
inversely related to 
medullary thyroid 
cancer. The 
association between 
obesity and cancer in 
men was not 
significant in 
stratified analysis. 
7/11 
Convincing 
evidence for 
cancer incidence. 
Zhao, Z. 
G. et al 
(2015)(15)  
Meta-
analysis. 
Participants 
from Korea, 
Norway, 
Sweden, 
Austria and 
the US. 
7 
prospective 
studies met 
the inclusion 
criteria with 
a total of 
8,099,411 
participants. 
Associations 
between 
different 
levels of BMI 
and risk of 
cancer. 
Overweight and obesity 
were associated with an 
increased incidence of 
cancer; the risk for 
overweight was 1.13 (95% 
CI: 1.04–1.22), and for 
obesity 1.29 (95% CI: 
1.18–1.41) compared with 
a healthy BMI. 
Increased cancer 
risk. 
Obesity was 
associated with 
cancer risk among 
men and women. 
9/11 
Uterine 
Aune, D. 
et al 
(2015)(25) 
Systematic 
review and 
meta-
analysis.  
Mostly 
participants 
from Europe 
and the US. 
32 
prospective 
studies were 
included 
with a total 
population 
of 6,445,402 
subjects. 
Associations 
between 
different 
adiposity 
measures and 
cancer 
incidence. 
A 5 kg/m2 unit increment 
in BMI was associated 
with increased risk of 
uterine cancer incidence 
and mortality; 1.54 (95% 
CI: 1.47–1.61) and 1.45 
(95% CI: 1.30–1.63 
respectively. Each 5-unit 
Increased cancer 
risk. 
There was evidence 
that the association 
between BMI and 
endometrial 
cancer was 
nonlinear, with risk 
increasing more 
noticeably for BMI 
10/11 Convincing 
evidence for 
cancer incidence. 
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BMI increase from BMI at 
age 18–25 years was 
associated with cancer 
incidence (1.45, 95% CI: 
1.28–1.64). Weight gain 
between age 18–20 and 
baseline showed a 5 kg 
increase in weight gain 
was also associated with 
cancer incidence (1.16, 
95% CI: 1.12–1.20). The 
risk of developing uterine 
cancer was increased by 
1.27 (95% CI: 1.17–1.39) 
and 1.21 (95% CI: 1.13–
1.29) per every 10 cm 
increment in WC or 0.1 
unit of WHR. 
over 25 kg/m2. In 
addition, the 
association of BMI 
was stronger among 
never-users of 
menopausal therapy 
that ever-users, 
although the effect 
was significant for 
both groups. No 
heterogeneity was 
seen for 
menopausal status. 
Jenabi, E. 
et al 
(2015)(26) 
Meta-
analysis. 
Mostly 
participants 
from Europe 
and the US. 
40 studies 
were 
included. Of 
them, 20 
were cohort 
studies, 
involving 
32,281,242 
participants. 
Associations 
between 
different 
levels of BMI 
and risk of 
cancer. 
Overweight and obesity 
were associated with an 
increased incidence of 
cancer; the risk for 
overweight was 1.34 (95% 
CI: 1.20–1.48) and for 
obesity 2.54 (95% CI: 
2.27–2.81) in cohort 
studies.  
Increased cancer 
risk. 
There was 
substantial 
heterogeneity 
among cohort and 
case-control 
studies, with 
stronger effects in 
case-control 
studies. 
9/11 
Convincing 
evidence for 
cancer incidence. 
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Secord, A. 
A. et al 
(2016)(151) 
Systematic 
review and 
meta-analysis 
A wide 
range of 
countries. 
18 
prospective 
studies 
fulfilled the 
criteria. 
Associations 
between 
different 
levels of BMI 
and mortality. 
Obesity was only 
associated with mortality 
for values greater than 40 
kg/m2 (1.66, 95% CI: 
1.10–2.51). 
Increased risk of 
death for 
participants with 
obesity grade 
III. 
No effects of 
obesity were seen 
for values below 
40. 
5/11 
 Zhang, Y. 
et al 
(2014)(152) 
Systematic 
review and 
meta-analysis. 
A wide 
range of 
countries. 
However, 
most of the 
studies were 
based in 
North 
America. 
18 studies 
fulfilled the 
criteria; 7 
were cohort 
studies. 
Associations 
between 
different 
levels of BMI 
and cancer 
incidence. 
Overweight and obesity 
were associated with an 
increased incidence of 
cancer, the risk for 
overweight was 1.32 (95% 
CI: 1.16–1.50) and for 
obesity 2.54 (95% CI: 
2.11–3.06). 
Increased cancer 
risk. 
Subgroup analyses 
showed the positive 
associations were 
independent of 
study design, 
geographic 
locations, alcohol 
use, smoking habit 
and menopausal 
therapy. 
9/11 Convincing 
evidence for 
cancer incidence. 
Cervical 
Poorolajal, 
J. et al 
(2016)(101) 
Meta-
analysis. 
A wide 
range of 
countries. 
9 studies 
were 
included; 2 
were cohort 
studies. The 
total sample 
consisted of 
128,233 
participants. 
Associations 
between 
different 
levels of BMI 
and cancer 
incidence. 
The pooled analysis of 
cohort studies yielded a 
significant association with 
overweight but not with 
obesity. RR for overweight 
was 1.10 (95% CI: 1.03–
1.17).  
Increased cancer 
risk. 
No evidence of 
heterogeneity was 
detected. However, 
effects estimates 
were reported based 
on study design. The 
quality of the 
different studies 
ranged from low to 
moderate. 
Drawbacks: limited 
number of studies. 
10/11 Weak.  
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Non-Hodgkin Lymphoma (NHL) *No systematic reviews or meta-analyses were identified during the literature search. Thus, we examined large prospective studies. 
Patel, A. V. 
et al 
(2013)(98) 
Prospective 
cohort. 
Cancer 
Prevention 
Study-II 
Nutrition 
Cohort (US). 
152,423 men 
and women 
with 15 
years of 
follow-up. 
Associations 
between 
different 
levels of BMI 
and cancer 
incidence. 
Obese individuals (BMI ≥30 
kg/m2) had higher risk of 
NHL incidence (HR 1.23, 
95% CI: 1.08–1.40) 
compared with participants 
with a healthy BMI (18.5–
25 kg/m2). However, the 
effect of the association was 
significant only in men 
when stratified analysis was 
performed. Regarding 
histological subsites, obesity 
was significantly associated 
with diffuse large B-cell 
lymphoma (DLBCL) and T-
cell lymphoma among men 
and women. 
Increased cancer 
risk incidence of 
DLBCL and T-
cell lymphoma. 
The subtypes 
included in the 
analysis were 
all B-cell lymphoid 
neoplasms and T-
cell lymphoid 
neoplasms. 
N/A Weak.  
Bertrand, 
K. A. et al 
(2013)(153) 
Prospective 
cohorts. 
The Health 
Professional
s Follow-up 
Study and 
the 
Nurses’ 
Health 
Study. 
46,390 men 
and 116,794 
women. 
Associations 
between 
different 
levels of BMI 
at different 
stages in life 
and cancer 
incidence. 
Middle adult BMI was 
associated with all NHL; a 
5-unit increase in BMI in 
men increased the risk of 
NHL 1.13 (95% CI: 1.00–
1.29). On the other hand, no 
effect was observed among 
women. BMI at young 
adulthood and adolescent 
somatotype was positively 
associated with all NHL in 
men and all NHL, DLBCL 
and follicular lymphoma 
(FL) in women. 
Increased cancer 
risk, in 
particular with 
early lifetime 
BMI. 
Although some 
differences in risk 
estimates were 
noted for men and 
women, there was 
no clear pattern of 
differences in 
associations and no 
statistical evidence 
of heterogeneity in 
effects by sex. 
N/A Weak. 
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Grey literature 
Lauby-
Secretan, 
Béatrice et 
al (2016)(24) 
Body Fatness and Cancer — Viewpoint 
of the IARC Working Group. 
Associations 
between 
different 
levels of BMI 
and cancer 
incidence. 
The highest BMI category 
(vs. a healthy BMI) has been 
associated with these 
cancers: oesophagus 
(adenocarcinoma) RR 4.8 
(3.0–7.7); colon and rectum 
1.8 (1.3–2.5); liver 1.8 (1.6–
2.1); pancreas 1.5 (1.2–1.8); 
corpus uteri 7.1 (6.3–8.1); 
ovary 1.1 (1.1–1.2); kidney 
(renal-cell) 1.8 (1.7–1.9). A 
5 kg/m2 unit increment in 
BMI was associated with 
increased risk of thyroid 1.1 
(1.0-1.1) and breast 
(postmenopausal) 1.1 (1.1–
1.2). 
Increased risk.    N/A IARC stated 
“there is sufficient 
level of evidence” 
for the 
aforementioned 
cancers. 
World Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2017)(29)  
Breast cancer: We identified 183 
publications from 181 studies that examined 
BMI during adulthood. 
Associations 
between 
different 
adiposity 
measures and 
cancer 
incidence. 
BMI was positively 
associated with breast cancer 
risk (summary RR per 
5kg/m2 1.07 (95% CI: 1.04–
1.11). However, this risk 
differs by menopausal status. 
A protective effect was 
observed per 5-unit increase 
in BMI in premenopausal 
women and an increased risk 
was seen in postmenopausal 
women. The respective risks 
were: 0.93 (0.90–0.97) and 
1.12 (1.09–1.15). Weight 
gain (from ages 18–25 years 
to study baseline/recent 
Increased risk 
for measures of 
general and 
central 
adiposity. 
No significant 
association was 
found with breast 
cancer mortality. 
BMI at early 
adulthood (age 18–
<30 years) was 
significantly 
inversely associated 
with any breast 
cancer risk. The 
effect of the 
association between 
weight gain and 
world regions was 
significant although 
N/A   
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follow-up) was associated 
with increased risk of 
postmenopausal cancer. Per 
5 kg of weight gain, risk 
increases 1.06 (1.05–1.08). 
Each 10 cm increment in 
WC was positively 
associated with 
postmenopausal breast 
cancer risk. RRs were 1.11 
(95% CI: 1.09–1.13). 
the risk was slightly 
higher in Asian 
populations. 
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2015)(116)  
Oesophageal cancer: 16 studies were 
included in the dose-response meta-analysis. 
Associations 
between 
different 
adiposity 
measures and 
cancer 
incidence. 
There was an increased risk 
of oesophageal 
adenocarcinoma (OAC) 
with BMI whereas a 
protective effect was 
observed with squamous 
cell carcinoma. The 
respective RRs were 1.48 
(1.35–1.62) and 0.64 (0.56–
0.73). Additionally, 
increased risk for OAC was 
observed with weight gain 
and WC; risk increases 1.15 
(1.09–1.22) per 5kg 
increment in weight gain 
and 1.34 (1.17–1.52) per 10 
cm increase in WC. 
Increased risk 
for measures of 
general and 
central 
adiposity. 
Risks of 
oesophageal 
adenocarcinoma did 
not vary by sex or 
world regions. 
N/A   
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World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2017)(20)  
Colorectal cancer: 27 studies were 
identified after the 2010 SLR. 
Associations 
between 
different 
adiposity 
measures and 
cancer 
incidence. 
BMI was associated with 
cancer from any site of the 
colorectum. A 5kg/m2 
increase was associated 
with a risk of 1.07 (1.05–
1.09) for colon and 1.02 
(1.01–1.04) for rectal 
cancer. Colorectal cancer 
risk also increased with 
higher WC and WHR. 
Increased risk 
for measures of 
general and 
central 
adiposity. 
The association of 
BMI with 
colorectal cancer 
risk was slightly 
higher in men than 
in women. In 
addition, the effect 
of BMI was similar 
across different 
world regions. 
N/A   
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2014)(66)  
Bladder cancer: 22 studies were identified. Associations 
between 
different 
adiposity 
measures and 
cancer 
incidence. 
A 5kg/m2 unit increment in 
BMI was associated with 
increased risk (1.03, 95% 
CI: 0.97–1.09).  
No effect. Risk for BMI 
appears to be 
heterogeneous by 
geographic location 
with a significant 
increased risk for 
Asian population 
(RR 1.20, 1.01–
1.42). 
N/A   
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2012)(30)  
Endometrial cancer: 34 studies were 
identified. 
Associations 
between 
different 
adiposity 
measures and 
cancer 
incidence. 
A 5kg/m2 unit increment in 
BMI was associated with 
increased risk (1.50, 95% 
CI: 1.42–1.59). Higher 
BMI at ages 18–25 years 
was associated with 
increased risk (1.42, 95% 
CI: 1.22–1.66) per 5 kg/m2 
unit increment. 
Additionally, measures of 
central adiposity were 
associated with increased 
risk. 
Increased risk 
for measures of 
general and 
central 
adiposity. 
The increased risk 
of endometrial 
cancer was found 
among women who 
have used 
menopausal therapy 
or never-users, 
although the risk 
was higher among 
never-users.  
N/A   
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World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2015)(40)  
Kidney cancer: 28 studies were included.  Associations 
between 
different 
adiposity 
measures and 
cancer 
incidence and 
mortality. 
A 5kg/m2 unit increment in 
BMI was associated with 
increased incidence (1.30, 
95% CI: 1.25–1.35) and 
mortality (1.32, 95% CI: 
1.01–1.71). For weight 
gain RR per 5kg was 1.11 
(95% CI: 1.07–1.14). 
Measures of central 
adiposity were associated 
with increased risk. 
Increased risk 
for measures of 
general and 
central 
adiposity. 
Risks were similar 
among men and 
women. 
N/A   
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2013)(39)  
Ovarian cancer: 26 prospective studies 
were included. 
Associations 
between 
different 
adiposity 
measures and 
cancer 
incidence. 
A 5kg/m2 unit increment in 
BMI was associated with 
increased risk (1.06, 95% 
CI: 1.02–1.11). For weight 
gain, RR per 5kg of weight 
was 1.05 (95% CI: 1.02–
1.07). 
Increased cancer 
risk. 
In stratified 
analyses by 
menopausal status 
effects were 
similar. 
N/A   
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2015)(21)  
Liver cancer: 15 studies were included. Associations 
between 
different 
adiposity 
measures and 
cancer 
incidence. 
A 5kg/m2 unit increment in 
BMI was associated with 
increased risk (1.30, 95% 
CI: 1.16–1.46). 
Increased cancer 
risk. 
Risks were similar 
among men and 
women. 
N/A   
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World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2014)(31)  
Prostate cancer: 64 studies were included. Associations 
between 
different 
adiposity 
measures and 
cancer 
incidence. 
There was no evidence of 
association between BMI 
and total prostate cancer. 
However, when analyses 
were conducted by 
subtypes a 5kg/m2 
increment in BMI was 
associated with fatal 
cancer (RR 1.11, 1.06–17). 
Likewise, weight gain was 
not associated with total 
cancer but it was with fatal 
(1.03, 95% CI: 1.01–1.06) 
per 5kg increase in weight. 
No effect with 
total cancer. 
Risk were only 
significant for fatal 
prostate cancer. 
N/A   
Life stages 
Childhood **There was only one systematic review, examining childhood obesity and the likelihood of developing cancer in adulthood. 
Llewellyn, 
A. et al 
(2016)(89)  
Systematic 
review and 
meta-analysis. 
Participants 
from 
England, 
Scotland, 
Denmark, 
Israel and 
Norway. 
Approximatel
y 231,268 
participants. 
Associations 
between 
childhood 
obesity and 
development 
of cancer later 
in life. 
Childhood obesity between 
ages 7 and 11 years was 
associated with increased 
risk for ‘all cancers’ (1.14, 
1.00–1.29) and liver cancer 
among men (1.27, 1.11–
1.45). In analyses for 
children aged 12 and over, 
the highest BMI (compared 
with the lowest) was 
associated with liver cancer 
in men and women, colon 
cancer incidence and 
mortality, ovarian cancer and 
kidney cancer. 
Increased risk. No effect was 
detected for breast 
cancer. The study 
concluded that the 
ability of 
childhood/ 
adolescent BMI 
measurement to 
predict adult 
morbidities was 
poor. The inception 
of most of the 
studies was around 
the 50s.  
7/11 Possible. 
When conducting the literature search, we found no systematic reviews or meta-analyses for migrants, culturally and linguistically diverse communities or Aboriginal populations. 
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Summary table physical activity 
 
Source 
(author, 
year) 
Study 
type 
(reviews) 
Population/
setting 
N (number of 
studies, 
number of 
participants) 
Intervention/ 
comparator 
Outcomes 
Direction/ 
magnitude of 
effect 
Comment/ notes 
Amstar 
score 
Level of evidence 
(convincing, 
probable, possible 
and weak) 
All cancers 
Kyu, H. H. 
et al 
(2016)(58) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
52 prospective 
studies. 
Effects of 
physical 
activity (PA) 
and cancer 
risk. 
The highest vs. the lowest 
category of PA was 
associated with a reduced 
risk for breast and colon 
cancer; the respective risks 
were 0.86 (0.83–0.90) and 
0.79 (0.74–0.85). 
Reduced risk. Higher levels of 
total PA were 
associated with 
lower risk of breast 
and colon cancer. 
9/11 Convincing 
evidence for cancer 
incidence of the 
colorectum and 
breast. 
Ballard-
Barbash, R. 
(2012)(154) 
Systematic 
review. 
Participants 
from the 
US, Europe, 
China and 
Australia. 
27 studies; 
most of these 
studies were 
designed as 
either follow-
up studies of 
healthy cohorts 
or follow-up 
studies of case 
subjects from 
case-control 
studies. 
Effects of PA 
and cancer 
survivorship. 
When comparing the highest 
with the lowest category of 
activity, 4 studies found no 
association between PA and 
breast cancer–specific 
mortality; 7 studies reported 
non–statistically significant 
decreased risks and 6 studies 
observed a statistically 
significant decreased risk. 
Additionally, there was little 
evidence of effect 
modification by menopausal 
status, tumour stage and 
hormone receptor status. For 
other cancers, there were 6 
articles on colorectal cancer; 
Reduced risk For the purpose of the 
review, cancer 
survivor was defined 
according to the 
National Cancer 
Institute Office of 
Cancer Survivorship 
as “a person who is 
diagnosed with cancer 
from the onset of their 
diagnosis through the 
balance of his or her 
life”. The authors 
concluded that “there 
is fairly consistent 
evidence that physical 
activity either before 
N/A Convincing 
evidence for 
colorectal and 
breast cancer 
mortality. 
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of these, 3 studies found PA 
after diagnosis was associated 
with statistically significant 
reduced risks, with indication 
of a dose–response 
relationship. 1 article on 
prostate cancer found 
significant risk reduction, and 
2 articles on ovarian cancer 
found no association. 
or after breast cancer 
diagnosis is 
associated with a 
reduction in breast 
cancer–specific 
mortality”. 
Li, T. et al 
(2016)(54) 
Meta-
analysis. 
Participants 
from North 
America, 
Asia and 
Europe. 
71 cohort 
studies. 
Association 
between PA 
and cancer 
mortality. 
Individuals who participated 
in the highest PA level had 
reduced risks for cancer 
mortality in the general 
population (0.83, 95% CI: 
0.79–0.87) and among 
cancer survivors (0.78, 95% 
CI: 0.74–0.84). 
Reduced risk. In the general 
population, a 
minimum of 2.5 
h/week of moderate-
intensity activity led 
to a significant 13% 
reduction in cancer 
mortality. 
Additionally, a 
greater protective 
effect occurred in 
cancer survivors 
undertaking PA post-
diagnosis vs. pre-
diagnosis. Effects for 
the general 
population by sex did 
not differ. However, 
among cancer 
survivors, effects 
were only significant 
among women. 
9/11 Probable evidence 
for all cancer-cause 
mortality. 
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 Li, Y. et al 
(2016)(55) 
Systematic 
review and 
meta-
analysis. 
Participants 
from the 
US, China, 
Japan and 
Europe. 
32 
prospective 
studies. 
Association 
between pre-
diagnosis PA 
and all cancer 
mortality. 
Relative risk of all cancer 
mortality was 0.80 (95% CI: 
0.76–0.85) for highest vs. 
lowest PA group. 
Reduced risk.   8/11 Probable evidence 
for all cancer-cause 
mortality. 
Liu, L. et 
al 
(2016)(155) 
Systematic 
review and 
meta-
analysis. 
Participants 
from North 
America, 
Asia and 
Europe. 
126 
prospective 
studies.  
Effects of PA 
and cancer 
risk. 
Compared with the lowest 
level of leisure time physical 
activity (LTPA), the highest 
level had lower cancer risk 
(0.90, CI: 0.88–0.92). 
Participants who met the 
average guidelines of PA 
recommended by the WHO 
had reduced cancer risks 
(0.93, CI: 091–0.95). 
Reduced risk. Sub-analyses 
indicated a similar 
cancer risk 
reduction for LTPA 
in males and 
females. In 
stratified analysis 
by cancer type, 
LTPA reduced the 
risk for breast 
cancer and colon 
cancer. 
9/11 Possible. 
Schmid, D. 
et al 
(2015)(111) 
Systematic 
review and 
meta-
analysis. 
Participants 
from the 
US, Finland 
and Japan. 
6 cohort studies 
with a total 
population of 
71,654 
individuals. 
Association 
between 
physical 
fitness or 
cardio-
respiratory 
fitness and 
cancer 
mortality. 
Compared with low 
cardiorespiratory fitness 
(CRF), intermediate levels 
were associated with a 
decreased risks of total 
cancer mortality (0.80, CI: 
0.67–0.97) and high levels 
were associated with even 
lower risks (0.55, CI: 0.47–
0.65). 
Reduced risk. Cardiorespiratory 
fitness showed a 
strong inverse 
association with 
total cancer 
mortality. 
8/11 Possible evidence 
for all cancer-cause 
mortality. 
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Shi, Y. et 
al 
(2015)(156) 
Systematic 
review and 
meta-
analysis. 
Participants 
from Europe 
and China. 
30 
observational 
studies, of 
these, 10 
were cohort. 
Effects of PA 
(household) 
and cancer 
risk. 
In cohort studies, the highest 
category of activity, 
compared with the lowest, 
was associated with reduced 
cancer risk (0.92, 0.87–
0.97). In stratified analysis 
by sex, the association was 
only significant for women 
(0.78, 0.69–0.88). 
Reduced risk. Study participants 
were mostly women 
in cohort studies. 
9/11 There were very 
few studies on 
household PA to 
draw a conclusion 
Schmid, D. 
et al 
(2014)(157) 
Systematic 
review and 
meta-
analysis. 
Participants 
from North 
America, 
Australia, 
China and 
Europe. 
23 prospective 
studies with a 
total 
population of 
49,095 
subjects. 
Pre-and post-
diagnosis PA 
in relation to 
cancer 
mortality 
among breast 
or colorectal 
cancer 
survivors. 
Among breast cancer and 
colorectal survivors, the 
highest level of pre-
diagnosis PA, compared 
with the lowest, was 
associated with reduced total 
mortality and death from 
breast or colon cancer. The 
respective RRs were 0.77 
(0.69–0.88), 0.77 (0.66–
0.90) and 0.75 (0.62–0.91). 
Additionally, post-diagnosis 
PA was also related to total 
mortality from breast or 
colorectal cancer. Breast or 
CRC survivors who 
increased their PA by any 
level from pre- to post-
diagnosis diminished their 
total risk of mortality (RR 
0.61, 0.46–0.80) compared 
with those who did not 
change their behaviour.  
Reduced risk. The association 
between pre- or 
post-diagnosis PA 
and total mortality 
among breast 
cancer survivors did 
not differ according 
to BMI, 
menopausal status, 
or tumour oestrogen 
receptor status. 
However, 
postmenopausal 
women who 
engaged in PA had 
better cancer-
specific survival 
than premenopausal 
women. 
7/11 Convincing 
evidence for 
colorectal and 
breast cancer 
mortality. 
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Bladder 
Keimling, 
M. et al 
(2014)(105) 
Systematic 
review and 
meta-
analysis. 
Participants 
from North 
America, 
Europe and 
Asia. 
15 studies; 11 
were cohort 
studies. 
Association 
between 
physical 
activity (PA) 
and bladder 
cancer 
incidence. 
In cohort studies, the highest 
category of PA, compared 
with the lowest, was 
associated with reduced 
cancer risk (0.89, 0.80–
1.00).  
Reduced risk. In stratified 
analysis, 
association was 
only significant for 
women. 
7/11 Weak. 
Non-Hodgkin Lymphoma 
Jochem, C. 
et al 
(2014)(108) 
Systematic 
review and 
meta-
analysis. 
Participants 
from North 
America 
and Europe. 
25 studies; 17 
were cohort 
studies. 
The 
associations 
between 
physical 
activity (PA) 
and subtype-
specific 
haematologic 
cancer 
incidence. 
In cohort studies, the highest 
category of PA, compared 
with the lowest, had no 
effect on the risk of non-
Hodgkin lymphoma (0.93, 
0.83–1.04) or leukaemia 
(0.91, 0.74–1.12).  
Null. When combining 
the effect of case-
control and cohort 
studies, PA was 
associated with 
non-Hodgkin 
lymphoma 0.91 
(0.82–1.00). 
6/11 Weak. 
Breast 
Fontein, D. 
B. et al 
(2013)(158) 
Systematic 
review. 
Mostly from 
the US. 
17 studies, of 
which, 13 were 
prospective, 2 
were 
randomised 
controlled 
studies and 2 
were case-
control studies. 
Association 
between 
physical 
activity (PA) 
and cancer 
mortality after 
a breast cancer 
diagnosis. 
Pre-diagnostic PA led to a 
significantly better overall 
cancer survival in 5 out of 
11 studies. Regarding breast 
cancer–specific survival, 
risk was significantly lower 
in 3 out of 5 studies that 
assessed this outcome. 
Reduced risk.  Most studies 
demonstrate that 
PA has a positive 
effect on overall 
survival and breast 
cancer–specific 
survival. 
N/A Convincing 
evidence for cancer 
incidence and 
mortality. 
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Goncalves, 
A. K. et al 
(2014)(159) 
Systematic 
review. 
Participants 
from North 
America 
and Europe. 
21 studies; 7 
were cohort 
studies. 
Association 
between PA 
and cancer 
risk. 
In cohort studies, the highest 
category of activity, 
compared with the lowest, 
was associated with lower 
risks (0.61, 0.59–0.63). 
Reduced risk.   9/11 
Convincing 
evidence for cancer 
incidence and 
mortality. 
Lahart, I. 
M. et al 
(2015)(92) 
Systematic 
review and 
meta-
analysis. 
Participants 
from North 
America, 
Australia, 
China and 
Europe. 
22 prospective 
cohort studies. 
Association 
between PA 
and breast 
cancer 
mortality. 
Highest level of self-
reported pre-diagnosis 
lifetime activity (compared 
with lowest level), more 
recent activity (<12 years) 
and pre- and post-diagnostic 
activity were all associated 
with lower mortality risks. 
The respective RRs were 
0.73 (0.54–0.98), 0.84 
(0.73–0.97), 0.72 (0.56–
0.91) and 0.59 (0.45–0.78). 
Reduced risk. Meeting 
recommended PA 
guidelines post-
diagnosis yielded 
lower risks of breast 
cancer mortality 0.67 
(0.50–0.90). Effects 
in stratified analysis 
were stronger in 
women with BMI 
≥25 kg/m2 and 
postmenopausal 
survivors.  
9/11 
Pizot, C. et 
al 
(2016)(160) 
Meta-
analysis. 
Participants 
from North 
America, 
Japan, 
China and 
Europe. 
38 prospective 
studies. 
Association 
between PA 
and cancer 
risk incidence. 
Highest vs. lowest category 
of PA was associated with 
reduced cancer risk (0.88, 
0.85–0.90). In dose–
response analysis, steady 
reductions in risk were 
detected with increasing PA, 
without evidence for a 
threshold. 
Reduced risk. In stratified 
analysis, effects 
were not influenced 
by BMI or 
menopausal status. 
However, 
menopausal 
condition was 
unknown for 43% 
of women. On the 
other hand, risk 
reductions were 
only observed in 
women who had 
7/11 
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never used 
menopausal 
therapy. 
Wu, Y. et 
al 
(2013)(161) 
Meta-
analysis. 
Participants 
from the 
US, China, 
Japan and 
Europe. 
31 prospective 
studies. 
Association 
between PA 
and breast 
cancer risk. 
Highest vs. lowest category 
of PA was associated with 
reduced cancer risk (0.88, 
0.85–0.91). Assessment of 
activity during different 
periods of life found PA 
performed <25 years, 25–50 
years, >50 years or during 
follow-up was associated 
with lower risk of breast 
cancer. 
Reduced risk. Similar effect size 
was found for 
different domains 
of PA 
(occupational, non-
occupational, 
recreational and 
household). The 
effect size was 
stronger for 
vigorous activity 
than for moderate 
activity. 
6/11 
Convincing 
evidence for cancer 
incidence and 
mortality. 
Zhong, S. 
et al 
(2014)(57) 
Meta-
analysis. 
Participants 
from North 
America, 
Australia, 
China and 
Europe. 
16 prospective 
studies.  
Association 
between PA 
and breast 
cancer 
mortality. 
Participants who engaged in 
any amount of PA vs. low 
levels before diagnosis had 
lower risk of breast cancer–
specific mortality (0.82, 
95% CI: 0.74–0.91). 
Reduced risk. Post-diagnosis PA 
yielded the same 
effect estimates on 
breast cancer–
specific mortality as 
pre-diagnostic PA. 
Stratified analysis 
showed a significant 
effect in women 
with a BMI ≥25 
kg/m2 but not in 
those with a BMI 
<25. 
8/11 
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Colorectal 
Boyle, T. 
et al 
(2012)(51) 
Systematic 
review and 
meta-
analysis. 
Participants 
from the 
US, Europe, 
Japan and 
Australia. 
21 studies; 12 
were cohort 
studies. 
Association 
between 
physical 
activity (PA) 
and colon 
cancer risk by 
subsites. 
The most physically active 
individuals (vs. the least 
active) had similar reduced 
risks of proximal and distal 
colon cancer; the respective 
RRs were 0.73 (0.66–0.81) 
and 0.74 (0.68–0.80).  
Reduced risk. Risk did not differ 
by study design or 
sex. 
7/11 
Convincing 
evidence for cancer 
incidence and 
mortality. 
Johnson, 
C. M. et al 
(2013)(135) 
Meta-
analysis. 
A wide 
range of 
countries. 
21 studies; 12 
were cohort 
studies. 
PA score, which 
ranged from 1–5. 
1 was the lowest 
level and 5 the 
highest category 
of activity. 
There was a significant 
negative correlation between 
CRC risk and PA per 
increased score of 2 standard 
deviations (RR 0.88, 95% 
CI: 0.86–0.91). 
Reduced risk. For cohort studies, 
the relative risk of 
CRC was 0.91 
(95% CI: 0.88–
0.96). 
4/11 
Je, Y. et al 
(2013)(162) 
Meta-
analysis. 
Participants 
from the US 
and 
Australia. 
7 cohort 
studies. 
Association 
between PA and 
colorectal (CRC) 
specific 
mortality. 
Individuals with high PA 
before diagnosis or after 
diagnosis vs. participants 
with low levels had reduced 
risks of CRC mortality; the 
respective RRs were 0.70 
(0.56–0.87) and 0.65 (0.47–
0.92).  
Reduced risk. Participants who 
engaged in any 
amount of PA 
before diagnosis or 
after diagnosis had 
a lower risk of 
dying from 
colorectal cancer. 
8/11 
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Otto, S. J. 
et al 
(2015)(59) 
Systematic 
review and 
meta-
analysis. 
Participants 
from the US 
and 
Australia. 
4 cohort 
studies. 
Change over 
time in PA 
and its 
association 
with mortality 
in colorectal 
cancer 
patients. 
Increased PA post-diagnosis 
was associated with reduced 
CRC-specific mortality 
(0.66, 0.49–0.83). However, 
increase in PA from pre-
diagnosis to 5 months post-
diagnosis was not 
significant. 
Reduced risk. Survivors were 
defined according 
to the National 
Cancer Institute 
Office of Cancer 
Survivorship. 
9/11 
Convincing 
evidence for cancer 
incidence and 
mortality. 
Robsahm, 
T. E. et al 
(2013)(163) 
Systematic 
review and 
meta-
analysis. 
Participants 
from the 
US, Japan 
and Europe. 
11 cohort 
studies. 
Association 
between PA 
and colon 
cancer risk by 
subsites. 
Similar effect estimates were 
observed for proximal and 
distal colon; the RRs were 
0.76 (0.70–0.83) and 0.77 
(0.71–0.83). No effect was 
detected for the association 
between PA and rectal 
cancer. 
Reduced risk. Different domains 
of PA were 
combined to 
estimate effect 
sizes. 
6/11 
Oesophageal 
Chen, Y. et 
al 
(2014)(107) 
Meta-
analysis. 
Participants 
from the 
US, Europe, 
Canada and 
Korea. 
7 studies; 3 
were cohort 
studies. 
Association 
between 
physical 
activity (PA) 
and risk of 
oesophageal 
cancer.  
Highest vs. lowest category 
of PA in cohort studies was 
associated with reduced 
cancer risk (0.78, 0.66–
0.92). 
Reduced risk. No significant 
difference was 
observed in 
subgroup analysis 
by sex.  
7/11 Weak. 
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Fahey, P. 
P. et al 
(2015)(136) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
2 studies 
fulfilled the 
criteria. 
Estimation of 
the association 
between PA 
and mortality 
from 
oesophageal 
cancer. 
There was no effect 
observed from PA on risk of 
death for the highest 
category vs. the lowest 
(1.20, 95% CI: 0.91–1.58). 
Null. There were very 
few studies from 
which to properly 
assess this 
association. 
7/11 
Weak. Singh, S. 
et al 
(2014)(32) 
Systematic 
review and 
meta-
analysis. 
Participants 
from the 
US, Europe 
and Korea. 
10 studies; 4 
were cohort 
studies. 
Association 
between PA 
and risk of 
oesophageal 
cancer.  
Highest vs. lowest category 
of PA in cohort studies was 
associated with reduced 
cancer risk (0.84, 0.71–
1.00).  
Marginal. Subgroup analysis 
found lower risk for 
oesophageal 
adenocarcinoma 
and no association 
was detected for 
squamous cell 
carcinoma.  
10/11 
Lung 
Brenner, 
D. R. et al 
(2016)(47) 
Meta-
analysis. 
Participants 
from the 
US, Europe 
and Asia. 
27 studies; 21 
were cohort 
studies. 
Association 
between 
physical 
activity (PA) 
and risk of 
lung cancer.  
Highest vs. lowest category 
of PA in cohort studies was 
associated with reduced 
cancer risk (0.79, 0.70–
0.89).  
Reduced risk. Effect estimates did 
not differ by study 
design, sex or 
histological type. 
Effects were 
significant for 
former and current 
smokers but not for 
non-smokers. 
6/11 Convincing 
evidence for cancer 
incidence. 
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Buffart, L. 
M. et al 
(2014)(48) 
Meta-
analysis. 
Participants 
from the 
US, Europe, 
Japan and 
Korea. 
18 studies; 12 
were cohort 
studies. 
Association 
between PA 
and risk of 
lung cancer. 
Moderate to high PA vs. low 
levels was associated with 
reduced risk (0.79, 0.73–
0.86) for cohort studies. 
Reduced risk. Similar effect 
estimates were 
observed for 
moderate or vigorous 
activity. Stratified 
analyses did not 
differ by sex or study 
design. Additionally, 
lower risks were 
observed in current 
smokers or former 
smokers but not in 
non-smokers. 
9/11 
Convincing 
evidence for cancer 
incidence. 
Sun, J. Y. 
et al 
(2012)(49) 
Meta-
analysis. 
Participants 
from the 
US, Europe 
and Japan. 
14 prospective 
studies with a 
total of 
1,644,305 
subjects. 
Association 
between PA 
and risk of 
lung cancer. 
High and moderate levels of 
PA were associated with 
decreased risk of lung cancer 
compared with a low level of 
activity; for a high level of PA 
the RR was 0.77 (0.73–0.81); 
it was 0.87 (0.83–0.90) for 
moderate levels. 
Reduced risk. Effect estimates did 
not differ by sex. 
7/11 
Zhong, S. 
et al 
(2016)(50) 
Meta-
analysis. 
Participants 
from the 
US, Europe, 
Japan and 
Korea. 
18 studies; 12 
were cohort 
studies. 
Association 
between PA 
and risk of 
lung cancer. 
Highest vs. lowest category 
of PA in cohort studies was 
associated with reduced 
cancer risk (0.88, 0.83–
0.92).  
Reduced risk. Effect estimates did 
not differ by sex. In 
stratified analysis 
by smoking status, 
estimates were only 
significant in 
current and former 
smokers.  
9/11 
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Ovarian 
Zhong, S. 
et al 
(2014)(109) 
Meta-
analysis. 
Participants 
from the 
US, Europe, 
Japan and 
Australia. 
19 studies; 9 
were cohort 
studies. 
Association 
between non-
occupational 
physical 
activity (PA) 
and risk of 
ovarian cancer. 
No association was found in 
cohort studies. 
Null. Effect estimates 
were significant for 
case-control 
studies. 
9/11 
Weak. 
Zhou, L. 
M. et al 
(2014)(110) 
Meta-
analysis. 
Participants 
from the US 
and Europe. 
6 studies; 3 
were cohort 
studies. 
Association 
between 
recreational 
PA and cancer 
risk. 
Cohort studies did not find 
association with cancer risk. 
Null. Pooled estimate of 
case-control and 
cohort studies was 
not significant. 
7/11 
Pancreatic 
Behrens, 
G. et al 
(2015)(106) 
Systematic 
review and 
meta-
analysis. 
Participants 
from North 
America, 
Asia and 
Europe. 
30 studies; 22 
were cohort 
studies. 
Association 
between 
physical 
activity (PA) 
and risk of 
pancreatic 
cancer. 
Highest vs. lowest category 
of PA in cohort studies was 
associated with reduced 
cancer risk (0.93, 0.88–
0.98). PA over time 
(maintained for 10 years) 
yielded a slightly lower RR 
of 0.86 (0.76–0.97). 
Reduced risk. Effect estimates did 
not differ by 
domains of PA.  
6/11 
Possible evidence 
for cancer 
incidence. 
Farris, M. 
S. et al 
(2015)(164) 
Systematic 
review and 
meta-
analysis. 
Participants 
from North 
America, 
Asia and 
Europe. 
27 studies; 21 
were cohort 
studies. 
Association 
between leisure 
time physical 
activity (LTPA) 
and risk of 
pancreatic 
cancer. 
Highest vs. lowest category 
of PA in cohort studies was 
not associated with cancer 
risk. 
Null. LTPA was 
associated with 
cancer risk for the 
combined estimate 
of case-control and 
cohort studies 
(0.89, 0.83–0.96). 
8/11 
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Kidney 
Behrens, 
G. et al 
(2013)(104) 
Systematic 
review and 
meta-
analysis. 
Participants 
from the 
US, Europe 
and Asia. 
19 studies; 11 
were cohort 
studies. 
Association 
between 
physical 
activity (PA) 
and risk of 
kidney cancer. 
Highest vs. lowest category 
of PA in cohort studies was 
associated with lower cancer 
risk (0.89, 0.80–0.99). 
Reduced risk. The summary RR 
estimate was not 
affected by PA 
domain, timing in 
life of PA, gender 
and study design.  
7/11 Possible evidence 
for cancer 
incidence. 
Prostate 
Markozannes
, G. et al 
(2016)(147) 
Umbrella 
review. 
A wide 
range of 
countries. 
5 meta-analyses 
focused on 
physical 
activity (PA) 
indices (total, 
occupational 
and 
recreational). 
Association 
between PA 
and risk of 
prostate 
cancer. 
No associations between PA 
and risk of any type of 
prostate cancer presented 
strong evidence. 
Null.   N/A Weak. 
Thyroid 
Schmid, D. 
et al 
(2013)(14) 
Systematic 
review and 
meta-
analysis. 
Participants 
from the US 
and 
Norway. 
7 out of 11 
studies were 
cohort 
studies.  
Association 
between 
physical 
activity (PA) 
and risk of 
thyroid cancer. 
Highest vs. lowest category 
of PA in cohort studies was 
associated with cancer risk 
(1.28, 1.01–1.63). 
Increased risk. Highest vs. lowest 
category of PA was 
not associated with 
cancer risk when case-
control and cohort 
studies were 
combined. 
9/11 Possible evidence 
for cancer 
incidence. 
Uterine 
Keum, N. 
et al 
(2014)(165) 
Meta-
analysis. 
Participants 
from the US 
and Europe. 
20 studies, of 
which 10 
were cohort 
studies. 
Association 
between 
physical activity 
(PA) and risk of 
uterine 
incidence. 
Highest vs. lowest category 
of PA in cohort studies was 
associated with lower cancer 
risk (0.85, 0.73–0.98). 
Reduced risk.   7/11 
Probable evidence 
for cancer 
incidence. 
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Schmid, D. 
et al 
(2015)(53) 
Meta-
analysis. 
Participants 
from the US 
and Europe. 
33 studies; 19 
were cohort 
studies. 
Association 
between PA 
and risk of 
uterine cancer 
incidence. 
Highest vs. lowest category 
of PA in cohort studies was 
associated with lower cancer 
risk 0.84 (0.78-0.91). No 
significant associations were 
observed for PA during 
different periods of life and 
risk of cancer. 
Reduced risk. No evidence of 
heterogeneity 
between studies was 
observed. Effect 
estimates were similar 
across different PA 
domains (household, 
recreational and 
occupational) and 
intensity. 
7/11 
The following article was included from The Physical Activity Collaboration of the National Cancer Institute’s Cohort Consortium because of the lack of literature for some cancer 
types. 
Moore, S. 
C. et al 
(2016)(166) 
Pooled 
data. 
Participants 
from the US 
and Europe. 
12 prospective 
studies with a 
total of 1.4 
million 
people. 
Association 
between 
leisure time 
physical 
activity 
(LTPA) and 
risk of several 
cancer types. 
High vs. low levels of LTPA 
were associated with lower 
risks of 12 cancers: 
oesophageal adenocarcinoma, 
liver, lung, kidney, 
endometrial, myeloid 
leukaemia, myeloma, colon, 
head and neck, rectal, bladder 
and breast. LTPA was 
associated with higher risks of 
malignant melanoma (1.27, 
1.16–1.40) and prostate cancer 
(1.05, 1.03–1.08). 
Reduced risk. Adjustments for 
BMI attenuated the 
significant risk for 
liver and 
endometrial cancer.  
N/A   
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Grey literature  
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2017)(29)  
Breast cancer: 23 publications from 17 
studies were identified. 
Associations 
between total 
physical 
activity (PA) 
and cancer 
incidence. 
Highest vs. lowest category of 
activity was associated with 
lower risk of postmenopausal 
breast cancer (0.87, 0.79–
0.96). Similar risk effects were 
observed for occupational and 
recreational activity. Vigorous 
PA was inversely associated 
with premenopausal breast 
cancer risk (0.83, 0.73–0.95) 
for the highest vs. the lowest 
activity level.  
Decreased risk. No association was 
observed for 
premenopausal 
breast cancer with 
total, recreational or 
occupational 
activity. 
N/A   
Associations 
between 
recreational 
activity at 
different ages 
and cancer 
incidence. 
For early adulthood periods, 
non-significant inverse 
associations were reported in 
three studies. 
        
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2015)(116)  
Oesophageal cancer: 5 studies (seven 
publications) assessed PA. 
Associations 
between PA 
and cancer 
incidence. 
Highest vs. lowest category 
of PA was not associated 
with cancer risk. 
Null. RR was not 
significant (0.85, 
0.72–1.01). 
N/A   
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World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2017)(20)  
Colorectal cancer (CRC): 15 out of 17 
published studies were included. 
Associations 
between total 
PA and cancer 
incidence. 
Total PA was inversely 
associated with CRC risk. 
RRs for the highest 
compared with the lowest 
levels were 0.81 (0.69–0.95) 
for CRC and 0.80 (0.72–
0.88) for colon cancer. No 
significant association was 
observed for rectal cancer. 
Reduced risk. Highest vs. lowest 
category of 
recreational activity 
was also associated 
with lower risk of 
colon cancer (0.84, 
0.78–0.91). No 
association was 
detected for rectal 
cancer. 
N/A   
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2014)(66)  
Bladder cancer: 12 studies from 9 articles 
were included. 
Associations 
between PA 
and cancer 
incidence. 
Highest vs. lowest level of 
activity was not associated 
with cancer risk (0.94, 0.83–
1.06). 
Null.   N/A   
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2012)(30)  
Endometrial cancer: we identified 9 
cohort studies on recreational activity and 
5 on occupational PA. 
Associations 
between PA 
and cancer 
incidence. 
Occupational and 
recreational PA were 
associated with cancer risk. 
The respective RRs for the 
highest vs. the lowest PA 
levels were 0.79 (0.71–0.88) 
and 0.73 (0.58–0.93). 
Reduced risk.   N/A   
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World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2015)(40)  
Kidney cancer: 4 studies were included.  Associations 
between PA 
and cancer 
incidence. 
No association was observed 
for the highest vs. the lowest 
level of recreational activity. 
RR 0.84 (0.70–1.01). 
Null. Occupational 
activity was not 
associated with 
cancer risk either. 
N/A   
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2013)(39)  
Ovarian cancer: 2 studies were included. Associations 
between PA 
and cancer 
incidence. 
None of the identified 
studies reported a significant 
association between total PA 
levels and ovarian cancer 
risk. 
Null.   N/A   
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2015)(21)  
Liver cancer: 4 studies were included.  Associations 
between PA 
and cancer 
incidence. 
    There were very 
few studies from 
which to evaluate 
this association. 
N/A   
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Life stages: No systematic reviews or meta-analyses were found for the effect of PA during different life stages on cancer risk. 
No systematic reviews or meta-analyses were found for migrants, culturally and linguistically diverse communities or Aboriginal populations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review 
(2014)(31)  
Prostate cancer: 19 publications from 12 
studies were included. 
Associations 
between PA 
and cancer 
incidence. 
The highest vs. lowest level 
of occupational activity was 
associated with lower cancer 
risk (0.87, 0.80–0.95). 
Reduced risk. Total PA or 
recreational activity 
were not associated 
with cancer risk. 
N/A   
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Summary table of diet  
 
Source 
(author, year) 
Study type 
(reviews) 
Population/
setting 
N (number of 
studies, 
number of 
participants) 
Intervention/ 
comparator 
Outcomes 
Direction/ 
magnitude of 
effect 
Comment/ notes 
Amstar 
score 
Level of evidence 
(convincing, 
probable, 
possible and 
weak) 
All cancers 
Aune, D. et al 
(2016)(71) 
Systematic 
review and 
meta-analysis. 
Participants 
from 
Europe, the 
US and 
Asia. 
6 cohort 
studies were 
included. 
The highest vs 
the lowest 
level of grain 
intake.  
A 90 gram/day increase 
in total wholegrain was 
associated with a 
reduced risk of total 
cancer mortality (0.85, 
0.80–0.91). 
Additionally, when 
contrasting high and 
low consumption, the 
risk was 0.89 (0.82–
0.96). There was an 
inverse association 
between intake of 
wholegrain bread and 
total cancer but this 
association was weak 
for refined grains. 
Reduced risk of 
cancer 
mortality. 
For total grains, 
wholegrains, and 
refined grains, 30 g 
was considered a 
serving size (one 
slice of bread or 
one bowl of 
breakfast cereal). 
Most of the studies 
that assessed total 
cancer used a 
validated food 
frequency 
questionnaire 
(FFQ). 
8/11 Convincing 
evidence for all 
cancer-cause 
mortality with 
wholegrain 
intake, probable 
for fibre intake 
and possible for a 
‘Western diet’. 
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Bella, F et al 
(2017)(167) 
Meta-
analysis. 
Participants 
from Europe 
and the US.  
7 studies; 1 
was a cohort 
study. 
Cluster 
analysis 
comparing 
different 
dietary 
patterns. 
An increased risk of 
cancer was observed 
with the adoption of a 
high meat diet compared 
with a more plant-based 
dietary pattern (RR 
1.64, 95% CI: 1.02–
2.63); when analyses 
were performed by 
cancer location, 
increased risk was 
observed for colorectal 
cancer (1.74, 1.25–
2.44). A plant-based diet 
vs. a mixed food pattern 
was associated with 
lower cancer risk (0.88, 
0.82–0.95). No effect 
was detected when 
contrasting a meat-
based diet with mixed 
foods patterns.  
Increased risk 
for a high-meat 
diet. 
Inclusion criteria 
included ‘a 
posteriori’–derived 
dietary patterns 
based on principal 
component analysis 
(PCA) or cluster 
analysis.  
8/11 
Convincing 
evidence for all 
cancer-cause 
mortality with 
wholegrain 
intake, probable 
for fibre intake 
and possible for a 
‘Western diet’. 
Benisi-
Kohansal, S. 
et al (2016)(72) 
Systematic 
review and 
meta-analysis. 
A wide 
range of 
countries. 
6 
prospective 
cohort 
studies were 
included 
with a total 
of 2,282,603 
participants. 
Comparisons 
between the 
highest and 
lowest 
categories of 
intake of total 
wholegrains. 
An inverse association 
was observed between 
wholegrain intake and 
risk of mortality from 
total cancers (0.94, 
95% CI: 0.91–0.98). A 
90 g/d (3 servings) 
increase in total 
wholegrain 
consumption was 
associated with a lower 
risk of cancer mortality 
(0.90, 95% CI: 0.83–
Reduced risk of 
cancer 
mortality. 
FFQs were used in 
most of the studies. 
9/11 
  
 
 
DOCUMENT1 | SAX INSTITUTE 381 
0.98). 
Bloomfield, H. 
E. et al 
(2016)(168) 
Systematic 
review and 
meta-analysis. 
Most of the 
studies were 
conducted in 
the US. 
28 cohort 
studies. 
Highest vs. 
lowest 
Mediterranean 
diet adherence. 
Adherence to a 
Mediterranean diet led 
to a decreased risk in 
total cancer mortality 
(RR 0.86, 0.82–0.91). 
Additionally, there was 
a reduction in 
colorectal cancer 
incidence among those 
who adhered to this 
diet (0.91, 0.84–0.98). 
Reduced risk of 
cancer 
mortality. 
Meta-analysis was 
conducted among 
men and women. 
6/11 
Convincing 
evidence for all 
cancer-cause 
mortality with 
wholegrain 
intake, probable 
for fibre intake 
and possible for a 
‘Western diet’. 
Chen, G. C. et 
al (2016)(73) 
Systematic 
review and 
meta-analysis. 
Participants 
from Europe 
and the US.  
8 cohort 
studies. 
Wholegrain 
intake. 
An increment in 
wholegrain intake of 50 
g/d was associated with 
lower cancer mortality 
(0.82, 95% CI: 0.69–
0.96). In addition, a 
high (compared with 
low) intake of 
wholegrain yielded a 
lower risk for cancer 
mortality (0.89, 95% 
CI: 0.84–0.95). 
Reduced risk of 
cancer 
mortality. 
This study 
considered 50 g/d 
as 3 servings. 
8/11 
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Kim, Y. et al 
(2016)(65) 
Meta-
analysis. 
Participants 
from Europe 
and the US. 
3 cohort 
studies. 
Fibre intake 
and cancer 
risk. 
An increment of 10 
g/day in dietary fibre 
intake was associated 
with lower cancer 
mortality (0.94, 95% 
CI: 0.91–0.97). Highest 
vs. lowest intake of 
fibre was associated 
with a lower mortality 
risk (0.86, 0.79–0.93). 
Reduced risk of 
cancer 
mortality. 
Dietary fibre intake 
was assessed using 
FFQs. There were 
no significant 
differences by sex 
or geographical 
region. 
8/11 
Convincing 
evidence for all 
cancer-cause 
mortality with 
wholegrain 
intake, probable 
for fibre intake 
and possible for a 
‘Western diet’. 
Lippi, G. et al 
(2016)(169) 
Critical 
review. 
A wide 
range of 
countries. 
42 eligible 
meta-
analyses 
were finally 
included in 
this review.  
Meat 
consumption 
and cancer 
risk. 
The association of total 
red meat and processed 
meat with an increased 
cancer risk was 
consistent for 
colorectal and 
oesophageal cancers.  
Increased cancer 
risk. 
12 articles focused 
on colorectal and 6 
on oesophageal. 
N/A 
Liu, L. et al 
(2015)(74) 
Systematic 
review and 
meta-analysis. 
Participants 
from Europe 
and the US. 
25 cohort 
studies.  
Fibre intake 
and cancer 
risk. 
Highest vs. lowest 
intake of fibre had a 
reduced risk of cancer-
related mortality (HR 
0.83, 95% CI: 0.74–
0.91). Each 10 g/day 
increase in fibre intake 
was associated with 
lower cancer mortality 
(0.91, 95% CI: 0.88–
0.94). 
Reduced risk of 
cancer 
mortality. 
Data on fibre 
consumption were 
collected using self-
administered FFQ. 
Stratified analysis 
yielded the same 
effects in men and 
women. 
8/11 
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Makarem, N. 
et al 
(2016)(170) 
Systematic 
review.  
Participants 
from Nordic 
countries and 
the US. 
20 
longitudinal 
studies. 
Wholegrain 
intake and 
cancer risk. 
5 prospective cohort 
studies appraised the 
association between 
wholegrain intake and 
breast or endometrial 
cancer. No significant 
effect was observed in 
either cancer type. 
Additionally, 3 cohort 
studies evaluated the 
association with prostate 
cancer; of them, 2 
reported a null effect; 
and 4 out 9 studies 
reported a significant 
risk reduction of 
colorectal, upper 
aerodigestive tract or 
small intestine cancer. 
No effects for 
breast, 
endometrial or 
prostate cancer. 
Qualitative review. N/A 
Convincing 
evidence for all 
cancer-cause 
mortality with 
wholegrain 
intake, probable 
for fibre intake 
and possible for a 
‘Western diet’. 
Potter, J. et al 
(2016)(171) 
Systematic 
review.  
A wide 
range of 
countries. 
64 
longitudinal 
studies. 
Diet quality 
scores and risk 
and mortality 
from cancer. 
11 studies evaluated 
the relationship 
between incidence of 
any cancer and diet 
quality; of them, 3 
studies reported that 
better scores were 
associated with 
adherence to the lower-
risk Mediterranean diet 
and Healthy Eating 
Index (HEI). No 
consistent relationships 
between diet quality 
scores and cancer 
mortality were found. 
No effects of 
diet quality 
scores on 
cancer. 
The Mediterranean 
diet was described as 
traditional diet of 
people in the olive-
growing regions of 
the Mediterranean. 
This diet was 
characterised by a 
high intake of 
vegetables, legumes, 
fruits, nuts and 
wholegrain cereals, a 
moderate intake of 
dairy foods and fish; 
a moderate-high 
intake of 
N/A 
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monounsaturated 
lipids; a low intake of 
meat and processed 
meat products. The 
HEI is a food and 
nutrient score in 
which points are 
awarded based on 
intake from the five 
food groups (grains, 
fruit, vegetables, 
dairy, meats and 
alternatives) as well 
as an adequate intake 
of key nutrients 
(cholesterol, sodium, 
total and saturated 
fat). 
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Schwedhelm, C. 
et al (2016)(172) 
Systematic 
review and 
meta-analysis. 
A wide 
range of 
countries. 
14 cohort 
studies. 
The effects of 
adherence to 
diet-quality 
indices, 
dietary 
patterns and 
food 
consumption 
on cancer 
mortality. 
Reduced risk of overall 
mortality was observed 
for the highest vs. the 
lowest category of diet 
quality indices, 
vegetable consumption 
and fish consumption; 
the respective RR were 
0.78 (0.72–0.85), 0.86 
(0.79–0.94) and 0.85 
(0.78–0.93). On the 
other hand, a Western 
dietary pattern was 
associated with 
increased mortality 
(1.46, 1.27–1.68). 
Increased risk 
for a Western 
dietary pattern. 
Diet quality indices 
were combined 
(HEI, the WCRF/ 
AIRC dietary 
guidelines 
adherence score, 
Mediterranean diet, 
the DASH diet and 
the Recommended 
Food Score). The 
Western dietary 
pattern included a 
high intake of red 
and processed meat, 
refined grains, 
sweets and desserts, 
and high-fat dairy 
products. 
8/11 
Convincing 
evidence for all 
cancer-cause 
mortality with 
wholegrain 
intake, probable 
for fibre intake 
and possible for a 
‘Western diet’. 
Schwingshackl, 
L. et al 
(2015)(173) 
Systematic 
review and 
meta-analysis. 
Participants 
from Europe 
and the US. 
56 studies 
with a total 
of 1,784,404 
subjects. 17 
were cohort 
studies. 
Adherence to 
Mediterranean 
Diet (MD) on 
overall cancer 
incidence and 
mortality. 
In cohort studies, the 
highest adherence 
score to a MD was 
significantly associated 
with a lower risk of all-
cause cancer mortality 
(0.87, CI: 0.81–0.93), 
colorectal cancer (0.83, 
CI: 0.75–0.94) and 
liver cancer 
(0.62, CI: 0.47–0.82). 
Reduced risk of 
cancer 
mortality. 
No association was 
observed for 
oesophageal, 
ovarian, 
endometrial, and 
bladder cancer. 
When conducting 
stratified analyses, 
estimates from 
case-control studies 
were slightly lower 
than cohort studies. 
Stratified analysis 
by sex did not 
differ. 
10/11 
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Wang, X. et al 
(2016)(174) 
Meta-
analysis. 
A wide 
range of 
countries. 
17 cohort 
studies. 
Dose–
response 
relationship 
between red 
and processed 
meat 
consumption 
and cancer 
mortality. 
The relative risk of 
cancer mortality with 
an increase of one 
serving per day of 
processed meat was 
1.08 (95% CI: 1.06–
1.11). Red meat was 
not associated with 
cancer mortality. 
Increased risk of 
cancer mortality 
with processed 
meat. 
The serving size in 
this study was 
standardised as 100 
g (3.5 oz) for total 
and red meat and 50 
g (1.8 oz) for 
processed meat. 
Red and processed 
meat intake was 
measured by FFQ 
in all studies. 
9/11 
Convincing 
evidence for all 
cancer-cause 
mortality with 
wholegrain 
intake, probable 
for fibre intake 
and possible for a 
‘Western diet’. 
Wang, X. et al 
(2014)(175) 
Meta-
analysis. 
Participants 
from Europe, 
the US and 
Asia. 
16 cohort 
studies with 
a total of 
833,234 
participants. 
Dose–
response 
relationship 
between fruit 
and vegetable 
consumption 
and risk of 
cancer 
mortality. 
No association of fruit 
and vegetable 
consumption with 
cancer mortality was 
observed. 
No effect on 
cancer 
mortality. 
A serving size was 
defined as 77 g for 
vegetables and 80 g 
for fruit. 
9/11 
Aune, D. 
(2017)(176) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
28 cohort 
studies. 
Dose–
response 
relationship 
between fruit 
and vegetable 
consumption 
and risk of 
cancer 
mortality. 
A 200 g/day increment 
in fruit and vegetables 
was associated with a 
lower risk of cancer 
mortality (0.97, 95% 
CI: 0.95–0.99). Results 
for the consumption of 
fruit alone or 
vegetables were similar 
to the combined 
analysis. 
Reduced risk of 
cancer 
mortality. 
A serving size was 
defined as 80 g for 
fruit and vegetable 
intake. 
8/11 
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 Wei, H. et al 
(2016)(70) 
Meta-
analysis. 
Participants 
from Europe 
and the US.  
11 cohort 
studies with 
a total of 
816,599 
subjects. 
Wholegrain 
consumption 
and risk of 
cancer 
mortality. 
The highest 
consumption of 
wholegrain (compared 
with the lowest) was 
associated with lower 
cancer mortality (0.89, 
95% CI: 0.82–0.96). 
Additionally, each 3 
servings/d increment in 
wholegrain 
consumption reduced 
risk by 0.91 (95% CI: 
0.84–0.98).  
Reduced risk of 
cancer 
mortality. 
The dose–response 
relationship was 
assessed by 3 
servings/d 
increments. 
9/11 Convincing 
evidence for all 
cancer-cause 
mortality with 
wholegrain 
intake, probable 
for fibre intake 
and possible for a 
‘Western diet’. 
Bladder 
Vieira, A. R. 
et al (2015)(63) 
Systematic 
review and 
meta-analysis. 
Participants 
from Europe, 
the US and 
Asia. 
15 cohort 
studies 
fulfilled the 
inclusion 
criteria. 
Dose–
response 
relationship 
between fruit 
and vegetables 
and incidence 
or mortality 
from bladder 
cancer. 
Summary RRs for an 
increase of 1 
serving/day (80 g) were 
0.97 (95% CI: 0.95–
0.99) for fruits and 
vegetables combined, 
0.97 (95% CI: 0.94–
1.00) for vegetables 
and 0.98 (95% CI: 
0.96–1.00) for fruits. 
Reduced risk.  Results were 
similar among men 
and women. 
7/11 Probable evidence 
for cancer 
incidence and 
possible evidence 
for mortality with 
fruit and 
vegetable. 
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Wang, C. et al 
(2012)(177) 
Meta-
analysis. 
Participants 
from Europe, 
the US, 
Canada, 
Uruguay and 
Japan. 
21 studies; 
10 were 
cohort 
studies. 
Relationship 
between meat 
and bladder 
cancer risk. 
The highest 
consumption of red 
meat (compared with 
the lowest) was 
associated with 
increased cancer risk 
(1.17, 95% CI: 1.02–
1.34). Additionally, 
higher consumption of 
processed meat was 
associated with cancer 
risk (1.10, 95% CI: 
1.00–1.21).  
Increased risk. No evidence of 
heterogeneity was 
reported. 
4/11 
Probable evidence 
for cancer 
incidence and 
possible evidence 
for mortality with 
fruit and 
vegetable. 
Xu, C et al 
(2015)(178) 
Meta-
analysis. 
Participants 
from Europe, 
the US and 
Japan. 
14 cohort 
studies. 
Relationship 
between fruit 
and vegetables 
and bladder 
cancer risk. 
No association of fruit 
and vegetable 
consumption with 
cancer incidence was 
observed. 
Null effect. A serving size was 
assumed as 68.1 g 
for vegetables or 
127.3 g for fruits or 
97.7 g for fruit and 
vegetables 
combined. 
9/11 
Yao, Baodong 
et al 
(2014)(179) 
Meta-
analysis. 
Participants 
from Europe, 
the US and 
Asia. 
31 
studies;10 
were cohort 
studies; the 
total sample 
involved 
1,121,649 
participants. 
Relationship 
between fruit 
and vegetables 
and bladder 
cancer risk. 
A reduction in bladder 
cancer was observed 
for the highest vs. 
lowest intake of total 
fruit and vegetables 
(0.83, 0.69–0.99); it 
was 0.81 (0.70–0.93) 
for total vegetables and 
0.77 (0.69–0.87) for 
total fruit. 
Reduced risk.  A serving size was 
defined as 80 g for 
fruit and vegetable 
intake. In stratified 
analysis, results 
were not significant 
in cohort studies. 
7/11 
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Breast 
Albuquerque, 
R. C. et al 
(2014)(180) 
Systematic 
review.  
A wide 
range of 
countries. 
10 cohort 
studies out 
of 24 
studies.  
Western diet 
and breast 
cancer risk. 
A total of 24 studies 
(10 cohort studies and 
14 case-control studies) 
appraised a Western 
dietary pattern in terms 
of cancer risk. Of 
these, 8 studies showed 
a positive association 
with cancer, 1 study 
reported an inverse 
association and 15 did 
not find any 
association. 
Null effect. Western diet was 
defined as: a diet 
favouring red and 
processed meats, 
refined grains, 
potatoes and 
starches, snacks, 
sweets, fried foods 
and soft drinks. 
N/A 
Probable evidence 
for cancer 
incidence with 
fibre, fruit and red 
meat intake and 
possible with 
processed meat 
and vegetable 
intake. 
Aune, D. et al 
(2012)(68) 
Systematic 
review and 
meta-analysis. 
Participants 
from Europe, 
the US, 
Canada and 
China. 
16 cohort 
studies.  
Dietary fibre 
and cancer 
risk. 
The summary RR for 
the highest vs. the 
lowest intake of fibre 
was 0.93 (95% CI: 
0.89–0.98). 
Additionally, a 10 
g/day increment in 
dietary fibre was 
associated with a 
reduced risk of cancer 
(0.95, 95% CI: 0.91–
0.98). 
Reduced risk.  For specific 
domains of fibre 
(fruit, vegetables, 
soluble or insoluble 
or cereal) results 
were not 
significant. 
6/11 
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Aune, D. et al 
(2012)(67) 
Systematic 
review and 
meta-analysis. 
Participants 
from Europe, 
the US and 
Asia. 
15 studies; 
14 were 
cohort 
studies. 
Fruit and 
vegetable 
intake and 
cancer risk. 
The summary risk for 
the highest vs. the 
lowest intake was 0.89 
(95% CI: 0.80–0.99) 
for fruit and vegetables 
combined. In dose–
response analyses, a 
200 g/day increase in 
fruit and vegetables 
was associated with 
lower risk (0.96, 95% 
CI: 0.93–1.00). 
Reduced risk.  80 g was estimated 
to be a serving size. 
In stratified analysis 
for fruit or 
vegetables, RRs for 
fruit only were 
significant. 
6/11 
Probable evidence 
for cancer 
incidence with 
fibre, fruit and red 
meat intake and 
possible with 
processed meat 
and vegetable 
intake. 
Guo, J. et al 
(2015)(69) 
Meta-
analysis. 
Mostly 
participants 
from Europe 
and the US. 
14 
prospective 
studies. 
Relationship 
between red 
and processed 
meat and 
cancer risk. 
Summary RRs of 
breast cancer for the 
highest vs. the lowest 
categories were 1.10 
(1.02–1.19) for red 
meat and 1.08 (1.01–
1.15) for processed 
meat.  
Increased cancer 
risk. 
An increase of 120 
g/day of red meat or 
50 g/day of 
processed meat was 
associated with 
higher breast cancer 
risk: 1.11 (1.05–
1.16) and 1.09 
(1.03–1.16) 
respectively.  
6/11 
Peng, C. et al 
(2017)(181) 
Meta-
analysis. 
Most of the 
studies were 
conducted in 
the US. 
12 cohort 
studies. 
Fruit and 
vegetable 
intake and 
cancer 
mortality. 
No associations 
between fruit and/or 
vegetable intake and 
breast cancer 
prognosis. 
Null effect. Most studies used a 
validated FFQ to 
assess the 
consumption of 
fruit and 
vegetables. 
9/11 
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Van den 
Brandt, P. A. 
et al 
(2017)(182) 
Meta-
analysis. 
Participants 
from Europe 
and the US.  
5 cohort 
studies.  
Mediterranean 
diet and cancer 
risk. 
No association between 
adherence to the 
Mediterranean diet and 
postmenopausal breast 
cancer risk. 
Null effect. There was no 
evidence of 
between-study 
heterogeneity. 
4/11 
Probable evidence 
for cancer 
incidence with 
fibre, fruit and red 
meat intake and 
possible with 
processed meat 
and vegetable 
intake. 
Brennan, S. F. 
et al 
(2017)(183) 
Systematic 
reviews and 
meta-analysis. 
Participants 
from North 
America, 
Denmark, 
Belgium and 
Australia. 
15 
prospective 
cohort 
studies.  
Association 
between 
dietary fat and 
breast cancer 
mortality. 
Women with the 
highest vs. the lowest 
category of saturated 
fat intake had higher 
breast cancer–specific 
mortality (1.51, 1.09–
2.09). 
Increased risk. Total fat was not 
associated with 
cancer-specific 
mortality. 
7/11 
Cao, Y. et al 
(2016)(120) 
Meta-
analysis. 
Participants 
from the US, 
Europe, 
China and 
Japan. 
32 
prospective 
cohort 
studies.  
Association 
between 
dietary fat and 
breast cancer 
risk. 
Highest vs. lowest 
levels of dietary 
saturated, 
monounsaturated or 
polyunsaturated fat 
were not associated 
with the risk of breast 
cancer.  
Null. Most dietary 
assessments were 
self-administered 
FFQs. 
8/11 
Xia, H. et al 
(2015)(184) 
Meta-
analysis. 
A wide 
range of 
countries. 
52 studies; 
24 were 
cohort 
studies. The 
total number 
of 
participants 
was 
1,786,537.  
Association 
between 
dietary fat and 
breast cancer 
risk. 
No association was 
observed for pooled 
analysis of cohort 
studies. 
Null.   8/11 
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Colorectal  
Alexander, D. 
D. et al 
(2015)(117) 
Systematic 
review and 
meta-analysis. 
Participants 
from the US, 
Asia, Europe 
and Australia. 
27 cohort 
studies. 
Relationship 
between red 
and processed 
meat and 
cancer risk. 
Comparing the highest 
vs the lowest category 
of meat consumption 
(red and processed) 
showed an association 
with colorectal cancer 
risk (1.11, 1.03–1.19). 
Increased risk. Summary 
associations were 
markedly reduced 
and not statistically 
significant when 
red meat only was 
evaluated. 
7/11 
Probable evidence 
for cancer 
incidence with 
dairy intake and 
possible with 
fruit, vegetable 
and processed 
meat. 
Aune, D. et al 
(2012)(64) 
Systematic 
review and 
meta-analysis. 
Participants 
from Europe, 
the US and 
Asia. 
12 cohorts 
with a total 
of 1,170,942 
participants. 
Dairy products 
and colorectal 
cancer risk. 
Summary RR was 0.83 
(95% CI: 0.78–0.88) 
per 400 g/day of total 
dairy products. 
Additionally, 
comparing high intake 
vs. low yielded lower 
risk estimates (0.81, 
95% CI: 0.74–0.90). 
Reduced risk.  Stratified analysis 
showed the 
association with 
colon cancer is 
significant and 
insignificant for 
rectal cancer. No 
differences were 
found by sex. 
6/11 
Magalhaes, B. 
et al (2012)(185) 
Systematic 
review and 
meta-analysis. 
A wide 
range of 
countries. 
16 studies; 8 
were cohort 
studies. 
Dietary 
patterns and 
CRC risks. 
CRC risk was lower 
among subjects with a 
‘healthy’ dietary 
pattern (0.83, 95% CI: 
0.73–0.94) and higher 
among those with a 
Western pattern (1.19, 
95% CI: 1.04–1.37).  
Reduced risk 
with a ‘healthy’ 
dietary pattern. 
Studies quantified 
the association 
between CRC and 
dietary patterns 
(defined a 
posteriori). Healthy 
diet was defined as a 
pattern that tended to 
have high loadings 
of foods such as 
fruit, vegetables, 
poultry, fish, low-fat 
dairy and 
wholegrains. 
6/11 
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Stratified analyses 
were significant for 
colon cancer only  
Shi, Y. et al 
(2015)(186) 
Meta-
analysis. 
Participants 
from the US, 
Japan, Europe 
and Australia. 
16 cohort 
studies were 
included in 
cancer 
incidence 
and 4 in 
mortality. 
Poultry intake 
and cancer 
risk. 
An increase in poultry 
intake of 50 g/day was 
associated with lower 
cancer incidence 0.89 
(95% CI: 0.81–0.97). 
No association was 
observed for cancer 
mortality. In stratified 
analysis by sex, the 
effect was only 
significant in women.  
Reduced risk of 
cancer 
incidence. 
Similar risks were 
detected for colon 
and rectal cancers. 
Poultry intake was 
collected by self-
administered FFQ 
in most studies. 
4/11 
Probable evidence 
for cancer 
incidence with 
dairy intake and 
possible with 
fruit, vegetable 
and processed 
meat. 
Yu, X. F. et al 
(2014)(187) 
Meta-
analysis. 
Participants 
from the US, 
Japan, China, 
Europe and 
Australia. 
27 cohort 
studies with 
2,325,040 
subjects. 
Fish intake 
and gastro-
intestinal 
cancer risk.  
High fish consumption 
vs. low or non-
consumption was 
inversely associated 
with colorectal (0.93, 
0.87–0.99), colon 
(0.95, 0.91–0.98), 
rectal (0.85, 0.75–
0.95), oesophageal 
(0.91, 0.83–0.99) and 
hepatocellular (0.71, 
0.48–0.95) cancers. 
Reduced risks. No association was 
observed for 
pancreatic cancer. 
7/11 
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Zhu, B. el al 
(2014)(188) 
Meta-
analysis. 
Participants 
from Europe, 
the US and 
Asia. 
14 cohort 
studies with 
1,903,459 
participants. 
Dietary 
patterns and 
CRC risks. 
Higher legume 
consumption was 
associated with a 
decreased risk of CRC 
(0.91, 95% CI: 0.84–
0.98). 
Reduced risk.  FFQ was used for 
dietary assessment. 
7/11 
Oesophageal 
Choi, Y. et al 
(2013)(118) 
Meta-
analysis. 
Mostly 
participants 
from Europe, 
Asia and the 
US. 
27 studies; 3 
were cohort 
studies. The 
total 
population 
recruited 
among the 
cohort 
studies was 
1,149,981 
participants. 
Consumption 
of red and 
processed 
meat and 
oesophageal 
cancer risk. 
The combined RR of 
cohort studies 
comparing the highest 
and lowest categories 
was 1.26 (1.00–1.59) 
for red meat and 1.25 
(0.83–1.86) for 
processed meat. 
Increased risk 
for red meat 
consumption. 
Higher risk 
estimates were 
observed for case-
control studies. 
Effects estimates 
did not differ by 
sex. 
8/11 
Possible evidence 
for cancer 
incidence with 
fruit and 
processed meat. Han, Y. J. et al 
(2013)(189) 
Systematic 
review and 
meta-analysis. 
A wide 
range of 
countries. 
24 studies; 3 
were cohort 
studies. 
Fish 
consumption 
and risk of 
oesophageal 
cancer. 
The combined RR of 
cohort studies 
comparing the highest 
and lowest categories 
was 0.87 (0.60–1.27) 
for fish consumption. 
Null effect. No significant 
effect was observed 
in stratified analysis 
by cancer type. 
6/11 
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Jiang, G. et al 
(2016)(190) 
Meta-
analysis. 
A wide 
range of 
countries. 
20 studies; 3 
were cohort 
studies. 
Fish and 
poultry 
consumption 
and risk of 
oesophageal 
cancer. 
The combined RR of 
cohort studies 
comparing the highest 
and lowest categories 
of fish or poultry 
consumption showed 
no association with 
oesophageal risk. 
Null effect. Analysis by 
histological 
subtypes showed 
that individuals 
with the highest 
fish intake had a 
reduced risk of 
oesophageal 
squamous cell 
carcinoma. 0.73 
(0.58–0.92). 
7/11 
Salehi, M. et 
al (2013)(191) 
Systematic 
review and 
meta-analysis. 
Participants 
from Europe, 
the US and 
China. 
35 studies; 4 
were cohort 
studies. 
Meat and fish 
consumption 
and risk of 
oesophageal 
cancer.  
The combined RR of 
cohort studies 
comparing the highest 
and lowest categories 
of red meat 
consumption showed 
an association with 
increased risk of 
oesophageal cancer 
(1.32, 1.03–1.71). 
Conversely, 
consumption of white 
meat and fish was 
associated with lower 
risk; the respective RRs 
were 0.80 (0.63–1.00) 
and 0.59 (0.36–0.97). 
Increased risk. No association was 
observed with 
processed meat or 
total meat in cohort 
studies. 
8/11 
Possible evidence 
for cancer 
incidence with 
fruit and 
processed meat. 
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Zhu, H. C. et 
al (2014)(192) 
Systematic 
review and 
meta-analysis. 
Mostly 
participants 
from Europe, 
the US and 
China. 
35 studies; 7 
were cohort 
studies. 
Association 
between 
different types 
of meat and 
oesophageal 
cancer risk. 
The combined RRs of 
cohort studies 
comparing the highest 
and lowest categories 
of consumption of red 
and processed meat or 
poultry were not 
associated with 
oesophageal cancer. 
Null effect. Increased 
association was 
observed when 
pooling results from 
cohort and case-
control studies. 
8/11 
Kidney 
Bai, H. W. et 
al (2013)(193) 
Meta-
analysis. 
Participants 
from Nordic 
countries and 
the US. 
15 studies; 3 
were cohort 
studies. 
Fish 
consumption 
and risk of 
renal cancer. 
There was no 
significant association 
between fish 
consumption and risk 
of renal cancer. 
Null effect. The cohort studies 
were of high 
quality, using the 
Newcastle Ottawa 
Scale. 
9/11 Weak. 
Liver 
Yang, Y. et al 
(2014)(194) 
Meta-
analysis. 
Participants 
from Japan, 
the US and 
China. 
19 studies; 
10 were 
cohort 
studies. 
Vegetable and 
fruit intake 
and 
hepatocellular 
carcinoma 
(HCC) risk; 
(this is the 
most common 
type of liver 
cancer). 
The combined RR of 
cohort studies 
comparing the highest 
and lowest categories 
of vegetable intake was 
associated with HCC 
(0.66, 95% CI: 0.51–
0.86). Dose–response 
analysis showed that 
per 100 g/d increase in 
vegetable intake HCC 
risk was 0.92 (95% CI: 
0.88–0.96). 
Reduced risk.  No effect was 
observed with fruit 
intake. 
9/11 Weak 
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Lung 
Song, J. et al 
(2014)(195) 
Systematic 
review and 
meta-analysis. 
Participants 
from Europe, 
the US and 
Japan. 
20 studies; 3 
were cohort 
studies. 
Fish 
consumption 
and risk of 
lung cancer. 
The combined RR of 
cohort studies was 0.95 
(95% CI: 0.73–1.24) 
for highest vs. lowest 
category of fish intake. 
Null effect. Substantial 
heterogeneity 
among cohort and 
case-control 
studies. 
7/11 
 
Sun, Y. et al 
(2016)(196) 
Systematic 
review and 
meta-analysis. 
Participants 
from Europe 
and the US. 
8 studies; 4 
were cohort 
studies.  
Dietary 
patterns and 
lung cancer 
risk. 
Comparing the highest 
and lowest categories 
of healthy dietary 
patterns was associated 
with lower lung cancer 
risk; the combined RR 
of cohort studies was 
0.73 (95% CI: 0.61–
0.87). 
Reduced risk.  No heterogeneity 
between studies 
was reported. A 
healthy dietary 
pattern was 
characterised in 
most of the 
analysed studies as 
a high intake of 
vegetables and 
fruits, wholegrains, 
legumes, lean meats 
and fish, with low 
consumption of red 
and processed meat, 
and low-fat dairy. 
9/11 
Probable evidence 
for cancer 
incidence and 
possible for 
cancer mortality 
with fruit and 
vegetable intake. Vieira, A. R. 
et al (2016)(61) 
Systematic 
review and 
meta-analysis. 
A wide 
range of 
countries. 
29 cohort 
studies. 
Association 
between fruit 
and vegetables 
and lung 
cancer risk. 
Comparing the highest 
and lowest categories 
of vegetable and fruit 
intake was associated 
with a lower risk of 
lung cancer (0.86, 95% 
CI: 0.78–0.94). 
Additionally, per 100 
g/ day, the risk of lung 
cancer was 0.96 (95% 
CI: 0.94–0.98). 
Reduced risk.  Risks were similar 
for individual 
effects of 
vegetables or fruit. 
6/11 
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Wang, Y. et al 
(2015)(62) 
Meta-
analysis. 
Participants 
from the US, 
Japan, China 
and Europe.  
20 cohort 
studies. 
Association 
between fruit 
and vegetables 
and lung 
cancer risk. 
The highest vs. the 
lowest level of fruit 
and vegetable 
consumption was 
inversely associated 
with the risk of lung 
cancer (0.87, 0.79–
0.95). Stratified 
analysis by outcome 
(incidence or mortality) 
yielded the same 
results for fruit 
consumption (0.84, 
0.76–0.93). 
Reduced risk. Association of 
vegetable 
consumption was 
not significant for 
mortality. In dose–
response analysis, 
the risk of lung 
cancer did not 
decrease further 
after 2 servings 
/day of fruit. 
8/11 
Probable evidence 
for cancer 
incidence and 
possible for 
cancer mortality 
with fruit and 
vegetable intake. 
Yang, W. S. et 
al (2012)(197) 
Systematic 
review and 
meta-analysis. 
Participants 
from Europe, 
the US and 
Japan. 
34 studies; 
11 were 
cohort 
studies. 
Association 
between 
different types 
of meat and 
lung cancer 
risk. 
The combined RRs of 
cohort studies 
comparing the highest 
vs. the lowest category 
of ‘total meat’ or red 
meat intake were 
associated with lung 
cancer. The respective 
risks were 1.30 (95% 
CI: 1.05–1.60) and 
1.20 (95% CI: 1.10–
1.30). No effects were 
observed for other 
types of meats. 
Increased risk. All studies used 
FFQs for the 
assessment of meat 
consumption. Total 
meat was defined as 
consumption of any 
meat. 
9/11 
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Ovarian 
Crane, T. E. et 
al (2014)(198)  
Systematic 
review.  
Participants 
from Europe, 
the US and 
Canada. 
10 cohort 
studies. 
Association 
between 
different 
components of 
diet and 
ovarian cancer 
risk. 
Total fat was evaluated 
in 2 studies; 1 found an 
increased risk while the 
other did not find an 
effect. Total dairy was 
appraised in 4 studies; 
3 found a significant 
increased risk, which 
fluctuated between 
53% and 200%. 
Increased risk 
for a high intake 
of dairy 
products. 
Vegetable, fruit and 
red meat 
consumption had 
null effects on 
cancer risks. 
N/A 
Weak.  
Jiang, P. Y. et 
al (2014)(199) 
Meta-
analysis. 
Participants 
from Europe 
and the US. 
15 studies; 5 
were cohort 
studies. 
Fish 
consumption 
and risk of 
ovarian cancer. 
Fish consumption did 
not significantly affect 
the risk of ovarian 
cancer in cohort 
studies. 
Null effect. FFQ was used for 
dietary assessment. 
9/11 
Hou, R. et al 
(2015)(200) 
Meta-
analysis. 
Participants 
from North 
America, 
Europe, 
China and 
Australia. 
20 studies; 6 
were cohort 
studies. 
Association 
between 
dietary fat 
intake and 
ovarian cancer 
risk. 
No association was 
observed for intake of 
dietary fat and cancer 
risk. 
Null. Total dietary fat 
was associated with 
increased risk in 
cohort studies 
(1.12, 1.00–1.25). 
8/11 
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Pancreatic 
Alsamarrai, A. 
et al 
(2014)(115)  
Systematic 
review and 
meta-analysis. 
Mostly from 
Sweden, the 
US and 
Japan. 
26 
prospective 
studies with a 
total 
population of 
2,848,968. 
Association 
between fruit 
and vegetable 
intake and 
pancreatic 
cancer risk. 
The highest vs. the 
lowest levels of fruit 
were inversely 
associated with 
pancreatic cancer risk; 
the effect estimate was 
0.65, 95% CI: 0.52–
0.82). No significant 
association was 
observed for 
vegetables. 
Reduced risk. The reference 
groups for 
fruit and vegetable 
consumption were 
the lowest quantile 
category for each 
factor, and the 
exposed groups 
were the remaining 
quantiles. 
9/11 
Possible evidence 
for cancer 
incidence with 
fruit and 
processed meat. 
Larsson, S. C. 
et al 
(2012)(201) 
Meta-
analysis. 
Participants 
from Europe, 
the US and 
Japan. 
11 cohort 
studies. 
Consumption 
of red and 
processed 
meat and 
pancreatic 
cancer risk. 
An increase of 50 g per 
day in consumption of 
processed meat was 
associated with 
increased risk (1.19, 
95% CI: 1.04–1.36). 
Increased risk 
for processed 
meat. 
Cancer risk was not 
associated with red 
meat intake. 
However, stratified 
analysis by sex 
found an increased 
risk in men (1.29, 
95% CI: 1.08–
1.53). 
6/11 
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Lu, P. Y. et al 
(2017)(122) 
Meta-
analysis. 
Participants 
from the US, 
Japan, China 
and Europe.  
32 studies; 
18 were 
cohort 
studies. 
Dietary 
patterns and 
pancreatic 
cancer risk. 
The highest vs. the 
lowest category of a 
healthy dietary pattern 
was associated with a 
lower risk of cancer 
(0.85, 95% CI: 0.77–
0.95). On the other 
hand, a Western dietary 
pattern was associated 
with increased risk 
(1.24, 95% CI: (1.06–
1.45). In sensitivity 
analysis, dietary 
patterns in cohort 
studies were not 
associated with cancer 
risk. 
Increased risk 
with an 
unhealthy 
dietary pattern. 
Factor analysis was 
used to identify 
dietary patterns. A 
healthy pattern was 
described as high 
loadings of foods 
such as vegetables, 
fruits, wholegrains, 
olive oil, fish, soy, 
poultry and low-fat 
dairy. The Western 
pattern was 
characterised as high 
consumption of red 
and/or processed 
meat, refined grains, 
sweets, high‐fat 
dairy products, 
butter and potatoes, 
and a low intake of 
fruit and vegetables. 
9/11 Possible evidence 
for cancer 
incidence with 
fruit and 
processed meat. 
Wu, Q. J. et al 
(2016)(202) 
Meta-
analysis. 
Participants 
from Europe, 
the US and 
Japan. 
23 studies; 9 
were cohort 
studies. 
Association 
between fruit 
and vegetable 
intake and 
pancreatic 
cancer risk. 
The combined RRs of 
cohort studies 
comparing the highest 
vs. lowest category of 
vegetable intake was 
associated with a lower 
risk of pancreatic 
cancer (0.89, 0.80–
1.00). No association 
was found in the 
summary RR of cohort 
studies of fruit intake 
and cancer. 
Reduced risk. Results varied by 
study design; 
effects were 
stronger in case-
control studies. 
9/11 
Possible evidence 
for cancer 
incidence with 
fruit and 
processed meat. 
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Zhao, Z. et al 
(2017)(203) 
Systematic 
review and 
meta-analysis. 
A wide 
range of 
countries. 
28 studies; 
16 were 
cohort 
studies. 
Association 
between red 
and processed 
meat and 
pancreatic 
cancer 
incidence. 
No association was 
observed with red meat 
or processed meat. 
Null effect. Stratified analysis 
showed risk was 
significantly higher 
in men for red meat 
than for women 
(1.21, 95% CI: 
1.07–1.37). 
8/11 
Yao, X. et al 
(2015)(204) 
Meta-
analysis. 
Participants 
from North 
America, 
Australia and 
Europe. 
20 studies;7 
were cohort 
studies.  
Association 
between 
dietary fat 
intake and 
pancreatic 
cancer risk. 
No association was 
observed for the 
highest intake vs. the 
lowest intake of 
saturated fat.  
Null.   8/11 
Prostate 
Markozannes, 
G. (2016)(147) 
Umbrella 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
113 meta-
analysis. 
Association 
between 
vegetable 
intake and 
prostate 
cancer risk. 
An increase of 100 g/d 
of vegetables was 
associated with 
reduced prostate cancer 
(0.99, 95% CI: 0.98–
1.00). 
Null effect. This umbrella 
review ranked the 
evidence based on 
p-values. 
N/A 
Possible evidence 
for cancer 
incidence with 
vegetable and 
processed meat. 
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 Aune, D. et al 
(2015)(205) 
Systematic 
review and 
meta-analysis. 
Participants 
from the US, 
Japan, 
Singapore, 
Europe and 
Australia. 
32 
prospective 
studies. 
Association 
between 
intake of dairy 
products and 
prostate 
cancer 
incidence or 
mortality. 
The highest vs. the 
lowest intake of dairy 
products was 
associated with higher 
risk (1.09, 95% CI: 
1.02–1.17). In the 
dose–response 
analysis, the summary 
RR was 1.07 (95% CI: 
1.02–1.12) per 400 g/d 
increments. In stratified 
analysis, higher intake 
was only significant in 
non-advanced prostate 
cancer. 
Increased risk. Analysis of 
advanced prostate 
cancer included 
studies that reported 
high-stage, high-
grade, non-localised 
and advanced 
cancers. 
7/11 
Bylsma, L. C. 
et al 
(2015)(119) 
Systematic 
review and 
meta-analysis. 
Participants 
from Europe, 
the US, 
Canada and 
Japan. 
19 cohort 
studies. 
Consumption 
of red and 
processed 
meat and 
prostate 
cancer risk. 
The highest vs. the 
lowest intake of 
processed meat was 
associated with 
increased risk (1.05, 
95% CI: 1.01–1.10). 
No association was 
observed for red meat. 
Increased risk. No evidence of a 
dose–response 
relationship was 
observed for 
incremental intake 
levels of processed 
meat. 
6/11 
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Fabiani, R. et 
al (2016)(206)  
Systematic 
review and 
meta-analysis. 
Participants 
from the US 
and Australia. 
12 studies; 3 
were cohort 
studies. 
Dietary 
patterns and 
prostate 
cancer risk. 
Three dietary patterns 
were identified: 
healthy, Western and 
carbohydrate. None of 
them was associated in 
the combined RR with 
cancer risk. 
Null effect. Dietary patterns 
were defined a 
posteriori. A 
Western pattern was 
characterised by a 
high loading of red 
meat, processed 
meat, eggs and 
sweets; the healthy 
pattern by a high 
loading of 
vegetables and fruit, 
poultry, fish and 
wholegrains; and the 
carbohydrate pattern 
by a high loading of 
bread, pasta and rice. 
8/11 
Possible evidence 
for cancer 
incidence with 
vegetable and 
processed meat. 
Meng, H. et al 
(2014)(207) 
Meta-
analysis. 
Participants 
from the US, 
Japan, Europe 
and Australia. 
16 cohort 
studies. 
Association 
between fruit 
and vegetable 
intake and 
prostate 
cancer 
incidence. 
The highest vs. the 
lowest consumption 
showed no association 
between vegetable and 
fruit consumption and 
prostate cancer 
incidence. 
Null effect. Relationships 
between prostate 
cancer and 
vegetable and fruit 
consumption were 
consistent in all 
geographical areas. 
7/11 
Sheng, T. et al 
(2015)(208) 
Meta-
analysis. 
Participants 
from Europe, 
the US and 
Japan. 
17 studies; 5 
were cohort 
studies. 
Association 
between 
dietary fibre 
consumption 
and prostate 
cancer 
incidence. 
The highest vs. the 
lowest intake of dietary 
fibre showed no 
association with 
prostate cancer 
incidence. 
Null effect. In stratified 
analyses, results 
were consistent by 
region. 
9/11 
Possible evidence 
for cancer 
incidence with 
vegetable and 
processed meat. 
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Xu, C. et al 
(2015)(209) 
Systematic 
review and 
meta-analysis. 
Participants 
from North 
America and 
Europe. 
14 cohort 
studies. 
Association 
between 
dietary fat 
intake and 
prostate 
cancer risk. 
No association was 
detected for saturated 
fat intake and cancer 
risk. 
Null.   9/11 
Non-Hodgkin Lymphoma (NHL) 
Wang J. et al 
(2016)(210) 
Meta-
analysis. 
Participants 
from Europe 
and the US.  
16 studies; 3 
were cohort 
studies. 
Association 
between total 
dairy product 
consumption 
and NHL 
incidence. 
The combined RRs of 
cohort studies 
comparing the highest 
vs. the lowest category 
of total dairy product 
intake showed no 
association with risk of 
NHL (1.02, 95% CI: 
0.88–1.17).  
Null effect. In stratified 
analyses, a positive 
association between 
total dairy 
consumption and 
NHL risk was 
found only in case-
control studies. 
8/11 Weak. 
Uterine 
Zhao, J. et al 
(2016)(211) 
Meta-
analysis. 
Participants 
from North 
America, 
Europe and 
China. 
21 studies; 7 
were cohort 
studies. 
Association 
between 
dietary fat 
intake and 
uterine cancer 
risk. 
No association was 
observed for the 
highest intake vs. the 
lowest intake of 
saturated fat in the 
cohort studies. 
Null. No association was 
detected for the 
pooled analysis 
(case-control and 
cohort studies). 
7/11 Weak. 
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Grey literature 
World Cancer 
Research Fund 
International 
Systematic 
Literature 
Review 
(2017)(29)  
Breast cancer: Patterns of diet:  Associations 
between 
different 
patterns and 
macro 
components of 
diet and 
cancer risk. 
The highest vs. the 
lowest score of a 
Mediterranean diet 
assessed in eight 
studies showed 
inconsistent and non-
significant 
associations. 
Additionally, 2 out of 8 
studies on dietary score 
showed a significant 
reduced risk of breast 
cancer. 
Null. Risk did not differ 
for premenopausal 
or postmenopausal 
cancers. 
N/A   
Fruit and vegetables No significant 
association was 
detected for high vs. 
low intake of 
vegetables and cancer 
risk; on the other hand, 
fruit consumption was 
associated with a lower 
risk of any cancer and 
postmenopausal 
cancer; the respective 
RRs were 0.94 (0.90–
0.98) and 0.92 (0.87–
0.98). 
Reduced risk 
with fruit 
consumption. 
Vegetable 
consumption was 
statistically 
associated with a 
lower risk of 
oestrogen receptor 
negative (ER−) 
breast cancer (0.82, 
95% CI: 0.74–
0.90). 
N/A   
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Red and processed meat Red meat was 
associated with 
increased risk of any 
cancer (1.12, 1.01–
1.24); no association 
was observed for 
processed meat. 
Increased cancer 
risk. 
In stratified 
analyses by 
menopausal status, 
effects became 
insignificant. 
N/A   
Dairy products A 200 g/day increment 
in dairy products was 
associated with a lower 
risk of cancer (0.96, 
95% CI: 0.94–0.99). 
Decreased risk. In stratified 
analyses by 
menopausal status, 
effects were 
significant only for 
premenopausal 
breast cancer. 
N/A   
Fibre intake A 10 g/d increase in 
fibre intake was 
associated with a lower 
risk of any breast 
cancer (0.95, 95% CI: 
0.93–0.98). 
Decreased risk. In stratified 
analyses by 
menopausal status, 
effects were 
significant only for 
postmenopausal 
breast cancer. 
N/A   
Saturated fat A 10g/day increase in 
saturated fat was 
associated with risk of 
any cancer (1.04, 1.01–
1.07). 
Increased risk. No association was 
observed for pre- or 
postmenopausal 
cancer in stratified 
analysis. 
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World Cancer 
Research Fund 
International 
Systematic 
Literature 
Review 
(2015)(116)  
Oesophageal cancer: Fruit and vegetables  Associations 
between 
different 
patterns and 
macro 
components of 
diet and 
cancer risk. 
A 100 g/day increment 
in fruit was associated 
with a lower risk of 
cancer (0.94, 0.89–
1.00). 
Null. No association was 
observed for 
vegetable 
consumption. In 
stratified analysis 
by histological 
type, risks were 
only reduced in 
squamous cell 
carcinoma. 
N/A   
Red and processed meat A 50 g/day increase in 
processed meat was 
associated with 
increased risk of cancer 
(1.39, 1.09–1.77). 
Increased cancer 
risk. 
In stratified analysis 
by histological type, 
risk was only 
significant for 
squamous cell 
carcinoma. 
N/A   
World Cancer 
Research Fund 
International 
Systematic 
Literature 
Review 
(2017)(20)  
Colorectal cancer (CRC): Patterns of diet  Associations 
between 
different 
patterns and 
macro 
components of 
diet and 
cancer risk. 
Mediterranean diet was 
assessed in 5 studies; 
inverse but not 
significant associations 
were observed in most 
studies. 
Null.   N/A   
Wholegrain A 90 g/d increase in 
wholegrain intake was 
associated with lower 
risk (0.83, 95% CI: 
0.78–0.89). 
Decreased risk. Stratified analysis 
by site showed 
effect estimates 
were significant for 
colon but not rectal 
cancer. 
N/A   
Fruit and vegetables A 100 g/d increase in 
total fruit and vegetable 
intake was associated 
with reduced risk for 
CRC (0.98, 95% CI: 
0.97–0.99). 
Reduced risk.   N/A   
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Red and processed meat A 100 g/d increase in 
red and processed meat 
consumption was 
associated with higher 
risk of colon cancer 
(1.19, 1.10–1.30). 
Increased risk. After stratification 
by sex, the 
association 
remained 
significant in men, 
but not 
in women. 
N/A   
Fibre intake A 10 g/d increase in 
dietary fibre was 
associated with a 
reduced risk of CRC 
(0.93, 0.87–1.00). 
Null. After stratification 
by sex, risk did not 
differ. 
N/A   
Dairy products A 400 g/d increment in 
total dairy intake was 
0.87 (95% CI: 0.83–
0.90). 
Reduced risk. Risk differed by 
site; significant 
effects were 
observed for colon 
but not rectal 
cancer. 
N/A   
World Cancer 
Research Fund 
International 
Systematic 
Literature 
Review 
(2014)(66)  
Bladder cancer: Fruit and vegetables Associations 
between 
different 
patterns and 
macro 
components of 
diet and 
cancer risk. 
Each single serving (80 
grams/day) increase in 
fruit and vegetable 
intake was associated 
with lower risk (0.97, 
95% CI: 0.95–0.99). 
Reduced risk.   N/A   
Red and processed meat No association was 
observed for red or 
processed meat 
consumption. 
Null.   N/A   
Dairy products No association was 
found for dairy 
products and risk of 
cancer. 
Null.   N/A   
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World Cancer 
Research Fund 
International 
Systematic 
Literature 
Review 
(2012)(30)  
Endometrial cancer: Fruit and vegetables  Associations 
between 
different 
patterns and 
macro 
components of 
diet and 
cancer risk. 
100 grams/day increase 
in fruit and vegetable 
intake was associated 
with bladder cancer 
risk (1.05, 95% CI: 
1.00–1.10). Also, a 100 
g/day increment in fruit 
intake was associated 
with endometrial 
cancer risk (1.05, 95% 
CI: 1.01–1.10). 
Null. Risks were 
estimated from 2 
cohort studies. 
N/A   
Red and processed meat No association was 
found for red or 
processed meat and 
risk of cancer. 
        
World Cancer 
Research Fund 
International 
Systematic 
Literature 
Review 
(2015)(40)  
Kidney cancer: Fruit and vegetables   Associations 
between 
different 
patterns and 
macro 
components of 
diet and 
cancer risk. 
No association was 
found for fruit and 
vegetable consumption 
and risk of cancer. 
Null.   N/A   
Red and processed meat No association was 
observed for red and 
processed meat and 
risk of cancer. 
Null.   N/A   
Fibre intake 10 grams/day 
increment in dietary 
fibre was associated 
with cancer risk (0.87, 
95% CI: 0.79–0.95). 
Reduced risk.   N/A   
World Cancer 
Research Fund 
International 
Systematic 
Literature 
Ovarian cancer: Fruit and vegetables   Associations 
between 
different 
patterns and 
macro 
A 100 g/d increase in 
vegetable intake was 
associated with ovarian 
cancer (0.94, 95% CI: 
0.88–1.00). 
Null. Risk was not 
associated with fruit 
intake. 
N/A   
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Review 
(2013)(39)  
Red and processed meat components of 
diet and 
cancer risk. 
Neither red nor 
processed meat was 
associated with cancer 
risk. 
Null.   N/A   
Dairy products No significant 
association was detected 
for diary product intake 
and cancer risk. 
Null.   N/A   
Fibre intake No association was 
found for fibre intake 
and risk of ovarian 
cancer. 
Null.   N/A   
Saturated fat No association was 
found for dose–
response analysis of 
saturated fat intake and 
risk of ovarian cancer. 
Null.   N/A   
World Cancer 
Research Fund 
International 
Systematic 
Literature 
Review 
(2015)(21)  
Liver cancer: Fruit and vegetables  Associations 
between 
different 
patterns and 
macro 
components of 
diet and 
cancer risk.  
No significant 
association was 
detected for fruit intake 
and cancer risk. 
Null.   N/A   
Red and processed meat Neither red nor 
processed meat was 
associated with cancer 
risk. 
Null.   N/A   
World Cancer 
Research Fund 
International 
Systematic 
Literature 
Review 
(2014)(31)  
Prostate cancer: Fruit and vegetables  Associations 
between 
different 
patterns and 
macro 
components of 
diet and 
A 100 g/d increase in 
vegetable intake was 
associated with 
prostate cancer risk 
(0.99, 95% CI: 0.98–
1.00). No association 
was found for fruit 
Null. In stratified analysis 
by prostate cancer 
type, no effect was 
observed in 
advanced or non-
advanced prostate 
cancer. 
N/A   
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cancer risk. consumption. 
Red and processed meat Neither red nor 
processed meat was 
associated with cancer 
risk. 
Null. Risk did not differ 
by prostate cancer 
type. 
N/A   
Dairy products A 400 g/d increase in 
total dairy intake was 
associated with 
prostate cancer risk 
(1.07, 95% CI: 1.02–
1.12). 
Increased cancer 
risk. 
In stratified 
analyses by type of 
prostate cancer, 
effects were only 
significant for non-
advanced cancer. 
N/A   
Saturated fat No association was 
found for saturated fat 
and risk of cancer. 
        
 
Life stages: There was only one systematic review, examining the association of maternal and index child’s diet with subsequent leukaemia risk. However, the review was excluded based on the 
assessment of case-control studies only. 
 
No systematic reviews or meta-analyses were found for migrants, culturally and linguistically diverse communities or Aboriginal populations. 
 
 
 
 
Summary table of alcohol 
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Source 
(author, 
year) 
Study type 
(review) 
Population/ 
setting 
N (number of 
studies, 
number of 
participants) 
Intervention/ 
comparator 
Outcomes 
Direction/ 
magnitude of 
effect 
Comment/ notes 
Amstar 
score 
Level of evidence 
(convincing, 
probable, 
possible and 
weak) 
All cancers 
Jin et al, 
(2013)(212) 
Systematic 
review and 
meta-
analysis. 
US, Japan, 
Netherlands, 
France, 
Denmark, 
China, Korea, 
India, 
Sweden. 
18 
prospective 
studies, more 
than 585,562 
participants 
(for 14 
studies only 
person-years 
were 
reported). 
Any drinking, 
light drinking 
(<= 1 drink/day 
or <= 12.5 g 
ethanol/day), 
moderate 
drinking (2–3 
drinks/day or > 
12.5 and < 50 g 
ethanol/day) and 
heavy drinking 
(>= 4 drinks/day 
or >= 50 g 
ethanol/day) vs. 
non- and 
occasional 
RR 1.05 (1.00–1.10) for 
drinking vs. non- and 
occasional drinking; 0.91 
(0.89–0.94) for light 
drinking vs. non- and 
occasional drinking; 1.02 
(0.99–1.06) for moderate 
drinking vs. non- and 
occasional drinking; 1.31 
(1.23–1.39) for heavy 
drinking vs. non- and 
occasional drinking. For 
drinking vs. non- and 
occasional drinking, 
there was significant 
heterogeneity by source 
J-shaped 
association. 
Significant 
heterogeneity for 
drinkers vs. non- and 
occasional drinkers, 
but not for each of 
the three levels of 
drinking vs. non- and 
occasional drinkers. 
9/11 Possible 
evidence for all 
cancer-cause 
mortality. 
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drinking for RR 
and 95% CIs of 
all cancer 
mortality. 
Restricted cubic 
spline of 
association 
between alcohol 
consumption and 
RR and 95% CIs 
of all cancer 
mortality. 
of cohort (higher risk in 
population-based cohorts 
than occupation-specific 
cohorts) and by quality 
score (higher risk in 
studies with at least 
median-quality score 
than studies with below 
median-quality score). 
When fitting a restricted 
cubic spline, increased 
alcohol consumption was 
associated with a J-
shaped risk of all cancer 
mortality, with evidence 
of nonlinearity overall 
and when restricted to 
men or women. The 
lowest risk was found at 
12.7 g ethanol/day RR 
0.97 (0.94–1.00) and 
there was a significant 
increased risk from 27.2 
g ethanol/day RR 1.04 
(1.00–1.08) at this point.  
 
Schwedhelm 
et al, 
(2016)(213) 
Systematic 
review and 
meta-
analysis. 
Asia, North 
America, 
Europe. 
80 studies; 
38 were 
cohort 
studies. 
Overall mortality 
among cancer 
survivors and 
alcohol intake. 
Higher alcohol 
consumption was 
positively associated 
with overall mortality 
(RR 1.08, 95% CI: 1.02–
1.16). 
Increased risk. Significant 
heterogeneity was 
reported.  
8/11 Possible 
evidence for all 
cancer-cause 
mortality. 
Bladder 
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Choi et al, 
(2017)(75) 
Systematic 
review and 
meta-
analysis. 
Japan, 
Netherland, 
UK, US. 
4 
prospective 
studies, 
1,533,336 
participans. 
Very light 
drinking (<= 0.5 
drinks/day or <= 
7.5 g 
ethanol/day), 
light drinking (> 
0.5 and <= 1 
drink/day or > 
7.5 and <= 15 g 
ethanol/day) and 
moderate 
drinking (> 1 and 
<= 2 drinks/day 
or >15 and <= 30 
g ethanol/day) 
vs. non- and 
occasional 
drinking for RR 
and 95% CIs of 
bladder cancer.  
RR 1.22 (0.82–1.82) for 
very light drinking vs. 
non- or occasional 
drinking; 1.09 (0.92–
1.23) for light drinking 
vs. non- or occasional 
drinking (no differences 
when stratified by sex); 
1.06 (0.77–1.47) for 
moderate drinking vs. 
non- or occasional 
drinking (no difference 
when restricted to 
women). 
No significant 
effect. 
I-squared statistic 
reported but a formal 
test of heterogeneity 
was not conducted, 
nevertheless used 
random-effects 
model. 
7/11 Weak. 
Bagnardi et 
al, 
(2015)(214) 
Systematic 
review and 
meta-
analysis. 
UK, 
Netherlands, 
US. 
3 
prospective 
studies. 
Light drinking 
(<= 12.5 g 
ethanol/day) and 
moderate 
drinking (> 12.5 
and <= 50 g 
ethanol/day) vs. 
non- and 
occasional 
drinking for RR 
and 95% CIs of 
bladder cancer. 
RR 1.10 (0.87–1.41) for 
light drinking vs. non- 
and occasional drinking; 
1.03 (0.76–1.40) for 
moderate drinking vs. 
non- and occasional 
drinking. 
No significant 
effect. 
NOTE: APPEARS 
TO CONTAIN 
SAME SET OF 
STUDIES AS 
Pelucchi et al., 2012. 
Heterogeneity test 
not reported but used 
random-effects 
model. 
4/11 Weak. 
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Pelucchi et 
al, 
(2012)(215) 
Systematic 
review and 
meta-
analysis. 
US, 
Netherlands, 
UK. 
3 
prospective 
studies, 
~1.31 
million 
participans. 
Moderate alcohol 
consumption (< 3 
drinks/day, < 
37.5 g of 
ethanol/day) vs. 
non-drinking for 
RR and 95% CIs 
of bladder 
cancer. 
RR 1.07 (0.85–1.36) for 
moderate alcohol 
consumption vs. non-
drinking. 
No significant 
effect. 
NOTE: APPEARS 
TO CONTAIN 
SAME SET OF 
STUDIES AS 
Bagnardi et al., 2015. 
There were no 
prospective studies 
found for heavy 
alcohol consumption. 
No significant 
heterogeneity. 
5/11 
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Breast 
Choi et al, 
(2017)(75) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
41 
prospective 
studies, at 
least 
5,253,831 
participants 
(participants 
not reported 
for one 
study). 
Very light 
drinking (<= 
0.5 drinks/day 
or <= 7.5 g 
ethanol/day), 
light drinking 
(> 0.5 and <= 
1 drink/day or 
> 7.5 and <= 
15 g 
ethanol/day) 
and moderate 
drinking (> 1 
and <= 2 
drinks/day or 
>15 and <= 30 
g ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of breast 
cancer 
incidence and 
mortality. 
RR 1.04 (1.01–1.07) for 
very light drinking vs. non- 
or occasional drinking for 
incidence; 1.09 (1.06–1.12) 
for light drinking vs. non- 
or occasional drinking for 
incidence; 1.13 (1.11–1.15) 
for moderate drinking vs. 
non- or occasional drinking 
for incidence. RR 0.79 
(0.64–0.97) for very light 
drinking vs. non- or 
occasional drinking for 
mortality; 1.06 (0.97–1.16) 
for light drinking vs. non- 
or occasional drinking for 
mortality; 1.04 (1.01–1.07) 
for moderate drinking vs. 
non- or occasional drinking 
for mortality. 
Increased risk 
for incidence for 
light and 
moderate 
drinking, 
decreased risk 
for mortality for 
very light 
drinking, 
increased risk 
for mortality for 
moderate 
drinking. 
i-squared statistic 
reported but a formal 
test of heterogeneity 
was not conducted, 
nevertheless used 
random-effects 
model. 
7/11 Convincing 
evidence for 
cancer incidence 
and probable for 
cancer mortality. 
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Gou et al, 
(2013)(84) 
Systematic 
review and 
meta-
analysis. 
Italy, UK, 
US, Canada, 
Denmark, 
France, 
Sweden, 
Germany, 
Australia. 
25 
prospective 
studies. 
Pre- and post-
breast cancer 
diagnosis 
highest vs. 
lowest 
category 
drinking and 
HR and 95% 
CI of breast 
cancer 
mortality or 
breast cancer 
recurrence. 
HR 1.05 (0.93–1.19) for 
breast cancer mortality 
with pre-diagnosis highest 
vs. lowest category 
drinking; 1.08 (0.94–1.25) 
for breast cancer mortality 
with post-diagnosis highest 
vs. lowest category 
drinking. HR 1.24 (0.89–
1.73) for breast cancer 
recurrence with pre-
diagnosis highest vs. 
lowest category drinking; 
1.17 (0.83–1.66) for breast 
cancer recurrence with 
post-diagnosis highest vs. 
lowest category drinking. 
No results became 
significant when pre- and 
post-diagnosis drinking 
were combined. No results 
became significant when 
stratified by oestrogen 
receptor status. When 
stratified by menopausal 
status, highest vs. lowest 
category drinking (pre- or 
post-diagnosis) was 
significantly associated 
with breast cancer 
recurrence, HR 1.52 (1.21–
1.90), but no other results 
became significant. 
Drinking (pre- or post-
No significant 
effect in overall 
analysis, but 
increased risk of 
breast cancer 
recurrence in 
premenopausal 
women, and 
increased risk of 
breast cancer 
mortality from 
drinking > 20 g 
ethanol/day. 
Heterogeneity test 
not reported but used 
random-effects 
model. Not specified 
if women only. 
7/11 Convincing 
evidence for 
cancer incidence 
and probable for 
cancer mortality. 
Convincing 
evidence for 
cancer incidence 
and probable for 
cancer mortality. 
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diagnosis) > 20 g 
ethanol/day was associated 
with breast cancer 
mortality [HR 1.14 (1.02–
1.27)] but not breast cancer 
recurrence [HR 1.04 (0.83–
1.30)].  
Bagnardi et 
al, 
(2015)(214) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
43 
prospective 
studies. 
Light drinking 
(<= 12.5 g 
ethanol/day) 
and moderate 
drinking (> 
12.5 and <= 
50 g 
ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of breast 
cancer. 
RR 1.06 (1.03–1.10) for 
light drinking vs. non- and 
occasional drinking; 1.22 
(1.17–1.27) for moderate 
drinking vs. non- and 
occasional drinking. 
Increased risk. Heterogeneity test 
not reported but used 
random-effects 
model. 
4/11 
Bagnardi et 
al, 
(2013)(216) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
39 
prospective 
studies. 
Light drinkers 
(<= 1 drink/day 
or <= 12.5 g 
ethanol/day) vs. 
non-drinkers for 
RR and 95% 
CIs of breast 
cancer. 
RR 1.05 (1.02–1.09) for 
light drinkers vs. non-
drinkers. 
Increased risk. NOTE: APPEARS 
TO CONTAIN 
SAME SET OF 
STUDIES AS Seitz 
et al., 2012. 
Heterogeneity test 
not reported but used 
random-effects 
model. 
4/11 
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Seitz et al., 
(2012)(217) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
39 
prospective 
studies. 
Light alcohol 
consumption 
(<= 1 drink 
/day or <= 
12.5 g 
ethanol/day) 
vs. non-
drinking for 
RR and 95% 
CIs of breast 
cancer. 
RR 1.05 (1.02–1.09) for 
light alcohol consumption 
vs. non-drinking. 
Increased risk. NOTE: APPEARS 
TO CONTAIN 
SAME SET OF 
STUDIES AS 
Bagnardi et al., 2013. 
Significant 
heterogeneity 
detected. 
4/11 
Convincing 
evidence for 
cancer incidence 
and probable for 
cancer mortality. 
Sheild et al, 
(2016)(218) 
Systematic 
review. 
A wide 
range of 
countries. 
15 meta-
analyses or 
pooled 
analyses. 
Risk 
associated 
with increased 
alcohol 
consumption. 
13 analyses found an 
association with increased 
risk, 1 with decreased risk, 
and 1 with no significant 
difference in risk. Post-
diagnosis alcohol 
consumption was not 
related to recurrence or 
breast cancer–specific 
survival. Relationship 
between pre-diagnosis 
alcohol consumption and 
breast cancer–specific 
survival was inconsistent. 
Conflicting results for 
interaction between alcohol 
and folate status or ER 
receptor tumour status. 
Significant interaction 
between alcohol and  
CASP8-rs17468277 gene. 
Increased risk 
in most studies. 
The two meta-
analyses that did not 
find a significant 
effect were both 
based on the Chinese 
population. 
3/11 
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Mahabir et 
al, (2013)(219) 
Systematic 
review. 
Prospective: 
US; case-
control: 1 US 
and 3 not 
stated. 
6 studies (2 
prospective 
and 4 case-
control). 
Prospective 
studies: High 
alcohol 
consumption 
during 
adolescence 
with unstated 
comparator. 
Prospective studies: High 
alcohol consumption 
associated with ‘non-
significant increased risk’ 
of adult breast cancer. 
Case-control studies: 
Results were 
‘inconsistent’. 
No significant 
effect. 
The prospective 
studies were the 
Nurses’ Health Study 
I and II. 
1/11 
Convincing 
evidence for 
cancer incidence 
and probable for 
cancer mortality. 
Simapivapan 
et al, 
(2016)(220) 
Systematic 
review 
(narrative 
synthesis). 
US, 
Germany, 
Denmark. 
16 studies; 
14 were 
cohort 
studies. 
Association 
between 
alcohol intake 
and breast 
cancer 
recurrence or 
development 
of second 
primary breast 
cancer. 
Alcohol and breast cancer 
recurrence: 6 out of 11 did 
not find a statistical 
significance; 2 studies found 
a modest risk associated 
with pre-diagnostic alcohol 
intake and 3 with post-
diagnostic alcohol intake 
and recurrence. 
No significant 
effect. 
Second primary 
breast cancer is 
defined as 
development of 
contralateral breast 
cancer. 
9/11 
Chen et al, 
(2016)(221) 
Meta-
analysis. 
North 
America, 
Europe. 
26 studies; 
8 were 
cohort 
studies. 
Association 
between wine 
drinking and 
breast cancer. 
The combined result of 
cohort studies was 
associated with increased 
risk of cancer comparing 
the highest vs. the lowest 
intake of wine; RR 1.25 
(1.07–1.46). 
Increased risk. Stronger effect was 
observed among case 
control studies. 
7/11 
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Mourouti et 
al, (2015)(222) 
Systematic 
review. 
A wide 
range of 
countries. 
27 studies; 
20 were 
cohort 
studies. 
Association 
between 
alcohol intake 
and cancer 
incidence. 
26 studies included in this 
review showed modest or 
high alcohol consumption 
was associated with a 
moderate increase in breast 
cancer incidence. 
Increased risk. Alcohol intake is 
widely recognised as 
one of the 
behaviours most 
consistently 
associated with 
increased breast 
cancer risk, 
independently of the 
type of alcoholic 
drink consumed and 
of menopausal 
status. 
N/A Convincing 
evidence for 
cancer incidence 
and probable for 
cancer mortality. 
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Zeisser et al, 
(2014)(223) 
Systematic 
review. 
US, Europe, 
Australia. 
60 studies; 
26 were 
cohort 
studies. 
Association 
between 
alcohol intake 
and cancer 
incidence or 
mortality. 
In studies free from 
occasional-drinker bias, the 
risks for breast cancer were 
1.09 (1.02–1.16) for low-
level drinkers, 1.37 (1.32–
1.43) for hazardous-level 
drinkers and 1.34 (1.29–
1.45) for harmful-level 
drinkers. 
Increased risk. Drinking categories 
were defined as 
follows, using grams 
of ethanol consumed 
per day: (i) former 
drinkers now 
completely 
abstaining; (ii) 
occasional drinkers, 
consuming less than 
one drink a week 
(0.01–1.43 g/day); 
(iv) low-level 
drinkers, 1 
drink/month to 2 
drinks/day (1.5–24 
g/day); (v) 
hazardous-level 
drinkers, 2–4 
drinks/day (25–44 
g/day); and (vi) 
harmful-level 
drinkers, more than 4 
drinks/day (>44 
g/day). 
5/11 
Convincing 
evidence for 
cancer incidence 
and probable for 
cancer mortality. 
Ali et al, 
(2014)(224)  
Meta-
analysis. 
Europe, 
North 
America, 
Japan, 
Australia.  
11 case-
cohort 
studies. 
Association 
between 
moderate 
consumption 
of alcohol and 
breast cancer–
specific 
survival 
(BCSS). 
Of the 11 studies that 
reported on BCSS, 6 
reported no association and 
4 reported that increased 
alcohol intake was 
associated with increased 
breast cancer–specific 
mortality. 
No significant 
effect. 
Individuals who 
consumed more than 
2 units of alcohol per 
day (14 U per week) 
were defined as 
moderate drinkers. It 
was not possible to 
combine estimates in 
a formal meta-
5/11 
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analysis. 
Jayasekara et 
al, (2016)(76) 
Systematic 
review and 
meta-
analysis. 
US, 
Denmark. 
3 
prospective 
studies, 
199,318 
participants. 
Lifetime 
alcohol 
consumption 
(highest vs. 
lowest 
category) and 
RR and 95% 
CI of breast 
cancer.  
Lifetime alcohol 
consumption (highest vs. 
lowest category) was 
associated with a RR of 
1.48 (1.33–1.64). 
Increased risk. No significant 
heterogeneity. 
6/11 Convincing 
evidence for 
cancer incidence 
and probable for 
cancer mortality. 
Cervix 
Choi et al, 
(2017)(75) 
Systematic 
review and 
meta-
analysis. 
US, UK. 2 
prospective 
studies, 
1,404,489 
participants. 
Light drinking 
(> 0.5 and <= 1 
drink/day or > 
7.5 and <= 15 g 
ethanol/day) 
and moderate 
drinking (> 1 
and <= 2 
drinks/day or 
>15 and <= 30 
g ethanol/day) 
vs. non- and 
occasional 
drinking for RR 
and 95% CIs of 
cervical cancer. 
RR 1.02 (0.88–1.19) for 
light drinking vs. non- or 
occasional drinking, 0.99 
(0.83–1.17) for moderate 
drinking vs. non- or 
occasional drinking. 
No significant 
effect. 
i-squared statistic 
reported but a formal 
test of heterogeneity 
was not conducted, 
nevertheless used 
random-effects 
model. 
7/11 Weak. 
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Bagnardi et 
al, 
(2015)(214) 
Systematic 
review and 
meta-
analysis. 
UK, US, 
Japan, 
Korea. 
5 studies (2 
prospective 
and 3 case-
control). 
Light drinking 
(<= 12.5 g 
ethanol/day) 
and moderate 
drinking (> 12.5 
and <= 50 g 
ethanol/day) vs. 
non- and 
occasional 
drinking for RR 
and 95% CIs of 
cervical cancer. 
Fractional 
polynomial 
curve of 
association 
between alcohol 
consumption 
and RR and 
95% CIs of 
cervical cancer. 
RR 0.87 (0.75–1.01) for 
light drinking vs. non- and 
occasional drinking; 0.90 
(0.73–1.11) for moderate 
drinking vs. non- and 
occasional drinking. When 
fitting a fractional 
polynomial, increased 
alcohol consumption was 
not significantly associated 
with risk of cervical 
cancer. 
No significant 
effect. Number 
of studies too 
small to draw 
any conclusion. 
Heterogeneity test 
not reported but used 
random-effects 
model. 
4/11 Weak. 
Colorectal 
Choi et al, 
(2017)(75) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
22 
prospective 
studies, 
8,161,523 
participants. 
Very light 
drinking (<= 
0.5 drinks/day 
or <= 7.5 g 
ethanol/day), 
light drinking 
(> 0.5 and <= 
1 drink/day or 
> 7.5 and <= 
15 g 
ethanol/day) 
RR 1.10 (0.94–1.28) for 
very light drinking vs. non- 
or occasional drinking for 
incidence (no differences 
when stratified by sex or 
by site [colon/rectum]); 
1.04 (1.01–1.06) for light 
drinking vs. non- or 
occasional drinking for 
incidence (significant only 
in men when stratified by 
Increased risk 
for incidence 
for light and 
moderate 
drinking (men 
only), increased 
risk for 
mortality with 
moderate 
drinking in 
women only. 
i-squared statistic 
reported but a formal 
test of heterogeneity 
was not conducted, 
nevertheless used 
random-effects 
model. 
7/11 Convincing 
evidence for 
cancer incidence 
and probable for 
cancer mortality. 
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and moderate 
drinking (> 1 
and <= 2 
drinks/day or 
>15 and <= 30 
g ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of 
colorectal 
cancer 
incidence and 
mortality. 
sex, not significant when 
stratified by site 
[colon/rectum]); 1.10 
(1.03–1.19) for moderate 
drinking vs. non- or 
occasional drinking for 
incidence (significant only 
in men when stratified by 
sex, not significant when 
stratified by site 
[colon/rectum]). RR 0.88 
(0.70–1.12) for very light 
drinking vs. non- or 
occasional drinking for 
mortality (no differences 
when stratified by sex), 
0.97 (0.83–1.14) for light 
drinking vs. non- or 
occasional drinking for 
mortality (no differences 
when stratified by sex), 
1.55 (0.67–3.58) for 
moderate drinking vs. non- 
or occasional drinking for 
mortality (significant 
increased risk in women 
when stratified by sex). 
Bagnardi et 
al, 
(2015)(214) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
33 
prospective 
studies. 
Light drinking 
(<= 12.5 g 
ethanol/day), 
moderate 
drinking (> 12.5 
and <= 50 g 
ethanol/day) 
RR 1.01 (0.95–1.06) for 
light drinking vs. non- and 
occasional drinking; 1.20 
(1.12–1.29) for moderate 
drinking vs. non- and 
occasional drinking; 1.41 
(1.23–1.63) for heavy 
Increased risk. Heterogeneity test 
not reported but used 
random-effects 
model. 
4/11 
Convincing 
evidence for 
cancer incidence 
and probable for 
cancer mortality. 
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and heavy 
drinking (> 50 g 
ethanol/day) vs. 
non- and 
occasional 
drinking for RR 
and 95% CIs of 
colorectal 
cancer. 
drinking vs. non- and 
occasional drinking. 
Bagnardi et 
al, (2013)(216)  
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
26 
prospective 
studies. 
Light drinkers 
(<= 1 
drink/day or 
<= 12.5 g 
ethanol/day) 
vs. non-
drinkers for 
RR and 95% 
CIs of 
colorectal 
cancer. 
RR 1.00 (0.95–1.05) for 
light drinkers vs. non-
drinkers. 
No significant 
effect. 
Heterogeneity not 
reported but used 
random-effects 
model. 
4/11 
Magalhaes et 
al, (2012)(185) 
Systematic 
review and 
meta-
analysis. 
US, France, 
Canada, 
Sweden, 
Uruguay. 
6 studies 
(unclear 
what 
proportion 
were 
prospective 
vs. case-
control). 
A ‘drinker’ 
dietary pattern 
vs. other dietary 
patterns 
(healthy and 
Western 
combined) on 
RR and 95% CI 
of colorectal 
cancer and 
subsites. 
Drinker dietary 
pattern was 
characterised by 
A drinker dietary pattern 
was associated with a RR 
of 0.98 (0.77–1.26) for 
colorectal cancer; 0.96 
(0.92–1.12) for colon 
cancer; 0.94 (0.75–1.19) 
for proximal colon cancer; 
1.08 (0.83–1.41) for distal 
colon cancer; and 0.83 
(0.47–1.45) for rectal 
cancer. 
No significant 
effect. 
This was a study 
comparing three 
dietary patterns 
rather than alcohol 
consumption per se. 
No significant 
heterogeneity. 
5/11 Convincing 
evidence for 
cancer incidence 
and probable for 
cancer mortality. 
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high alcohol 
consumption (a 
hierarchical 
agglomerative 
clustering 
method was 
used). 
Zhang et al, 
(2015)(225) 
Meta-
analysis. 
US, Europe, 
Singapore, 
Korea, 
Australia. 
21 studies; 
9 were 
cohort 
studies. 
Association 
between beer 
consumption 
and incidence 
of colorectal 
cancer (CRC). 
Any beer drinking was 
associated with increased 
risk in cohort studies 
compared with non-
drinkers 1.08 (1.02–1.15). 
An increased intake of one 
drink of beer per day was 
associated with increased 
risk RR in cohort studies of 
1.13 (1.03–1.16). 
Increased risk.  A drink of beer was 
defined as a 12 
ounce serving or 330 
ml per bottle, or 13 g 
of ethanol. 
Definitions of light, 
moderate and heavy 
intake were derived 
from dietary 
guidelines for 
Americans; the 
respective values 
were: <1 drink/day, 
1–2, and ≥2 
drinks/day. 
8/11 
Convincing 
evidence for 
cancer incidence 
and probable for 
cancer mortality. 
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Cai et al, 
(2014)(85) 
Meta-
analysis. 
US, Korea, 
Japan, 
China. 
9 cohort 
studies. 
Alcohol 
drinking and 
the risk of 
colorectal 
cancer death. 
Non- and 
occasional 
drinkers were 
considered the 
reference 
category. 
Compared with non- and 
occasional drinkers, the 
pooled RR was 1.21 (1.01–
1.46) for heavy drinkers 
(≥50 g/day of ethanol).  
Increased 
mortality. 
1 drink was 
standardised to 12.5g 
and 1 ounce to 28 g. 
The dose–response 
analysis showed a J-
shaped relationship 
between alcohol 
consumption and 
CRC mortality 
among men and 
women. In subgroup 
analysis of heavy 
drinkers, results were 
only significant in 
men. 
8/11 
Jayasekara et 
al, (2016)(76) 
Systematic 
review and 
meta-
analysis. 
US, Europe. 2 
prospective 
studies, 
526,164 
participans. 
Lifetime 
alcohol 
consumption 
(highest vs. 
lowest 
category) and 
RR and 95% 
CI of 
colorectal 
cancer. 
Lifetime alcohol 
consumption (highest vs. 
lowest category) was 
associated with a RR of 
1.86 (1.47–2.36). 
Increased risk. No significant 
heterogeneity. 
6/11 Convincing 
evidence for 
cancer incidence 
and probable for 
cancer mortality. 
Head/neck 
Choi et al, 
(2017)(75) 
Systematic 
review and 
meta-
analysis. 
US, 
Netherlands, 
UK. 
2 
prospective 
studies, 
222,034 
participants. 
Very light 
drinking (<= 
0.5 drinks/day 
or <= 7.5 g 
ethanol/day), 
light drinking 
RR 1.11 (0.75–1.65) for 
very light drinking vs. non- 
or occasional drinking; 
1.00 (0.75–1.33) for light 
drinking vs. non- or 
occasional drinking; 1.18 
No significant 
effect. 
i-squared statistic 
reported but a formal 
test of heterogeneity 
was not conducted, 
nevertheless used 
random-effects 
7/11 Probable 
evidence for 
cancer incidence. 
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(> 0.5 and <= 
1 drink/day or 
> 7.5 and <= 
15 g 
ethanol/day) 
and moderate 
drinking (> 1 
and <= 2 
drinks/day or 
>15 and <= 30 
g ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of head 
and neck 
cancer. 
(0.67–2.07) for moderate 
drinking vs. non- or 
occasional drinking. 
model. 
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Choi et al, 
(2017)(75) 
Systematic 
review and 
meta-
analysis. 
US, UK, 
Singapore, 
Korea. 
7 
prospective 
studies, at 
least 
3,422,717 
participants. 
(participants 
for one 
study not 
reported). 
Light drinking 
(> 0.5 and <= 
1 drink/day or 
> 7.5 and <= 
15 g 
ethanol/day) 
and moderate 
drinking (> 1 
and <= 2 
drinks/day or 
>15 and <= 30 
g ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of oral 
cavity and 
pharynx 
cancer 
incidence and 
mortality. 
RR 0.96 (0.84–1.11) for 
light drinking vs. non- or 
occasional drinking for 
incidence (no differences 
when stratified by sex); 
1.12 (1.01–1.24) for 
moderate drinking vs. non- 
or occasional drinking for 
incidence (only significant 
in women when stratified 
by sex); 0.71 (0.24–2.16) 
for light drinking vs. non- 
or occasional drinking for 
mortality in men; 0.75 
(0.27–2.06) for moderate 
drinking vs. non- or 
occasional drinking for 
mortality in men. 
No significant 
effect for light 
drinking, 
increased risk 
for moderate 
drinking for 
incidence in 
women but not 
in men, and no 
significant 
effect for 
mortality in 
men. 
i-squared statistic 
reported but a formal 
test of heterogeneity 
was not conducted, 
nevertheless used 
random-effects 
model. 
7/11 
Probable 
evidence for 
cancer incidence. 
Bagnardi et 
al, 
(2015)(214) 
Systematic 
review and 
meta-
analysis. 
US, UK, 
Korea, and 
possibly one 
other 
country. 
5 
prospective 
studies. 
Light drinking 
(<= 12.5 g 
ethanol/day), 
moderate 
drinking (> 12.5 
and <= 50 g 
ethanol/day) 
and heavy 
drinking (> 50 g 
ethanol/day) vs. 
non- and 
occasional 
RR 0.86 (0.60–1.23) for 
light drinking vs. non- and 
occasional drinking; 1.25 
(1.02–1.53) for moderate 
drinking vs. non- and 
occasional drinking; 3.13 
(1.59–6.19) for heavy 
drinking vs. non- and 
occasional drinking. 
Increased risk. Heterogeneity test 
not reported but used 
random-effects 
model. 
4/11 
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drinking for RR 
and 95% CIs of 
oral cavity and 
pharynx cancer. 
Bagnardi et 
al, 
(2015)(214) 
Systematic 
review and 
meta-
analysis. 
US, UK, 
Korea. 
3 
prospective 
studies. 
Light drinking 
(<= 12.5 g 
ethanol/day), 
moderate 
drinking (> 12.5 
and <= 50 g 
ethanol/day) 
and heavy 
drinking (> 50 g 
ethanol/day) vs. 
non- and 
occasional 
drinking for RR 
and 95% CIs of 
larynx cancer. 
RR 0.81 (0.61–1.07) for 
light drinking vs. non- and 
occasional drinking; 1.09 
(0.70–1.72) for moderate 
drinking vs. non- and 
occasional drinking; 1.12 
(0.75–1.67) for heavy 
drinking vs. non- and 
occasional drinking. 
No significant 
effect. 
NOTE: APPEARS 
TO CONTAIN 
SAME SET OF 
STUDIES AS 
Bagnardi et al., 2013. 
Heterogeneity not 
reported but used 
random-effects 
model. 
4/11 
Probable 
evidence for 
cancer incidence. 
Bagnardi et 
al, 
(2013)(216) 
Systematic 
review and 
meta-
analysis. 
US, UK, 
Korea. 
3 
prospective 
studies. 
Light drinkers 
(< 1 drink/day 
or <= 12.5 g 
ethanol/day) vs. 
non-drinkers for 
RR and 95% 
CIs of oral 
cavity and 
pharynx cancer. 
RR 1.01 (0.70–1.45) for 
light drinkers vs. non-
drinkers. 
No significant 
effect. 
Heterogeneity not 
reported but used 
random-effects 
model. 
4/11 
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Bagnardi et 
al, 
(2013)(216) 
Systematic 
review and 
meta-
analysis. 
US, UK, 
Korea. 
3 prospective 
studies. 
Light drinkers 
(< 1 drink/day 
or <= 12.5 g 
ethanol/day) vs. 
non-drinkers for 
RR and 95% 
CIs of larynx 
cancer. 
RR 0.96 (0.71–1.30) for 
light drinkers vs. non-
drinkers. 
No significant 
effect. 
NOTE: APPEARS 
TO CONTAIN 
SAME SET OF 
STUDIES AS 
Bagnardi et al., 2015. 
Heterogeneity not 
reported but used 
random-effects 
model. 
4/11 
Probable 
evidence for 
cancer incidence. 
Turati et al, 
(2013)(80) 
Systematic 
review and 
meta-
analysis. 
UK, US, 
Japan. 
4 prospective 
studies, at 
least 
1,445,764 
participants 
(for one 
study only 
person-years 
is reported). 
Drinkers (also 
moderate and 
heavy drinkers) 
vs. non- or 
occasional 
drinkers for RR 
and 95% CIs of 
oral and 
pharyngeal 
cancer. 
Moderate 
drinkers: 1-2 
drinks/day. 
Heavy drinkers: 
>= 4 
drinks/day. 
RR 1.34 (0.88–2.05) for 
drinkers vs. non- or 
occasional drinkers. 
Restricting to men only: 
2.17 (1.71–2.74). 
Restricting to women only: 
1.01 (0.91–1.12). RR 0.90 
(0.80–1.00) for moderate 
drinkers vs. non- or 
occasional drinkers. RR 
4.25 (3.03–5.96) for heavy 
drinkers vs. non- or 
occasional drinkers (result 
is for men only). 
Increased risk, 
but not for 
drinking overall 
when restricted 
to women. 
An update of a 
previous meta-
analysis. Significant 
heterogeneity for 
drinkers vs. non- or 
occasional drinkers, 
but not for other 
analyses of 
prospective studies. 
6/11 
Kidney 
Choi et al, 
(2017)(75) 
Systematic 
review and 
meta-
analysis. 
US, 
Netherlands, 
UK. 
7 
prospective 
studies, 
1,783,028 
participants. 
Very light 
drinking (<= 
0.5 drinks/day 
or <= 7.5 g 
ethanol/day), 
light drinking 
(> 0.5 and <= 1 
RR 0.73 (0.50–1.08) for 
very light drinking vs. non- 
or occasional drinking (no 
differences when restricted 
to women); 0.90 (0.81–
1.00) for light drinking vs. 
non- or occasional drinking 
No significant 
effect for light 
drinking, 
decreased risk 
for moderate 
drinking overall 
and in women. 
i-squared statistic 
reported but a formal 
test of heterogeneity 
was not conducted, 
nevertheless used 
random-effects 
model. 
7/11 
Convincing 
evidence for 
cancer incidence. 
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drink/day or > 
7.5 and <= 15 g 
ethanol/day) 
and moderate 
drinking (> 1 
and <= 2 
drinks/day or 
>15 and <= 30 
g ethanol/day) 
vs. non- and 
occasional 
drinking for RR 
and 95% CIs of 
renal cell 
carcinoma. 
(not significant when 
stratified by sex); 0.93 
(0.86–1.00) for moderate 
drinking vs. non- or 
occasional drinking 
(significant in women 
when stratified by sex). 
Bagnardi et 
al, 
(2015)(214) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
6 
prospective 
studies. 
Light drinking 
(<= 12.5 g 
ethanol/day), 
moderate 
drinking (> 12.5 
and <= 50 g 
ethanol/day) 
and heavy 
drinking (> 50 g 
ethanol/day) vs. 
non- and 
occasional 
drinking for RR 
and 95% CIs of 
kidney cancer. 
RR 0.93 (0.85–1.02) for 
light drinking vs. non- and 
occasional drinking; 0.74 
(0.64–0.86) for moderate 
drinking vs. non- and 
occasional drinking; 0.88 
(0.16–4.92) for heavy 
drinking vs. non- and 
occasional drinking. 
Consistent with 
a protective 
association but 
only one of 
three categories 
of alcohol 
consumption 
were 
significant. 
Heterogeneity test 
not reported but used 
random-effects 
model. 
4/11 
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Song et al, 
(2012)(81) 
Systematic 
review and 
meta-
analysis. 
US, Finland, 
Canada, 
Netherlands, 
Sweden, UK. 
15 
prospective 
studies (3 
prospective 
studies and 1 
pooled 
analysis of 
12 
prospective 
studies), 
2,192,962 
participants. 
Highest vs. 
lowest category 
of alcohol 
consumption 
for RR and 95% 
CIs of renal cell 
carcinoma. 
Restricted cubic 
spline of 
association 
between alcohol 
consumption 
and RR and 
95% CIs of 
renal cell 
carcinoma. 
RR 0.71 (0.63–0.78) for 
highest vs. lowest category 
of alcohol consumption. 
Restricting to men only: 
0.71 (0.61–0.80). Restricting 
to women only: 0.70 (0.56–
0.84). Restricting to beer 
only: 0.75 (0.55–0.95). 
Restricting to wine only: 
0.81 (0.65–0.97). Restricting 
to spirits only: 0.87 (0.77–
0.97). When fitting a 
restricted cubic spline, 
increased alcohol 
consumption was associated 
with decreased risk of renal 
cell cancer, with no evidence 
of nonlinearity (p = 0.10). 
Decreased risk. No significant 
heterogeneity. 
8/11 
Convincing 
evidence for 
cancer incidence. 
Bellocco et 
al, (2012)(82) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
16 
prospective 
studies (4 
prospective 
studies and 
1 pooled 
analysis of 
12 
prospective 
studies); at 
least 3.5 
million 
participants 
(for one 
study only 
Drinkers (also 
light, 
moderate and 
heavy 
drinkers) vs. 
non-drinkers 
for RR and 
95% CIs of 
renal cell 
carcinoma. 
Light drinkers: 
< 12.5 g 
ethanol/day; 
moderate 
drinkers: >= 
RR 0.80 (0.69–0.92) for 
drinkers vs. non-drinkers; 
0.89 (0.82–0.97) for light 
drinkers; 0.74 (0.61–0.88) 
for moderate drinkers; and 
1.74 (0.28–10.70) for 
heavy drinkers. 
Any, light and 
moderate 
drinking 
associated with 
protection, no 
significant 
difference for 
heavy drinking. 
Significant 
heterogeneity for any 
and heavy drinking 
analyses, but not for 
light and moderate 
analyses. 
8/11 
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person-
years is 
reported). 
12.5 and < 50 
g ethanol/day; 
heavy 
drinkers: >= 
50 g 
ethanol/day. 
Xu et al, 
(2015)(83) 
Meta-
analysis. 
A wide 
range of 
countries. 
7 cohort 
studies and 
one pooled 
analysis of 
12 cohort 
studies. 
Association 
between 
alcohol 
drinking and 
risk of renal 
cell carcinoma 
(RCC) (most 
common 
cancer type). 
When compared with 
non/occasional drinking, 
the pooled RRs were 0.86 
(0.76–0.96) for any 
drinking, and 0.75 (0.66–
0.86) for moderate 
drinking. 
Reduced risk. Light, moderate, and 
heavy drinking were 
defined as ethanol 
intake of <12.5 g/day 
(<1 drink/day), 12.5–
37.5 g/day (2–3 
drinks/day), and 
>37.5 g/day (>3 
drinks/day) 
respectively. In 
subgroup analysis, 
results were only 
significant for 
women with any or 
light drinking. Effect 
estimates did not 
differ by beverage-
specific analysis 
(wine, beer or 
liquor).  
10/11 Convincing 
evidence for 
cancer incidence. 
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Leukaemia 
Rota et al, 
(2014)(124) 
Systematic 
review and 
meta-
analysis. 
US, Korea, 
Japan, UK, 
Netherlands
. 
18 studies; 8 
were cohort 
studies. 
Association 
between 
alcohol 
consumption 
and risk of 
leukaemia. 
No association was 
observed between levels 
of alcohol and risk of 
leukaemia. 
No significant 
effect. 
Pooled estimates 
from cohort studies 
reported a reduced 
risk 0.91 (0.82–
1.00) for any 
drinking compared 
with non/occasional 
drinkers. 
6/11 Weak. 
Liver 
Choi et al, 
(2017)(75) 
Systematic 
review and 
meta-
analysis. 
US, UK. 2 prospective 
studies, 
1,404,489 
participants. 
Light drinking 
(> 0.5 and <= 1 
drink/day or > 
7.5 and <= 15 
g ethanol/day) 
and moderate 
drinking (> 1 
and <= 2 
drinks/day or 
>15 and <= 30 
g ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of liver 
cancer. 
RR 0.95 (0.76–1.20) for 
light drinking vs. non- or 
occasional drinking (no 
difference when restricted 
to women); 1.26 (1.00–
1.58) for moderate 
drinking vs. non- or 
occasional drinking (not 
significant when 
restricted to women). 
Increased risk 
with moderate 
drinking but 
not light 
drinking. 
i-squared statistic 
reported but a 
formal test of 
heterogeneity was 
not conducted, 
nevertheless used 
random-effects 
model. 
7/11 Convincing 
evidence for 
cancer incidence 
and probable for 
mortality.  
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Bagnardi 
et al, 
(2015)(214) 
Systematic 
review and 
meta-
analysis. 
UK, Japan, 
Korea and 
possibly 
other 
countries. 
9 prospective 
studies. 
Light drinking 
(<= 12.5 g 
ethanol/day), 
moderate 
drinking (> 
12.5 and <= 50 
g ethanol/day) 
and heavy 
drinking (> 50 
g ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of liver 
cancer. 
RR 0.85 (0.74–0.97) for 
light drinking vs. non- 
and occasional drinking; 
1.00 (0.87–1.17) for 
moderate drinking vs. 
non- and occasional 
drinking; 1.12 (1.02–
1.23) for heavy drinking 
vs. non- and occasional 
drinking. 
J-shaped 
association. 
Heterogeneity test 
not reported but 
used random-effects 
model. 
4/11 
Convincing 
evidence for 
cancer incidence 
and probable for 
mortality. 
Bagnardi 
et al, 
(2013)(216) 
Systematic 
review and 
meta-
analysis. 
UK, Japan, 
Korea and 
possibly 
other 
countries. 
7 prospective 
studies. 
Light drinkers 
(< 1 drink/day 
or <= 12.5 g 
ethanol/day) 
vs. non-
drinkers for 
RR and 95% 
CIs of liver 
cancer. 
RR 1.00 (0.85–1.18) for 
light drinkers vs. non-
drinkers. 
No significant 
effect. 
Heterogeneity not 
reported but used 
random-effects 
model. 
4/11 
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Turati et 
al, 
(2014)(86) 
Systematic 
review and 
meta-
analysis. 
Europe, US, 
Asia. 
19 prospective 
studies. 
Association 
between 
alcohol and 
liver cancer 
incidence or 
mortality. 
Moderate alcohol 
drinking vs. non-drinking 
was not associated with 
liver cancer occurrence. 
On the other hand, heavy 
drinking was associated 
with increased risk 1.16 
(1.01–1.34). 
Increased risk. Moderate drinking 
was defined as <3 
drinks per day and 
heavy drinking as 
≥3 drinks per day. 
Most of the 
participants were 
from Asia. In 
subgroup analysis 
by outcome, heavy 
drinking was only 
associated with 
mortality. 
7/11 Convincing 
evidence for 
cancer incidence 
and probable for 
mortality. 
Lung 
Choi et al, 
(2017)(75) 
Systematic 
review and 
meta-
analysis. 
US, 
Denmark, 
Canada, UK, 
Korea, Hong 
Kong. 
15 prospective 
studies, at least 
4,524,555 
participants 
(participants 
for one study 
not reported). 
Very light 
drinking (<= 
0.5 drinks/day 
or <= 7.5 g 
ethanol/day), 
light drinking 
(> 0.5 and <= 1 
drink/day or > 
7.5 and <= 15 
g ethanol/day) 
and moderate 
drinking (> 1 
and <= 2 
drinks/day or 
>15 and <= 30 
g ethanol/day) 
vs. non- and 
RR 0.89 (0.84–0.93) for 
very light drinking vs. non- 
or occasional drinking for 
incidence (when stratified 
by sex significant only in 
women).                         
0.91 (0.90–0.94) for light 
drinking vs. non- or 
occasional drinking for 
incidence (no differences 
when stratified by sex); 
0.98 (0.91–1.07) for 
moderate drinking vs. non- 
or occasional drinking for 
incidence (no differences 
when stratified by sex). RR 
0.81 (0.69–0.94) for very 
Light drinking 
was associated 
with a 
decreased 
incidence of 
both female 
and male lung 
cancer. 
i-squared statistic 
reported but a 
formal test of 
heterogeneity was 
not conducted, 
nevertheless used 
random-effects 
model. 
7/11 Possible 
decreased risk. 
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occasional 
drinking for 
RR and 95% 
CIs of lung 
cancer 
incidence and 
mortality. 
light drinking vs. non- or 
occasional drinking for 
mortality (when stratified 
by sex significant only in 
women); 0.90 (0.79–1.04) 
for light drinking vs. non- 
or occasional drinking for 
mortality (when stratified 
by sex significant 
decreased risk in men); 
0.94 (0.45–1.94) for 
moderate drinking vs. non- 
or occasional drinking for 
mortality in women; 0.78 
(0.68–0.90) for moderate 
drinking vs. non- or 
occasional drinking for 
mortality in men. 
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Bagnardi 
et al, 
(2015)(214) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
18 prospective 
studies. 
Light drinking 
(<= 12.5 g 
ethanol/day), 
moderate 
drinking (> 
12.5 and <= 50 
g ethanol/day) 
and heavy 
drinking (> 50 
g ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of lung 
cancer. 
RR 0.85 (0.82–0.89) for 
light drinking vs. non- 
and occasional drinking; 
0.97 (0.91–1.04) for 
moderate drinking vs. 
non- and occasional 
drinking; 1.07 (0.93–
1.25) for heavy drinking 
vs. non- and occasional 
drinking. 
Protective 
association for 
light drinking 
and no 
significant 
effect for 
moderate or 
heavy 
drinking. 
Heterogeneity test 
not reported but 
used random-effects 
model. 
4/11 Possible 
decreased risk. 
Lymphoma 
Bagnardi 
et al, 
(2015)(214) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
9 studies (2 
prospective 
and 7 case-
control 
studies). 
Light drinking 
(<= 12.5 g 
ethanol/day), 
moderate 
drinking (> 
12.5 and <= 50 
g ethanol/day) 
and heavy 
drinking (> 50 
g ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of Hodgkin 
RR 0.73 (0.59–0.89) for 
light drinking vs. non- 
and occasional drinking, 
0.73 (0.60–0.87) for 
moderate drinking vs. 
non- and occasional 
drinking; 0.63 (0.41–
0.97) for heavy drinking 
vs. non- and occasional 
drinking. When fitting a 
fractional polynomial, 
increased alcohol 
consumption was 
associated with decreased 
risk of Hodgkin 
Decreased risk. Heterogeneity test 
not reported but 
used random-effects 
model. 
4/11 Weak. 
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lymphoma. 
Fractional 
polynomial 
curve of 
association 
between 
alcohol 
consumption 
and RR and 
95% CIs of 
Hodgkin 
lymphoma. 
lymphoma. 
Bagnardi et 
al, 
(2015)(214) 
Systematic 
review and 
meta-
analysis. 
UK, US, 
Japan, 
Finland, 
Korea, and 
possibly 
other 
countries. 
9 prospective 
studies. 
Light drinking 
(<= 12.5 g 
ethanol/day), 
moderate 
drinking (> 
12.5 and <= 50 
g ethanol/day) 
and heavy 
drinking (> 50 
g ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of non-
Hodgkin 
lymphoma. 
RR 1.02 (0.93–1.12) for 
light drinking vs. non- 
and occasional drinking; 
0.87 (0.77–0.97) for 
moderate drinking vs. 
non- and occasional 
drinking, 0.74 (0.59–
0.92) for heavy drinking 
vs. non- and occasional 
drinking. 
Decreased risk. Heterogeneity test 
not reported but 
used random-effects 
model. 
4/11 
Weak. 
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Tramacere 
et al, 
(2012a)(226) 
Systematic 
review and 
meta-
analysis. 
US. 2 prospective 
studies, 
600,277 
participants. 
Drinkers (also 
light and 
moderate-to-
heavy drinkers) 
vs. non-
drinkers for 
RR and 95% 
CIs of Hodgkin 
lymphoma. 
Light drinkers: 
<= 1 drink/day, 
moderate-to-
heavy drinkers: 
> 1 drinks/day. 
RR 0.92 (0.63–1.33) for 
drinkers vs. non-drinkers; 
1.00 (0.53–1.90) for light 
drinkers; and 0.76 (0.45–
1.27) for moderate-to-
heavy drinkers. 
There was no 
significant 
effect for 
prospective 
studies; 
however, the 
results are 
consistent with 
a protective 
effect. 
No significant 
heterogeneity. 
5/11 
Tramacere 
et al, 
(2012b)(125) 
Systematic 
review and 
meta-
analysis. 
US, 
Finland, 
UK, Japan. 
8 prospective 
studies, ~2.2 
million 
participants. 
Drinkers (also 
light, moderate 
and heavy 
drinkers) vs. 
non-drinkers 
for RR and 
95% CIs of 
non-Hodgkin 
lymphoma. 
Light drinkers: 
<= 1 drink/day; 
moderate 
drinkers: > 1 to 
< 4 drinks/day; 
heavy drinkers: 
>= 4 
drinks/day. 
RR 0.96 (0.88–1.04) for 
drinkers vs. non-drinkers; 
1.00 (0.92–1.10) for light 
drinkers; 0.89 (0.78–1.01) 
for moderate drinkers; 
and 0.79 (0.60–1.05) for 
heavy drinkers. 
There was no 
significant 
effect for 
prospective 
studies, 
however the 
results are 
consistent with 
a protective 
effect. 
Significant 
heterogeneity in the 
moderate drinkers 
analysis, but not for 
the other analyses. 
5/11 Weak. 
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Melanoma 
Choi et al, 
(2017)(75) 
Systematic 
review and 
meta-
analysis. 
US. 3 prospective 
studies, 
252,356 
participants. 
Light drinking 
(> 0.5 and <= 1 
drink/day or > 
7.5 and <= 15 
g ethanol/day) 
and moderate 
drinking (> 1 
and <= 2 
drinks/day or 
>15 and <= 30 
g ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of 
melanoma. 
RR 1.44 (1.18–1.76) for 
light drinking vs. non- or 
occasional drinking (not 
significant when 
restricted to women); 
1.77 (1.35–2.33) for 
moderate drinking vs. 
non- or occasional 
drinking (not significant 
when stratified by sex). 
Increased risk 
overall. 
i-squared statistic 
reported but a 
formal test of 
heterogeneity was 
not conducted, 
nevertheless used 
random-effects 
model. 
7/11 Probable 
evidence for 
cancer 
incidence. 
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Rota et al, 
(2014)(77) 
Systematic 
review and 
meta-
analysis. 
US, UK. 2 prospective 
studies, 
1,348,884 
participants. 
Light drinking 
(<= 1 
drink/day or 
<= 12.5 g 
ethanol/day) 
and moderate-
to-heavy 
drinking (> 1 
drink/day or > 
12.5 g 
ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of 
melanoma. 
RR 1.20 (1.06–1.37) for 
drinking vs. non- or 
occasional drinking; 1.25 
(1.15–1.35) for light 
drinking vs. non- or 
occasional drinking; 1.29 
(1.17–1.43) for moderate-
to-heavy drinking vs. 
non- or occasional 
drinking. 
Increased risk. NOTE: APPEARS 
TO CONTAIN 
SAME SET OF 
STUDIES AS 
Bagnardi et al., 
2015. No significant 
heterogeneity. 
6/11 
Probable 
evidence for 
cancer 
incidence. Bagnardi 
et al, 
(2015)(214) 
Systematic 
review and 
meta-
analysis. 
US, UK. 2 prospective 
studies. 
Light drinking 
(<= 12.5 g 
ethanol/day) 
and moderate 
drinking (> 
12.5 and <= 50 
g ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of 
melanoma. 
RR 1.25 (1.13–1.38) for 
light drinking vs. non- 
and occasional drinking; 
1.27 (1.13–1.42) for 
moderate drinking vs. 
non- and occasional 
drinking. 
Increased risk. NOTE: APPEARS 
TO CONTAIN 
SAME SET OF 
STUDIES AS Rota 
et al., 2014. 
Heterogeneity test 
not reported but 
used random-effects 
model. 
4/11 
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Oesophageal 
Choi et al, 
(2017)(75) 
Systematic 
review and 
meta-
analysis. 
UK, 
Netherlands. 
3 prospective 
studies, 
1,425,216 
participants. 
Very light 
drinking (<= 
0.5 drinks/day 
or <= 7.5 g 
ethanol/day), 
light drinking 
(> 0.5 and <= 1 
drink/day or > 
7.5 and <= 15 g 
ethanol/day) 
and moderate 
drinking (> 1 
and <= 2 
drinks/day or 
>15 and <= 30 
g ethanol/day) 
vs. non- and 
occasional 
drinking for RR 
and 95% CIs of 
oesophageal 
adenocarcinom
a and gastric 
cardia cancer. 
RR 1.17 (0.69–1.98) for 
very light drinking vs. 
non- or occasional 
drinking; 0.83 (0.52–1.33) 
for light drinking vs. non- 
or occasional drinking; 
0.81 (0.56–1.17) for 
moderate drinking vs. 
non- or occasional 
drinking. 
No significant 
effect. 
i-squared statistic 
reported but a 
formal test of 
heterogeneity was 
not conducted, 
nevertheless used 
random-effects 
model. 
7/11 
Possible 
increased risk 
for squamous 
cell carcinoma. 
Prabhu et 
al, 
(2013)(227) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
34 studies (9 
prospective 
and 25 case-
control 
studies). 
Drinking < 200 
g ethanol/week 
and >= 200 g 
ethanol/week 
vs. non-
drinking for 
odds ratio 
OR 1.71 (1.22–2.42) for 
drinking < 200 g 
ethanol/week, 4.65 (3.61–
5.99) for drinking >= 200 g 
ethanol/week vs. non-
drinking. For >= 200 g 
ethanol/week, the OR 
Increased risk, 
but no 
significant 
difference in 
this risk 
between 
different 
Significant 
heterogeneity in the 
main analysis, when 
restricting to case-
control studies and 
when restricting to 
Europe/Asia/East 
8/11 
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(OR) and 95% 
CI of 
oesophageal 
squamous cell 
carcinoma, 
with a focus on 
differences by 
continent / 
region. 
when restricting to Europe 
was 3.42 (2.29–5.09), 
northern Europe 2.92 
(1.88–4.53), southern 
Europe 5.93 (3.18–11.06), 
Asia 5.05 (3.40–7.49) and 
East Asia 6.15 (3.80–9.96). 
It is stated that the 
differences by country of 
origin were not significant. 
For >= 200 g 
ethanol/week, the OR 
when restricting to high-
quality studies was 3.49 
(2.82–4.32). For >= 200 g 
ethanol/week, the OR 
when restricting to cohort 
studies was 3.51 (3.09–
4.00) and case-control 
studies was 5.20 (3.30–
8.18). 
countries. Asia. In the analysis 
exploring 
differences by 
continent/region, in 
most studies the 
country was used 
and in one study 
country of origin 
was used. 
Bagnardi 
et al, 
(2015)(214) 
Systematic 
review and 
meta-
analysis. 
UK, US, 
Japan, 
China, 
Korea, 
Netherlands
, and 
possibly 
other 
countries. 
13 prospective 
studies. 
Light drinking 
(<= 12.5 g 
ethanol/day), 
moderate 
drinking (> 
12.5 and <= 50 
g ethanol/day) 
and heavy 
drinking (> 50 
g ethanol/day) 
vs. non- and 
occasional 
RR 1.20 (0.84–1.71) for 
light drinking vs. non- 
and occasional drinking; 
1.92 (1.44–2.58) for 
moderate drinking vs. 
non- and occasional 
drinking; 3.56 (2.25–
5.64) for heavy drinking 
vs. non- and occasional 
drinking. 
Increased risk. Heterogeneity test 
not reported but 
used random-effects 
model. 
4/11 Possible 
increased risk 
for squamous 
cell carcinoma. 
  
 
 
DOCUMENT1 | SAX INSTITUTE 448 
drinking for 
RR and 95% 
CIs of 
oesophageal 
squamous cell 
carcinoma. 
Bagnardi 
et al, 
(2015)(214) 
Systematic 
review and 
meta-
analysis. 
UK, US, 
Netherlands, 
Europe. 
4 prospective 
studies. 
Light drinking 
(<= 12.5 g 
ethanol/day), 
moderate 
drinking (> 
12.5 and <= 50 
g ethanol/day) 
and heavy 
drinking (> 50 
g ethanol/day) 
vs. non- and 
occasional 
drinking for RR 
and 95% CIs of 
oesophageal 
adenocarcinom
a and gastric 
cardia. 
RR 0.88 (0.74–1.03) for 
light drinking vs. non- 
and occasional drinking; 
0.82 (0.62–1.07) for 
moderate drinking vs. 
non- and occasional 
drinking; 1.11 (0.48–
2.56) for heavy drinking 
vs. non- and occasional 
drinking. 
No significant 
effect. 
Heterogeneity test 
not reported but 
used random-effects 
model. 
4/11 Weak evidence 
for 
adenocarcinoma. 
Bagnardi 
et al, 
(2013)(216) 
Systematic 
review and 
meta-
analysis. 
UK, US, 
Japan, 
China, 
Korea and 
possibly 
other 
countries. 
9 prospective 
studies. 
Light drinkers 
(< 1 drink/day 
or <= 12.5 g 
ethanol/day) 
vs. non-
drinkers for 
RR and 95% 
CIs of 
oesophagus 
RR 1.34 (0.96–1.87) for 
light drinkers vs. non-
drinkers. 
No significant 
effect. 
Heterogeneity not 
reported but used 
random-effects 
model. 
4/11 Possible 
increased risk 
for squamous 
cell carcinoma. 
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squamous cell 
carcinoma. 
Jarl et al, 
(2012)(228) 
Systematic 
review and 
meta-
analysis. 
Europe, 
East Asia, 
South 
America. 
9 studies 
(unclear what 
proportion 
prospective 
and case-
control 
studies). 
OR and 95% 
CIs of 
oesophageal 
cancer among 
persons who 
had ceased 
alcohol 
consumption 
compared with 
continuing 
drinkers, over 
time. 
Five studies found an 
increased risk of 
oesophageal cancer within 
the first ~10 years of 
drinking cessation 
compared with people who 
remained current drinkers; 
four studies did not. The 
meta-analysis estimated 
that in the subset of 
“mainly European studies”, 
it would take 12.5 years 
after ceasing alcohol 
consumption before a 
person had the same level 
of risk as a current drinker, 
and 29.1 (18.6–48.7) years 
before a person had the 
same level of risk as a 
never-drinker [16.5 (12.7–
23.8) years when studies 
from all countries were 
included]. After cessation, 
it was found each 
additional year of cessation 
was associated with an OR 
of oesophageal cancers of 
0.94 (0.92–0.96). The OR 
for never-drinkers 
compared with current 
Increased risk 
within the first 
~12.5 years of 
drinking 
cessation, then 
a decreased 
risk thereafter. 
Significant 
heterogeneity was 
detected; however, 
this was accounted 
for after study 
factors such as 
study type and 
location variables 
were added to the 
model. 
5/11 Possible 
increased risk 
for squamous 
cell carcinoma. 
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drinkers was 0.36 (no 
confidence interval given). 
Tramacere 
et al, 
(2012c)(229) 
Systematic 
review and 
meta-
analysis. 
UK, US, 
Netherlands
. 
4 prospective 
studies, ~1.8 
million 
participants. 
Drinkers (also 
light, moderate 
and heavy 
drinkers) vs. 
non-drinkers 
for RR and 
95% CIs of 
oesophageal 
and gastric 
cardia 
adenocarcinom
aLight drinkers: 
<= 1 drink/day; 
moderate 
drinkers: > 1 to 
< 4 drinks/day; 
heavy drinkers: 
>= 4 
drinks/day. 
RR 0.96 (0.85–1.09) for 
drinkers vs. non-drinkers; 
RR 0.92 (0.78–1.09) for 
light drinkers; RR 0.86 
(0.64–1.16) for moderate 
drinkers; RR 1.03 (0.81–
1.30) for heavy drinkers. 
No significant 
effects. 
No heterogeneity 
for prospective 
studies. 
5/11 Weak evidence 
for 
adenocarcinoma. 
Fahey et 
al, 
(2015)(136) 
Systematic 
review and 
meta-
analysis. 
US, Asia, 
Europe, 
Australia. 
8 studies 
fulfilled the 
criteria.  
Estimation of 
the association 
between 
alcohol and 
mortality from 
oesophageal 
cancer. 
The risk of death for 
participants with the 
highest weekly alcohol 
consumption compared 
with the lowest was 
significant for squamous 
cell carcinoma (SCC) 1.40 
(1.07–1.82); no effect was 
observed for 
adenocarcinoma. 
Increased risk 
for SCC. 
Moderate 
heterogeneity was 
observed among 
studies. 
7/11 Possible 
increased risk 
for squamous 
cell carcinoma. 
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Ovary 
Choi et al, 
(2017)(75) 
  
Systematic 
review and 
meta-
analysis. 
US, 
Canada, 
UK. 
5 prospective 
studies, 
1,654,968 
participants. 
Very light 
drinking (<= 
0.5 
drinks/day or 
<= 7.5 g 
ethanol/day), 
light drinking 
(> 0.5 and <= 
1 drink/day or 
> 7.5 and <= 
15 g 
ethanol/day) 
and moderate 
drinking (> 1 
and <= 2 
drinks/day or 
>15 and <= 
30 g 
ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of 
ovarian 
cancer. 
RR 1.00 (0.82–1.22) for 
very light drinking vs. 
non- or occasional 
drinking; 1.02 (0.88–
1.20) for light drinking 
vs. non- or occasional 
drinking; 1.20 (0.92–
1.56) for moderate 
drinking vs. non- or 
occasional drinking. 
No significant 
effect. 
i-squared statistic 
reported but a 
formal test of 
heterogeneity was 
not conducted, 
nevertheless used 
random-effects 
model. 
7/11 
Weak 
Bagnardi 
et al, 
(2015)(214) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
13 prospective 
studies (3 
prospective 
studies and 1 
pooled 
Light 
drinking (<= 
12.5 g 
ethanol/day) 
and moderate 
RR 1.02 (0.96–1.08) for 
light drinking vs. non- 
and occasional drinking; 
1.08 (0.99-–1.19) for 
moderate drinking vs. 
No significant 
effect. 
Heterogeneity test 
not reported but 
used random-effects 
model. 
4/11 
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analysis of 10 
prospective 
studies). 
drinking (> 
12.5 and <= 
50 g 
ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of 
ovarian 
cancer. 
non- and occasional 
drinking. 
Rota et al, 
(2012a)(230) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
13 prospective 
studies (3 
prospective 
studies and 1 
pooled 
analysis of 10 
prospective 
studies), 
1,946,053 
participants. 
Drinkers (also 
light and 
moderate 
drinkers) vs. 
non-drinkers 
for RR and 
95% CIs of 
epithelial 
ovarian cancer. 
Light drinkers: 
<= 1 drink/day; 
moderate 
drinkers: > 1 to 
< 3 drinks/day. 
RR 1.03 (0.97–1.09) for 
drinkers vs. non-drinkers; 
RR 1.02 (0.96–1.08) for 
light drinkers; RR 1.10 
(0.96–1.25) for moderate 
drinkers. 
No significant 
effect. 
There was no 
significant 
heterogeneity. No 
prospective studies 
were found for 
heavy drinkers. 
7/11 
Weak 
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Yan-Hong 
et al, 
(2015)(231) 
Meta-
analysis. 
North 
America, 
UK, Sweden, 
Netherlands, 
Japan.  
13 prospective 
studies with a 
total of 
1,996,841 
individuals. 
Association 
between 
different 
levels of 
alcohol intake 
and incidence 
of ovarian 
cancer. 
Low levels of alcohol 
consumption were 
associated with decreased 
ovarian cancer risk; RR 
0.96 (0.93–1.00). 
Reduced risk.  Low intake of 
alcohol was defined 
as consuming 
<15g/day. Moderate 
and heavy alcohol 
consumption were 
not associated with 
risk of ovarian 
cancer. 
9/11 
Pancreas 
Choi et al, 
(2017)(75) 
Systematic 
review and 
meta-
analysis. 
US, Sweden, 
Netherlands, 
Korea, Hong 
Kong. 
9 prospective 
studies, 
2,958,607 
participants. 
Very light 
drinking (<= 
0.5 drinks/day 
or <= 7.5 g 
ethanol/day), 
light drinking 
(> 0.5 and <= 1 
drink/day or > 
7.5 and <= 15 
g ethanol/day) 
and moderate 
drinking (> 1 
and <= 2 
drinks/day or 
>15 and <= 30 
g ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of 
RR 1.06 (0.87–1.30) for 
very light drinking vs. non- 
or occasional drinking for 
incidence (no differences 
when restricted to men); 
1.02 (0.83–1.26) for light 
drinking vs. non- or 
occasional drinking for 
incidence (no differences 
when restricted to men); 
1.03 (0.86–1.23) for 
moderate drinking vs. non- 
or occasional drinking for 
incidence (no differences 
when stratified by sex). RR 
0.52 (0.23–1.15) for very 
light drinking vs. non- or 
occasional drinking for 
mortality in men; 0.93 
(0.78–1.11) for light 
drinking vs. non- or 
No significant 
effect. 
i-squared statistic 
reported but a 
formal test of 
heterogeneity was 
not conducted, 
nevertheless used 
random-effects 
model. 
7/11 Probable 
evidence for 
cancer 
incidence. 
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pancreatic 
cancer 
incidence and 
mortality. 
occasional drinking for 
mortality (no differences 
when stratified by sex), 
0.95 (0.72–1.27) for 
moderate drinking vs. non- 
or occasional drinking for 
mortality (no differences 
when stratified by sex). 
Alsamarrai 
et al, 
(2014)(115) 
Systematic 
review and 
meta-
analysis. 
US. 2 prospective 
studies, 
814,510 
participants. 
Drinking vs. 
non-drinking 
for RR and 
95% CI of 
pancreatic 
cancer. 
RR 1.01 (0.80–1.27) for 
drinking vs. non-drinking. 
No significant 
effect. 
Significant 
heterogeneity 
detected. Both 
studies were of high 
quality. Test for 
publication bias was 
only performed 
when examining 
analyses of 3 or 
more studies. 
8/11 
Probable 
evidence for 
cancer 
incidence. 
Bagnardi 
et al, 
(2015)(214) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
18 prospective 
studies. 
Light drinking 
(<= 12.5 g 
ethanol/day), 
moderate 
drinking (> 
12.5 and <= 50 
g ethanol/day) 
and heavy 
drinking (> 50 
g ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of 
RR 0.95 (0.89–1.01) for 
light drinking vs. non- 
and occasional drinking; 
1.06 (0.99–1.13) for 
moderate drinking vs. 
non- and occasional 
drinking; 1.18 (1.08–
1.28) for heavy drinking 
vs. non- and occasional 
drinking. 
Increased risk 
with heavy 
drinking. 
Heterogeneity test 
not reported but 
used random-effects 
model. 
4/11 
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pancreatic 
cancer. 
Lu et al, 
(2017)(122)  
Meta-
analysis. 
US, Japan, 
China, 
Europe.  
12 studies; 5 
were cohort 
studies. 
Drinking 
patterns and 
pancreatic 
cancer risk.  
The highest drinking 
pattern was associated 
with increased risk 1.29 
(1.10–1.48) compared 
with the lowest. Pooled 
analysis of only cohort 
studies was 1.14 (1.06–
1.23) for the highest 
pattern compared with the 
lowest. 
Increased risk. Different forms of 
alcohol intake were 
converted into grams 
of ethanol per day 
(alcohol consumption 
< 12.5 g/day (1 
drink/day) for men or 
7.5 g/day (0.5 
drinks/day) for 
women was defined 
as a low alcohol 
intake; consumption 
>50 g/day (4 
drinks/day) for men 
or 25 g/day (2 
drinks/day) for 
women was defined 
as a high alcohol 
intake; and 
consumption >12.5 
g/day (1 drink/day) 
and <50 g/day (4 
drinks/day) for men 
or >7.5 g/day (0.5 
drinks/day) and <25 
g/day (2 drinks/day) 
for women was 
defined as a light–
moderate alcohol 
intake). 
9/11 
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Wang et 
al, 
(2016)(79) 
Meta-
analysis. 
US, Japan, 
Australia, 
Europe.  
19 cohort 
studies with a 
total sample 
of 4,211,129 
individuals. 
Association 
between light 
(0–12 g per 
day), 
moderate 
(≥12–24 g per 
day), or 
heavy alcohol 
(≥24 g per 
day) intake 
and the risk 
of pancreatic 
cancer. 
Heavy alcohol intake was 
associated with an 
increased risk of 
pancreatic cancer 1.15 
(1.06–1.25) compared 
with the lowest group. 
Light or moderate intake 
was not associated with 
the outcome. Alcohol 
intake greater than 15 
g/day seems to be 
associated with an 
increased pancreatic 
cancer incidence. 
Increased risk. A drink was defined 
as 12 g of alcohol. 
In subgroup 
analysis by sex, 
results were only 
significant for men 
with heavy alcohol 
intake. Analysis by 
types of alcohol 
showed that heavy 
liquor consumption 
was associated with 
increased risk in 
both men and 
women. 
9/11 
Probable 
evidence for 
cancer 
incidence. 
Maisonneuve 
et al, 
(2015)(232)  
Summary 
review of 
meta-
analytical 
studies. 
A wide 
range of 
countries. 
Summary of 
4 meta-
analyses. 
Association 
between 
alcohol intake 
and 
pancreatic 
cancer risk. 
Daily consumption of 30 
g of alcohol, or the 
equivalent of >3 glasses 
of any alcoholic drink, 
was associated with a 
20% increased risk of 
cancer compared with 
non- or occasional 
drinkers. 
Increased risk. Confidence 
intervals were not 
reported. 
N/A 
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Prostate 
Choi et al, 
(2017)(75) 
Systematic 
review and 
meta-
analysis. 
US, 
Netherlands, 
Canada, 
Denmark, 
Korea, Hong 
Kong. 
19 
prospective 
studies, 
1,639,337 
participants. 
Very light 
drinking (<= 
0.5 drinks/day 
or <= 7.5 g 
ethanol/day), 
light drinking 
(> 0.5 and <= 1 
drink/day or > 
7.5 and <= 15 
g ethanol/day) 
and moderate 
drinking (> 1 
and <= 2 
drinks/day or 
>15 and <= 30 
g ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of prostate 
cancer 
incidence and 
mortality. 
RR 1.16 (0.94–1.44) for 
very light drinking vs. 
non- or occasional 
drinking for incidence; 
1.04 (0.97–1.11) for light 
drinking vs. non- or 
occasional drinking for 
incidence; 1.04 (0.96–
1.11) for moderate 
drinking vs. non- or 
occasional drinking for 
incidence. RR 0.92 (0.68–
1.25) for very light 
drinking vs. non- or 
occasional drinking for 
mortality; 1.14 (0.85–
1.52) for light drinking 
vs. non- or occasional 
drinking for mortality; 
1.72 (0.72–4.22) for 
moderate drinking vs. 
non- or occasional 
drinking for mortality. 
No significant 
effect. 
i-squared statistic 
reported but a 
formal test of 
heterogeneity was 
not conducted, 
nevertheless used 
random-effects 
model. 
7/11 Weak. 
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Bagnardi 
et al, 
(2015)(214) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
20 prospective 
studies. 
Light drinking 
(<= 12.5 g 
ethanol/day), 
moderate 
drinking (> 
12.5 and <= 50 
g ethanol/day) 
and heavy 
drinking (> 50 
g ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of 
pancreatic 
cancer. 
RR 1.04 (1.01–1.08) for 
light drinking vs. non- 
and occasional drinking; 
1.06 (0.99–1.13) for 
moderate drinking vs. 
non- and occasional 
drinking; 1.04 (0.90–
1.21) for heavy drinking 
vs. non- and occasional 
drinking. 
Increased risk 
with light 
drinking but not 
with moderate 
or heavy 
drinking. 
Consistent with 
a slight 
increased risk. 
Heterogeneity test 
not reported but 
used random-effects 
model. 
4/11 Weak. 
Rota et al, 
(2012b)(233) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
22 prospective 
studies. 
Drinkers, light 
drinkers (< 1 
drink or <= 
12.5 g 
ethanol/day), 
moderate 
drinkers (> 1 to 
< 4 drinks or > 
12.5 to < 50 g 
ethanol/day) 
and heavy 
drinkers (>= 4 
drinks or >= 50 
g ethanol/day) 
vs. non-
drinkers for 
RR 1.06 (1.00–1.13) for 
drinkers vs. non-drinkers; 
RR 1.04 (1.01–1.08) for 
light drinkers; RR 1.06 
(0.99–1.14) for moderate 
drinkers; RR 1.04 (0.90–
1.21) for heavy drinkers. 
Overall, no 
evidence of a 
material 
association. 
There was 
significant 
heterogeneity for 
the analysis of 
drinkers overall and 
moderate drinkers, 
but not for light 
drinkers and heavy 
drinkers. 
6/11 
Weak 
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RR and 95% 
CIs of prostate 
cancer. 
Zhao et al, 
(2016)(234) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
27 studies 
were 
included; 17 
were 
prospective 
studies. 
Risks of 
prostate cancer 
incidence or 
mortality 
associated with 
different levels 
of alcohol 
intake 
(grams/day) vs. 
abstainers.  
There was a significant 
increased risk of prostate 
cancer among low 
drinkers [1.08 (1.04–
1.11)], medium [1.07 
(1.02–1.12)], high 1.14 
[(1.08–1.22)] and higher 
volume [1.18 (1.10–
1.27)] drinkers. In fact, 
any drinking was 
associated with increased 
risk [1.08 (1.01-1.17)].  
Increased risk. Low volume was 
defined as 
consumption of 
alcohol between 
1.30 and < 25 
g/day, medium 
between 25 and <45 
g/day, high between 
45 and <65 g/day, 
higher volume as 
65+ g/day. No 
effect modification 
was observed by 
study design. 
8/11 
Thyroid 
Choi et al, 
(2017)(75) 
Systematic 
review and 
meta-
analysis. 
Canada, 
UK, US. 
6 prospective 
studies, 
2,234,536 
participants. 
Very light 
drinking (<= 
0.5 
drinks/day or 
<= 7.5 g 
ethanol/day), 
light drinking 
(> 0.5 and <= 
1 drink/day or 
> 7.5 and <= 
15 g 
ethanol/day) 
and moderate 
RR 1.01 (0.76–1.36) for 
very light drinking vs. 
non- or occasional 
drinking; 0.89 (0.79–
1.00) for light drinking 
vs. non- or occasional 
drinking (not significant 
when stratified by sex); 
0.68 (0.56–0.84) for 
moderate drinking vs. 
non- or occasional 
drinking (significant in 
women when stratified by 
Decreased risk 
for light 
drinking 
overall, 
decreased risk 
for moderate 
drinking 
overall and in 
women. 
i-squared statistic 
reported but a 
formal test of 
heterogeneity was 
not conducted, 
nevertheless used 
random-effects 
model. 
7/11 
Possible 
decreased risk. 
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drinking (> 1 
and <= 2 
drinks/day or 
>15 and <= 
30 g 
ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of thyroid 
cancer. 
sex). 
Bagnardi 
et al, 
(2015)(214) 
Systematic 
review and 
meta-
analysis. 
A wide 
range of 
countries. 
9 studies (6 
prospective 
and 3 case-
control 
studies). 
Light drinking 
(<= 12.5 g 
ethanol/day) 
and moderate 
drinking (> 
12.5 and <= 50 
g ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of thyroid 
cancer. 
Fractional 
polynomial 
curve of 
association 
between 
alcohol 
consumption 
and RR and 
RR 0.81 (0.74–0.88) for 
light drinking vs. non- and 
occasional drinking; 0.81 
(0.71–0.94) for moderate 
drinking vs. non- and 
occasional drinking. When 
fitting a fractional 
polynomial, increased 
alcohol consumption was 
associated with decreased 
risk of thyroid cancer, but 
this decrease was not 
significant in the heaviest 
drinkers. 
Decreased risk.  Heterogeneity test 
not reported but 
used random-effects 
model. 
4/11 
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95% CIs of 
thyroid cancer. 
Uterus 
Choi et al, 
(2017)(75)  
Systematic 
review and 
meta-
analysis. 
US, Sweden, 
Netherlands, 
Canada, UK. 
9 prospective 
studies, 
1,714,633 
participants. 
Very light 
drinking (<= 
0.5 drinks/day 
or <= 7.5 g 
ethanol/day), 
light drinking 
(> 0.5 and <= 1 
drink/day or > 
7.5 and <= 15 
g ethanol/day) 
and moderate 
drinking (> 1 
and <= 2 
drinks/day or 
>15 and <= 30 
g ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of 
endometrial 
cancer. 
RR 0.95 (0.80–1.12) for 
very light drinking vs. 
non- or occasional 
drinking; 0.98 (0.93–
1.03) for light drinking 
vs. non- or occasional 
drinking; 0.93 (0.84–
1.04) for moderate 
drinking vs. non- or 
occasional drinking. 
No significant 
effect. 
i-squared statistic 
reported but a 
formal test of 
heterogeneity was 
not conducted, 
nevertheless used 
random-effects 
model. 
7/11 Weak. 
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Bagnardi 
et al, 
(2015)(214) 
Systematic 
review and 
meta-
analysis. 
UK, 
Sweden, 
Netherlands, 
US, and 
possibly 
other 
countries. 
8 prospective 
studies. 
Light 
drinking (<= 
12.5 g 
ethanol/day) 
and moderate 
drinking (> 
12.5 and <= 
50 g 
ethanol/day) 
vs. non- and 
occasional 
drinking for 
RR and 95% 
CIs of 
endometrial 
cancer. 
RR 0.97 (0.92–1.02) for 
light drinking vs. non- 
and occasional drinking; 
1.06 (0.89–1.26) for 
moderate drinking vs. 
non- and occasional 
drinking. 
No significant 
effect. 
Heterogeneity test 
not reported but 
used random-effects 
model. 
4/11 Weak. 
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Zhou et al, 
(2017)(126) 
Meta-
analysis. 
North 
America, 
Europe. 
10 prospective 
studies with a 
total of 
1,612,798 
participants. 
Association 
between 
alcohol intake 
and 
endometrial 
cancer (EC) 
risk. 
No effects were observed 
for different alcoholic 
beverages or levels. 
No significant 
effect. 
Moderate alcohol 
consumption was 
defined as 
consumption of less 
than 1 drink per day 
and heavy as 
consuming more 
than 1 drink per 
day; this was done 
according to the 
Dietary Guidelines 
for Americans. For 
dose–response 
relationships, all 
measures of alcohol 
intake were 
converted to grams 
per day, with one 
standard drink 
containing 12 g of 
alcohol. In 
subgroup analyses, 
this association was 
not modified by 
other lifestyle 
factors. 
10/11 Weak. 
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Grey literature 
International 
Agency for 
Cancer 
Research, 
(2012)(78) 
Views and 
expert 
opinions of 
an IARC 
Working 
Group on 
the 
Evaluation 
of 
carcinogeni
c risks to 
humans. 
A wide 
range of 
countries. 
N/A Alcohol 
consumption. 
Alcohol consumption is 
causally related to cancers 
of the oral cavity and 
pharynx, larynx, 
oesophagus (squamous cell 
carcinoma), colorectum 
(including both colon and 
rectum; possible there may 
only be an increased risk at 
> 30 g ethanol/day), liver 
and female breast. Alcohol 
consumption may be 
causally related to an 
increased risk of pancreatic 
cancer at > 30 g 
ethanol/day; however, this 
remains unconfirmed. 
Studies generally find an 
inverse association 
between alcohol 
consumption and risk of 
Hodgkin and non-Hodgkin 
lymphoma. Alcohol 
consumption is not 
associated with risk of 
oesophageal 
adenocarcinoma, kidney or 
bladder cancer. There was 
little evidence for an 
association between 
alcohol consumption and 
ovarian or prostate cancer. 
Increased risk 
for at least 7 
cancer types; 
possible 
decreased risk 
for 2 cancer 
types. 
  N/A Convincing for 
increased risk of 
7 cancer types 
(oral cavity, 
pharynx, larynx, 
oesophageal 
squamous cell 
carcinoma, 
colorectum, 
liver and female 
breast).  
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There was not enough 
evidence or inconsistent 
evidence for associations 
between alcohol 
consumption and risk of 
lung, male breast, cervical, 
endometrial and thyroid 
cancers and leukaemia 
(including for maternal 
consumption during 
pregnancy and risk of 
leukaemia in children) and 
melanoma. 
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review, 
(2017)(29) 
Systematic 
review and 
meta-
analysis. 
A range of 
countries. 
62 studies. Association 
between 
alcohol intake 
and breast 
cancer risk. 
In dose–response analysis, 
a 10 g increment in 
alcohol a day was 
associated with any 
incidence of breast cancer, 
premenopausal or 
postmenopausal. The 
respective RR were, 1.07 
(1.05–109), 1.05 (1.02–
1.08) and 1.09 (1.07–
1.12). No effect was 
detected for breast cancer 
mortality. 
Increased risk. Three studies 
reported results on 
alcohol intake in 
early ages and breast 
cancer risk; 
inconsistent results 
were observed. In 
stratified analysis by 
region and any 
breast cancer, 
association was only 
significant for 
European and North 
American regions. 
Risk of any cancer 
did not differ by 
type of alcohol 
(liquor, wine or 
beer). 
N/A   
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World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review, 
(2017)(20) 
Systematic 
review and 
meta-
analysis. 
A range of 
countries. 
8 studies 
were 
identified 
after the 
2010 
systematic 
literature 
review. 
Association 
between 
alcohol intake 
and colorectal 
cancer risk. 
In dose–response 
analysis, a 10 g increment 
in alcohol intake a day 
was associated with 
colorectal cancer risk; RR 
1.07 (1.05–1.09). 
Increased risk. Association did not 
differ by sex, 
tumour site or 
geographical 
location. 
N/A   
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review, 
(2014)(66)  
Systematic 
review and 
meta-
analysis. 
A range of 
countries. 
22 studies. Association 
between 
alcohol intake 
and bladder 
cancer risk. 
There was no evidence of 
a dose response between 
alcohol intake and 
bladder cancer. 
No significant 
effect. 
  N/A   
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review, 
(2012)(30)  
Systematic 
review and 
meta-
analysis. 
A range of 
countries. 
10 cohort 
studies. 
Association 
between 
alcohol intake 
and 
endometrial 
cancer risk. 
There was no evidence of 
a dose response between 
alcohol intake and 
endometrial cancer. 
No significant 
effect. 
Risks did not differ 
by types of alcohol 
(beer, wine, liquor). 
N/A   
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World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review, 
(2015)(40)  
Systematic 
review and 
meta-
analysis. 
A range of 
countries. 
8 cohort 
studies were 
included in 
the meta-
analysis. 
Association 
between 
alcohol intake 
and kidney 
cancer risk. 
In dose–response 
analysis, a 10 g increment 
in alcohol intake a day 
was associated with 
reduced kidney cancer 
risk. RR 0.92 (0.86–0.97). 
Reduced risk. Risk did not differ 
by sex. In dose 
response analysis 
by types of alcohol, 
results were only 
significant for beer. 
N/A   
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review, 
(2013)(39)  
Systematic 
review and 
meta-
analysis. 
A range of 
countries. 
10 cohort 
studies were 
included in 
the meta-
analysis. 
Association 
between 
alcohol intake 
and ovarian 
cancer risk. 
The results found no 
evidence of association of 
alcohol intake with 
ovarian cancer risk. 
No significant 
effect. 
  N/A   
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review, 
(2015)(21)  
Systematic 
review and 
meta-
analysis. 
A range of 
countries. 
19 cohort 
studies were 
included in 
the meta-
analysis. 
Association 
between 
alcohol intake 
and liver 
cancer risk. 
An increase of 10 grams 
of ethanol per day was 
associated with increased 
risk 1.04 (1.02–1.06). 
Increased risk. Effect estimates 
were stronger in 
women than in men. 
The summary RR 
for incidence of 
liver cancer was 
1.12 (1.05–1.18) 
and 1.02 (1.01–
1.03) for mortality. 
N/A   
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World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review, 
(2015)(116)  
Systematic 
review and 
meta-
analysis. 
A range of 
countries. 
8 studies 
were 
included in 
the dose–
response 
meta-
analysis. 
Alcohol 
consumption 
and risk of 
oesophageal 
cancer. 
In dose–response 
analysis, a 10 gram 
increment in intake of 
ethanol/day was 
associated with an 
increased risk of 
oesophageal squamous 
cell carcinoma: RR 1.25 
(1.12–1.41); but not of 
oesophageal 
adenocarcinoma: RR 1.00 
(0.98–1.02). 
Increased risk 
for oesophageal 
squamous cell 
carcinoma but 
not oesophageal 
adenocarcinom
a. 
Significant 
heterogeneity in 
oesophageal 
squamous cell 
carcinoma analysis. 
N/A   
World 
Cancer 
Research 
Fund 
International 
Systematic 
Literature 
Review, 
(2014)(31)  
Systematic 
review. 
    Alcohol 
consumption 
and risk of 
prostate 
cancer. 
“Limited evidence — no 
conclusion.” 
N/A   N/A   
 
Life stages: For adolescence, see Mahabir et al., 2013. No other systematic review or meta-analyses were found specifically focusing on other life stages. 
 
Priority population groups: No systematic reviews or meta-analyses were found specifically focusing on migrants, culturally and linguistically diverse communities or Aboriginal populations. 
 
RR, relative risk. OR, odds ratio. HR, hazards ratio. CI, confidence interval. UK, United Kingdom. US, United States. 
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APPENDIX B 
 
“FAT BUT FIT” IN THE CLEAR STUDY 
 
Appendix B.1 
 
The Cancer, Lifestyle and Evaluation of Risk Study (CLEAR) started participant 
recruitment in 2006. To be eligible in this study, cases and controls had to be 
residents in the state of New South Wales (NSW), Australia and were older than 18 
years of age. Cases were eligible if they self-reported a new cancer diagnosis up to 
18 months before enrolment whereas controls were spouses of cases who were 
cancer-free. Identification of potential participants was conducted by a targeted and 
non-targeted recruitment approach. The former used medical or health related 
databases and provided about 75% all potential participants (7,862 cases and 1,972 
controls) while the latter provided the remaining 25% (3,240 cases and 829 controls); 
the estimated case response rate ranged between 20-40% and the participation of 
spouse controls was around 50%. Cancers with short survival rate may be 
underrepresented.  
 
After assessment for eligibility, 8,569 cases and 2,247 control qualified to participate 
in the study. Following consent, all participants completed a self-administered 
questionnaire. Most of the questions were drawn from well-established studies to 
maintained comparability, validity and reliability, requesting information on 
anthropometric measures, smoking status, alcohol consumption, physical activity, 
sociodemographic characteristics, sex-specific hormonal and reproductive history, 
history of tattoos and piercings, cancer screening and testing, familial history of 
cancer and diet. Verification of self-reported cancer was corroborated against the 
NSW cancer registry for 20% of participants since linkage updates were not 
available due to delays in processing cancer registrations. Therefore, a total of 3,375 
participants (2,944 cases and 791 controls) were used to calculate the positive 
predictive value (PPV) to confirm accuracy of self-report which was around 95% for 
most cancers analysed in Chapter 6 with the exception of ovarian cancer (76%).  
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The CLEAR design allows to use spouses of cases as a pool of potential controls 
who can be matched by sex specific cancers, providing several choices of controls 
based on the outcome of interest. Partner-matching at the design stage was simply to 
provide CLEAR with a source of controls, not as a method for adjusting for certain 
confounders. Age adjustment and all other confounder adjustment were conducted 
through multivariable regression analysis.  
 
A comparison of several sociodemographic characteristics of CLEAR cases and 
controls with the NSW Population Health Survey showed in general consistent 
proportions between the three groups based on sex, migration status, English 
language and educational attainment. 
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Appendix B.2 
 
Any cancer group in females consisted of the following cancers 
 
Cancer type Frequency Percent 
Breast 2016 52.4 
Bowel 418 10.9 
Other 189 4.9 
Lung 160 4.2 
Ovary 148 3.9 
Thyroid 147 3.8 
Non-Hodgkin 
Lymphoma 
114 3.0 
Uterus 80 2.1 
Endometrium 72 1.9 
Kidney 53 1.4 
Leukemia 49 1.3 
Cervix 47 1.2 
Lymphoma NOS 43 1.1 
Hodgkin Lymphoma 38 1.0 
Multiple Myeloma 38 1.0 
Pancreas 38 1.0 
Bladder 32 0.8 
Multiple primary 32 0.8 
Brain 30 0.8 
Stomach 21 0.5 
Liver 17 0.4 
Anus 16 0.4 
Esophagus 13 0.3 
Tongue 11 0.3 
Other skin cancer 10 0.2 
Throat 7 0.2 
Tonsil 6 0.2 
Total 3845 100 
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Any cancer group in males consisted of the following cancers 
 
 
 
Cancer type Frequency Percent 
Prostate 1231 41.2 
Bowel 516 17.3 
Other 214 7.3 
Lung 117 3.9 
Non-Hodgkin 
Lymphoma 
106 3.6 
Bladder 79 2.7 
Kidney 75 2.5 
Multiple Myeloma 67 2.2 
Testis 58 1.9 
Esophagus 55 1.8 
Leukemia 51 1.7 
Lymphoma NOS 50 1.7 
Multiple primary 49 1.6 
Brain 40 1.3 
Throat 40 1.3 
Thyroid 38 1.3 
Pancreas 37 1.2 
Tongue 32 1.1 
Tonsil 28 1.0 
Liver 27 0.9 
Stomach 24 0.8 
Hodgkin Lymphoma 22 0.7 
Other skin cancer 14 0.5 
Breast 10 0.3 
Anus 6 0.2 
Total 2986 100 
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Appendix B.3 
 
 
 
 
 
 
 
Cross tabulation between vigorous and less vigorous activity to derive levels of 
physical activity; red zone (nil) (n=2422), yellow (low) (n=1800), blue (moderate) 
(n=2358) and green (high PA level) (n=2243). 
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Appendix B.4 
 
List of potential confounders besides physical activity and body mass index 
identified in the CLEAR study New South Wales, Australia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These confounders were identified in the references used for this paper in addition to 
well established cohort studies such: as European Prospective Investigation into 
Cancer (EPIC), Nurses’ Health Study (NHS), Melbourne Collaborative Cohort 
Cancer 
type 
Potential confounder 
Uterine 
(UC) 
17,20,38-42 
Age                   
Ethnicity 
Smoking status        
Age at menarche 
Oral contraception 
Menopausal status                                 
Nulliparity 
HRT 
Education                                         
Diabetes  
Alcohol 
Ovarian 
(OC) 
43-45 
Age 
Ethnicity 
Smoking status 
Oral contraception 
Tubal ligation 
Unilateral oophorectomy 
Menopausal status 
Maternal history of ovarian cancer 
Age at menarche 
Parity 
Hysterectomy 
Alcohol 
HT                                                   
Education 
Infertility                                            
 
Breast  
(BC) 
19,27-34 
Age                                                      
Oral contraception 
Maternal history of breast cancer 
Age at menarche       
Breastfeeding   
Age at first pregnancy                         
Parity                                                  
HRT 
Education                                           
Alcohol 
Smoking 
 
Prostate 
(PC) 
46-50 
Age                                                     
Smoking status                                   
BPH 
Education       
Paternal history of prostate cancer 
Alcohol 
Ethnicity                                            
PSA test 
Diabetes                                             
SES 
 
Colorectal 
(CRC) 
15,16,35-37 
Age 
Sex                                                       
Education                                           
Screening  
Smoking 
Parental history of colorectal cancer 
Colorectal polyps 
Ethnicity 
Alcohol                                               
Diabetes 
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Appendix B.6 
 
Odds ratios and 95% CI of cancer risk according to BMI and PA levels in women 
and men from the CLEAR study, including missing covariates 
 
 
 
 
 
 
 
 
 
Adjusted Odds Ratios (95% CI) 
 Body Mass Index 
Cancer 
type 
Healthy 
range 
Ca/ 
Co 
Overweight 
Ca/ 
Co 
Obese 
Ca/ 
Co 
Women 
Any 
cancera 
1.00 
(Reference) 
1767
/470 
1.02 
(0.87-1.19) 
1227/
334 
1.13 
(0.94-1.35) 
P-value 0.41 
964/ 
239 
BCb 
1.00 
(Reference) 
558/ 
346 
1.08 
(0.88-1.32) 
459/ 
274 
1.06 
(0.85-1.33) 
P-value 0.75 
367/ 
212 
CRCc 
1.00 
(Reference) 
187/ 
470 
1.00 
(0.77-1.31) 
143/ 
344 
0.89 
(0.66-1.21) 
P-value 0.73 
101/ 
234 
UCd 
1.00 
(Reference) 
61/ 
372 
0.84 
(0.54-1.30) 
39/ 
252 
1.96 
(1.30-2.98) 
P-value 0.004 
59/ 
157 
OCe 
1.00 
(Reference) 
67/ 
437 
0.83 
(0.54-1.26) 
46/ 
326 
1.29 
(0.82-2.01) 
P-value 0.19 
45/ 
216 
Men 
Any 
cancerf 
1.00 
(Reference) 
887/ 
306 
1.09 
(0.92-1.30) 
1464/
473 
1.42 
(1.15-1.75) 
P-value 0.003 
839/ 
209 
CRCg 
1.00 
(Reference) 
130/ 
306 
1.31 
(1.00-1.72) 
247/ 
473 
2.18 
(1.60-2.98) 
P-value<.0001 
174/ 
209 
PCh 
1.00 
(Reference) 
355/ 
306 
1.21 
(0.99-1.49) 
637/ 
473 
1.53 
(1.19-1.96) 
P-value 0.004 
319/ 
209 
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Adjusted Odds Ratios (95% CI) 
Physical Activity Levels 
 Nil 
Ca/ 
Co 
Low 
Ca/ 
Co 
Moderate 
Ca/ 
Co 
High 
Ca/ 
Co 
Missing 
Ca/ 
Co 
Women 
Any 
cancera 
1.00 
(Reference) 
1206/ 
263 
0.69 
(0.57-0.84) 
761/ 
237 
0.77 
(0.64-0.93) 
999/ 
293 
0.84 
(0.69-1.03) 
P-value 0.003 
879/ 
231 
0.43 
(0.16-1.15) 
12/6 
BCb 
1.00 
(Reference) 
439/ 
212 
0.66 
(0.51-0.86) 
254/ 
179 
0.72 
(0.57-0.91) 
349/ 
233 
0.80 
(0.63-1.02) 
P-value 0.01 
339/ 
204 
0.37 
(0.08-1.71) 
3/4 
CRCc 
1.00 
(Reference) 
154/ 
267 
0.54 
(0.39-0.75) 
71/ 
242 
0.71 
(0.53-0.95) 
121/ 
298 
0.60 
(0.43-0.83) 
P-value 0.001 
84/ 
240 
0.27 
(0.03-2.29) 
1/6 
UCd 
1.00 
(Reference) 
57/ 
180 
0.56 
(0.34-0.93) 
31/ 
190 
0.66 
(0.44-1.04) 
45/ 
228 
0.45 
(0.26-0.76) 
P-value 0.02 
24/ 
180 
2.46 
(0.36-16.76) 
2/3 
OCe 
1.00 
(Reference) 
44/ 
239 
0.79 
(0.47-1.31) 
28/ 
227 
1.02 
(0.65-1.62) 
46/ 
280 
0.88 
(0.53-1.45) 
P-value 0.74 
33/ 
221 
1.86 
(0.33-10.52) 
5/2 
Men 
Any 
cancerf 
1.00 
(Reference) 
777/ 
233 
0.98 
(0.79-1.23) 
630/ 
211 
1.00 
(0.81-1.23) 
840/ 
266 
1.04 
(0.85-1.28) 
P-value 0.93 
925/ 
276 
1.79 
(0.40-8.09) 
18/2 
CRCg 
1.00 
(Reference) 
145/ 
233 
0.96 
(0.69-1.34) 
100/ 
211 
1.00 
(0.74-1.37) 
141/ 
266 
1.13 
(0.83-1.53) 
P-value 0.85 
163/ 
276 
1.30 
(0.16-10.59) 
2/2 
PCh 
1.00 
(Reference) 
283/ 
233 
1.00 
(0.75-1.32) 
259/ 
211 
1.11 
(0.85-1.45) 
371/ 
266 
1.10 
(0.85-1.43) 
P-value 0.58 
390/ 
276 
3.25 
(0.61-17.41) 
8/2 
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APPENDIX C 
 
“FAT BUT FIT” IN THE 45 AND UP STUDY 
 
Appendix C.1 
 
The 45 and Up Study was conceived as a large population-based cohort study 
with the aim of investigating a broad set of exposures and outcomes of public 
health significance in the ageing population, in response to gaps in the existing 
evidence. Recruitment started in 2006 with the objective of enrolling 250,000 
participants by the end on 2009. Potential participants were men and women aged 
45 years and over and resident in New South Wales (NSW), Australia who were 
registered in the Department of Human Services database (formerly known as 
Medicare Australia); this database includes Australian citizens, permanent 
residents and some temporary residents and refuges. Eligible participants were 
randomly sampled and mailed an invitation to join the study, an information 
leaflet, study questionnaire and consent form with a reply-paid envelope. The 
study over-sampled individuals older than 80 years and those who lived in rural 
and remote areas. The estimated response rate was around 18%. 
 
The baseline questionnaire included questions on sociodemographic and ethnic 
background, measures of health status, past medical and surgical history, cigarette 
smoking, alcohol consumption, diet, physical activity, reproductive and hormonal 
factors, healthcare and medication use. Questionnaire data can be linked to 
routinely collected administrative data from several databases and registries by the 
New South Wales Centre for Health Record Linkage (CHeRel).   
 
Limitations of the study involve unavailability of clinical data on measures such 
as blood pressure, spirometry, anthropometry and cognition as well as restricted 
participation of people from culturally and linguistically diverse (CALD) 
background with insufficient literacy in English. Based on the low response rate, 
the cohort of participants is unlikely to be directly representative of the general 
population of NSW.     
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APPENDIX D 
 
“FAT BUT FIT” IN THE CMS 
Appendix D.1 
 
 
The Copenhagen Males Study (CMS) was originally created to evaluate the role 
of physical activity and physical fitness in relation to cardiovascular disease in 
middle aged men since population data was scarce in the 70s. Recruitment started 
in 1970 and ended in 1971; 6,125 males workers were invited to participate from 
a variety of companies located in Copenhagen, Denmark, including the Danish 
railroad company, the Copenhagen Telephone company, armed forces, customs 
service, the Danish National Bank, the Post and Telegraph company, and Larsen 
& Nielsen construction company. The selection of these companies was based on 
the wide range of physical activity levels required to perform those jobs, 
providing different levels of exposure to assess the outcome of interest.  
 
At the end of the recruitment period, 5,249 male workers aged 40-59 were 
recruited with an estimated response rate of 87.3%. Based on information 
provided by the participating companies, there are no reasons to believe that non 
respondents differ from respondents. After informed consent was provided and a 
baseline questionnaire was completed; every participant underwent a medical 
examination which consisted of (i) a short interview, (ii) anthropometric and 
blood pressure, and (iii) indirect measurement of maximal aerobic power. 
Examinations took place at each site, maintaining the room temperature between 
17 and 22 degrees to avoid variability in those assessments. Smoking was not 
allowed for at least 30 minutes before the examination. Questions on physical 
activity were developed by Finn Gyntelberg as at that time there were no 
validated measures of physical activity. Thus, physical activity was categorised in 
a rather broad way.  
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Appendix D.2 Adjusted hazard ratios (HR) and 95% confidence intervals (CI) for cancer incidence according to time-varying BMI and PA; 
and baseline CRF in the CMS, excluding the first ten years of follow-up and underweight participants. 
 
 
 
  BMI Kg/m2 HR (95% CI)* Physical Activity HR (95% CI)* CRF* 
Cancer type Events <25 ≥25-<30 ≥30 P-valueA 
Almost 
nothing 
Some A lot 
P-
valueA 
10 ml/kg/min 
(VO2 max) 
P-valueA 
Prostate 371 1.00 
1.04 
(0.83-1.29) 
0.76 
(0.47-1.23) 
0.26 1.00 
0.73 
(0.53-1.02) 
0.77 
(0.55-1.07) 
0.12 
1.00 
(0.86-1.16) 
0.96 
Colorectal 275 1.00 
1.12 
(0.86-1.45) 
0.67 
(0.38-1.18) 
0.17 1.00 
1.12 
(0.74-1.69) 
1.08 
(0.71-1.66) 
0.71 
0.93 
(0.78-1.11) 
0.42 
Oral and 
digestive 
494 1.00 
1.14 
(0.94-1.39) 
0.98 
(0.68-1.41) 
0.91 1.00 
1.25 
(0.92-1.70) 
1.07 
(0.78-1.47) 
0.68 
0.90 
(0.79-1.03) 
0.12 
Respiratory 
and thoracic 
388 1.00 
0.85 
(0.68-1.06) 
0.54 
(0.34-0.86) 
0.01 1.00 
0.91 
(0.67-1.25) 
0.83 
(0.60-1.16) 
0.27 
0.72 
(0.61-0.84) 
0.001 
Genito-
urinary 
518 1.00 
1.07 
(0.88-1.29) 
0.81 
(0.55-1.20) 
0.30 1.00 
0.76 
(0.58-1.00) 
0.75 
(0.57-0.99) 
0.04 
1.03 
(0.90-1.16) 
0.70 
Other cancer 311 1.00 
1.01 
(0.79-1.30) 
1.12 
(0.72-1.75) 
0.61 1.00 
1.04 
(0.71-1.53) 
1.02 
(0.69-1.51) 
0.92 
0.92 
(0.78-1.09) 
0.35 
All-cancers 1,711 1.00 
1.02 
(0.92-1.13) 
0.84 
(0.68-1.03) 
0.09 1.00 
0.97 
(0.83-1.13) 
0.89 
(0.76-1.05) 
0.17 
0.90 
(0.83-0.96) 
0.003 
 
 
*Multivariable model adjusted for: birth decades, smoking and grams of tobacco a day, alcohol, SES, systolic blood pressure, diastolic blood 
pressure, previous AMI, diabetes and the other study variables. (all covariates are time-dependent except for birth decade, previous AMI, SES 
and CRF).  
A ‘P-value’ for each variable corresponds to a test of whether all HRs = 1  
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Appendix D.3 Adjusted hazard ratios (HR) and 95% confidence intervals (CI) for cancer related death according to time-varying BMI and PA; 
and baseline CRF in the CMS, excluding the first ten years of follow-up and underweight participants. 
 
 
 
 
  BMI Kg/m2 HR (95% CI) Physical Activity HR (95% CI) CRF 
Cancer type Events <25 ≥25-<30 ≥30 P-value 
Almost 
nothing 
Some A lot P-value 
10 
ml/kg/min 
(VO2 max) 
P-value 
Prostate 245 1.00 
1.01 
(0.77-1.32) 
0.66 
(0.36-1.21) 
0.18 1.00 
0.78 
(0.51-1.18) 
0.84 
(0.55-1.29) 
0.44 
0.96 
(0.80-1.16) 
0.67 
Colorectal 197 1.00 
0.98 
(0.72-1.32) 
0.73 
(0.40-1.35) 
0.32 1.00 
0.87 
(0.56-1.37) 
0.83 
(0.52-1.31) 
0.42 
0.89 
(0.72-1.10) 
0.28 
Oral and 
digestive 
398 1.00 
1.00 
(0.80-1.24) 
0.94 
(0.64-1.39) 
0.96 1.00 
1.12 
(0.81-1.54) 
0.85 
(0.60-1.20) 
0.34 
0.89 
(0.76-1.03) 
0.12 
Respiratory 
and thoracic 
431 1.00 
0.90 
(0.73-1.11) 
0.49 
(0.30-0.78) 
0.003 1.00 
0.92 
(0.68-1.24) 
0.80 
(0.58-1.10) 
0.17 
0.66 
(0.58-0.79) 
<0.001 
Genito-
urinary 
364 1.00 
0.95 
(0.76-1.19) 
0.66 
(0.41-1.08) 
0.10 1.00 
0.96 
(0.67-1.37) 
0.99 
(0.69-1.43) 
0.95 
0.92 
(0.79-1.08) 
0.31 
Other cancer 299 1.00 
0.76 
(0.59-0.98) 
0.77 
(0.48-1.23) 
0.04 1.00 
1.20 
(0.80-1.80) 
1.13 
(0.74-1.72) 
0.56 
0.87 
(0.73-1.03) 
0.11 
All-cancers 1,489 1.00 
0.92 
(0.82-1.03) 
0.74 
(0.59-0.92) 
0.006 1.00 
0.99 
(0.84-1.17) 
0.90 
(0.76-1.07) 
0.24 
0.82 
(0.76-0.89) 
<0.001 
 
 
 
*Multivariable model adjusted for: birth decades, smoking and grams of tobacco a day, alcohol, SES, systolic blood pressure, diastolic blood 
pressure, previous AMI, diabetes and the other study variables. (all covariates are time-dependent except for birth decade, previous AMI, SES 
and CRF).  
A ‘P-value’ for each variable corresponds to a test of whether all HRs = 1  
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Appendix D.4 Adjusted hazard ratios and 95% CI for the interaction between BMI and PA on cancer incidence of All-cancers combined, 
colorectal and prostate cancer. 
*Multivariable model adjusted for: birth decades, smoking and grams of tobacco a day, alcohol, SES, systolic blood pressure, diastolic blood 
pressure, previous AMI, diabetes, physical activity, BMI, CRF and interaction between BMI-PA.  
1.00 (Referent)
0.97 (0.82-1.18)
0.62 (0.43-0.90)
1.09 (0.94-1.26)
1.10 (0.95-1.28)
1.10 (0.85-1.42)
1.08 (0.86-1.37)
1.16 (0.93-1.45)
0.78 (0.51-1.19)
P-interaction 0.58
1.00 (Referent)
1.02 (0.70-1.50)
0.50 (0.18-1.40)
1.05 (0.72-1.52)
1.16 (0.80-1.67)
0.75 (0.36-1.56)
0.85 (0.45-1.60)
0.98 (0.55-1.77)
0.79 (0.28-2.23)
P-interaction 0.43
1.00 (Referent)
1.30 (0.94-1.78)
0.57 (0.23-1.44)
1.10 (0.80-1.53)
1.07 (0.76-1.49)
1.38 (0.77-2.45)
1.76 (1.13-2.76)
1.23 (0.73-2.07)
0.69 (0.21-2.21)
P-interaction 0.96Cancer Incidence
   
A lot PA
< 25kg/m2
25- <30 kg/m2
≥30 kg/m2
Some PA
< 25kg/m2
25- <30 kg/m2
≥30 kg/m2
Almost nothing
< 25kg/m2
25- <30 kg/m2
≥30 kg/m2
.5 1 2 4 .5 1 2 4 .5 1 2 4
All cancers Colorectal Prostate
 
                                    Adjusted Hazard Ratios (95% CI)
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Appendix D.5 Adjusted hazard ratios and 95% CI for the interaction between BMI and PA on cancer incidence of genito-urinary, oral and 
digestive, other cancers; and respiratory and thoracic cancers. 
*Multivariable model adjusted for: birth decades, smoking and grams of tobacco a day, alcohol, SES, systolic blood pressure, diastolic blood 
pressure, previous AMI, diabetes, physical activity, BMI, CRF and interaction between BMI-PA. 
1.00 (Referent)
0.80 (0.57-1.12)
0.30 (0.11-0.82)
1.09 (0.81-1.46)
0.91 (0.67-1.25)
0.64 (0.35-1.17)
0.94 (0.58-1.53)
1.18 (0.78-1.80)
0.65 (0.28-1.52)
P-interaction 0.94P-interaction 0.42
1.00 (Referent)
1.05 (0.78-1.42)
0.49 (0.22-1.06)
1.12 (0.85-1.50)
1.25 (0.95-1.66)
1.32 (0.84-2.07
0.84 (0.51-1.37)
1.02 (0.66-1.59)
1.20 (0.63-2.29)
1.00 (Referent)
0.86 (0.60-1.25)
1.08 (0.55-2.15)
0.97 (0.68-1.37)
1.10 (0.78-1.55)
1.22 (0.68-2.17)
1.08 (0.64-1.84)
0.84 (0.47-1.50
0.55 (0.17-1.79)
P-interaction 0.95
1.00 (Referent)
0.80 (0.57-1.12)
0.30 (0.11-0.82)
1.09 (0.81-1.46)
0.91 (0.67-1.25)
0.64 (0.35-1.17)
0.94 (0.58-1.53)
1.18 (0.78-1.80)
0.65 (0.28-1.52)
P-interaction 0.84
Cancer Incidence
   
A lot PA
< 25kg/m2
25- <30 kg/m2
≥30 kg/m2
Some PA
< 25kg/m2
25- <30 kg/m2
≥30 kg/m2
Almost nothing
< 25kg/m2
25- <30 kg/m2
≥30 kg/m2
.5 1 2 4 .5 1 2 4 .5 1 2 4 .5 1 2 4
Genito-urinary Oral and digestive Other cancers Respiratory and thoracic
 
                                    Adjusted Hazard Ratios (95% CI)
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Appendix D.6 Adjusted hazard ratios and 95% CI for the interaction between BMI and PA on cancer mortality of All-cancers combined, 
colorectal and prostate cancer. 
 
*Multivariable model adjusted for: birth decades, smoking and grams of tobacco a day, alcohol, SES, systolic blood pressure, diastolic blood 
pressure, previous AMI, diabetes, physical activity, BMI, CRF and interaction between BMI-PA.  
1.00 (Referent)
0.96 (0.81-1.14)
0.56 (0.37-0.84)
1.16 (0.99-1.36)
1.01 (0.86-1.20)
1.00 (0.75-1.31)
1.15 (0.89-1.47)
1.08 (0.85-1.38)
0.73 (0.46-1.14)
P-interaction 0.52
1.00 (Referent)
1.33 (0.84-2.12)
1.08 (0.41-2.83)
1.69 (1.09-2.63)
1.08 (0.67-1.74)
0.69 (0.26-1.82)
1.35 (0.67-2.71)
1.42 (0.73-2.77
1.01 (0.30-3.40)
P-interaction 0.32
1.00 (Referent)
1.25 (0.85-1.82)
0.47 (0.12-1.52)
1.04 (0.70-1.56)
0.98 (0.64-1.48)
1.07 (0.52-2.24)
1.66 (0.94-2.93)
1.16 (0.61-2.22)
0.65 (0.16-2.73)
P-interaction 0.95
Cancer Mortality
   
A lot PA
< 25kg/m2
25- <30 kg/m2
≥30 kg/m2
Some PA
< 25kg/m2
25- <30 kg/m2
≥30 kg/m2
Almost nothing
< 25kg/m2
25- <30 kg/m2
≥30 kg/m2
.5 1 2 4 .5 1 2 4 .5 1 2 4
All cancers Colorectal Prostate
 
                                    Adjusted Hazard Ratios (95% CI)
  
 
 
 
487 
Appendix D.7 Adjusted hazard ratios and 95% CI for the interaction between BMI and PA on cancer mortality of genito-urinary, oral and 
digestive, other cancers; and respiratory and thoracic cancers. 
*Multivariable model adjusted for: birth decades, smoking and grams of tobacco a day, alcohol, SES, systolic blood pressure, diastolic blood 
pressure, previous AMI, diabetes, physical activity, BMI, CRF and interaction between BMI-PA.  
1.00 (Referent)
1.00 (0.73-1.38)
0.57 (0.24-1.32)
0.96 (0.70-1.32)
0.98 (0.71-1.36)
0.91 (0.560-1.68)
1.28 (0.79-2.08)
0.81 (0.46-1.43)
0.55 (0.17-1.76)
P-interaction 0.85
1.00 (Referent)
1.19 (0.84-1.69)
0.69 (0.31-1.53)
1.63 (1.18-2.25)
1.33 (0.95-1.85)
1.43 (0.86-2.40)
1.19 (0.70-2.01)
1.31 (0.81-2.12)
1.54 (0.77-3.09)
P-interaction 0.11
1.00 (Referent)
0.87 (0.60-1.26)
0.83 (0.39-1.76)
1.18 (0.84-1.66)
0.85 (0.59-1.24)
1.04 (0.57-1.89)
1.07 (0.61-1.87)
0.73 (0.40-1.36)
0.18 (0.02-1.30)
P-interaction 0.64
1.00 (Referent)
0.81 (0.59-1.12)
0.34 (0.14-0.85)
1.08 (0.81-1.45)
1.00 (0.74-1.35)
0.60 (0.33-1.10)
0.99 (0.62-1.58)
1.20 (0.80-1.82)
0.53 (0.21-1.34)
P-interaction 0.42
Cancer Mortality
   
A lot PA
< 25kg/m2
25- <30 kg/m2
≥30 kg/m2
Some PA
< 25kg/m2
25- <30 kg/m2
≥30 kg/m2
Almost nothing
< 25kg/m2
25- <30 kg/m2
≥30 kg/m2
.5 1 2 4 10 .5 1 2 4 10 .5 1 2 4 10 .5 1 2 4 10
Genito-urinary Oral and digestive Other cancers Respiratory and thoracic
 
                                    Adjusted Hazard Ratios (95% CI)
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APPENDIX E 
  
“FAT BUT FIT” AND CANCER, PILOT STUDY IN THE 
DANISH HEALTH EXAMINATION SURVEY.  
(unpublished data) 
 
Previous studies using the Danish Health Examination Survey cohort  have not yet 
addressed cancer prevention although cancer is one of the most pressing public 
health issues worldwide.(1) Therefore, this preliminary analysis examined main 
and interactive effects of body fatness and physical activity on the risk of 
developing the most common types of cancer in adults. This was a supplementary 
study similar to those repeated in the main chapters of this thesis, assessing the 
“fat but fit” hypothesis with respect to cancer risk in a Danish cohort.    
 
Study design, setting and subjects 
 
The Danish Health Examination Survey (DANHES 2007-2008) was conceived as 
a research database for cross-sectional and follow-up analyses. The survey was 
established to investigate the role of a wide range of exposures, including 
smoking, alcohol and physical activity on different health outcomes. Details of the 
study design, sampling method, data collection and protocols have been published 
elsewhere.(2) In 13 municipalities of Denmark, a total of 538,497 eligible 
participants aged over 18 years were invited to participate; of them, 76,484 men 
and women joined the study by signing a consent and completing a basic sex-
specific questionnaire. Recruitment was conducted over a period of a month in 
each municipality and the estimated response rate was 14%.(2) For the purpose of 
this analysis, we used baseline data and record linkage data from the Danish 
Cancer Registry through the Danish Civil Registration System (CRS). CRS stores 
personal information based on the unique personal identification number, enabling 
accurate linkage and coverage amongst all people living in Denmark.(3) This 
analysis was approved by the National Institute of Public Health (NIPH).  
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Identification of cases 
 
For the individual cancer types examined in this study, incident cancers were 
identified, and dates of diagnoses obtained through linkage data from the Danish 
Cancer Registry for all cancer registrations until the 31st of October 2017. This 
registry is population-based and contains records for all incident malignant 
neoplasms in the Danish population from 1943 onwards with mandatory reporting 
since 1987 by several independent sources to ensure completeness and high 
quality data.(4) Cancer incidence was coded according to the tenth revision of the 
International Classification of Diseases (ICD-10). The following codes were used 
for lung cancer (LC) C34, colon cancer (CC) C18, prostate cancer (PC) C61, 
female breast cancer (BC) C50, uterine cancer (UC) C54-C55 and all cancers 
combined except malignant neoplasms of the skin C00-C41, C45-C97, B21. Skin 
cancers were excluded as the association with PA might be confounded by 
ultraviolet (UV) sun exposure and increased risk of sunburn.(6) 
 
Data collection 
 
The basic sex-specific questionnaire collected information on socio-demographic 
characteristics, height, weight, smoking habits, alcohol intake, physical activity 
and personal medical history.  
 
Study variables 
 
Body mass index 
 
Body mass index, expressed in kg/m2, was derived from self-reported weight (kg) 
and height (m) from the basic questionnaire. Consistent with established methods, 
participants with a calculated BMI of <15kg/m2 or >50kg/m2 were excluded from 
the analysis due to an increased probability of measurement error.(7) The effect of 
body mass in statistical analysis was obtained per unit increase in BMI.   
 
Physical activity 
 
From the basic questionnaire, PA was estimated as the average level performed 
during the previous year. The four predefined levels were based on the categories 
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proposed by Saltin and Grimby with minor modifications:(8) (i) vigorous consisted 
of strenuous activities typically including competition or endurance training 
conducted frequently or several times a week, (ii) moderate activities such 
exercise, endurance training or heavy gardening for at least 4 hours a week, (iii) 
light activities encompassed walking, cycling, walking or biking to work, or other 
light activities for a minimum of 4 hours a week; and (iv) inactive included 
reading, TV-watching or similar sedentary activities.(8) As the number of 
participants who engaged in vigorous activities was small (1,766 men and 1,065 
women); this category was combined with moderate activity to create a moderate 
to vigorous PA (MVPA) group. The inactive group was used as the reference 
category. 
 
Statistical analysis 
 
Analyses were conducted separately for each site-specific cancer. Adjusted hazard 
ratios (HRs) and 95% confidence intervals (CI) were estimated for cancer 
incidence according to BMI and PA, using Cox regression with age as the 
underlying time variable. For cancer incidence, participants were censored if they 
died, were diagnosed with other cancers or were alive at the end of follow up 
period (31st of October 2017), whichever came first. Additionally, potential two-
way interactions between BMI and PA was examined on the different cancer 
outcomes of interest by adding appropriate interaction terms to the models. Based 
on the nature of the interaction, the multiplicative scale was used since this 
interaction does not depend on the scale used.(9) All models were adjusted for: 
educational attainment (<10, 10-12, 13-14 or 15+ years), smoking status (never-
smoker, ex-smoker, occasional smoker, daily smoker (1-15 g of tobacco/day) and 
alcohol intake (yes or no). Statistical analyses were performed using STATA 
software, version 14.2.  
 
Results 
 
During almost 10 years of follow-up, 792 incident cases of female breast cancer 
were ascertained via cancer registry, 148 of uterine, 188 of colon, 159 lung 
cancers and 1,890 total cancers among females. In men, 761 cases of prostate 
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cancer were accrued, 198 colon cancers and 1,838 total cancers among males 
were obtained, excluding skin cancers.   
  
An increased in one unit of BMI (kg/m2) was positively associated with cancer 
risk in women and men. Increased cancer risks were observed for breast, uterus 
and any cancer site combined in females. Elevated risk of cancer was noted for 
colon and any cancer site combined in males. On the other hand, a reduced risk 
was found for female lung cancer.  Appendix D.1 shows the adjusted HRs and 
95% confidence intervals (CIs) for different types of cancer incidence by sex.  
 
Physical activity, in particular any level, was negatively associated with female 
lung cancer and MVPA was related to reduced risk of any cancer combined in 
women. In men, PA was not associated with any cancer risk (Appendix D.2).  
 
In these analyses the “fat but fit” interaction was not observed for any cancer type 
assessed (Appendix D.3); P-values for the interaction between BMI and PA were 
not significant (greater than 0.10). 
 
Appendix E.1 Cox proportional hazards of incidence of cancer according to 
body mass index. 
 
Cancer type BMI 
 Events Multivariable HR1 
Women   
Breast 792 1.02 (1.01-1.03) 
P-value2 0.004 
Colon 188 1.01 (0.98-1.04) 
P-value2 0.61 
Lung 159 0.95 (0.92-0.99) 
P-value2 0.02 
Uterine 148 1.06 (1.03-1.09) 
P-value2 <0.001 
Any cancer 1,890 1.01 (1.00-1.02) 
P-value2 0.01 
Men   
Colon 198 1.04 (1.00-1.07) 
P-value2 0.04 
Lung 163 0.98 (0.95-1.03) 
P-value2 0.65) 
Prostate 761 1.01 (0.99-1.03) 
P-value2 0.52 
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Any cancer 1,838 1.01 (1.00-1.03) 
P-value2 0.03 
 
1 Multivariable model adjusted for: age (underline time scale), PA, education, 
smoking and alcohol. 
2 “P-value” is for test of linear association in the log hazard scale, using the 
continuous version of BMI in the cox model.  
 
 
Appendix E.2 Cox proportional hazards of incidence of cancer according to 
levels of physical activity 
 
Cancer type Physical activity 
 Events Multivariable HR1 
Women 
 Inactive 
(Reference) 
Light MVPA 
Breast 792 
1.00 1.06 (0.87-1.31) 0.84 (0.64-1.09) 
P-value2 0.19 
Colon 188 
1.00 0.99 (0.66-1.48) 1.07 (0.64-1.79) 
P-value2 0.78 
Lung 159 
1.00 0.65 (0.45-0.95) 0.43 (0.24-0.78) 
P-value2 0.02 
Uterine 148 
1.00 0.90 (0.58-1.40) 0.82 (0.46-1.44) 
P-value2 0.49 
Any cancer 1,890 
1.00 0.94 (0.83-1.07) 0.85 (0.76-1.00) 
P-value2 0.05 
Men     
Colon 198 
1.00 1.07 (0.72-1.58) 0.88 (0.55-1.40) 
P-value2 0.59 
Lung 163 
1.00 0.70 (0.48-1.03) 0.81 (0.51-1.29) 
P-value2 0.07 
Prostate 761 
1.00 1.15 (0.92-1.43) 1.22 (0.96-1.55) 
P-value2 0.11 
Any cancer 1,838 
1.00 1.00 (0.88-1.14) 1.07 (0.92-1.24) 
P-value2 0.36 
 
1 Multivariable model adjusted for: age (underline time scale), BMI, education, 
smoking and alcohol. 
2 “P-value” for each variable corresponds to a test of whether all HRs=1.  
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Appendix E.3 Statistical assessment of the “fat but fit” hypothesis according to 
different types of cancer by sex. 
 
 
 
 
 
 
 
 
 
 
1 Multivariable model adjusted for: age (underline time scale), BMI, PA, 
education, smoking and alcohol. 
 
Discussion 
 
In this preliminary analysis, the “fat but fit” was not supported in the DANHES 
data. BMI was associated with cancer risk, in particular with increased risk for 
breast, uterine and any cancer combined in women. Additionally, an increase in 
BMI was associated with colon and any cancer combined in men. Conversely, an 
increase in BMI per unit was found to be related to a marginal reduction in lung 
cancer risk.  
 
Physical activity was negatively associated with reduced risks of lung and any 
cancer combined in women, whereas no effect was evident with cancer risk in 
men. The World Cancer Research Fund and the American Institute for Cancer 
Research panel have concluded that there is convincing evidence for an 
association between PA and a reduced risk of colon cancer and probable evidence 
for female breast and endometrial cancer.(10) Our analysis did not detect such 
associations. Challenges encountered with the use of the PA question in this study 
include a possible lack of validity in Danish populations(11) and possible 
misclassification of participants’ level of activity as the question includes some 
moderate activities in the light category, leading to the introduction of errors 
which can attenuate the effect of PA on cancer risk.(12, 13)  
 
Strengths of this analysis include the prospective nature of the study design, data 
linkages to cancer registry and the relatively long follow-up period. Given the 
Cancer type P-interaction1 
 Women Males 
Breast 0.31 - 
Colon 0.22 0.74 
Lung 0.80 0.93 
Uterine 0.76 - 
Prostate - 0.89 
Any cancer 0.79 0.81 
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results of this preliminary analysis, findings must be interpreted with caution. 
Another potential shortcoming is that exposure variables were ascertained by self-
report. Additionally, the study may have been underpowered to detect an effect of 
public health importance since most cancer outcomes consisted of relatively few 
cases. 
 
Conclusion 
 
Given the possible consequences of physical activity misclassification on the 
estimates of cancer risk, findings of the “fat but fit” hypothesis are not biased 
since exposure misclassification does not affect an interaction parameter at the 
multiplicative scale, if it is not present.(14) Therefore, these results do not support 
the “fat but fit” hypothesis in this Danish cohort. This preliminary study provides 
corroborative support to the earlier (published) studies in this thesis, that also did 
not find evidence for the “fat but fit” hypothesis in relation to cancer risk.      
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